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Abstract 
Respiratory syncytial virus (RSV) is the most significant cause of paediatric acute respiratory 
infection (ARI). RSV and other respiratory viruses are commonly co-detected with potentially 
pathogenic bacteria, such as Streptococcus pneumoniae, in the upper airways of young children. 
While these bacteria are known to be carried asymptomatically, they are also capable of 
opportunistic infections. Interactions between RSV and S. pneumoniae have been demonstrated in 
both clinical and molecular studies. However, the clinical significance of these interactions remains 
debated, and the effect of clinically relevant strain variation in both virus and bacteria on these 
interactions is also unknown. This work aimed to better understand the role of S. pneumoniae 
colonisation during RSV infections. 
 
To determine the effect of RSV and S. pneumoniae co-detection on disease severity during ARI, 
molecular pathogen screening of nasopharyngeal samples was conducted in a cohort of young 
children under the age of two years presenting with ARI at the emergency department of the Royal 
Brisbane Children’s Hospital, Australia. S. pneumoniae was co-detected in approximately 52% of 
RSV infections, and co-detection was associated with increased disease severity, suggesting that S. 
pneumoniae plays a pathogenic role in severe paediatric RSV infections. 
 
Having established a clinical role for S. pneumoniae during RSV infection, the dynamics of 
pneumococcal colonisation of the nasal cavity was investigated in the four weeks prior and 
subsequent to an RSV infection in a longitudinal birth cohort of Brisbane-based children. 
Approximately 33% of infants and young children with RSV infections were colonised by S. 
pneumoniae prior to the RSV detection, and strain characterisation of S. pneumoniae in the weeks 
immediately surrounding the viral infection suggested that any observed growth of S. pneumoniae 
during RSV infection arose from the pre-existing strain colonising the URT. In another 14% of 
RSV infections, S. pneumoniae was first detected during the virus infection, suggesting 
simultaneous acquisition of RSV and S. pneumoniae and possible co-transmission of the two 
pathogens.  
 
The results from the two paediatric cohorts suggested an interaction between RSV and S. 
pneumoniae that was advantageous to the bacteria. It was therefore hypothesised that the molecular 
mechanisms governing RSV and S. pneumoniae interactions might be pneumococcal strain-specific 
and stronger in strains frequently co-detected with RSV. Studies have shown that RSV can increase 
S. pneumoniae colonisation by enhancing pneumococcal adherence to airway epithelia, and virions 
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can bind directly to the bacterium to form co-pathogen complexes. These interactions are in part 
mediated through the binding interactions between S. pneumoniae surface receptors and the RSV G 
surface glycoprotein. RSV G is highly variable, both antigenically and genetically, and is the main 
protein used to type RSV into subtypes A and B. The genetic variation of RSV G was characterised 
from nasopharyngeal samples of young children under the age of five years with respiratory 
symptoms collected from Pathology Queensland Central at the Royal Brisbane Women’s Hospital. 
The core genetic variation, through multilocus sequence typing, and molecular serotype of S. 
pneumoniae isolates from the same cohort was also determined. S. pneumoniae co-detection was 
more common with RSV-A compared to RSV-B; however, there were no clear associations 
between virus co-detection and bacteria strains.  
 
An in vitro binding assay was developed to specifically investigate pneumococcal strain variation in 
adherence to immortalised airway epithelial cells during RSV infection or after pre-binding with 
RSV virions. S. pneumoniae strains were isolated from the paediatric pathology cohort to 
investigate whether strains isolated from patients with RSV infections exhibited greater adherence 
to RSV infected epithelial cells. The results suggested that the effect of RSV on pneumococcal 
adherence to the epithelial cells differed between S. pneumoniae strains and isolates, although no 
significant association was identified between strains isolated from children with RSV infections 
and increased RSV-mediated adherence.  
 
This project has demonstrated a pathogenic role for S. pneumoniae in RSV infection of young 
children. The results suggest that one mechanism of this interaction may be mediated through 
binding interactions between the bacteria and RSV surface glycoproteins, potentially resulting in 
outgrowth of S. pneumoniae colonising the URT during virus infection or possible co-transmission 
of virus and bacteria. The results from the paediatric cohorts have suggested that the presence of 
both S. pneumoniae and RSV should be considered during the diagnosis and treatment of paediatric 
ARI, while the molecular investigations have given insight into the strain-specific variation of 
interactions between the two pathogens, and provided a panel of characterised, clinically relevant S. 
pneumoniae isolates for use in further studies. 
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1. Introduction and literature review 
1.1 Introduction 
Paediatric acute respiratory infection (ARI) is a significant cause of childhood mortality and 
morbidity worldwide. In children younger than five years, severe lower respiratory infection results 
in an estimated 12 million hospital admissions and 300,000 deaths annually, with the vast majority 
of fatalities occurring in developing countries (2). Respiratory syncytial virus (RSV) is the most 
important cause of ARI in infants and young children, although other respiratory viruses and 
bacteria can also cause disease (3, 4). These bacteria are often members of the respiratory 
microbiota, carried asymptomatically but also capable of causing opportunistic infections, such as 
Streptococcus pneumoniae (4, 5). Viral/bacterial co-infections have also been reported (reviewed in 
Brealey et al. (6)), particularly well characterised in secondary bacterial infections following 
influenza virus infection (7). However, outside of epidemics, influenza is a relatively infrequent 
pathogen of young children (8). There is some evidence to suggest that bacterial co-infections with 
common paediatric viruses like RSV may be clinically relevant in young children (9-15). However, 
as healthy young children are often colonised by potentially pathogenic bacteria, distinguishing true 
bacterial co-infection, i.e. a pathogenic role for the bacteria, from colonisation can be difficult. It is 
also unclear whether viruses stimulate an outgrowth of pathogenic bacteria from those already 
colonising the respiratory tract, or if these bacteria are acquired with or after the viral infection and 
establish colonisation and subsequent infection. This project aimed to better understand the role of 
potentially pathogenic bacteria such as S. pneumoniae in RSV infections of young children, 
including the clinical significance of co-detected bacteria, the effect of RSV infection on S. 
pneumoniae colonisation and the molecular mechanisms governing the interaction between virus 
and bacteria. 
 
1.2 The paediatric respiratory tract in health 
1.2.1 Upper respiratory microbiota 
The upper respiratory tract (URT), including the nasal cavity, nasopharynx and oropharynx, is 
colonised by bacteria almost immediately from birth (16, 17). Early life colonisation by specific 
bacteria may play an important role in respiratory health and disease, with some species associated 
with number and frequency of ARI and the subsequent development of asthma (5, 18, 19). 
Composition of the URT microbiota has been shown to be affected by many factors, including 
mode of birth delivery, breastfeeding, number of siblings, childcare attendance, season (particularly 
in temperate climates), antibiotic exposure, and number of ARI episodes (5, 16-18, 20, 21). 
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Longitudinal studies profiling the nasopharyngeal microbiota from Australia and Europe suggest 
that as early as 6 weeks after birth, the nasopharynx is colonised by species of typically skin-
dwelling bacteria, such as Staphylococcus or Corynebacterium (5, 17, 18). Over time these species 
are replaced with stable colonisation by Moraxella or Alloiococcus/Dolosigranulum, with transient 
acquisition of Streptococcus and Haemophilus (5, 17, 18). Stable profiles such as those dominated 
by Moraxella or Alloiococcus/Dolosigranulum have been associated with breastfeeding and fewer 
ARI episodes in some studies (18), although Moraxella has also been associated with ARI episodes 
in others (5). The species S. pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are 
common opportunistic pathogens in young children, carried asymptomatically as well as capable of 
respiratory disease (22-24). Unstable profiles like those dominated by Streptococcus and 
Haemophilus are commonly reported in young children with ARI symptoms at the time of 
sampling, and in young children with frequent ARI episodes between sampling (5, 18, 19, 25). 
Colonisation by Moraxella, Streptococcus and Haemophilus has been associated with interaction 
with older children such as siblings as well as childcare attendance (5, 18). Some evidence suggests 
that, counter-intuitively, antibiotic usage may select for colonisation by these bacteria during health 
(5), although other studies have detected decreases in potentially pathogenic bacteria after antibiotic 
use (15, 21).  
 
1.2.2 Asymptomatic virus carriage 
Respiratory viruses are usually associated with symptomatic disease, however, they have also been 
shown to be carried asymptomatically in the URT of young children (21, 26-29). Asymptomatic 
respiratory viral carriage has been reported in up to 70% of children under two years of age (20, 21, 
27), and as early as two days after birth (30). Human rhinoviruses (hRV) are known to cause 
respiratory disease, however, they are commonly found in both asymptomatic and symptomatic 
children, with prevalences ranging from 10-40% and 25-50%, respectively, in children aged under 
three years (21, 26, 27, 29, 31). Recent developments in the molecular typing of hRV strains 
suggest that some hRV types, specifically hRV-C, may be more disease-associated than others (32, 
33). Similar to hRV, respiratory enteroviruses have been found in health and disease (21, 27), with 
some strains capable of causing epidemics, like the enterovirus strain D68 responsible for a 2014 
outbreak in the United States (34). The role of bocavirus, adenovirus, coronaviruses and 
polyomaviruses in paediatric ARI is less clear. These viruses are generally less frequently identified 
in the URT of children, and have been found in healthy children and those with ARI (21, 26, 27, 29, 
31, 35, 36). Furthermore, bocavirus, adenovirus, coronaviruses, polyomaviruses, hRV and 
respiratory enteroviruses are often co-detected with each other and other respiratory viruses during 
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ARI and during health, complicating the determination of their contribution to disease presentation 
(21, 27, 36-38). Conversely, while other respiratory virus (Influenza A virus (IAV), RSV, 
metapneumovirus (MPV) and parainfluenza viruses (PIV)) can be carried asymptomatically, they 
are rarely identified in healthy children, indicating that these viruses are generally causative agents 
of respiratory disease (21, 27, 29). 
 
1.2.3 Viral interactions with the respiratory microbiota during health 
While viral and bacterial interactions in the paediatric respiratory tract are more commonly 
investigated in the context of ARI (discussed in detail in the following sections), a few studies have 
focused on possible interactions during health. Studies of respiratory virus and bacteria carriage in 
healthy children have identified positive associations between the detection of hRV and the 
detection of S. pneumoniae, H. influenzae and M. catarrhalis (21, 26, 32). Positive associations 
have also been reported between adenovirus and M. catarrhalis (21, 26). One study also reported 
positive associations between RSV and H. influenzae, and influenza viruses and Staphylococcus 
aureus, however, RSV and influenza each accounted for only 2-3% of samples (21), suggesting that 
these interactions would be rarely observed in healthy children. Understanding the complex 
pathogen interactions that take place in the paediatric respiratory tract even in the absence of 
symptoms is important to contextualise any studies of viral/bacterial co-infection during ARI. 
 
1.3 Paediatric ARI 
1.3.1 Aetiology and diagnosis 
ARIs can be divided into URT infections and lower respiratory tract (LRT) infections. URT 
infections include rhinitis (common cold), sinusitis, otitis media and other ear infections, 
pharyngitis and laryngitis. Respiratory viruses are responsible for the majority of URT infections, 
including hRV, RSV, PIV, influenza viruses, MPV and less frequently, respiratory enteroviruses. 
Generally viral URT infections are self-limiting and resolve without treatment; however, 
complications can cause significant problems (4). Well documented complications of viral URT 
infections include bacterial sinusitis and bacterial otitis media, with S. pneumoniae, nontypeable H. 
influenzae and M. catarrhalis most frequently implicated (39, 40).  
 
URT infections can shift to LRT infections through aspiration of infectious particles, resulting in 
pneumonia and bronchiolitis. RSV is the main cause of bronchiolitis, while both viruses and 
bacteria can cause pneumonia. RSV, PIV and influenza viruses are important causes of viral 
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pneumonia (4), although influenza viruses rarely cause severe LRT infection in young children aged 
< 5 years. For example, a 15 year study across the United States estimated that RSV is responsible 
for 15-fold more hospitalisations in infants < 1 year of age compared to influenza viruses, and 5-
fold more in children aged 1-4 years, despite overall hospitalisation rates between the two 
pathogens remaining similar in the whole population (8). Even in influenza epidemics such as the 
2009 H1N1 pandemic, the contribution of the epidemic strain to paediatric viral ARI cases has been 
found to remain unchanged (41). There is also increasing recognition of the role of hRV-A and 
hRV-C in paediatric LRT infections requiring hospitalisation (33). S. pneumoniae (the 
pneumococcus) and H. influenzae type b are most commonly responsible for bacterial pneumonia, 
followed by nontypeable H. influenzae, S. aureus and other streptococci species (4). Mycoplasma 
pneumoniae and Chlamydia pneumoniae are important causes of atypical pneumonia, and both can 
cause other LRT and URT infections (42, 43). Bordetella pertussis is responsible for the childhood 
respiratory disease known as whooping cough, and can cause life-threatening disease manifestations 
in neonates and young infants, such as respiratory distress syndromes (44).  
 
Pneumococcal pneumonia following IAV has been well described in both children and adults, with 
clear enhancement of disease severity (45-47). In young children with community acquired 
pneumonia (CAP), mixed viral and bacterial infections have been identified from LRT samples in 
approximately 30% of patients, with commonly detected bacteria including S. pneumoniae, H. 
influenzae, M. catarrhalis and S. aureus (48-53). High loads of the same species of potentially 
pathogenic bacteria have been detected in approximately 40% of LRT samples from children with 
RSV infections (11, 54, 55). Studies of the nasopharyngeal microbiota during RSV infection have 
also identified increased abundances of H. influenzae, S. pneumoniae and Moraxella species 
compared to non-RSV infections or healthy controls (1, 14, 15, 25, 56). 
 
Identifying the aetiological agents responsible for ARI symptoms in young children can be difficult. 
There is an abundance of distinct viruses and bacteria species, as well as individual strains, which 
can cause similar respiratory symptoms. Accurate and rapid diagnosis is particularly important in 
severe LRT infections, where morbidity and mortality are highest (2). Several studies have 
attempted to define clinical markers to distinguish between viral pneumonia, bacterial pneumonia 
and mixed infection, with limited success (10, 11, 50, 52-54, 57-60). A few studies have found that 
high C-reactive protein levels, increased white blood cell counts, the presence of plural effusion or a 
high fever may indicate a bacterial co-infection during viral pneumonia (52, 53, 58, 60), but an 
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equal number of studies have found no discriminating features between aetiologies (10, 11, 50, 54, 
57). 
 
Ideally, laboratory confirmation of a suspected viral, bacterial or mixed infection should be carried 
out, to ensure the correct treatment is given. The gold standard for diagnosing viral ARI is virus 
isolation in cell culture, a time-consuming procedure (3-10 days) that assumes the virus can 
replicate well in cell culture, which is not the case for several of the more recently discovered 
respiratory viruses, such as MPV and some coronaviruses (61, 62). Multiplex polymerase chain 
reaction (PCR) assays are now most commonly used for identification of respiratory viruses from 
URT samples, due to their improved sensitivity, specificity, speed (hypothetically 2-24 hours) and 
ability to screen for multiple viruses and types in a single assay (63). For RSV and influenza virus 
diagnosis, rapid antigen-detection immunoassays have also been developed, which can be 
performed in less than an hour and do not require specialised equipment or expertise (64). The gold 
standard for diagnosing bacterial infections is isolation through culture from a site normally 
considered sterile, such as the lung or the blood. Urinary antigen detection assays are available for 
the diagnosis of pneumococcal CAP in adults; however, the test has low specificity in young 
children due to the high rates of pneumococcal carriage in that population (65). Multiplex and 
singleplex PCR assays for the molecular detection of common bacterial pathogens from respiratory 
samples have also been developed (66-69), but are currently used in surveillance and research, 
rather than as a diagnostic method. For laboratory confirmation of bacterial LRT infections, culture 
or molecular methods should be applied to LRT samples, such as bronchoalveolar lavage fluid or 
sputum, however, obtaining such samples from young children is difficult, and there is the risk of 
contamination from URT flora. URT samples like nasopharyngeal aspirates or swabs are easier to 
obtain but have limited use for diagnostic purposes due to the high prevalence of asymptomatic 
carriage of viruses and bacteria in young children. 
 
1.3.2 Treatment and prevention 
While viruses are the most common cause of both URT and LRT infections, prescription of 
antibiotics in young children is common (70-73). Randomised controlled trials of antibiotic 
treatments for paediatric bronchiolitis, most commonly caused by RSV, have found limited effect 
on clinical outcomes like length of hospitalisation stay, despite reductions in bacterial load in the 
URT (72-74). Thus, there are concerns that in many paediatric ARI cases, antibiotic prescriptions 
are unjustified and potentially contribute to the development of antibiotic resistance (70). Specific 
antivirals have been developed for IAV and are used in severe cases requiring hospitalisation and 
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cases with increased risk of complications (e.g. children aged < 2 years); however, for the other 
important viral respiratory pathogens no antivirals are currently available. Treatment is therefore 
limited to supportive care, such as supplemental oxygen or intubation with mechanical ventilation. 
Supportive care is used in bacterial pneumonia in conjunction with antibiotic treatment. When 
bacterial pneumonia is suspected, broad-spectrum penicillins are usually immediately administered 
orally or intravenously, depending on age and severity. However, antimicrobial resistance has been 
observed in both S. pneumoniae and H. influenzae isolates, with β-lactam antibiotic resistance 
reported in up to 40% of pneumococcal isolates (75-77) and 10-25% of H. influenzae isolates (78). 
Ideally, antibiotic sensitivity testing should be carried out and treatment altered as appropriate; 
however, this is not always practical, particularly in low-income settings. Intravenous 
cephalosporins are generally used as a second-line treatment, should penicillin resistance be 
detected or treatment with the first-line penicillins fail, however, they are also used in severe 
pneumonia cases in young children. Vancomycin is also used in severe cases in children aged > 4 
months. 
 
To reduce the incidence of bacterial respiratory infections, in Australia vaccines against B. 
pertussis, H. influenzae type b, and 13 of the most important S. pneumoniae serotypes are part of 
the National Immunisation Program for children, with the first immunisation occurring at two 
months of age. While these vaccines have reduced infection due to the strains covered by the 
vaccines, there is some evidence that rates of infection due to non-vaccine strains, such as 
nontypeable H. influenzae and other pneumococcal serotypes, have increased (78-81). The only 
respiratory virus vaccines currently available are the yearly seasonal influenza vaccines, which can 
be administered from 6 months of age. Seasonal influenza vaccines theoretically provide protection 
against the most prevalent influenza A and B virus strains circulating each season. However, they 
rely on accurate prediction of each season’s circulating strains and their formulation has to be 
evaluated annually. While several universal influenza vaccine candidates have been designed, all 
are in pre-clinical stages of development (82). There are some vaccine candidates for RSV and 
some PIV types which have entered clinical trials (83-85). A prophylactic monoclonal antibody, 
palivizumab, is available for infants and young children at high risk of severe RSV infection (e.g. 
preterm infants), to reduce hospitalisations rates (86); however, given its cost (estimated at  
> US$200,000 per quality-adjusted life years saved), it has limited use in the general population 
(87, 88).  
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Due to the high prevalence of co-infections in young children, a reduction in influenza virus and 
RSV infections by vaccination could have the added benefit of reducing the incidence of bacterial 
co-infections in that population. In the elderly, seasonal influenza vaccination has been associated 
with a reduced risk for severe bacterial CAP (89), while in young children a live attenuated 
influenza vaccine reduced the incidence of all-cause acute otitis media (90). Likewise, 
immunisation of young children against the most prevalent pneumococcal serotypes also 
corresponded with reduced incidences of viral pneumonia (91) and reduced hospitalisations due to 
RSV (92). Thus, an effective RSV vaccine may further reduce rates of, for example, non-vaccine 
serotypes of S. pneumoniae. With the increasing rates of bacterial antimicrobial resistance and the 
potential overprescription of antibiotics for viral ARI, is it important to characterise the spectrum of 
the clinically relevant pathogens and co-pathogens of paediatric ARI, to focus the design of 
effective preventative measures and accurate, rapid diagnostic assays. 
 
1.4 Clinical significance of co-infections 
1.4.1 Disease severity 
Determining the contribution of viral/bacterial co-infection to disease severity is highly complex, 
particularly among the paediatric population. Aside from the difficulties in determining the 
causative agents of paediatric ARI, inherent differences between the child’s age, previous 
exposures, environmental conditions and genetic background can contribute to severity and 
therefore complicate the identification of valid trends within clinical cohorts. In addition, variation 
in techniques, diagnostic cut-off values and pathogens targeted between individual studies further 
confound the determination of the overall clinical significance of viral/bacterial co-infection. 
Furthermore, severe ARI burden is highest in resource poor countries (2), in settings where it is 
often difficult to gain an accurate assessment of the role of co-infections. 
 
Despite the complexities surrounding clinical studies of co-infection, there is growing evidence for 
enhanced disease severity during polymicrobial ARI in young children (Table 1.1). Increased 
morbidity and mortality associated with bacterial superinfection were observed in adults and 
children during the IAV pandemics of the twentieth century (93-95), as well as during the most 
recent 2009 H1N1 pandemic (47, 96). Some studies of CAP and bronchiolitis have found children 
with both virus and bacteria detected tend to have longer hospital stays and a higher degree of 
disease severity (52, 53, 97), while studies of young children with severe RSV infections have 
shown that young children with bacterial co-infections have increased hospital stays, admission to 
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intensive care units and use of assisted ventilation compared to sole RSV infections (9-13). 
Detection of potentially pathogenic bacteria in the nasopharynx has also been associated with 
increased severity during paediatric RSV infections (14, 15). However, the associations identified in 
these clinical studies are often weak and only occasionally reach statistical significance. There are 
also several studies finding no association between co-detection of RSV or other respiratory viruses 
with bacteria and markers of disease severity (54, 57, 98, 99), leaving some uncertainty as to the 
true contribution of bacteria to viral ARI.   
 
The high number of confounding factors and inter-patient variation inherent in cross-sectional 
cohort studies limits their ability to detect complex associations between detected pathogens and 
disease severity indicators. Studies controlling inter-patient variation are needed to better 
understand co-detections and associated clinical presentations. Longitudinal cohort studies are ideal, 
where infants are recruited early in life and followed over several years, during which time a record 
of ARI episodes and the associated severity are kept and both viral and bacterial carriage is 
regularly monitored. Results from the limited number of longitudinal studies conducted to date 
suggest that respiratory health is associated with stable nasopharyngeal colonisation by 
Staphylococcus, Corynebacterium and Alloiococcus in the first year of life, while colonisation with 
potential pathogens like S. pneumoniae, H. influenzae and M. catarrhalis increases the risk of LRT 
infection during viral URT infection, resulting in increased markers of inflammation, such as fever 
(5, 18, 19). Chapter 3 of this thesis makes use of samples from the Observational Research in 
Childhood Infectious Diseases (ORChID) cohort (100), a Brisbane longitudinal birth cohort 
investigating both viral and bacterial URT carriage weekly in infants through the first two years of 
life. Such longitudinal studies of viral and bacterial carriage can help answer several questions 
about the development of viral/bacterial co-infections in young children. 
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Table 1.1. Overview of the literature demonstrating the effect of viral and bacterial co-detection on disease severity during paediatric ARI. 
Study Disease Population 
(years of age) 
Country Co-detected 
pathogens 
Co-detection 
incidence 
Effect of co-
detection on 
patient 
Bacterial detection 
method 
(sample site) 
Positive correlations between co-detection and clinical severity parameters 
Ghani et al. 2012 
(101) 
Viral ARI 175 hospitalised 
children (<2) 
South Africa NA (common 
viruses: hRV, RSV, 
AdV, IAV; 
bacteria: 
Acinetobacter 
baumannii, Kp, Sa) 
39% Significantly longer 
PICU/ 
hospitalisation stays 
and duration of 
ventilation 
Culture (blood, 
lung, trachea) 
Wei et al. 2015 (60) ARI 3181 hospitalised 
children (<16) 
China RSV + Sp
1
, RSV + 
Hp
1
, PIV + Sp
1
, 
IAV + Sp
1 
17% Significantly more 
frequent 
presentation of 
fever and cough  
Culture (NP) 
Honkinen et al. 
2011 (50) 
CAP 76 hospitalised 
children (<15) 
Finland hRV + Sp
1
 66% All cases of 
treatment failure 
(n=6) had co-
infection 
Culture and PCR 
(LRT) 
Kurz et al. 2013 
(52) 
CAP 279 hospitalised 
children (<18) 
Austria NA (common 
viruses:  
Enterovirus, IAV, 
RSV, AdV; 
bacteria:  Sp, Mp, 
Cp) 
10% Insignificantly 
longer 
hospitalisation stays 
Culture (blood), 
antigen assays 
(urine), qPCR (NP) 
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Study Disease Population 
(years of age) 
Country Co-detected 
pathogens 
Co-detection 
incidence 
Effect of co-
detection on 
patient 
Bacterial detection 
method 
(sample site) 
Michelow et al. 
2004 (53) 
CAP 154 hospitalised 
children (<18) 
USA NA (common 
viruses:  IAV, RSV, 
PIV1-3; bacteria:  
Sp, Mp, Cp) 
23% Increased 
inflammation, 
temperature,   
procalcitonin levels, 
pleural effusions, 
hospitalisation and  
ventilation 
requirements 
Culture and PCR 
(blood, pleural 
cavity) 
Okada et al. 2012 
(58) 
CAP 903 hospitalised 
children (<15) 
Japan NA (common 
viruses:  RSV, 
hRV, PIV1-3; 
bacteria:  Sp, Hi, 
Mp) 
18% Increased WBC and 
CRP levels in 
bacteria-only and 
co-infection 
compared to viral-
only infection 
qPCR and culture 
(NP) 
Ricart et al. 2013 
(97) 
Bronchiolitis 484 hospitalised 
infants (<1) 
Spain NA (common 
viruses: RSV, hRV; 
bacteria: Sp) 
3% (bacteria / 
yeast) 
Significantly higher 
number with severe 
clinical score 
Culture (blood, 
urine, lung) 
Kneyber et al. 2005 
(10) 
RSV LRT infection 38 PICU infants 
(<1) 
Netherlands RSV + Sa
1
, RSV + 
Hi
1
 
26% Insignificantly 
longer duration of 
ventilation 
Culture (blood, 
trachea) 
Leung et al. 2014 
(13) 
RSV infection 117 PICU children 
(<18) 
Hong Kong RSV + Sa
1
 12% Insignificantly 
increased mortality 
and duration of stay 
Culture (trachea, 
blood) 
11 
 
Study Disease Population 
(years of age) 
Country Co-detected 
pathogens 
Co-detection 
incidence 
Effect of co-
detection on 
patient 
Bacterial detection 
method 
(sample site) 
Resch et al. 2007 
(9) 
RSV infection 42 hospitalised 
preterm infants 
Austria RSV + Sp
1
 10% Significantly higher 
PICU admission 
and longer 
hospitalisation stays 
Culture (blood, 
urine, stool, 
trachea) 
Cebey-Lopez et al. 
2016 (12) 
RSV infection 66 hospitalised 
children (<2) 
Spain RSV + Hi
1
, 
RSV + Sp
1
 
11% Significantly 
increased PICU 
admission, use of 
respiratory support, 
severity scores and 
number with severe 
respiratory distress 
PCR (blood) 
Thorburn et al. 
2006 (11) 
RSV bronchiolitis 165 hospitalised 
children (<5) 
UK RSV + Hi
1
, RSV + 
Sa
1
, RSV + Mc
1
, 
RSV + Sp
1
 
42% Significantly longer 
ventilatory support 
Culture (lung) 
Suarez-Arrabal et 
al. 2015 (15) 
RSV bronchiolitis 136 hospitalised 
children (<2) 
USA RSV + Hi, RSV + 
Mc 
NA Longer 
supplemental 
oxygen; increased 
cytokine production 
Culture (NP) 
de Steenhuijsen 
Piters et al. 2016 
(14) 
RSV infection 106 children (<2) Netherlands RSV + 
Streptococcus, RSV 
+ Hi 
NA Significantly more 
hospitalisations; 
increased host 
inflammatory 
response 
16S rRNA NGS 
profiling (NP) 
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Study Disease Population 
(years of age) 
Country Co-detected 
pathogens 
Co-detection 
incidence 
Effect of co-
detection on 
patient 
Bacterial detection 
method 
(sample site) 
Stockman et al. 
2010 (102) 
Sa  pneumonia 17 hospitalised 
children (<5) 
Italy RSV + Sa
1
 29% All co-infected 
children were 
admitted to PICU 
and required 
ventilation 
Culture (blood) 
Lauinger et al. 2013 
(103) 
Severe hRV ARI 167 hospitalised 
children (<16) 
UK hRV + Sp
1
, hRV + 
Kp
1
, hRV + 
Pseudomonas 
aeruginosa
1
 
8% Non-viral 
(fungi/bacteria) co-
infections 
associated with 
increased admission 
to PICU 
Culture or immuno-
fluorescence 
(respiratory tract) 
O’Brien et al. 2000 
(46) 
IAV (H1N1) and Sp 
infection 
13 hospitalised 
children (<18) 
USA IAV + Sp 77% Influenza was a risk 
factor for severe Sp 
pneumonia 
Culture (blood, 
pleural cavity) 
Techasaensiri et al. 
2010 (104) 
Invasive Sp disease 129 hospitalised 
children (<18) 
USA IAV + Sp
1
, hRV + 
Sp
1
, AdV + Sp
1
, 
RSV + Sp
1
 
34% Insignificantly more 
frequent PICU 
admission and 
longer PICU stay 
 
 
 
 
 
Culture (from 
normally sterile 
site) 
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Study Disease Population 
(years of age) 
Country Co-detected 
pathogens 
Co-detection 
incidence 
Effect of co-
detection on 
patient 
Bacterial detection 
method 
(sample site) 
Negative or no correlations between co-detection and clinical severity parameters 
Vissers et al. 2016 
(98) 
RSV infection 105 hospitalised 
children (<2) 
Netherlands Correlation between 
RSV and Sp loads 
NA Significantly 
increased cytokine 
production; 
decreased disease 
severity 
qPCR (NP) 
Vu et al. 2011 (99) Pneumonia 550 hospitalised 
children (<5) 
Vietnam RSV + Sp, IAV + 
Sp
1
 
54% None observed PCR (NP) 
Nuolivirta et al. 
2010 (105) 
Bronchiolitis 142 hospitalised 
children (<0.5) 
Finland RSV + Bordetella 
pertussis
1
 
67% None observed B. pertussis PCR 
(NP) 
Duttweiler et al. 
2004 (54) 
RSV bronchiolitis 127 hospitalised 
children (<6) 
Switzerland RSV + Hi
1
, RSV + 
Mc
1
, RSV + Sp
1
, 
RSV + Sa
1
 
44% None observed Culture (trachea) 
Lehtinen et al. 2006 
(57) 
Viral wheezing 220 hospitalised 
children (<16) 
Finland hRV + Sp
1
, RSV + 
Sp
1
, picornavirus + 
Sp
1
, enterovirus + 
Sp
1
 
18% None observed Antibody assays 
(serum) 
1
Not statistically significant in study, or significance not evaluated. AdV (adenovirus), IAV (influenza A virus), IBV (influenza B virus), PIV 
(parainfluenza virus), Cp (Chlamydophila pneumoniae), Kp (Klebsiella pneumoniae), Hi (Haemophilus influenzae), Hp (Haemophilus parainfluenzae), 
Mc (Moraxella catarrhalis), Mp (Mycoplasma pneumoniae), Nm (Neisseria meningitidis), Sa (Staphylococcus aureus), Se (Staphylococcus 
epidermidis), Sp (Streptococcus pneumoniae), NGS (next generation sequencing), NP (nasopharynx), PICU (paediatric intensive care unit), qPCR 
(real-time PCR), WBC (white blood cells), CRP (C-reactive protein). 
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1.4.2 Development of asthma 
The effect of respiratory co-infections during early childhood may extend beyond immediate 
disease presentation and resolution. Events during the first years of life can lead to persisting 
immunological phenotypes that determine the risk of allergic disease and asthma (106), and both 
viruses and bacteria are capable of inappropriately modulating key immune pathways. It is therefore 
conceivable that paediatric viral/bacterial co-infections may play a role in the induction or 
progression of asthma. Multiple wheezy LRT infections in early infancy have been associated with 
increased risk of later development of persistent wheeze, a hallmark of asthma (107, 108). Both 
viral and bacterial infections, including RSV and S. pneumoniae, have been independently 
associated with acute wheezy episodes in young children (109-111), however, few studies have 
investigated the long-term consequences of polymicrobial infections during early life. In school-
aged children, co-detection of hRV with S. pneumoniae or M. catarrhalis has been shown to 
increase the likelihood of asthma exacerbations (112). A recent study of the nasopharyngeal 
microbiota in a longitudinal birth cohort found that colonisation by potentially pathogenic bacteria 
during ARI increased risk of febrile LRT infection and development of asthma (5). Such studies 
highlight the need to understand the short- and long-term consequences of polymicrobial infections 
during early life. 
 
1.5 Mechanisms governing enhanced disease severity 
1.5.1 Synergistic stimulation of inflammation 
The severity of paediatric respiratory infections is closely linked to inflammation and associated 
tissue damage in the airways. Several clinical, in vitro and in vivo studies have found associations 
between viral/bacterial co-infections, increased disease severity and inflammation; however, 
determining the precise contribution of co-infection-induced inflammation to disease severity in 
young children within a clinical setting has been difficult, due to the numerous confounding 
parameters which need to be considered. While increased inflammation in CAP with a mixed viral 
and bacterial aetiology has been reported (53, 58), several studies of paediatric ARI have found 
little difference in clinical parameters of inflammation (including white blood cell counts, C-
reactive protein levels and radiographic findings) between viral only, bacterial only and mixed viral 
and bacterial infections (11, 50, 52). In young children with RSV infections, nasopharyngeal 
colonisation by potentially pathogenic bacteria, particularly Gram negative bacteria like H. 
influenzae, has been associated with increased concentrations of inflammatory mediators like 
interleukin (IL)-6, IL-8 and matrix metallopeptidase 9 (MMP-9) (14, 15, 98). Some of these RSV 
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studies have found that this increased inflammation also correlated with increased measures of 
disease severity, such as hospitalisation or duration of supplemental oxygen (14, 15). However, 
another RSV study found that increased levels of MMP-9 correlated with increased colonisation by 
S. pneumoniae and decreased disease severity (98), suggesting inflammation may have been 
important in controlling infection and disease. These studies suggest that while inflammation is a 
necessary component of an appropriate immune response, required to clear invading pathogens and 
alleviate disease, an overly robust response may lead to immunopathology and the exacerbation of 
symptoms. 
 
Inflammation is induced by signaling cascades upon recognition of specific pathogen components 
by one of a wide array of pattern recognition receptors (PRRs), and considerable overlap exists 
between the inflammatory pathways triggered by viruses and by bacteria, including, for example, 
RSV and S. pneumoniae (Figure 1.1). Innate immune recognition of S. pneumoniae occurs 
primarily at the cell surface by toll-like receptors (TLR) 2 and 4 (113), while RSV is primarily 
detected by the intracellular PPRs RIGI and NOD2 (114). Cytosolic PRRs are also capable of 
recognising components of internalised S. pneumoniae, including NOD2, TLR9 and a currently 
unidentified cytosolic DNA sensor (115-117). RSV has also been shown to trigger TLRs at the cell 
surface (TLR 2/6 and 4) or in intracellular compartments (TLR 3) (118-120). Both S. pneumoniae 
and RSV have been shown to stimulate inflammasome activation (121, 122). The culmination of the 
multiple signalling pathways triggered by S. pneumoniae primarily results in an NF-κB-mediated 
inflammatory response, while RSV infection results in a strong interferon response. There is, 
however, potential for considerable overlap between the signalling pathways triggered by each 
pathogen, which could lead to synergistic stimulation of inflammation during co-infection.  
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Figure 1.1. PRR signalling in response to RSV and S. pneumoniae infection. Research conducted on 
RSV or S. pneumoniae in isolation has identified a number of distinct, and overlapping, signalling 
pathways that are stimulated by detection of these pathogens by intracellular or cell surface-
associated PRRs. Red and blue lines indicate PRR detection of S. pneumoniae and RSV, 
respectively. Black lines show subsequent signalling pathways. Dashed lines indicate interactions 
where the exact mechanism is unknown. AIM2: absent in melanoma 2, IL: interleukin, IKK: IκB 
kinase, IRF: interferon regulatory factor, MyD88: myeloid differentiation primary response gene 
88, NF-κB: nuclear factor κ-light-chain-enhancer of activated B cells, NLRP3: nucleotide-binding 
domain and leucine-rich repeat containing family, pyrin domain containing 3, NOD2: nucleotide-
binding oligomerization domain-containing protein 2, RIGI: retinoic acid-inducible gene 1, STING: 
stimulator of interferon genes, TLR: toll-like receptor, TNF: tumour necrosis factor, TRAF: TNF 
receptor associated factor, TRIF: toll/interleukin 1 receptor domain-containing adapter inducing 
interferon-β. 
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An overly robust inflammatory response could theoretically lead to excessive neutrophil influx and 
a cytokine storm, accentuating lung damage and significantly increasing morbidity. A study of the 
host transcriptome response to RSV infection in young children found that RSV was associated 
with nasopharyngeal microbiota profiles dominated by H. influenzae and Streptococcus (14). 
Compared to other microbiota profiles, young children with H. influenzae and Streptococcus 
enriched profiles had significantly increased hospital admissions and a distinct host inflammatory 
response involving overexpression of genes related to TLR signaling and neutrophil recruitment and 
activation (14). Synergistically enhanced RSV-induced cytokine production has been reported in 
immortalised and primary bronchial epithelial cells lines after pre-exposure to H. influenzae (123). 
In the lungs of mice, neutrophils, other inflammatory infiltrates and pro-inflammatory cytokines 
have been observed during IAV or RSV and bacterial co-infection (124-128). RSV has also been 
shown to augment the inflammatory response of PRRs upon recognition of Gram positive bacterial 
cell wall components (129). This influx of neutrophils and other inflammatory mediators may cause 
lung injury without effectively clearing bacterial pathogens (7). Tissue damage may be further 
exacerbated by the downregulation of lung repair responses, as shown during IAV/bacterial co-
infection of mice (125, 130). Supporting these findings, the suppression of excess inflammation 
during co-infection has been shown to be important for protection from severe disease in mice, 
mediated through the induction of glucocorticoids and anti-inflammatory cytokines (127, 131). 
 
1.5.2 Viral modulation of bacterial virulence  
It has also been suggested that virus-induced inflammation, tissue damage and fever may trigger 
changes in bacterial gene expression, resulting in a more pathogenic phenotype. Temperature 
increases modelling fever have been found to trigger the expression of immune evasion factors in 
the opportunistic pathogen Neisseria meningitidis (132). Fever and other host cell damage signals 
induced by IAV infection have been shown to stimulate S. pneumoniae biofilm dispersal, leading to 
bacteria with an increased ability to disseminate from the nasopharynx of mice, resulting in 
infection of sites such as the lung and the blood (133, 134). Corroborating these studies, Leung et 
al. (135) found the microbiome of IAV positive patients contained significantly higher expression 
levels of genes involved in cell motility and signal transduction, such as chemotaxis and flagellum 
assembly, compared to those of IAV negative pneumonia patients. Furthermore, extensive 
alterations in pneumococcal gene expression have been observed in both IAV-dispersed S. 
pneumoniae and S. pneumoniae after direct binding to RSV, both of which were associated with 
increased pneumococcal virulence in mice (128, 134).  
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1.6 Viral promotion of bacterial colonisation and outgrowth 
1.6.1 Increased bacterial adherence 
Bacterial colonisation of the URT is thought to be required for subsequent infection of the airways. 
Respiratory viruses have been shown to promote bacterial colonisation and augment the outgrowth 
of opportunistic pathogens within the respiratory microbiota. Viral infection of airway epithelial 
cells has been found to aid bacterial adherence to the URT by a number of mechanisms, although 
the effect differs between viruses, bacterial strains and experimental models. Free RSV virions have 
been shown to bind directly to H. influenzae and S. pneumoniae (128, 136, 137), which could 
through proximity augment each pathogen’s binding to their respective host cell receptors (Figure 
1.2A). There is also some evidence that the RSV G glycoprotein, localised at the host cell 
membrane of virus infected cells, can act as a receptor for bacteria (Figure 1.2B) (136, 137). The S. 
pneumoniae membrane-associated enzyme penicillin binding protein 1a (PBP1a) has recently been 
identified as one of the binding partners of RSV G (128).  
 
Respiratory viruses can also upregulate the expression of host cell surface proteins to which 
respiratory bacteria can then bind (Figure 1.2C) (128, 138-145). For example, host and 
pneumococcal transcriptomics have demonstrated the upregulation of a human fibronectin-domain 
containing protein (FND3A) by PIV3, while the bacterial fibronectin-binding gene glnQ was shown 
to be upregulated in S. pneumoniae adhering to PIV3 infected cells (146). RSV and PIV3 have also 
been shown to upregulate host cell receptors like platelet activating factor receptor (PAFR) to which 
bacterial cell wall-associated phosphorylcholine can then bind (138, 147). Additional host cell 
receptors for bacterial adherence have been found to be exposed by viral neuraminidase activity 
(148, 149). Virus-induced cell death has also been suggested to lead to exposure of the epithelial 
basement membrane and receptors like fibronectin, to which bacteria have been shown to adhere 
(Figure 1.2D) (94-96, 150). 
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Figure 1.2. Mechanisms of virus-mediated bacterial adherence to URT epithelium. S. pneumoniae 
and RSV are used as an example; however, similar mechanisms of interaction have been reported 
between common airway bacteria and IAV, PIVs, hRVs and human adenovirus. Direct binding 
between a virion and a bacterium has been reported, and the virion may as a bridge aiding bacterial 
adhesion (A). S. pneumoniae has been shown to bind directly to RSV G glycoprotein, through 
penicillin binding protein 1a (PBP1a). Attachment of RSV fusion protein to host cell receptors will 
then bring S. pneumoniae into close proximity to the host epithelia, increasing the potential for 
subsequent attachment of the bacterium to host receptors. During viral infection, viral glycoproteins 
are expressed at the host cell surface, and these can act as additional receptors for bacterial 
adherence, such as RSV G (B). Viruses have been shown to increase expression of host cell surface 
molecules to which bacteria can bind (C). For example, RSV may modulate human platelet 
activating factor receptor (PAFR) expression, which binds to phosphorylcholine in the cell wall of 
S. pneumoniae, while viral upregulation of human fibronectin type III domain containing protein 
(FND3A) has been shown to be concurrent to upregulation of a fibronectin-binding protein (glnQ) 
in S. pneumoniae. Virus-mediated epithelia damage can lead to exposure of the basement 
membrane and additional receptors for bacteria attachment, e.g. fibronectin and pneumococcal 
adhesion and virulence A (pavA) (D). 
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1.6.2 Decreased bacterial clearance 
The respiratory epithelial layer is the first line of defence against bacterial infection and viral 
disruption of this barrier can lead to ineffective bacterial clearance. Impairment of mucociliary 
function by IAV, RSV and adenovirus has been shown to lead to decreased clearance of S. 
pneumoniae and H. influenzae (128, 151, 152). Decreased clearance of H. influenzae by RSV has 
also been observed in the chinchilla nasopharynx, mediated by decreased expression of 
antimicrobial peptides (153). 
 
Virus-induced dysfunction of bacteria phagocytosis by innate immune cells may also decrease 
bacterial clearance in the respiratory tract. Both macrophages and neutrophils are important for 
controlling S. pneumoniae colonisation and disease; however, IAV has been shown to induce 
alveolar macrophage cell death, impairing early pneumococcal clearance (154). Synergistic 
stimulation of type I interferons by IAV and S. pneumoniae has been found to decrease macrophage 
recruitment in murine lungs (155), while virus-induced interferon-γ was shown to suppress 
macrophage phagocytosis of pneumococci (156). Neutrophil recruitment has also been shown to be 
downregulated by IAV, through suppression of cytokine and chemokine production triggered by 
virus-induced glucocorticoids and type I interferons (131, 157). This suppression of lymphocyte 
recruitment by IAV, resulting in reduced bacterial clearance, contrasts with the RSV and bacterial 
synergistic increases in inflammatory cell infiltrates discussed in Chapter 1.5.1 as a mechanism of 
enhanced disease severity, highlighting the complex and specific nature of viral and bacterial 
interactions in the respiratory tract. 
 
1.7 Bacterial modulation of viral infections 
Several studies have now shown that the presence of a specific bacterial species may promote viral 
infection in the respiratory tract. A double-blind, placebo-controlled trial of over 37,000 young 
children in South Africa demonstrated that immunisation against 9 pneumococcal serotypes not 
only reduced the incidence of pneumonia due to S. pneumoniae, but also prevented approximately 
33% of pneumonias associated with respiratory viruses (91). The authors of the study suggested that 
the reduction of virus-associated pneumonia was due to prevention of superimposing bacterial co-
infection, thereby decreasing severity. It is also possible that a reduction in S. pneumoniae carriage 
could reduce children’s susceptibility to viral infection. Similarly, it has been shown that higher 
seroconversion rates to MPV in children under two years of age are associated with nasopharyngeal 
carriage of S. pneumoniae (158). In vitro, pre-incubation of human bronchial epithelial cells with S. 
pneumoniae was also shown to increase cell susceptibility to MPV infection (158). Enhanced RSV 
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and MPV infection of primary epithelial cells has been demonstrated by the simultaneous addition 
of synthetic bacterial lipopeptides or S. pneumoniae, suggesting bacterial presence could promote 
viral infection by facilitating viral attachment to host cells (159, 160). These results were replicated 
in vivo, where pneumococcal colonisation of the nasopharynx of cotton rats enhanced RSV 
infection (160). While most research has focused on S. pneumoniae, H. influenzae has been shown 
to enhance hRV infection, by stimulating expression of viral host cell receptors (161, 162). 
Stimulation of immortalised bronchial epithelial cells by H. influenzae prior to RSV infection has 
also been shown to contribute to virus-induced cytokine production, although no effect was 
observed on virus replication (123). 
 
Bacteria may also contribute to elevated virion production or release from airway cells. Subsequent 
S. pneumoniae challenge after IAV infection has been found to cause an increase in viral titres 
(163). A mathematical model established that the increase was likely due to bacterial enhancement 
of virion production and release from infected cells (163). S. aureus proteases have been found to 
cleave and thereby activate IAV haemagglutinin in a viral and bacterial strain-dependent manner, 
increasing viral replication in the lungs of mice (164). Bacterial neuraminidase has also been shown 
to rescue influenza viruses from inhibition of viral neuraminidase, suggesting pneumococcal and 
influenza neuraminidases may synergistically promote virion release (165). Increased expression of 
pneumococcal neuraminidase genes has also been demonstrated upon exposure to RSV infected 
differentiated airway epithelial cells compared to mock infection (128). Unlike influenza viruses, 
RSV does not contain any neuraminidase activity. However, bacterial neuraminidase treatment has 
been shown to enhance RSV infection in vitro (160, 166). Specifically, treatment of differentiated 
bronchial epithelial cells with commercially available bacterial neuraminidase resulted in a dose-
dependent enhancement of RSV infection (160).  However, pneumococcal neuraminidase activity 
did not correlate with enhanced RSV infection in an in vitro model of RSV infection after S. 
pneumoniae colonisation (160). While the exact role of pneumococcal neuraminidase in RSV 
infection may be unclear, evidence from IAV/S. pneumoniae co-infection studies suggest it may be 
possible to design therapeutics that target enzyme activities shared by both viral and bacterial 
pathogens. Influenza neuraminidase inhibitors have been shown, in both in vitro and in vivo studies, 
to have the capacity to inhibit S. pneumoniae neuraminidase activity (167-169). Such inhibitors, if 
found to be effective in humans, could represent potential treatment options for IAV/S. pneumoniae 
co-infections.  
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1.8 Viral and bacterial co-transmission 
Given the transmission of both respiratory viruses and bacteria occurs through respiratory 
secretions, it is logical to hypothesise that bacteria and virus may be simultaneously passed on to 
new hosts. Studies of IAV/S. pneumoniae co-infection in mice and ferrets have found IAV infection 
can enhance S. pneumoniae acquisition (170, 171). The effect was more robust when contact 
animals acquiring S. pneumoniae were pre-infected with IAV; however, bacterial colonisation was 
still increased when donor animals were infected with IAV before transmission to IAV-naive 
contact animals (171). In contrast, S. pneumoniae colonisation of cotton rats followed by RSV 
infection has not been shown to result in transmission of either virus or bacteria to contact animals 
(160). The alternative hypothesis, that RSV infection could enhance S. pneumoniae acquisition, was 
not investigated in the study. 
 
Both viruses and bacteria have been shown to promote fluid accumulation in the airways by altering 
ion transport of the respiratory epithelia, which is expected to facilitate transmission between hosts 
(172, 173). Co-transmission of viral-bacterial complexes, formed from direct binding of bacterium 
and virion, could be enhanced by synergistic increases in respiratory secretions. Studies of 
households and childcare centres have shown simultaneous carriage of viruses and bacteria in the 
respiratory tract and separate transmission of viral or bacterial agents between children (174-176). 
However, to date specific co-transmission of viruses with bacteria in such environments has not 
been clearly demonstrated. Elucidation of the role of co-transmission and the synergistic 
mechanisms that underpin paediatric respiratory co-infection is important for our understanding of 
respiratory health during early childhood and may lead to changes in clinical treatments and 
management protocols. 
 
1.9 RSV 
1.9.1 Significance 
Given the importance of RSV as a paediatric pathogen (3), and the evidence suggesting that 
clinically relevant interactions may occur between the virus and potentially pathogenic respiratory 
bacteria (6), RSV was the viral pathogen focused on in this project. Since no vaccine is currently 
available and palivizumab prophylaxis is only used in high risk cases, the incidence of RSV is high, 
with the majority of young children experiencing an RSV infection at least once before the age of 
two years (177). While disease presentation is often mild with cold-like symptoms, it can progress 
to severe LRT infections and with no antivirals available, treatment is limited to supportive care. 
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Globally, RSV is responsible for an estimated 200,000 deaths and over three million 
hospitalisations per year (3). The virus is commonly transmitted through direct and indirect contact 
with large respiratory droplets (178). In temperate climates seasonal RSV epidemics occur during 
the winter months, while in subtropical and tropical climates peak incidences occur in the rainy 
season, where the high humidity is thought to prolong virion survival in respiratory droplets (179). 
 
1.9.2 Virology 
RSV is an enveloped virus and as of 2016 is classified as an Orthopneumovirus from the family 
Pneumoviridae (180). Its single stranded, negative sense RNA genome is around 15,000 nucleotides 
in length and encodes for eleven proteins. The polymerase (L), phosphoprotein (P) and 
transcriptional regulators (M2-1 and M2-2) are involved in RNA synthesis, while the nucleocapsid 
protein (N) encapsidates and protects the RNA genome (181). The non-structural proteins (NS1 and 
NS2) are involved in host immune evasion, including inhibition of the type I interferon response 
(182, 183). The matrix protein (M) forms part of the inner envelope surface, while the small 
hydrophobic (SH), fusion (F) and attachment (G) proteins are transmembrane surface glycoproteins 
(181). G and F are both involved in virus entry (host receptor binding and virion fusion with the 
host cell membrane, respectively) and are the major targets of the host humoral immune response 
(184). 
 
1.9.3 Genetic diversity 
Two subtypes of RSV have been described, RSV-A and RSV-B, based on antigenic characterisation 
of F and G using monoclonal antibodies (185, 186), with the main differences between virus strains 
found in G (186). Analysis of differences in genomic sequences between virus strains has also 
confirmed both the existence of two distinct subtypes and the widest variation in the G gene (187-
192). For this reason genotyping of RSV strains has been based on partial or complete sequencing 
of G (190). The ectodomain of G contains two hypervariable regions separated by a putative 
receptor binding domain that is conserved in both RSV-A and RSV-B. The second C-terminal 
hypervariable region (HVR2) is sufficient for distinguishing between subtypes and has thus been 
used by the majority of studies investigating RSV genetic diversity (190, 193-204). More recently, 
whole genome sequencing has also been applied to RSV strains from various clinical settings (188, 
189, 191, 192), adding valuable information to our understanding of RSV evolution.  
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Based on G, many genotypes of both RSV-A and RSV-B have been described, some circulating 
locally and many globally (188, 192). Co-circulation of multiple subtypes and genotypes has been 
frequently reported in a single RSV season, although usually one genotype is predominant (189-
194, 196-202, 204-209). Within a population the prevalent RSV subtype and genotype has been 
reported to shift every few years (190, 193, 194, 199, 201, 205, 206, 209), most likely due to short-
lived, specific herd immunity (210). Genotype replacement has also been observed, where the 
emergence of a new genotype has appeared to have had a selective advantage, resulting in the 
replacement of previous lineages by the new genotype in a population (194, 205, 206, 209). 
Genotype replacement was clearly observed in RSV-B strains in the early 2000s. A 60 nucleotide 
duplication event in HVR2 of an RSV-B strain was first observed in 1999 in Buenos Aires 
(genotype BA) (211) and rapidly spread worldwide (212). At least twelve BA sub-genotypes have 
now been described (194, 206, 212, 213), and they are consistently identified as the predominant 
RSV-B strains in seasonal epidemics (188, 189, 191-196, 200, 202, 206, 208, 209, 214). In RSV-A, 
global patterns of RSV epidemics demonstrate that in the mid 1990s genotypes GA2 and GA7 were 
prevalent, with the emergence of GA5 and the divergence of GA2 into NA1 and NA2 in the 2000s 
(188, 194, 201). In 2010, an NA1 variant with a 72 nucleotide duplication in HVR2 was identified 
in Ontario, Canada (genotype ON1) (203, 207). ON1 and similar NA1 variants with the large 
duplication have since been reported worldwide, although they have yet to replace GA2, NA1 and 
GA5 in the population (192, 194, 195, 197, 198, 202, 203, 215, 216).   
 
The clinical significance of different RSV subtypes and genotypes is currently unclear. Early 
paediatric studies comparing the severity of RSV-A and RSV-B infections found either RSV-A was 
associated with increased disease severity (217), or no difference between subtypes (218, 219). 
More recent studies comparing disease severity between genotypes have also been inconclusive, 
with some studies finding no difference in severity measures between circulating RSV-A and RSV-
B strains (200, 202, 220), and others finding increased severity in RSV-A genotypes (221, 222). 
Within RSV-A, there is also mixed evidence on the clinical significance of ON1 compared to other 
genotypes. ON1 has been reported to be associated with increased ARI severity (223), reduced 
severity (195, 197) and no difference between ON1 and other circulating RSV strains (202). 
Discrepancies between studies are probably in part due to the many factors that can confound any 
clinical study of paediatric ARI, as previously discussed in Chapter 1.4.1. However, it has been 
suggested that successful new genotypes may possess novel antigenicity and thus ability to evade 
host immunity, resulting in hospitalisation spikes on introduction to a naive population, such as 
associated with the emergence of ON1, without an inherent ability to cause more severe disease 
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(197, 201). This hypothesis is consistent with the increases in hospital and ICU admissions 
associated with ON1 compared to other RSV strains (197, 198), and the large epidemics associated 
with NA1 and NA2 when they first emerged in Japan in the mid 2000s but not observed since 
(201). 
 
1.10 Streptococcus pneumoniae 
1.10.1 Significance 
S. pneumoniae has been shown to have clinically relevant interactions with RSV and other 
respiratory viruses (6), thus it was the main bacterium of focus for this thesis. Even with wide-
spread pneumococcal vaccine use, S. pneumoniae carriage is estimated to be 30-60% in children 
under five years of age (75-77, 224) and can be up to 80% in low-income countries (225). Invasive 
pneumococcal disease (IPD) is the most severe form of S. pneumoniae infection, and includes 
meningitis, septicaemia or bacteremic pneumonia. In Australia in 2015, the annual rate of IPD in 
children aged under five years was estimated at over 12 per 100,000 (226). It is more difficult to 
estimate the incidence of pneumococcal pneumonia without IPD in the paediatric population, since 
only confirmed IPD cases are notifiable in Australia and epidemiological studies must rely on 
hospitalisation coding; however, between 2005-2007 (before the introduction of the most recent 
pneumococcal conjugate vaccine) it was estimated that the hospitalisation rate of children under 
five years due to pneumococcal pneumonia was between 5-8 per 100,000 (227). Antibiotic 
resistance is a growing problem with many bacterial pathogens, and resistance has been observed in 
S. pneumoniae to both first- and second-line antibiotics commonly used to treat bacterial pneumonia 
(75-77, 81).  
 
Children can acquire several different strains of S. pneumoniae over time through respiratory 
droplets and acquisition is known to be increased by increased contact with other (older) children, 
such as with siblings and at childcare centres (22, 224). Similar to many respiratory pathogens, 
incidences of pneumococcal pneumonia and IPD peak in the winter months (226, 227), possibly in 
part due to triggers by respiratory virus activity. Studies of pneumococcal disease activity in 
children have found associations between IPD and hospitalisations due to respiratory viral 
infections in the preceding four weeks (92, 228-233). RSV activity specifically has been associated 
with variations in the incidence of bacteremic pneumonia in young children (234).  
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1.10.2 Bacteriology 
S. pneumoniae is a Gram positive, encapsulated diplococcus from the Firmicutes phylum. The 
polysaccharide capsule is an essential virulence factor and is used to serotype S. pneumoniae 
isolates. At least 97 serotypes of S. pneumoniae have been identified to date (235). Because the 
capsule is the major target of the immune system, vaccine design has focused on generating an 
immune response against the polysaccharide capsule (236). Although cross protection against 
closely related serotypes can occur, immunity following infection is usually serotype specific (237-
240). Current vaccines licensed for use in humans only provide protection against a subset of 
serotypes deemed to be the most pathogenic, particularly those associated with invasive disease. 
Many serotypes can cause non-invasive disease and the distribution of serotypes varies over time 
and between ages, clinical presentation and geographic region (240-242). Before the development 
of the current pneumococcal vaccines it was estimated that 6-11 serotypes were responsible for over 
70% of all IPD in children aged under five years worldwide (243). These serotypes included 1, 5, 
6A, 6B, 14, 19F, and 23F. Serotypes 1, 5 and 14 together accounted for 28-43% of IPD globally, 
including in Africa and Asia where pneumococcal disease morbidity and mortality are the highest, 
while serotype 18C was common in high-income countries (243).  
 
Vaccines based on the polysaccharide capsule of these most important disease-associated serotypes 
have been continually developed, with protection against increasing numbers of serotypes. Two S. 
pneumoniae vaccines are currently part of the National Immunisation Program in Australia; the 23-
valent pneumococcal polysaccharide vaccine (PPV23) and the 13-valent pneumococcal conjugate 
vaccine (PCV13) (244). Pneumococcal polysaccharide vaccines have poor immunogenicity in 
children < 2 years of age and in Australia PPV23 is only recommended for adults aged > 65 years 
and medically at risk children (244), thus PPVs will not be discussed further. PCVs involve the 
chemical coupling of serotype-specific S. pneumoniae polysaccharides to an immunogenic protein 
carrier, which enables an adequate immune response to the vaccine to be generated by young 
children. PCV13 provides protection against serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 
19F, and 23F. In Australia it is administered in three primary doses at 2, 4 and 6 months of age, 
with a booster at 18 months of age for medically at risk children (244). PCV13 replaced the 7-valent 
PCV7 (protection against 4, 6B, 9V, 14, 18C, 19F and 23F) in the National Immunisation Program 
in July 2011. A single supplementary dose of PCV13 was also available from October 2011 to 
October 2012 for children aged 12-35 months who completed primary immunisation with PCV7 
(244). 
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Wide spread use of PCVs have dramatically decreased the incidence of pneumococcal disease due 
to vaccine serotypes in children aged < 5 years (79, 80, 227, 245). However, there is some concern 
that vaccination against only a subset of serotypes promotes replacement by non-vaccine strains that 
could then cause serious disease (22). This serotype replacement was observed in some settings 
after the introduction of PCV7, where hospitalisation increases were observed due to IPD caused by 
non-PCV7 serotypes, such as 19A, although the overall IPD incidences generally remained lower 
than in the pre-PCV7 era (79-81). Reports investigating serotype replacement resulting from 
PCV13 usage have not yet observed a negative effect on hospitalisation rates (245), however, 
increases in carriage of non-vaccine serotypes have been observed in young children since 
introduction of PCV13, particularly 23B and 15A/B/C (75, 76).  
 
To predict and monitor serotype replacement, accurate surveillance of pneumococcal serotypes 
involved only in carriage and those that are associated with disease is important. The gold standard 
method for serotyping S. pneumoniae isolates is the Quellung reaction, which involves microscopic 
evaluation of bacterial colonies after testing with type-specific antisera. The Quellung reaction is 
both laborious and expensive, as a complete set of antisera is required for correct identification. 
There has therefore been a shift to molecular serotyping methods, including multiplex sequential 
PCR (246), microarray (235) and sequencing of capsular genes (capsular sequence typing) (247). 
These methods are appropriate for typing individual isolates (246, 247) and the majority can 
effectively detect the dominant serotype in a clinical sample, however, most are not capable of 
detecting minor serotypes when multiple serotypes are present (235). A recent study evaluating 
serotyping methods for investigation of pneumococcal carriage in the population found that culture 
amplification followed by microarray out-performed other methods (235). 
 
1.10.3 Genetic diversity 
The genome of S. pneumoniae is approximately two million nucleotides in length. Most strains can 
uptake DNA from the environment, resulting in genetic variability through horizontal gene transfer, 
the acquisition of novel genes from donor organisms, and homologous recombination (248, 249). 
The species thus has a set of core genomic sequences shared by all strains, and a set of accessory 
genome sequences only present in a subset of isolates (together referred to as the pan-genome) 
(249-251). Between strains, isolates share approximately 74% of their core genome, with 
homologous recombination the driving evolutionary process for diversity (250). Phylogenetic 
analyses of polymorphisms in the core genome of 44 S. pneumoniae strains have identified six 
major lineages of genetically related strains (249, 250). These clusters generally correlated poorly 
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with capsular serotype, geographic location and disease- or carriage-associated isolates (249, 250). 
Furthermore, while most genes known to be associated with pathogenicity were shared by all 
strains, they were also present in non-pathogenic strains of the closely related species Streptococcus 
mitis, Streptococcus oralis and Streptococcus infantis (249, 250). Differences in core genome 
content between pneumococcal isolates responsible for bacteraemia and meningitis have also not 
correlated with disease presentation (252). Thus, core genome variability alone is insufficient to 
determine the virulence of a particular strain. 
 
While whole genome sequencing provides the most valuable information about a strain, for large 
numbers of isolates the cost can be prohibitive. Multilocus sequence typing (MLST) is an 
alternative method to assess core genetic diversity of bacteria, involving the sequencing regions of 
multiple (usually seven) housekeeping genes and the assigning of an allele for each gene based on 
the different sequences present within the species (253). The set of alleles forms an allelic profile 
that defines a sequence type (ST). For S. pneumoniae, 400-500 nucleotide regions of the seven 
housekeeping genes aroE, gdh, gki, recP, spi, xpt and ddl are sequenced (254). STs can be further 
grouped into clonal complexes based on their similarity to a central allelic profile, with the 
assumption that they share a recent common ancestor. Generally, phylogenies inferred from MLST 
data correlate well with phylogenies inferred from whole genome analysis (250, 255). In this 
project, both MLST and molecular capsular serotyping were used to assess the diversity of a panel 
of S. pneumoniae strains isolated from children with ARI symptoms. 
 
1.11 Scope of thesis 
1.11.1 Aims 
The aim of this thesis is to advance our understanding of the role of potentially pathogenic bacteria 
such as S. pneumoniae during RSV infections in young children. In summary, the work conducted 
for this thesis had four main aims: 1) to determine the contribution of potentially pathogenic 
bacteria to disease severity during paediatric ARI; 2) to establish the effect of RSV infection on S. 
pneumoniae colonisation dynamics in young children; 3) to investigate the genetic diversity of S. 
pneumoniae and RSV strains co-occurring in young children; and 4) to evaluate the binding 
interactions of different pneumococcal strains to RSV in airway epithelial cell culture. 
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1.11.2 Research chapter outline 
Each research chapter in this thesis addresses one of the four aims summarised in Chapter 1.11.1, 
investigated in three different cohorts (outlined in Figure 1.3). The work conducted for Chapter 2 
aimed to further clarify the clinical significance of bacterial interactions with RSV, as there is 
conflicting evidence from previous studies surrounding bacterial enhancement of disease severity 
during paediatric RSV infection (Table 1.1). Nasopharyngeal colonisation by potentially pathogenic 
bacteria was therefore investigated in a prospective clinical cohort of infants and young children 
with severe viral ARI. RSV and S. pneumoniae co-detection was associated with increased disease 
severity; thus, the remainder of this thesis focuses on interactions between these two pathogens.  
 
While the study described in Chapter 2 established a pathogenic role for S. pneumoniae during 
severe paediatric RSV infections, the majority of RSV infections in young children do not result in 
a hospital visit (177). The work conducted in Chapter 3 aimed to determine the interaction 
dynamics of RSV and S. pneumoniae across the spectrum of illness, from asymptomatic infection to 
LRT infection. S. pneumoniae colonisation patterns were therefore investigated in a longitudinal 
community cohort of young children before, during and after an RSV infection, using capsular 
sequence typing to differentiate between pneumococcal strains. Approximately one third of young 
children with RSV infections were colonised by S. pneumoniae prior to the RSV detection, and in 
the subset of samples analysed, the pre-existing pneumococcal strain colonising the URT in health 
was found to persist during and immediately after the RSV detection. While the dominant 
pneumococcal strain remained constant within a child, between children a variety of pneumococcal 
strains were observed, consistent with the wide diversity previously observed in S. pneumoniae 
strains colonising young children (75, 76). 
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Figure 1.3. Outline of aims of thesis, cohorts utilised and corresponding thesis research chapters 
structure. 
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The diversity of S. pneumoniae strains observed in the study described in Chapter 3, and the known 
diversity of RSV strains in the paediatric population (188, 236) led to the question investigated in 
the final two research chapters of this thesis: do specific RSV and S. pneumoniae strains interact 
preferentially with each other? There is evidence that RSV and S. pneumoniae can synergistically 
interact in cell culture and animal models through binding interactions between the bacteria and the 
RSV G glycoprotein, the extent of which appears in part dependent on the pneumococcal strain 
(128, 136, 137, 140). However, previous binding studies of RSV and S. pneumoniae have been 
performed with a small range of pneumococcal isolates and cell culture-adapted RSV strains, which 
may not closely resemble those circulating and potentially interacting in the paediatric population. 
In Chapter 4, the capsular and core genetic diversity of S. pneumoniae and the genetic diversity of 
the RSV G gene were therefore simultaneously investigated in a cohort of young children with ARI 
symptoms. In Chapter 5, the effect of pneumococcal strain variation was investigated in vitro by 
evaluating binding interactions between RSV and S. pneumoniae in cell culture using the S. 
pneumoniae strains isolated from the Chapter 4 cohort.  
 
Ideally, the severe ARI cohort described in Chapter 2 or the community cohort described in Chapter 
3 would have been optimal to perform the diversity study and in vitro experiments. However, the 
molecular methods of RSV and S. pneumoniae strain characterisation for Chapter 4 required 
substantial concentrations of pathogen DNA from the provided nucleic acid extracts, and the 
experiments for Chapter 5 required bacteria isolation through culture from clinical samples. Access 
to both raw samples and large quantities of nucleic acid extracts from our collaborators was limited, 
as both studies were part of larger cohort investigations involving multiple collaborating groups 
who required access to samples and extracts. As a time- and cost-effective alternative, I accessed 
data and S. pneumoniae isolates from a paediatric ARI study that I had previously published with 
collaborators, where viral and bacterial co-detection was investigated during symptoms of ARI in 
young children. The advantages of this cohort included previously performed RSV typing, allowing 
investigation of G protein variation with bacterial co-detection patterns, and bacterial detection by 
culture, allowing isolation, characterisation and subsequent experimentation with S. pneumoniae 
strains co-detected with RSV and other respiratory viruses.         
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2. Effect of RSV and S. pneumoniae co-detection on disease severity during paediatric ARI 
2.1 Introduction 
As previously discussed in Chapter 1.4, the clinical significance of RSV/bacterial co-infections 
during paediatric ARI is currently unclear, although current evidence suggests co-detection of S. 
pneumoniae or H. influenzae may be associated with more severe RSV infections in young children 
(9-11, 13-15). The majority of paediatric ARI studies investigating associations between specific 
viral and bacterial interactions and disease severity have taken place in temperate climates in the 
northern hemisphere (9-11, 14, 15, 54, 57, 98). These climates are characterised by distinct seasonal 
epidemics of respiratory viruses peaking in winter each year (179). Seasonal shifts in the URT 
microbiota of healthy children have also been observed in temperate climates (20). In contrast, in 
the moderate climate of Perth, Australia, only limited seasonal effects on the nasopharyngeal 
microbiota have been observed in young children (5).  
 
The setting of the study investigated in this chapter, Brisbane, Australia, has a subtropical climate 
with only moderate variations in temperature over the year, where the RSV seasonal epidemic 
peaks early in the year during the rainy season (March-April) or in the winter months in relatively 
dry years (56, 179). Differences in the climate and environment of study locations may affect the 
carriage of respiratory viruses and bacteria, thereby influencing the potential for clinically 
significant interactions to occur between pathogens. We (1) and others (56) have previously found 
increased co-detection of H. influenzae and S. pneumoniae with RSV in Brisbane-based cohorts of 
children with ARI, however neither of these studies investigated the effect of the co-detections on 
disease severity. While there is no reason to assume that these possible effects would be any less 
severe than those studied in other climates, due to the conflicting evidence concerning the 
relationship between viral and bacterial co-detections and disease severity, a number of studies from 
diverse populations are required to fully understand the complex interactions of potential pathogens 
in the respiratory tract and their effect on host disease (6). In this study, the respiratory viruses and 
bacteria present during viral ARI were further characterised in a cohort of young children aged less 
than two years presenting at the emergency department (ED) of a Brisbane children’s hospital. The 
effect of co-detections on disease severity was also investigated, using hospitalisation, use of 
supportive care and a clinical disease severity score as measures of severity. 
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2.2 Materials and methods 
2.2.1 Study population and sample collection 
Collaborators at The University of Queensland (UQ) Child Health Research Centre (CHRC) 
prospectively recruited young children aged less than two years from those presenting with 
symptoms of bronchiolitis, wheeze or asthma to the Royal Children’s Hospital, Brisbane, between 
September 2011 and October 2014, as part of the Protective Immunity in Special Populations 
(PISP) cohort. Participants were excluded if they had serious co-morbidities, gestational age < 37 
weeks, gestational weight < 2.5 kg or required significant resuscitation. Upon study enrolment, 
previous medical history and current treatments were recorded, including admission to hospital, use 
of supplemental oxygen and use of assisted ventilation. Severity of illness was evaluated using a 
criteria-based scoring system that evaluated clinical criteria including oxygen saturation, inspiratory 
breath sounds on auscultation, expiratory wheeze, use of accessory muscles of respiration and 
cognitive state (Table 2.1). The criteria culminated in a single clinical disease severity score 
between 0 (well) and 10 (severe disease). Nasopharyngeal aspirates (NPAs) were taken by trained 
personnel following routine procedures, centrifuged and the supernatant stored at -80°C. 
 
Table 2.1. Criteria-based scoring system for quantifying clinical disease severity. 
Criteria 0 points 0.5 points 1 point 2 points 
Oxygen 
saturation  
> 95% in room 
air  
90-95% in room 
air  
> 95% on 
oxygen  
< 90% on 
oxygen  
Inspiratory 
breath sounds  
Normal  Slightly unequal  Markedly 
unequal  
Decreased / 
absent  
Expiratory 
wheezing  
None  Mild  Moderate  Marked  
Accessory 
muscles  
None  Mild  Moderate  Maximal  
Cerebral 
function 
Normal  Agitated when 
disturbed  
Depressed / 
agitated  
Markedly 
depressed / 
coma  
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Six to eight weeks later, participants were requested to return for a convalescent visit, after 
symptoms had resolved. Current symptoms (if any) were recorded and children with evidence of 
sinus or ear infections were excluded. Nasal swabs (2011- 2012) or nasal washes (2013-2014) were 
collected by trained personnel following routine procedures and stored at -80°C. 
 
The study was approved by the human research ethics committee of Children’s Health Queensland 
Health and Hospital Service (approval number HREC/11/QRCH/47). Parents gave written consent 
for their children to participate in the study. 
 
2.2.2 Pathogen detection 
Nucleic acid extraction and virus screening were carried out by the Queensland Paediatric 
Infectious Diseases Laboratory (UQ CHRC). Briefly, specimens were tested for 17 viruses using 
previously validated and published real-time PCR assays (256). Virus detection included RSV-A, 
RSV-B, PIV1-3, IAV, influenza B virus, hRV, MPV, human adenovirus, human bocavirus, human 
enterovirus, polyomaviruses WU and KI and coronaviruses HKU1, OC43, NL63 and 29E. Samples 
were extracted on the Qiagen X-tractor gene (Qiagen, Australia) according to manufacturer’s 
instructions. The extraction efficiency was assessed by spiking samples with a known concentration 
of Equine Herpes virus, and the quality of specimen collection was assessed by testing for the 
presence of a marker of human genomic DNA, endogenous retrovirus 3 (ERV3). All PCR reaction 
master mixes used Quantitect Probe PCR mix (Qiagen, Australia) for DNA viruses and One-Step 
RT-PCR kit (Qiagen, Australia) for RNA viruses. 
 
Purified nucleic acid extractions were then made available to our laboratory for bacterial screening. 
The load of S. pneumoniae, M. catarrhalis and H. influenzae for each sample was determined using 
quantitative real-time PCR assays for pneumolysin (ply) (68), outer membrane protein B (copB) 
(67) and protein D (hpd) (69),  respectively. Since cross-reactivity of ply has been reported between 
closely related Streptococcus species, the presence of S. pneumoniae was confirmed through a real-
time PCR assay for autolysin (lytA) (66). The total microbial load of each sample was estimated 
using a quantitative real-time PCR assay targeting the 16S ribosomal RNA (rRNA) gene (forward 
primer: 5’-GYACWCACCGCCCGT, reverse primer: 5’ AAGGAGGTGWTCCARCC, provided by 
the Australian Centre for Ecogenomics, UQ). Absolute quantification was carried out using a 
standard curve of 10-fold dilutions of a pGEM-T easy plasmid (Promega, Sydney, Australia) 
containing the cloned target gene, quantified by the average of three readings from the NanoDrop 
Spectrophotometer ND-1000 (Thermo Fisher Scientific, Australia) and converted to estimated 
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genome copies per µl (or gene copies per µl for the 16S assay). Extracts were diluted at 1:5 or 1:10 
and 1:50 or 1:100 and 4 µl were added to reactions with a final volume of 10 µl. The 16S assay was 
carried out with 5 µl per reaction of SYBR Green PCR Master Mix (Life Technologies, Australia) 
while the other assays were carried out with 5 µl of TaqMan Fast Universal PCR Master Mix (Life 
Technologies, Australia). For TaqMan assays, the following conditions were used: 2 minutes at 
50
o
C, 10 minutes at 95
o
C followed by 40 cycles of 15 seconds at 95
o
C and 1 minute at 60
o
C. For 
the 16S assay, the 2 minutes at 50
o
C cycle was omitted, and a disassociation step was added (2 
minutes at 95
o
C, 15 seconds at 60
o
C). No-template controls (4 µl water) were included in all assays. 
Samples with cycle threshold (CT) values > 40 were considered to contain negligible amounts of 
the target gene, and were defined as negative for that species.   
 
2.2.3 Statistical analysis 
Statistical analysis was carried out in software package R 3.0.1 (257). For analysis RSV-A and 
RSV-B detection results were pooled, as were PIV1, 2 and 3 detection, polyomaviruses WU and 
KU detection and coronaviruses HKU1, OC43, NL63 and 29E. The number of viral species 
detected in a sample was split into a binary variable of single virus vs. multiple viruses detected. 
The month of ED visit was split into a binary variable of spring/summer vs. autumn/winter. 
Samples with missing patient data were removed from analysis. 
 
Univariable analysis was carried out using the epicalc R package (258). Proportions with p values 
from Fisher’s exact tests or chi-squared tests were reported for comparison of categorical variables. 
Median, interquartile range (IQR) and p values from ranksum tests were reported for comparison of 
continuous variables between groups. Pearson product moment correlation coefficients and 
corresponding p values were reported from comparisons between continuous variables. 
 
Variables that were significant at p < 0.05 in the univariable analysis were used in logistic 
regression to model factors contributing to the detection of RSV, hRV, multiple viruses, S. 
pneumoniae, H. influenzae and M. catarrhalis, with adjustment for age, sex, history of wheezing 
illness and season of ED visit. Firth’s penalised likelihoods were used to correct for small-sample 
bias, reported as effect sizes (ES) with 95% confidence intervals. The analysis was carried out with 
the logistf R package (259). Variables that had p values < 0.1 in the logistic regression models were 
entered into a single partial correlation matrix using the ppor R package (260), which evaluates the 
independent correlation between each two pairs of variables while controlling for all others. Partial 
correlations with p values < 0.01 and < 0.05 were viewed in Cytoscape 3.3.0 (261), to obtain a 
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visual representation of the interactions network. Such analysis techniques have been used 
effectively by others (21) to investigate the interactions between viruses and bacteria in the 
respiratory tract. 
 
To analyse the effect of pathogen detection and interactions on disease severity, linear regression 
models (for overall severity scores and severity score components) and logistic regression models 
with Firth’s penalised likelihoods (for admission to hospital, use of supplemental oxygen and use of 
assisted ventilation) were used with adjustment for age, sex, history of wheezing illness and season 
of ED visit. For each clinical parameter, a simple model was built that included the confounding 
factors and detection of RSV, hRV, multiple viruses, S. pneumoniae, H. influenzae and M. 
catarrhalis. Multiple interaction models were then built for each clinical parameter to reflect the co-
detections between specific pathogens identified in the partial correlation analysis with adjustment 
for patient demographics and other pathogen detections. In each case, the ES, standard error and p 
value for each variable is reported.  
 
In the convalescent samples there was insufficient statistical power to investigate associations 
between pathogens; however, the difference between bacterial loads at the acute and convalescent 
visit was analysed using Wilcoxon matched-pairs signed rank tests in Prism 7 (GraphPad Software, 
USA). 
 
2.3 Results 
2.3.1 Patient demographics and pathogen detection 
NPAs were collected from 60 infants and young children with acute ARI symptoms between 
September 2011 and October 2014. Two samples were virus negative, and were thus excluded from 
analysis. The median age of the remaining 58 participants was 4.8 months (IQR: 2.4-8.4 months) 
and 53% were male (Table 2.2). Approximately 22% of young children had a previous history of 
wheezing illness and two individuals had been diagnosed with asthma. Participant recruitment 
occurred throughout each year, with 60% of participants visiting the ED during autumn and winter. 
 
RSV and hRV were the most commonly detected viruses (Table 2.2). Detection of multiple viral 
species in a patient was common, with up to four viruses detected in one sample. RSV was the most 
frequent sole virus observed (17 of 32 samples), while hRV was the most common co-viral 
pathogen (20 of 26 samples). Bacterial DNA was detected in all 58 samples, and 48 (83%) were 
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positive for at least one of the three targeted species. Seventeen samples (29%) were positive for all 
three target species. S. pneumoniae was detected in 45% of samples, H. influenzae in 48% and M. 
catarrhalis in 72%.  
 
Table 2.2. Participant characteristics and pathogen detection. 
Number of samples 58 
Demographics 
 Median age in months (IQR) 4.8 (2.4,8.4) 
Male (%) 31 (53.4) 
ED visit during autumn/winter (%) 35 (60.3) 
Diagnosed asthma (%) 2 (3.4) 
History of wheezing illness (%) 16 (22.2) 
Clinical parameters 
 Received supplemental oxygen in ED (%) 11 (20.0) 
Admitted to hospital (%) 31 (57.4) 
Received assisted ventilation in ED (%) 4 (7.3) 
Median clinical disease severity score (IQR) 1 (0.5,2) 
Severity score criteria 
 Median score – oxygen saturation (IQR) 0 (0,0) 
Median score – inspiratory breath sounds (IQR) 0 (0,0) 
Median score – expiratory wheezing (IQR) 0.5 (0,1) 
Median score – accessory muscles (IQR) 0.5 (0,1) 
Median score – cerebral function (IQR) 0 (0,0) 
Bacterial detection 
 S. pneumoniae (%) 26 (44.8) 
H. influenzae (%) 28 (48.3) 
M. catarrhalis (%) 42 (72.4) 
S. pneumoniae ply load
1
 (IQR) 2.1 x 10
1
 (0, 3.5 x 10
3
) 
H. influenzae load
1
 (IQR) 0 (0, 4.0 x 10
3
) 
M. catarrhalis load
1
 (IQR) 5.6 x 10
2
 (0, 1.3 x 10
4
) 
Total microbial load
2
 (IQR) 1.5 x 10
5
 (3.9 x 10
4
, 6.3 x 10
5
) 
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Viral detection 
 RSV (%) 29 (50.0) 
RSV-A (%) 21 (36.2) 
RSV-B (%) 8 (13.8) 
hRV (%) 28 (48.3) 
Enteroviruses (%) 8 (13.8) 
PIV (%) 7 (12.1) 
PIV-1 (%) 0 (0) 
PIV-2 (%) 2 (3.4) 
PIV-3 (%) 5 (8.6) 
MPV (%) 5 (8.6) 
Influenza A virus (%) 2 (3.4) 
Influenza B virus (%) 0 (0) 
Adenovirus (%) 6 (10.3) 
Bocavirus (%) 4 (6.9) 
Polyomaviruses (%) 5 (8.6) 
Coronaviruses (%) 2 (3.4) 
No. of viral species detected per sample (IQR) 1 (1,2) 
Single virus detected (%) 32 (55.2) 
Multiple viruses detected (%) 26 (44.8) 
1
Median genomes per µl. 
2
Median 16S rRNA gene copies per µl. 
 
2.3.2 Pathogen interactions 
In the univariable analysis (Appendix 8.1 Table A2.1), detection of multiple viruses, S. pneumoniae 
and H. influenzae were all associated with an increase in age (p = 0.021, p < 0.001 and p < 0.001, 
respectively). Enteroviruses, adenoviruses and bocaviruses were exclusively detected with other 
viruses, and hRV was also associated with the presence of multiple viruses (p < 0.001). A negative 
association was observed between RSV and hRV (p < 0.001). H. influenzae detection was 
positively associated with M. catarrhalis and S. pneumoniae (p = 0.013 and p = 0.009, 
respectively). S. pneumoniae was also positively associated with detection of adenovirus, bocavirus 
and multiple viruses (p = 0.006, p = 0.035 and p = 0.002, respectively), while H. influenzae was 
associated with detection of adenovirus and polyomaviruses (p = 0.009 and p = 0.021, respectively). 
S. pneumoniae detection was increased in the presence of RSV (51.7% positive in RSV cases vs. 
38 
 
37.9% in non-RSV cases) and hRV (57.1% positive in hRV cases vs. 33.3% in non-hRV cases); 
however the differences were not statistically significant. 
 
Based on these results, multivariable logistic regression models were used to further investigate the 
associations between RSV, hRV, multiple viruses, polyomaviruses, S. pneumoniae, H. influenzae 
and M. catarrhalis. All models were adjusted for age, sex, history of wheezing illness and season of 
ED visit. Due to collinearity between the presence of multiple viruses and detection of 
enteroviruses, adenoviruses and bocaviruses, only the detection of multiple viruses was included in 
the models.  
 
In the logistic regression models (Figure 2.1), RSV and hRV remained negatively associated       
(ES = -3.908, p < 0.001), while hRV and detection of multiple viruses remained positively 
associated (ES = 2.524, p = 0.007). A positive association between S. pneumoniae and RSV 
detection was also observed (ES = 1.815, p = 0.030). Other associations identified in the univariable 
analysis were no longer significant at p < 0.05. 
 
All variables that had associations with a significance level p < 0.1 were included in the partial 
correlation matrix analysis. The results were visualised in an interaction network (Figure 2.2). 
Partial correlations with p < 0.01 and p < 0.05 are shown. Increasing age was associated with H. 
influenzae and S. pneumoniae detection, while decreasing age correlated with RSV and hRV 
detection. All associations observed in the logistic regression models persisted. Furthermore, an 
association between S. pneumoniae and hRV was observed. The association between H. influenzae 
and M. catarrhalis was also strengthened. 
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Figure 2.1. Associations between pathogen detections  in multivariable logistic regression models 
with adjustment for confounding factors and detection of S. pneumoniae (A), H. influenzae (B), M. 
catarrhalis (C), multiple viruses per sample (D), RSV (E) and hRV (F). Effect size (penalised 
maximum likelihoods) and 95% confidence intervals (CI) are shown. Black points represent 
likelihoods significant at p < 0.05, dark grey points p < 0.1 and light grey points p > 0.1. PyV: 
Polyomaviruses, Sp: S. pneumoniae, Hi: H. influenzae, Mc: M. catarrhalis. 
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Figure 2.2. Interactions between viruses and bacteria in the URT during paediatric viral ARI. 
Network built from output of partial correlation matrix analysis. Associations with p < 0.01 (solid 
line) and p < 0.05 (dashed line) are shown. Line thickness indicates magnitude of partial 
correlation. Positive (red lines) and negative (blue lines) correlations are shown. Age was the only 
confounding factor found to have a significant effect, indicated by arrow heads on edge lines. Sp: S. 
pneumoniae, Hi: H. influenzae, Mc: M. catarrhalis. 
  
2.3.3 Effect on disease severity 
Clinical disease severity scores for all young children ranged from 0 to 6 (median score 1) with 
57% of participants admitted to hospital (Table 2.2). In the univariable analysis (Appendix 8.1 
Table A2.1) increasing severity scores were associated with increasing age (p = 0.015) and a 
previous history of wheezing illness (p = 0.007). No other patient demographic variables were 
significantly associated with clinical parameters. When pathogen detection was investigated, 
increased severity scores were associated with detection of RSV (p = 0.031), multiple viruses        
(p = 0.035) and S. pneumoniae (p = 0.01). 
 
The associations of RSV, hRV, multiple viruses, S. pneumoniae, H. influenzae and M. catarrhalis 
with each clinical parameter were investigated in multivariable regression models with adjustment 
for confounding factors. In addition, models with pathogen interaction terms reflecting those 
identified in the partial correlation analysis were also investigated (Table 2.3 and Appendix 8.1 
Table A2.2). Higher severity scores were associated with RSV (ES = 1.055, p = 0.032), and 
specifically with RSV and S. pneumoniae co-detection (ES = 1.203, p = 0.028). This association 
was particularly evident when the distribution of severity scores, separated by RSV and S. 
pneumoniae detection status, was visualised (Figure 2.3A). In addition, the severity scores of young 
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children with RSV tended to increase with higher loads of S. pneumoniae (as estimated by the gene 
ply), a trend not observed in RSV negative patients (Appendix 8.1 Figure A2.1). Severity scores 
were not associated with any other pathogen detection or patient demographic variable after 
adjustment for confounding factors. 
 
Each individual component of the severity score criteria was also investigated in the regression 
models. Use of accessory muscles was associated with RSV (ES = 0.434, p = 0.039), and RSV and 
S. pneumoniae co-detection (ES = 0.522, p = 0.026) (Table 2.3, Figure 3B). Expiratory wheezing 
was strongly associated with RSV and S. pneumoniae co-detection (ES = 0.635, p = 0.005), with all 
‘marked wheezing’ (score of 2) occurring in young children with both (Figure 2.3C). While not 
significant, increased wheeze scores were also observed in young children with a history of 
wheezing illness (ES = 0.330, p = 0.085). Interestingly, unequal inspiratory breath sounds were 
associated with hRV detection (ES = 0.278, p = 0.003) and co-detection of hRV and S. pneumoniae 
(ES = 0.322, p = 0.001), despite no association with other components of the severity score. 
However, the effect was minimal, with a shift from ‘normal’ to ‘slightly unequal’ (score of 0 vs. 
0.5) (Figure 2.3D). The other severity score components, admission to hospital and use of 
supplemental oxygen were not associated with any variable (Appendix 8.1 Table A2.2).  
 
Despite no association identified between RSV and H. influenzae in the partial correlation analysis, 
associations between RSV and H. influenzae co-detection and disease severity have been previously 
reported (14, 15), thus models of each clinical parameter with an RSV and H. influenzae interaction 
term were also investigated (Table 2.3 and Appendix 8.1 Table A2.2). An interaction between RSV 
and H. influenzae was found to have no significant associations with any clinical parameters.  
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Table 2.3. Associations between pathogen detections and severity parameters with adjustment for confounding factors. 
Explanatory variables
1 
Clinical disease severity score Use of accessory muscles score Expiratory wheezing score Inspiratory breath sound score 
ES SE p value ES SE p value ES SE p value ES SE p value 
Age 0.639 0.508 0.216 0.207 0.218 0.349 0.014 0.205 0.945 0.200 0.079 0.016 
Male 0.273 0.393 0.491 -0.019 0.168 0.910 0.184 0.159 0.253 0.042 0.061 0.496 
History of wheezing illness 0.331 0.461 0.477 0.058 0.198 0.770 0.330 0.186 0.085 -0.049 0.072 0.502 
ED visit during autumn/winter 0.125 0.413 0.763 0.133 0.177 0.458 -0.028 0.167 0.870 0.028 0.064 0.661 
RSV detected 1.055 0.474 0.032 0.434 0.203 0.039 0.316 0.191 0.108 0.120 0.074 0.114 
hRV detected 0.398 0.552 0.476 0.105 0.237 0.659 -0.067 0.223 0.767 0.278 0.086 0.003 
Multiple viruses detected 0.066 0.472 0.89 -0.095 0.202 0.641 0.260 0.19 0.181 -0.097 0.074 0.194 
Sp detected 0.151 0.485 0.757 0.085 0.208 0.686 0.319 0.196 0.113 0.027 0.076 0.719 
Hi detected 0.115 0.442 0.796 -0.008 0.189 0.965 -0.04 0.178 0.822 0.016 0.069 0.817 
Mc detected 0.478 0.463 0.308 -0.072 0.198 0.718 0.221 0.187 0.244 0.079 0.072 0.278 
RSV and Sp interaction             
RSV + Sp - 1.119 0.636 0.087 0.362 0.272 0.191 0.300 0.257 0.250 0.214 0.096 0.033 
RSV - Sp + 0.212 0.630 0.738 0.017 0.269 0.949 0.304 0.254 0.240 0.116 0.095 0.231 
RSV + Sp + 1.203 0.525 0.028 0.522 0.224 0.026 0.635 0.212 0.005 0.143 0.079 0.080 
hRV and Sp interaction             
hRV + Sp - 0.399 0.645 0.540 0.276 0.270 0.314 -0.065 0.260 0.805 0.191 0.096 0.055 
hRV - Sp + 0.153 0.631 0.810 0.296 0.265 0.271 0.321 0.255 0.216 -0.080 0.094 0.404 
hRV + Sp + 0.549 0.622 0.384 0.156 0.261 0.553 0.252 0.251 0.323 0.322 0.093 0.001 
Hi and Mc interaction             
Hi + Mc - -0.672 0.978 0.496 -0.061 0.424 0.887 -0.461 0.392 0.247 0.005 0.154 0.977 
Hi - Mc + 0.250 0.528 0.639 -0.087 0.229 0.705 0.099 0.211 0.642 0.076 0.083 0.367 
Hi + Mc + 0.585 0.531 0.278 -0.081 0.230 0.727 0.177 0.213 0.412 0.095 0.084 0.262 
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Explanatory variables
1 
Clinical disease severity score Use of accessory muscles score Expiratory wheezing score Inspiratory breath sound score 
ES SE p value ES SE p value ES SE p value ES SE p value 
RSV and hRV interaction             
RSV + hRV - 1.247 0.597 0.044 0.630 0.251 0.017 0.371 0.241 0.133 0.083 0.093 0.379 
RSV - hRV + 0.563 0.637 0.383 0.275 0.268 0.311 -0.019 0.257 0.942 0.246 0.099 0.018 
RSV + hRV + 1.311 0.964 0.182 0.394 0.405 0.337 0.208 0.390 0.597 0.425 0.150 0.008 
hRV and >1 virus interaction             
hRV + 1 virus 0.928 0.676 0.178 0.296 0.292 0.317 0.179 0.271 0.513 0.226 0.107 0.042 
hRV - >1 virus 0.674 0.652 0.308 0.123 0.282 0.664 0.541 0.261 0.046 -0.157 0.103 0.138 
hRV + >1 virus 0.438 0.520 0.406 0.001 0.225 0.995 0.181 0.208 0.390 0.183 0.082 0.033 
RSV and Hi interaction             
RSV + Hi - 0.504 0.630 0.429 0.428 0.276 0.130 -0.022 0.246 0.930 0.065 0.100 0.519 
RSV - Hi + -0.312 0.545 0.571 -0.013 0.239 0.958 -0.301 0.213 0.166 -0.026 0.086 0.752 
RSV + Hi + 1.157 0.660 0.088 0.425 0.290 0.151 0.267 0.258 0.308 0.135 0.104 0.206 
1
For each severity parameter, a simple model was built with patient demographics and pathogen detection variables. Multiple interaction models were 
then built to reflect co-detections between specific pathogens with adjustment for patient demographics and other pathogen detections. Full results are 
shown for each simple model. In the interaction models, only results for the interaction term are shown, as there was little difference in the other 
parameters between the models. The effect size (ES), the standard error (SE) of the coefficient and the p value (testing whether the coefficient is 
significantly different from zero) are displayed, with coefficients significant at p < 0.05 highlighted in bold. Sp: S. pneumoniae, Hi: H. influenzae, Mc: 
M. catarrhalis, +: detected, -: not detected. 
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Figure 2.3. Distribution of disease severity parameters by virus and bacteria co-detection status. 
Clinical disease severity scores stratified by RSV and S. pneumoniae co-detection (A). Severity 
score component ‘use of accessory muscles’ stratified by RSV and S. pneumo iae co-detec ion (B). 
Severity score component ‘expiratory wheezing’ scores stratified by RSV and S. pneumoniae co-
detection (C). Severity score component ‘inspiratory breath sounds’ scores stratified by hRV and S. 
pneumoniae co-detection (D). Box and whisker plots with median and IQR are shown. + indicates 
positive detection of hRV, RSV or S. pneumoniae, - indicates negative detection. Sp: S. 
pneumoniae. 
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2.3.4 Comparison of RSV subtypes A and B 
In the 29 RSV positive samples from the acute visit, RSV subtype A was more common than 
subtype B (72.4% and 27.6%, respectively). No variables were associated with RSV-A compared to 
RSV-B in univariable analysis (Appendix 8.1 Table A2.3). Only young children with RSV-A 
required supplemental oxygen or ventilation (p = 0.075 for the former) and more were hospitalised 
(63.2% vs. 37.5%, p = 0.398), however, severity scores were similar between the subtypes. S. 
pneumoniae was co-detected equally with RSV-A and RSV-B (52.4% vs. 50%, p = 1), however, M. 
catarrhalis tended to be more commonly detected with RSV-A than RSV-B (81.0% vs. 37.5%,       
p = 0.067). Since no significant interactions were identified with univariable analysis, multivariable 
analysis was not performed. 
 
2.3.5 Pathogen detection at convalescence 
Nasal samples were available from 27 infants and young children at convalescence, collected on 
average 8 weeks after the acute visit (range 5-15 weeks). Eleven were virus positive (5 with hRV, 2 
with PIV3, 1 with hRV + polyomavirus WU, 1 with adenovirus + polyomavirus WU, 1 with 
polyomavirus KI and 1 with coronavirus HKU1). Three samples were negative for all target 
bacteria, and in two of those 16S DNA could not be detected. The total microbial load of each 
sample was usually decreased between the acute and convalescent visits (Figure 2.4A). 
Approximately 50% of participants with S. pneumoniae and H. influenzae had cleared the bacteria 
by convalescence (Table 2.4) and the loads of these species were also reduced (Figure 2.4B and C). 
It should be noted that the pneumococcal load for each sample may be slightly inflated, particularly 
at convalescence, due to use of the ply quantitative PCR assay, which is known to have low 
specificity between closely related Streptococcus species (66). M. catarrhalis persisted in all 
participants who were positive at the acute visit, however, the load generally decreased (Figure 
2.4D). Colonisation by bacterial species following the acute visit was infrequent. However, as the 
sample type and site varied between acute and convalescent visits (nasopharyngeal aspirate and 
nasal swab/wash, respectively) pathogen detection results from the convalescent visit should be 
interpreted with caution. 
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Figure 2.4. Total microbial load (A), S. pneumoniae load (B), H. influenzae load (C) and M. 
catarrhalis load (D) in each matched patient sample at the acute and convalescent visit. Dotted line 
indicates limit of assay detection. Displayed p value calculated from difference in loads between 
visits using a Wilcoxon matched-pairs signed rank test. Note, for B only samples with confirmed 
positive S. pneumoniae detection by the lytA PCR assay are shown. 
 
Table 2.4: Pathogen detection at convalescence compared to detection during ARI. 
Pathogen No. positive at 
acute visit 
No. still 
positive at 
convalescence 
No. negative at 
convalescence 
No. newly 
positive at 
convalescence 
RSV 14 0 14 0 
hRV 15 4 11 2 
S. pneumoniae
1
 14
 
7 5 1 
H. influenzae 13 7 6 1 
M. catarrhalis 20 20 0 2 
1
S. pneumoniae detection at convalescence could not be determined for two samples. 
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2.4 Discussion 
There is growing recognition that viral and bacterial interactions can occur during paediatric ARI, 
potentially affecting disease severity and outcome. The work of this chapter has identified an 
association between two important childhood pathogens, RSV and S. pneumoniae, in a Brisbane-
based paediatric cohort reporting to the ED with viral ARI. This interaction was associated with a 
significant enhancement of overall disease severity, as determined by criteria-based scoring. While 
several other interactions between respiratory viruses and bacteria were observed, including hRV 
and S. pneumoniae, and hRV with other viruses, these were not strongly associated with clinical 
measures of disease.  
 
The results provide further evidence for the hypothesis that RSV and S. pneumoniae interact with a 
clinically relevant synergism. The RSV G glycoprotein has previously been shown to act as a 
receptor for S. pneumoniae adherence, thus promoting pneumococcal colonisation of the airways 
(128, 136, 137). RSV has also been shown to enhance pneumococcal virulence in animal models, 
with co-infection resulting in increased inflammation (128, 137, 262). In young children, 
colonisation of the upper airways by Streptococcus species, such as S. pneumoniae, has also been 
correlated with increased disease severity with a greater likelihood of severe LRT infections with 
fever (5) and markers of increased inflammation during RSV infection (14, 15). However, the 
clinical relevance of RSV/S. pneumoniae co-infections among infants and young children is still 
under debate, due to conflicting results from clinical studies. Some investigations have shown a 
clear association between positive bacterial cultures and increased admission, duration of stay and 
use of supportive care at hospital and intensive care units (9-11, 13), while older and generally 
cross-sectional studies have found no association between co-detection of RSV or other respiratory 
viruses with bacteria and markers of disease severity (54, 57, 60, 98, 99). The longitudinal study 
reported by Teo et al. (5), in which every ARI over the first year of life was captured using culture-
independent techniques, clearly demonstrated that bacteria such as S. pneumoniae, H. influenzae 
and M. catarrhalis were associated with more severe LRT infections in the presence of respiratory 
viruses, whereas no such association was seen for Corynebacterium, Staphylococcus and 
Alloiococcus. These data strongly suggest that specific viral-bacterial interactions are associated 
with increased disease severity. 
 
In this cohort, RSV and S. pneumoniae was the only co-pathogen detection that was associated with 
increased disease severity. Surprisingly, while many clinical studies of paediatric ARI have reported 
strong positive associations between RSV and H. influenzae and a correlation with disease severity 
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(11, 14, 15, 25, 54-56, 263), no association between these two pathogens, or an association with 
disease severity, was found in this study. Likewise, no difference in overall severity of hRV ARI 
was observed when S. pneumoniae was co-detected, despite previous reports of synergism between 
these two pathogens (112, 141, 144). Interactions between RSV and H. influenzae, and hRV and S. 
pneumoniae have also been identified in the upper airways of healthy young children (21), 
suggesting interaction mechanisms independent of disease. RSV was also the only virus in this 
study that was independently associated with increased severity, despite frequent detection of hRV. 
While hRV strains can cause a wide range of clinical presentations, epidemiological evidence 
suggests that hRV-C may be particularly important in severe paediatric ARI (33). Typing of hRV 
was not performed in this study, thus correlations between specific subtypes with severity could not 
be investigated. 
 
Antagonism was identified between RSV and hRV, and no association between the presence of 
multiple viruses and increased ARI severity was found. The prevalence and clinical significance of 
multiple viral infections appears to vary depending on the viruses investigated and the cohort (38, 
264-267). However, antagonism has been reported between RSV and hRV in young children 
previously (38, 264, 267). A recent study in children < 2 years of age found that hRV detection 
during RSV ARI was significantly lower than hRV detection in age- and season- matched healthy 
controls (264). It has been suggested that the host immune response to viral infection, 
predominantly an interferon response, induces an antiviral state in the respiratory epithelium which 
may inhibit infection by other viruses (267). Alternatively, the immune evasion strategies employed 
by many respiratory viruses may increase host susceptibility to viral (or bacterial) co-infection, or 
increase the severity of infection when co-infections do occur (264). Associations between multiple 
viral infections, including RSV/hRV co-infection, and increased disease severity have been 
identified, often with clinical outcomes involving increased duration of symptoms and increased 
hospitalisation stays (38, 264-266). It has been suggested that a secondary viral infection, before the 
primary infection has resolved, may result in an additive effect on parameters like duration of 
symptoms (264). The majority of the participants in this study only attended the acute visit at the 
ED, thus longitudinal data, like duration of symptoms, was unable to be collected and the clinical 
effects of multiple viral infection could not be evaluated in more depth. Multiple virus detections 
did potentially confound the association between RSV and S. pneumoniae, since RSV was a 
frequent sole viral pathogen and S. pneumoniae was more common in multiple virus infections. The 
results of this study suggest that studies focussing on a single pathogen may not capture the full 
complexity of host, bacterial and viral interactions during paediatric ARI. 
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Limitations of this study are acknowledged. Factors like patient childcare attendance, number of 
siblings and vaccination status can influence bacterial carriage patterns and RSV transmission (56, 
176, 268), however, in this study such information was only collected at the convalescent visit and 
was unable to be included in the analysis due to small sample numbers. Adjustment for age was 
performed, as older age was associated with bacterial colonisation while younger age was 
associated with virus infection, particularly RSV; a significant association between RSV and S. 
pneumoniae only became evident after adjustment for confounding factors. The age range of 
paediatric ARI studies varies from neonates to children < 18 years, thus comparing results from 
studies with differently aged cohorts is difficult. The analysis was also corrected for season of ED 
visit, which had a limited effect on H. influenzae detection, but surprisingly did not affect detection 
of any of the other pathogens investigated (Figure 2.1). RSV infections are known to peak during 
autumn in Brisbane (56, 179), however the small sample size of this study may not have fully 
captured seasonal effects. Matched, healthy controls were also not available in this study, thus the 
cause-effect relationship of the co-pathogens identified could not be investigated. 
 
The dynamics of paediatric pathogen interactions in the URT are currently not well understood. In 
this study it cannot be determined whether RSV infection stimulated an outgrowth of S. 
pneumoniae, pneumococcal colonisation increased susceptibility to RSV infection, or whether both 
pathogens were concurrently acquired. All three scenarios are possible and each could conceivably 
contribute to increased clinical severity. The limited number of convalescence samples available in 
this study did allow some insight into the dynamics of bacterial colonisation after ARI. In contrast 
to studies of IAV and pneumococcal pneumonia in adults and mice, where influenza virus may 
increase host susceptibility to secondary bacterial infections for up to six months post virus 
infection (7), in this study, high loads of S. pneumoniae were detected during primary viral ARI and 
in only one instance was S. pneumoniae acquired between the acute and convalescent visits. A 
decrease in S. pneumoniae and H. influenzae detection rates was also observed at convalescence, 
whereas M. catarrhalis detection remained stable. Studies of the paediatric nasopharyngeal 
microbiota have reported associations between Streptococcus and Haemophilus with ARI compared 
to health (5, 18). Such studies have also identified Moraxella as a stable member of the microbiota, 
not present before the first ARI but stably present both in respiratory infections and health thereafter 
(5, 18). Longitudinal studies, where samples are taken before, during and after ARI episodes, such 
as that reported by Teo et al. (5) are required to better define the dynamics of pathogen interactions 
within paediatric patients. In Chapter 3, samples were accessed from one such longitudinal cohort to 
study the dynamics of S. pneumoniae colonisation during paediatric RSV infection. 
 50 
 
3. S. pneumoniae colonisation dynamics during RSV infection 
3.1 Introduction 
In Chapter 2, 52% of young children with a severe RSV infection were found to have high 
nasopharyngeal loads of S. pneumoniae. Furthermore, a pathogenic role for S. pneumoniae during 
these severe RSV infections was identified. Evidence from previous studies suggests that RSV may 
trigger an outgrowth of S. pneumoniae from the URT flora through promotion of bacterial 
adherence and disruption of bacterial clearance mechanisms (128, 138, 140, 262). However, we 
have previously hypothesised that, since RSV virion and S. pneumoniae complexes have been 
shown to form (128, 136, 137), these complexes may be co-transmitted in respiratory secretions, 
particularly in settings of rapid transmission such as childcare centres (6). Longitudinal studies with 
samples taken before, during and after an RSV infection within the same participant may represent 
the best way to differentiate between these hypotheses, however, to date such longitudinal studies 
have focused on characterising the nasopharyngeal microbiota, and have only shown increases in 
abundance of the Streptococcus genus during viral ARI, without species-level resolution and 
without reporting changes in abundances surrounding an ARI episode within individuals (5, 18).  
 
To expand on previous studies, in this chapter the colonisation dynamics of S. pneumoniae was 
investigated in the four weeks prior and subsequent to an RSV infection in individual participants 
less than two years of age. Nasal swabs were accessed from the ORChID study, a birth cohort of 
Brisbane-based young children followed for their first two years of life with weekly samples 
collected and screened for common respiratory viruses and bacteria species (100). The dominant 
strain of S. pneumoniae in each participant was established in a subset of samples through capsular 
sequence typing (CST), to determine whether individual S. pneumoniae strains were present prior to 
RSV infection and increased in abundance during RSV infection, or whether specific strains were 
newly introduced at the time of RSV infection, suggesting possible co-transmission. Colonisation 
patterns and strain detection were also compared between RSV subtypes. 
 
3.2 Methods 
3.2.1 Study population, sample collection and pathogen screening 
Participant recruitment, sample collection and pathogen screening were carried out by collaborators 
in the ORChID study team and have been described elsewhere (100). Briefly, newborn infants were 
enrolled with written consent from their parents at two hospitals in Brisbane, Australia. Infants were 
included if they were born at term, healthy and without underlying co-morbidities. Parents were 
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trained to take anterior nose swabs and to recognise respiratory symptoms, and were required to 
take samples weekly and keep a daily symptoms diary. Demographic data was collected upon study 
enrolment and telephone interviews were conducted every three months to update immunisation, 
breastfeeding and childcare attendance information. This study was approved by The Children’s 
Health Queensland (HREC/10/QRCH/16), the Royal Brisbane and Women’s Hospital 
(HREC/10/QRBW/125), and The University of Queensland (2010000820) Human Research Ethics 
Committees. 
 
Screening for respiratory pathogens was performed as described in Lambert et al. (100) with reverse 
transcriptase real-time PCR. Samples were screened for RSV-A, RSV-B, hRV, IAV, influenza B 
virus, PIV1-3, coronaviruses OC43, NL63, 229E and HKU1, MPV, human adenovirus, 
polyomaviruses WU and KI, bocavirus, S. pneumoniae, H. influenzae, M. catarrhalis, B. pertussis, 
Bordetella parapertussis, M. pneumoniae, C. pneumoniae and the Gram-negative Chlamydiae 
bacteria Simkania negevensis. Detection of the human genomic DNA marker ERV3 was included as 
an internal control to evaluate the quality of samples. Samples were classed as high quality if ERV3 
was detected, whereas ERV3 negative samples were classed as low quality and excluded from 
further analysis. 
 
3.2.2 Data and samples provided for use in this study 
Pathogen detection data (CT values) were provided for all participants where RSV was detected, 
with participant date of birth, presence and type of ARI based on symptoms, visit to general 
practitioner (GP) or hospital, and prescription of antibiotics data. Positive detection of a pathogen 
was defined as a CT value < 40. For samples in which RSV and S. pneumoniae were co-detected, 
pathogen detection data were also provided for the four weeks prior and four weeks subsequent to 
the RSV detection. Where RSV was detected on multiple weeks within that window, the window 
was extended to four weeks before and after the first and last RSV detection. S. pneumoniae 
colonisation patterns were defined for each RSV and S. pneumoniae co-detection episode based on 
this data. Episodes where S. pneumoniae was detected on at least three of the four weeks before 
RSV detection were classed as ‘colonised’, while episodes where S. pneumoniae was only detected 
one week prior to or the week of RSV detection were classed as ‘acquired’. Episodes where S. 
pneumoniae was detected on at least three of the four weeks after RSV detection were classed as 
‘persisted’ and episodes where S. pneumoniae was not detected in at least three of the four weeks 
after RSV detection were classed as ‘cleared’. 
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Based on this data, a subset of ‘colonised and persisted’ episodes was selected in which to 
determine the dominant S. pneumoniae strain. The week before RSV detection, the week(s) of RSV 
detection and the week following RSV detection were characterised. A subset of ‘acquired’ samples 
was also selected and the S. pneumoniae strain in the week of RSV detection was characterised, to 
determine whether individual strains were associated with the ‘colonised’ or ‘acquired’ phenotypes. 
Purified nucleic acid extract from the specified nose swabs were provided by our ORChID 
collaborators.  
 
For these episodes, participant date of birth, sex, number of siblings, age and subtype of first RSV 
detection and PCV immunisation status were provided. For each sample with pneumococcal strain 
characterisation, sample collection date, participant age at collection and attendance at childcare 
that week (formal care outside participant’s home, or informal care by family and friends) was 
provided. For each sample with a positive RSV detection, presence of ARI seven days either side of 
sampling date was provided. If ARI was present, then the type of ARI was provided (URT 
infection, LRT infection, LRT infection with wheeze), as was visit to a GP or hospital and 
prescription of antibiotics.  
 
3.2.3 Capsular sequence typing 
CST was carried out as previously described (247), by PCR amplification and Sanger sequencing of 
a 506 bp region of the wzh gene (also known as cpsB), a regulatory capsular biosynthesis gene 
known to vary sufficiently to distinguish between many important pneumococcal serotypes, with 
conserved regions for primer design (247, 269). While in some cases CST cannot distinguish 
between closely related serotypes, the main aim of this chapter was to follow intra-participant strain 
changes over time, rather than an epidemiological study of the most common serotypes colonising 
young children, which have been performed elsewhere (75, 76). CST thus has several advantages 
over other molecular typing methods. Firstly, a single PCR was sufficient in most cases to assign a 
capsular sequence type, necessary when only limited levels of nucleic acid extract were available 
from the study samples. Secondly, by amplifying all capsular sequences in a sample, CST could 
theoretically be used to identify carriage of multiple strains through deep sequencing of the CST 
amplicons. Following results from the Sanger sequencing of purified CST products, deep 
sequencing of these amplicons was not pursued, as it was decided that the additional data would not 
greatly add to the findings of the study, given the resources required for next generation sequencing 
(discussed further in Chapter 3.4). 
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CST was performed in PCRs of 25 µl in volume with 1X MyTaq HS Mix (Bioline, Australia), 0.5 
µM mix of the seven CST primers described in (247) and 5 µl of purified nucleic acid extract (or 5 
µl water for a no-template control). Cycling conditions were 95
o
C for 1 minute followed by 35 
cycles of 95
o
C for 15 seconds, 51
o
C for 30 seconds and 72
o
C for 30 seconds, with a final extension 
of 72
o
C for 7 minutes. Products were viewed by 1% agarose gel electrophoresis stained with 10 
mg/ml ethidium bromide and visualised on the Gel Logic 212 Pro UV transilluminator (Carestream, 
Australia). PCR products with a single, bright band at 500 bp were purified using the NucleoSpin 
PCR Clean-up Kit (Macherey-Nagel, Germany), following manufacturer’s instructions. Purified 
PCR product was quantified on the NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific, 
Australia) and approximately 5 ng/µl of purified PCR product was submitted to Sanger sequencing 
at the Australian Genome Research Facility (AGRF) with forward sequencing primer (247). 
 
Some samples had no or low levels of product amplification by agarose gel electrophoresis and 
were not sequenced, and others failed sequence quality control due to low concentrations of DNA. 
For these samples, a second round of CST PCR was performed as above using 2.5 µl of unpurified 
PCR product as the template with the following modifications: 0.2 µM each of the forward and 
reverse CST sequencing primers were used with an annealing temperature of 47
o
C and 30 cycles. In 
addition to a new no-template control (2.5 µl water), 2.5 µl of the no-template control from the first 
CST run was included in the second run, to ensure no low level amplification of contaminating 
DNA occurred. PCR products were viewed by agarose gel electrophoresis and bands at 500 bp were 
purified and sequenced as above. After the two rounds of PCR, samples that remained negative and 
those with faint bands which failed sequence quality control were excluded from further analysis.  
 
Sequencing quality control was performed in Sequence Scanner v1.0 (Applied Biosystems, 
Australia). The sequence chromatograms were viewed for evidence of secondary signals, which 
might indicate multiple sequences present in the purified PCR product, and other potential sequence 
aberrations. Sequences with a continuous read length < 500 bp were flagged for review and those   
< 300 bp excluded. Sequences were also excluded if the trace score was < 20.  
 
Sequences that passed quality control were compared to the CST database available at 
http://www.rivm.nl/mpf/spn/cst/ (247) using BLAST (270). Capsular sequence types were assigned 
based on >99% similarity to capsular sequence types in the database. The most common serotypes 
associated with each capsular sequence type were also recorded from the database.  
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3.2.4 Phylogenetic analysis 
To determine the relatedness of each sequence to each other, CST sequences were aligned using the 
MUSCLE algorithm (271) in MEGA7 (272) with default parameters. Positions in the alignment 
with ambiguous sequences that might negatively impact phylogenetic resolution were removed in 
ARB (273) by filtering out positions with < 50% similarity across the position and those with gaps 
in the majority of the position. A phylogenetic tree was estimated using the maximum likelihood 
method implemented in RAxML assuming a GAMMA model of rate heterogeneity and a GTR 
substitution model of nucleotide evolution (274). Bootstrapping was carried out to determine the 
robustness of individual nodes on the phylogeny, using 100 bootstrap replicates under the same 
substitution model described above. Phylogenetic tree was viewed and annotated in MEGA7 (272). 
 
3.2.5 Statistical analysis 
Analysis was predominantly performed with R (257) and the package epicalc (258), although some 
statistical tests were performed in Prism 7 (GraphPad Software, USA). Number of siblings was 
condensed into a binary variable representing siblings or only child. PCV immunisation status was 
condensed into a binary variable representing full PCV13 immunisation (PCV13 at 2, 4 and 6 
months of age) or partial/supplementary immunisation (PCV7 at 2 months, PCV13 at 4 and 6 
months or PCV7 at 2, 4 and 6 months with a supplementary PCV13 dose at 12 months). Age was 
taken as participant age on the first week of the RSV detection, and was condensed into a binary 
variable of participants aged < 1 year or > 1 year. Month of ARI episode was condensed into a 
binary variable of autumn/winter or summer/spring, based on the collection date of the majority of 
samples. Participants either did not attend childcare (formal or informal) or attended both formal 
and informal childcare, thus childcare was condensed into a binary variable representing attended 
childcare or not. LRT infection with wheeze was combined with LRT infection without wheeze. 
 
Pathogen detection data were separated into ‘before RSV detection’, ‘during RSV detection’ and 
‘after RSV detection’. Since real-time PCR CT values are inversely related to the amount of 
pathogen DNA present in a sample, CT values were used as proxies for pathogen detection loads. 
RSV detection occurred across two weeks during some episodes, thus CT values for each pathogen 
were averaged. If a pathogen was detected one week but not another, the participant was still 
classed as positive for that pathogen during RSV infection and the positive CT value was used. If 
the ARI type changed from the first week to the second, e.g. asymptomatic to URT infection, the 
more severe ARI type was used. Detection of other respiratory viruses (i.e. not RSV) was included 
in the analysis, as was detection of hRV specifically, as it was the most common non-RSV virus 
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detected. H. influenzae and M. catarrhalis were the only non-pneumococcal bacteria species 
detected frequently, and were included in the analysis. 
 
Comparison of categorical demographic, clinical and pathogen detection data was performed with 
Fisher’s exact or chi-square tests (as deemed appropriate by the epicalc function tableStack). 
Comparison of mean participant age and mean S. pneumoniae CT values between various 
categorical variables was performed with t-tests. For categorical analyses with associations 
identified as p < 0.05, binomial logistic regression was performed with adjustment for age, using 
the standard generalised linear models function in R.  Comparison of S. pneumoniae CT values 
before, during and after the RSV detection in the ‘colonised and persisted’ episodes was performed 
using repeated measures one-way analysis of variance (ANOVA) in Prism, with Holm-Sidak’s 
multiple comparison tests to correct for multiple hypothesis testing. The analysis was repeated 
separately for asymptomatic, URT and LRT infections, and prescription of antibiotics, using 
Dunnett’s multiple comparison tests. Correlations between S. pneumoniae CT values and H. 
influenzae or M. catarrhalis CT values were analysed using linear regression in Prism. 
 
3.3 Results 
3.3.1 RSV and S. pneumoniae co-detection 
Overall, 164 newborn infants were enrolled in the ORChID study led by Prof. Keith Grimwood, 
A/Prof. Stephen Lambert and Dr Robert Ware. RSV was detected in 105 swabs between January 
2011 and October 2014. Where RSV was detected multiple times in the same participant less than 
30 days apart, the detections were classed as a single RSV episode. Eighty-six RSV episodes were 
observed in 72 young children. Participants were reported by parents to have experienced symptoms 
of ARI in 62 RSV episodes (72.1%), with LRT infection symptoms in 33 episodes (38.4%). RSV 
and S. pneumoniae were co-detected in 44 of the 86 episodes (51.2%). 
 
RSV-A was detected in 61 episodes (70.9%), RSV-B was detected in 24 samples (27.9%) and one 
sample was positive for both RSV-A and RSV-B (1.2%). S. pneumoniae co-detection was similar 
between RSV-A and RSV-B positive nasal samples (52.5% vs. 50.0%, p = 1) (Table 3.1). The dual 
RSV-A and RSV-B episode was S. pneumoniae negative, and was excluded from analysis of factors 
associated with subtype. Subject age, presence and type of ARI, GP visit, hospital visit and 
antibiotic prescription were not associated with either subtype. M. catarrhalis and H. influenzae co-
detection were similar between subtypes, and while co-virus detection (i.e. the presence of another 
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respiratory virus, such as hRV, in addition to RSV) was more common with RSV-A, the difference 
was not significant (p = 0.060). 
 
M. catarrhalis detection was significantly more frequent in S. pneumoniae positive episodes          
(p = 0.002) (Table 3.2), an association which persisted after adjustment for age (adjusted odds ratio 
6.25, p < 0.001). Co-virus detection was also significantly more frequent when S. pneumoniae was 
detected (p = 0.025), and remained so after adjustment for age (adjusted odds ratio 5.78, p = 0.002). 
No other variables were associated with S. pneumoniae presence, including prescription of 
antibiotics; however, older age and visit to a GP were more common with S. pneumoniae detection 
during RSV infection (p = 0.144 and p = 0.180, respectively). 
 
Table 3.1. Univariable analysis of demographic, clinical and pathogen co-detection factors 
associated with RSV subtype. 
Variable RSV-A (n=61) RSV-B (n=24) p value 
Mean age in days (SD) 374.5 (178.2) 391.1 (184.2) 0.741 
Episode during autumn/winter (%) 45 (73.8) 18 (75.0) 1 
Asymptomatic
1 
URT infection
 
LRI infection
 
17 (29.3) 
17 (29.3) 
24 (41.4) 
3 (13.0) 
11 (47.8) 
9 (39.1) 
0.181 
Visited GP
1 
22 (40.7) 12 (52.2) 0.500 
Visited hospital
1 
6 (11.1) 1 (4.3) 0.667 
Prescribed antibiotics during ARI
1 
14 (25.5) 6 (26.1) 1 
Any respiratory virus co-detected (%) 22 (36.1) 3 (12.5) 0.060 
hRV co-detected (%) 11 (18.0) 2 (8.3) 0.334 
S. pneumoniae co-detected (%) 32 (52.5) 12 (50) 1 
H. influenzae co-detected (%) 12 (19.7) 2 (8.3) 0.331 
M. catarrhalis co-detected (%) 27 (44.3) 9 (37.5) 0.746 
1
Missing data: Complete clinical data were missing in nine episodes (4 missing ARI symptoms, 8 
missing GP and hospital visits and 7 missing antibiotic prescription). 
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Table 3.2. Univariable analysis of demographic, clinical and pathogen co-detection factors 
associated with S. pneumoniae detection. 
Variable S. pneumoniae 
detected (n=44) 
S. pneumoniae not 
detected (n=42) 
p value 
Mean age in days (SD) 415 (150.2) 350.4 (192.4) 0.144 
Episode during autumn/winter (%) 31 (70.5) 33 (78.6) 0.538 
RSV-A detected (%) 
RSV-B detected (%) 
A+B detected (%) 
32 (72.7) 
12 (27.3) 
0 (0) 
29 (69) 
12 (28.6) 
1 (2.4) 
0.903 
Asymptomatic
1 
URT infection 
LRI infection 
9 (22.0) 
13 (31.7) 
19 (46.3) 
11 (26.8) 
16 (39.0) 
14 (34.1) 
0.530 
Visited GP
1 
20 (52.6) 14 (35.0) 0.180 
Visited hospital
1 
2 (5.3) 5 (12.5) 0.432 
Prescribed antibiotics during ARI
1 
12 (30.8) 8 (20.0) 0.400 
Any respiratory virus co-detected (%) 16 (40.9) 7 (16.7) 0.025 
hRV co-detected (%) 9 (20.5) 4 (9.5) 0.266 
H. influenzae co-detected (%) 9 (20.5) 5 (11.9) 0.435 
M. catarrhalis co-detected (%) 26 (59.1) 10 (23.8) 0.002 
1
Missing data: Complete clinical data were missing in nine episodes (4 missing ARI symptoms, 8 
missing GP and hospital visits and 7 missing antibiotic prescription). 
 
3.3.2 S. pneumoniae colonisation dynamics 
S. pneumoniae colonisation patterns were assessed during the nine weeks surrounding an RSV 
detection in the 44 episodes in which RSV and S. pneumoniae were co-detected. Of these 44 
episodes, S. pneumoniae detection data in the four weeks prior and subsequent to the RSV detection 
were available for 40 episodes. These RSV episodes occurred in 38 infants and young children, 
with a minimum of six months between episodes from the same participant. High quality swabs 
were not always available for every participant for the full nine weeks, thus occasionally an episode 
was missing a week of data. Colonisation patterns were based on at least three weeks of data either 
side of the RSV detection. Four patterns of pneumococcal colonisation were observed in the four 
weeks prior and subsequent to the RSV episode (Figure 3.1A-D). S. pneumoniae was consistently 
detected in at least three of the four weeks before and after an RSV detection in 21 episodes (52.5% 
of S. pneumoniae co-detections). This pattern was called ‘colonised and persisted’. In 7 episodes 
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(17.5%) infants and young children were colonised before the RSV detection but S. pneumoniae 
was not detected in the subsequent weeks (‘colonised and cleared’). In another 7 episodes (17.5%) 
S. pneumoniae was only detected transiently in participants around the RSV detection (‘acquired 
and cleared’) while in the remaining 5 episodes (12.5%), S. pneumoniae was detected with the RSV 
infection and in the subsequent weeks (‘acquired and persisted’). 
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Figure 3.1. S. pneumoniae colonisation patterns in the weeks surrounding an RSV episode. Four 
colonisation patterns were observed, those where S. pneumoniae was only transiently detected 
during the weeks before and after the RSV detection (A), those were S. pneumoniae was acquired 
the same week as the RSV detection and persisted in the subsequent weeks (B), those where S. 
pneumoniae was detected before and during the RSV infection but was cleared afterwards (C) and 
those where S. pneumoniae was detected throughout the study window (D). S. pneumoniae load is 
approximated by CT value shown on an inverse axis, where points closer to 20 indicate a higher 
pneumococcal load. Mean and standard deviation are shown. Dotted line at 40 indicates limit of 
assay detection, below which samples were classed as negative. Colour of points is graded so that 
darker shades are closer to week 0 (i.e. the week RSV was first detected in the episode). 
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The colonisation patterns before and after each RSV infection were first analysed separately. 
Participants who were colonised before the RSV infection (28 episodes, 32.6% of the 86 RSV 
episodes) were compared to participants who apparently acquired S. pneumoniae with RSV (12 
episodes, 14.0% of RSV episodes) and those who were S. pneumoniae negative during RSV 
infection (42 episodes, 48.8% of RSV episodes). Participants negative for S. pneumoniae more 
frequently experienced asymptomatic RSV infection, whereas participants colonised with S. 
pneumoniae before the RSV infection more frequently exhibited LRT infection symptoms, although 
these differences were not statistically significant (p = 0.487) (Table 3.3). Prescription of antibiotics 
also tended to be more common in participants colonised by S. pneumoniae before the RSV 
detection (p = 0.120). Co-virus detection or co-detection of M. catarrhalis during the RSV infection 
was significantly more frequent in colonised or acquired S. pneumoniae episodes, compared to S. 
pneumoniae negative episodes (p = 0.037 and  p = 0.004, respectively), consistent with the 
observations in Chapter 3.3.1.   
 
Episodes in which S. pneumoniae was cleared immediately after the RSV detection (14 episodes) 
were compared to those where S. pneumoniae persisted for the majority of the weeks following 
RSV detection (26 episodes). No factors were associated with either pattern (Table 3.4), however, 
infants and young children who cleared S. pneumoniae more frequently experienced symptoms of 
LRT infection, visited a GP and were prescribed antibiotics (p = 0.673, p = 0.756 and p = 0.475, 
respectively). They also tended to be older than participants in whom S. pneumoniae persisted after 
RSV infection (p = 0.164). Unlike S. pneumoniae colonisation before and during RSV infection, co-
virus detection or co-detection of M. catarrhalis with RSV was not associated with presence or 
absence of S. pneumoniae in the subsequent weeks (p = 1 and p = 0.543, respectively). 
 
Comparison of all four patterns identified differential co-detection of other respiratory viruses, 
including hRV, during RSV infection, highest in ‘acquired and persisted’ and ‘colonised and 
cleared’ (p = 0.048) (Appendix 8.2 Table A3.1). No other factors were associated with a specific 
pattern; however, prescription of antibiotics was highest in ‘colonised and cleared’ episodes  
(p = 0.269).  
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Table 3.3. Univariable analysis of factors associated with RSV episodes where S. pneumoniae was 
acquired during the same week as the virus, where S. pneumoniae consistently colonised the URT 
in the four weeks before virus detection, and where S. pneumoniae was not detected with RSV. 
Variable Acquired 
(n=12) 
Colonised 
(n=28) 
Sp negative 
(n=42) 
p 
value 
Mean age in days (SD) 407.5 (139.8) 410 (158.3) 350.4 (192.4) 0.425 
Episode during autumn/winter (%) 9 (75) 19 (67.9) 33 (78.6) 0.602 
RSV-A detected (%) 
RSV-B detected (%) 
A+B detected (%) 
9 (75) 
3 (25) 
0 (0) 
21 (75) 
7 (25) 
0 (0) 
29 (69) 
12 (28.6) 
1 (2.4) 
0.970 
Asymptomatic
1 
URT infection 
LRI infection 
2 (18.2) 
2 (18.2) 
7 (63.6) 
5 (18.5) 
11 (40.7) 
11 (40.7) 
11 (26.8) 
16 (39) 
14 (34.1) 
0.487 
Visited GP
1
 5 (50) 14 (56) 14 (35) 0.232 
Visited hospital
1
 0 (0) 2 (8) 5 (12.5) 0.641 
Prescribed antibiotics during ARI
1
 1 (10) 10 (38.5) 8 (20) 0.120 
Any respiratory virus co-detected (%) 5 (41.7) 12 (42.9) 7 (16.7) 0.037 
hRV co-detected (%) 4 (33.3) 5 (17.9) 4 (9.5) 0.120 
H. influenzae co-detected (%) 1 (8.3) 7 (25) 5 (11.9) 0.371 
M. catarrhalis co-detected (%) 7 (58.3) 17 (60.7) 10 (23.8) 0.004 
1
Missing data: Complete clinical data were missing in eight episodes (3 missing ARI symptoms, 7 
missing GP and hospital visits and 6 missing antibiotic prescription). Sp: S. pneumoniae. 
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Table 3.4. Univariable analysis of factors associated with RSV episodes where S. pneumoniae was 
cleared in the weeks after co-detection with the virus and where S. pneumoniae colonisation 
persisted in the four weeks subsequent to RSV detection. 
Variable Cleared (n=14) Persisted (n=26) p value 
Mean age in days (SD) 477.4 (110.8) 384.1 (157.2) 0.164 
Episode during autumn/winter (%) 8 (57.1) 20 (76.9) 0.281 
RSV-A detected (%) 
RSV-B detected (%) 
A+B detected (%) 
9 (64.3) 
5 (35.7) 
0 (0) 
21 (80.8) 
5 (19.2) 
0 (0) 
0.278 
Asymptomatic
1 
URT infection 
LRI infection 
2 (14.3) 
4 (28.6) 
8 (57.1) 
5 (20.8) 
9 (37.5) 
10 (41.7) 
0.673 
Visited GP
1
 8 (61.5) 11 (50.0) 0.756 
Visited hospital
1
 0 (0) 2 (9.1) 0.519 
Prescribed antibiotics during ARI
1
 5 (38.5) 6 (26.1) 0.475 
Any respiratory virus co-detected (%) 6 (42.9) 11 (42.3) 1 
hRV co-detected (%) 4 (28.6) 5 (19.2) 0.694 
H. influenzae co-detected (%) 1 (7.1) 7 (26.9) 0.222 
M. catarrhalis co-detected (%) 7 (50.0) 17 (65.4) 0.543 
1
Missing data: Complete clinical data were missing in six episodes (2 missing ARI symptoms, 5 
missing GP and hospital visits and 4 missing antibiotic prescription). 
 
3.3.3 S. pneumoniae load during RSV infection 
To investigate the effect RSV had on pneumococcal load, S. pneumoniae CT values during RSV 
infection were compared with one week before and after the virus detection. Pneumococcal loads 
were first compared between the week prior and the week of RSV detection for participants who 
were colonised by S. pneumoniae before RSV detection (i.e. the ‘colonised and cleared’ and 
‘colonised and persisted’ patterns) (Figure 3.2A). Of these 28 episodes, 23 had high quality swabs 
available where S. pneumoniae was detected from the week prior to RSV detection. These 
participants tended to have increased S. pneumoniae loads during RSV infection compared to the 
prior week (mean CT value of 29.1 vs. 31.0, respectively, equating to an average 3.7-fold increase 
during RSV infection), although the difference was not statistically significant (p = 0.120). 
Secondly, pneumococcal loads were compared between the week of and the week following RSV 
detection for participants where S. pneumoniae was consistently detected after RSV infection (i.e. 
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the ‘colonised and persisted’ and ‘acquired and persisted’ patterns) (Figure 3.2B). Of these 26 
episodes, 22 episodes included high quality swabs where S. pneumoniae was detected from the 
week following RSV detection. These participants had similar loads both during and after the RSV 
infection (mean CT value of 29.2 vs. 29.1, respectively, p = 0.918). Finally, pneumococcal loads 
were compared between the week before, during and after RSV detection for participants where S. 
pneumoniae was detected consistently throughout the episode (‘colonised and persisted’ episodes) 
(Figure 3.2C). Of these 21 episodes, high quality swabs from all three weeks were available for 16 
episodes. S. pneumoniae CT values were not significantly different between the three weeks, 
although pneumococcal load tended to increase between the week before and the week of the RSV 
detection (mean CT value of 30.2 before RSV detection, mean CT value of 28.9 during RSV 
detection and mean CT value of 29.7 after RSV detection, p = 0.618). 
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Figure 3.2. Pneumococcal load the week before and during an RSV episode in participants 
colonised by S. pneumoniae before RSV detection (A), the week during and after an RSV episode 
in participants with persistent S. pneumoniae detection after RSV detection (B), and all three weeks 
surrounding RSV detection in participants with consistent S. pneumoniae detection through the 
RSV episode (C). S. pneumoniae load is approximated by CT value shown on an inverse axis, 
where points closer to 20 indicate a higher pneumococcal load. Mean and standard deviation are 
shown. Dotted line at 40 indicates limit of assay detection, below which samples were classed as 
negative. In C, samples from the same episode are indicated with a black line joining the before, 
during and after values. Sp: S. pneumoniae. 
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For the 16 ‘colonised and persisted’ episodes, mean S. pneumoniae CT values before, during and 
after the RSV detection were compared between various participant demographic, clinical and 
pathogen co-detection patterns (Table 3.5). During RSV infection, co-detection of M. catarrhalis 
was associated with higher pneumococcal load (p = 0.007). In the week before the RSV infection, 
co-detection of M. catarrhalis also tended to correspond with higher pneumococcal load                
(p = 0.073). In the week after the RSV infection, co-detection of H. influenzae was associated with 
a higher pneumococcal load (p = 0.044). While not statistically significant, participants 
experiencing asymptomatic infection or symptoms of LRT infections tended to have lower 
pneumococcal loads after RSV infection (p = 0.194), as did those prescribed antibiotics (p = 0.177).  
 
The relationship between pneumococcal load, ARI symptoms and antibiotic prescription was 
investigated further, by comparing S. pneumoniae CT values before, during and after the RSV 
detection for participants with asymptomatic, URT or LRT infection symptoms (Figure 3.3A) or for 
those prescribed antibiotics (Figure 3.3B). While participants with LRT infection symptoms tended 
to have pneumococcal loads that increased during the RSV infection then decreased in the 
following week, this difference was not statistically significant (p = 0.301) (Figure 3.3A). 
Participants with URT infection symptoms had significantly different S. pneumoniae CT values 
between the three weeks (p = 0.030), with generally highest loads in the week following RSV 
infection. Participants prescribed antibiotics during the RSV infection tended to have decreased 
loads the following week, although this difference was not statistically significant (p = 0.192) 
(Figure 3.3B). 
 
Both synergism and competition have been reported previously between S. pneumoniae, H. 
influenzae and M. catarrhalis in the URT (275). Since presence of M. catarrhalis and H. influenzae 
was associated with S. pneumoniae load during and after an RSV detection, respectively, possible 
interactions between the three bacterial species were explored further. The relationship between S. 
pneumoniae CT values and M. catarrhalis and H. influenzae CT values was investigated for the 40 
episodes where RSV and S. pneumoniae were co-detected, across the nine week window. Both H. 
influenzae and M. catarrhalis CT values were positively associated with S. pneumoniae CT values 
in samples where RSV was not detected (p = 0.003 and p < 0.0001, respectively), although with 
only a modest level of correlation (R
2
 = 0.187 and R
2
 = 0.218, respectively) (Figure 3.4). 
Interestingly, this trend was not as strong during RSV infection (p = 0.203 and p = 0.458, 
respectively). 
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Table 3.5. Associations of mean S. pneumoniae load the week before, during and after an RSV detection with participant clinical and pathogen co-
detection factors. S. pneumoniae load was approximated by CT value, thus a CT value closer to 40 indicates a lower S. pneumoniae load.  
Variable Before During After 
Mean (SD) p Mean (SD) p Mean (SD) p 
Episode during autumn/winter (n=12) 
Episode during spring/summer (n=4) 
31.1 (3.7) 
27.3 (2) 
0.069 28.8 (3.5) 
29.4 (4.5) 
0.776 30 (4.9) 
28.9 (4.3) 
0.702 
RSV-A detected (n=13) 
RSV-B detected (n=3) 
29.9 (3.7) 
31.2 (4) 
0.600 29.4 (3.8)  
26.9 (2.1) 
0.310 29.6 (5.2)  
30.2 (1) 
0.860 
Asymptomatic (n=3) 
URT infection (n=5) 
LRT infection (n=8) 
29.7 (3.3) 
31.4 (3.5) 
29.6 (4.1) 
0.685 30.8 (5.4)  
29.5 (4.3) 
27.8 (2.5) 
0.820 32.5 (7.7) 
26.8 (1.8) 
30.5 (4.1) 
0.194 
Visited GP (n=7)
1 
Did not visit GP (n=8) 
30.3 (4) 
30.2 (3.9) 
0.998 28.3 (2.3) 
29.5 (4.8) 
0.543 31.1 (4.1) 
28.7 (5.3) 
0.351 
Visited hospital (n=2)
1 
Did not visit hospital (n=13) 
28.7 (5.5) 
30.5 (3.7) 
NA 30.2 (3.1) 
28.8 (3.9) 
NA 28.8 (3.5) 
30 (5.1) 
NA 
Prescribed antibiotics during ARI (n=4)
1 
No antibiotics prescription (n=11) 
29.9 (3.6) 
30.4 (4) 
0.855 27.6 (2) 
29.4 (4.2) 
0.430 32.6 (4.7) 
28.8 (4.6) 
0.177 
Respiratory virus (not RSV) detected in swab  
(before n=5, during n=6, after n=6) 
Respiratory virus not detected in swab  
(before n=11, during n=10, after n=10) 
29.8 (3.5) 
 
30.4 (3.9) 
0.773 27.5 (2.3) 
 
29.8 (4.1) 
0.228 28 (1.9) 
 
30.8 (5.5) 
0.252 
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Variable Before During After 
Mean (SD) p Mean (SD) p Mean (SD) p 
hRV detected in swab  
(before n=4, during n=1, after n=4) 
hRV not detected in swab  
(before n=12, during n=15, after n=12) 
28.8 (3.1) 
 
30.7 (3.9) 
0.391 27.1 (NA) 
 
29.0 (3.7) 
NA 29.1 (0.68) 
 
30.0 (5.4) 
0.584 
H. influenzae detected in swab  
(before n=3, during n=4, after n=4) 
H. influenzae not detected in swab  
(before n=13, during n=12, after n=12) 
30.1 (3) 
 
30.2 (3.9) 
0.970 27 (4.3) 
 
29.6 (3.3) 
0.225 25.8 (2.4) 
 
31 (4.5) 
0.044 
M. catarrhalis detected in swab  
(before n=10, during n=10, after n=12) 
M. catarrhalis not detected in swab  
(before n=6, during n=6, after n=4) 
28.9 (3.1) 
 
32.3 (3.8) 
0.073 27.2 (2.8) 
 
31.9 (3) 
0.007 29.9 (4.9) 
 
29.1 (4.2) 
0.762 
1
One episode was missing GP, hospital and antibiotic prescription data. SD: standard deviation.
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Figure 3.3. S. pneumoniae load by symptoms of ARI (A) or antibiotic prescription (B) in the week 
before (circles), during (squares) and after (triangles) the RSV detection. S. pneumoniae load is 
approximated by CT value shown on an inverse axis, where points closer to 20 indicate a higher 
pneumococcal load. Dotted line at 40 indicates limit of assay detection, below which samples were 
classed as negative. Samples from the same episode are indicated with a black line joining the 
before, during and after values. Differences in CT values before, during and after RSV detection 
were evaluated using repeated-measures one-way ANOVA and corresponding p values are shown. 
Sp: S. pneumoniae. 
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Figure 3.4. Relationship between S. pneumoniae load and H. influenzae load (A) or M. catarrhalis 
load (B), in swabs that were taken when RSV was detected (blue circles) or in the four weeks 
before or after the RSV detection (grey triangles). Bacterial loads were approximated by CT values. 
Linear regression was used to model the relationship between CT values, assessed separately for 
RSV positive and RSV negative samples (blue and grey lines, respectively), with goodness of fit 
(R
2
) and p values reported. Dotted lines at 40 indicate limit of assay detection, below which samples 
were classed as negative. Only samples positive for both S. pneumoniae and H. influenzae or M. 
catarrhalis were included in the analyses. Sp: S. pneumoniae, Hi: H. influenzae, Mc: M. catarrhalis. 
 
3.3.4 S. pneumoniae strain characterisation 
The specific S. pneumoniae strains colonising participants during RSV infection and the week prior 
and subsequent to the virus detection were determined for 11 ‘colonised and persisted’ episodes by 
CST. S. pneumoniae strain was also determined for a further 6 ‘acquired’ episodes at the time of 
RSV detection. CST was successful in 36 of the 42 samples (85.7%) (Table 3.6). 
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In colonised episodes, the most common capsular sequence types were 23F-01 (3 episodes, 27.3%), 
23B-01 (2 episodes, 18.2%) and 06C-01 (2 episodes, 18.2%). In the 7 fully characterised episodes, 
within each episode the dominant capsular sequence type remained consistent throughout the testing 
period (Table 3.6), and the CST sequences from each episode clustered together in the phylogenetic 
tree (Appendix 8.2 Figure A3.1). The 4 successfully characterised acquired episodes shared similar 
capsular sequence types with the colonised episodes (Table 3.6). The exception was subject S159, 
who was colonised by a capsular sequence type with 95% identity to 20-01 (>99% identity was the 
desired cut-off for assigning a capsular sequence type).  
 
In the ‘colonised and persisted’ episodes that were analysed, CST established that the same S. 
pneumoniae strain persisted throughout the weeks immediately surrounding RSV detection. S. 
pneumoniae loads (i.e. CT values) for these characterised samples were therefore compared 
between participant demographic, clinical and pathogen co-detection variables for the 11 episodes. 
For these samples additional demographic data was available, including participant sex, one or 
more siblings, PCV immunisation status, prior exposure to RSV and attendance at childcare during 
the week the sample was taken. Similar to results from the larger analysis (Table 3.5), a visit to a 
GP and antibiotic prescription were associated with lower pneumococcal loads after the RSV 
infection (p = 0.030 and p = 0.047, respectively) (Appendix 8.2 Table A3.2). Detection of M. 
catarrhalis or H. influenzae at any point tended to correspond with higher pneumococcal loads      
(p < 0.2 and > 0.01 for all). The majority of participants had been fully immunised with PCV13 (8 
of the 10 with available immunisation data, 80.0%) and attended formal childcare (9 participants, 
81.8%), thus the effect of neither variable could be evaluated. Participant sex, siblings and prior 
exposure to RSV was not associated with S. pneumoniae CT value. 
 
Factors associated with the most common pneumococcal capsular sequence types were also 
investigated. For this analysis, the 11 colonised and 4 acquired episode datasets were combined and 
only data collected during RSV infection were used. S. pneumoniae capsular sequence types 
detected in more than one episode were included in the analysis; i.e. 23F-01 (3 episodes), 23B-01  
(3 episodes), 21-01 (2 episodes), 15C-01 (2 episodes) and 06C-01 (2 episodes). No factors were 
significantly associated with a specific pneumococcal strain (Appendix 8.2 Table A3.3).   
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Table 3.6. Capsular sequence types of S. pneumoniae the week before, the week(s) of and the week 
after the RSV detection in the colonised dataset, and the week of the RSV detection in the acquired 
dataset. 
Subject 
ID 
RSV 
subtype 
- first 
RSV 
detection 
Date Capsular sequence type Associated 
serotypes Week before 
RSV 
Week(s) 
during RSV 
Week after 
RSV 
Colonised episodes 
S021 A 11/03/2012 Undetermined 23B-01 23B-01 23B 
S109 A - first 6/10/2013 23B-01 23B-01;  
23B-01 
Undetermined 
S066 A 24/05/2013 23F-01 23F-01 23F-01 23F
1
, 15B, 
15C S104 B - first 3/04/2013 23F-01 23F-01 23F-01 
S150 B 17/03/2014 Undetermined 23F-01;  
23F-01 
23F-01 
S072 A - first 16/05/2012 21-01 21-01; 21-01 21-01 21 
S096 A
3 
1/06/2012 19F-03 19F-03 19F-03 19F
1
 
S098 A - first 5/08/2012 15A-01 15A-01 15A-01 15A 
S118 A - first 25/02/2013 15C-01 15C-01 15C-01 17A, 35B, 
35C 
S127 A 25/03/2013 06C-01 06C-01 06C-01 6C, 6A
2
, 6D 
S134 A - first 8/04/2013 06C-01 06C-01 Undetermined 
Acquired episodes 
S087 B - first 29/04/2013 --- 23B-01 --- 23B 
S128 A - first 28/04/2013 --- 21-01 --- 21 
S161 A 16/06/2013 --- 15C-01 --- 17A, 35B, 
35C 
S159 A - first 10/08/2014 --- 20-01
4
 --- 20, 13 
S121 A - first 22/10/2012 --- Undetermined ---  
S111 A - first 23/04/2013 --- Undetermined ---  
1
Serotypes included in PCV7. 
2
Serotypes included in PCV7 and PCV13. 
3
First RSV detection for 
subject S096 was unknown.
  4
The CST sequence of S159 shared only 95% identity with the 20-01 
capsular sequence type in the dataset. 
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3.4 Discussion 
S. pneumoniae was co-detected in approximately half of the RSV infections recorded in this 
community-based study of ARI in infants and young children aged < 2 years. While several 
pneumococcal colonisation patterns were observed during RSV infection, the most common was 
persistent colonisation throughout the RSV episode, with an increase in S. pneumoniae density 
during the RSV infection. In the seven fully characterised colonised samples, the same capsular 
sequence type was detected throughout the weeks immediately surrounding the RSV detection. 
While overall the increase in pneumococcal load before and during the RSV infection was not 
significant, the results do suggest that in these persistently colonised infants and young children, 
any observed increase in S. pneumoniae during RSV infection occurs from the pre-existing strains 
colonising the URT.  
 
Investigations of viral/bacterial co-infection dynamics based on influenza virus infections in adults 
have generally found that secondary bacterial pneumonia occurs at least a week following primary 
virus infection (7); however, evidence from previous studies suggests that RSV and S. pneumoniae 
interactions may occur more immediately than the delay observed in influenza/bacterial co-
infection (128, 137). In animal models, simultaneous RSV and S. pneumoniae infection of mice has 
been shown to result in severe pneumonia (128, 137), with increased bacteraemia compared to mice 
infected with RSV four days before S. pneumoniae challenge (137). In young children, longitudinal 
studies of the URT microbiota over the first years of life have demonstrated increases in 
Streptococcus abundances during ARI compared to health, probably due to S. pneumoniae (5, 18). 
However, this study is the first to show a trend towards increased numbers specifically of S. 
pneumoniae during an RSV infection, by following S. pneumoniae strain-specific carriage within an 
individual on a weekly basis. 
 
Several mechanisms for RSV promotion of S. pneumoniae colonisation have been explored in cell 
culture and animal models, as discussed in Chapter 1.6. RSV infection of airway epithelial cells has 
been demonstrated to enhance pneumococcal adherence to the epithelium, by increasing the number 
of host receptors and viral glycoproteins on the cell surface to which S. pneumoniae can adhere 
(128, 138, 140). The virus has been shown to impair mucociliary function of airway epithelial cells, 
reducing clearance of the bacteria (128). Reduced clearance of S. pneumoniae has also been 
observed in the lungs of mice challenged with the bacteria 1-7 days post RSV infection, possibly 
from virus-induced alterations in neutrophil function (262). Furthermore, direct binding of RSV and 
S. pneumoniae has been found to induce extensive changes in pneumococcal gene expression, 
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particularly upregulation of known virulence genes, which could further promote colonisation and 
outgrowth of S. pneumoniae in the URT (128).  
 
Over two thirds of the participants in this study with an RSV and S. pneumoniae co-detection were 
colonised by S. pneumoniae in the weeks before the viral infection. While viral promotion of 
bacterial colonisation has been well established, evidence is growing to suggest bacteria may also 
enhance viral infection in the respiratory tract, as discussed in Chapter 1.7. Specifically, 
pneumococcal strain-dependent enhancement of RSV infection has been demonstrated in primary 
epithelial cells and in a cotton rat model of S. pneumoniae colonisation before RSV challenge (160). 
Early colonisation by Streptococcus has also been associated with earlier first LRT infections in 
infants (5). The overall prevalence of S. pneumoniae colonisation within the ORChID cohort could 
not be analysed as part of this study (as this data was not available at the time this thesis was 
completed). Comparison of the overall prevalence of S. pneumoniae colonisation, particularly 
during seasonal periods of increased RSV infections, with the prevalence of S. pneumoniae in 
patients before an RSV infection, could be used to establish the relative risk of RSV infection 
caused by prior pneumococcal colonisation.  
 
While the majority of the infants and young children colonised by S. pneumoniae before the RSV 
detection remained colonised throughout, in seven episodes participants were negative for S. 
pneumoniae in the following four weeks. These participants tended to experience ARI episodes 
requiring a visit to a GP and antibiotic prescription more frequently than participants with the other 
colonisation patterns. It is likely that antibiotics reduced pneumococcal colonisation in the four 
participants (57.1%) who were prescribed them; however, the remaining three participants cleared 
the bacteria without reported use of antimicrobial drugs. Pneumococcal colonisation of the URT is a 
balancing act between the host immune response and bacterial immune evasion strategies (236). It 
seems probable that in these participants, the host immune response to S. pneumoniae during the 
RSV infection was sufficient to effectively clear the bacteria. In contrast, 26% of participants with 
S. pneumoniae persisting after the RSV episode were prescribed antibiotics without resulting in 
clearance of bacteria, thus a strong association between antibiotic prescription during ARI and S. 
pneumoniae carriage was not observed. The type of antibiotic prescribed, the duration of the 
antibiotic course, and whether the participant finished the course was unknown, all factors that may 
affect effective clearance of bacteria by antibiotics. Furthermore, the study’s use of real-time PCR 
in the bacterial screen allowed the detection of DNA from dead bacteria potentially killed by 
antibiotics or the host immune system. Other studies using molecular methods for bacterial 
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detection have also observed a limited effect of antibiotics on respiratory bacterial detection (56, 
98). Together these factors might explain the minimal effect of antibiotic prescription on 
pneumococcal colonisation observed here. 
 
Approximately 30% of infants and young children with an RSV and S. pneumoniae co-detection 
were negative for S. pneumoniae in the preceding four weeks. These episodes were possibly co-
transmission events, where S. pneumoniae may have been acquired at the same time as RSV. We 
have previously hypothesised that co-transmission of RSV and S. pneumoniae complexes may be 
possible in respiratory secretions (6), particularly given the high rates of RSV and S. pneumoniae 
co-detection previously demonstrated during paediatric ARI (1) (and Chapter 2). However, a cotton 
rat model of RSV infection following pneumococcal colonisation has reported no evidence of 
transmission of either virus or bacteria (160). Since samples in the ORChID cohort were taken 
approximately a week apart, it is possible that RSV and S. pneumoniae acquisition did not occur 
simultaneously and the virus increased the participant’s susceptibility to subsequent pneumococcal 
acquisition and colonisation in the days between virus exposure and sample collection. It is also 
possible that S. pneumoniae may have colonised the nasal cavity at levels below assay detection 
prior to RSV detection. The results from the ORChID cohort suggest that simultaneous acquisition 
of RSV and S. pneumoniae occurs in almost 15% of RSV infections in infants and young children, 
and co-transmission could be further investigated in a cohort of young children in a high 
transmission setting, such as households with multiple children or childcare centres. 
Characterisation of RSV and S. pneumoniae strains from samples taken weekly in such a cohort 
could assist in identifying specific co-transmission events. 
 
Given that in this cohort approximately 30% of S. pneumoniae co-detections with RSV were 
acquired with the virus, it was hypothesised that RSV may introduce new pneumococcal strains to 
the host during co-transmission, leading to replacement of strains already colonising the URT. 
However, CST of samples collected one week either side of RSV detection in a subset of episodes 
identified the same capsular sequence type persisting throughout the episode, suggesting no such 
strain replacement occurred. RSV has an incubation period of approximately 5 days (181), therefore 
it should be noted that the S. pneumoniae strain determined in the week before the RSV detection 
may not be representative of the strain colonising the URT before the virus first invaded the 
airways. It is theoretically possible that in some events, the identified S. pneumoniae strain could 
have been co-transmitted with RSV and reached detectible levels in the nose prior to detectable 
viral replication. Studies have shown that direct binding of RSV and S. pneumoniae can affect 
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pneumococcal adherence to airway epithelia and pneumococcal gene expression (128, 137), 
suggesting that interactions could occur between the two pathogens as soon as they encounter each 
other, before RSV has replicated in host cells to detectable levels. Future work therefore includes 
CST performed on samples from the colonised dataset collected two weeks before RSV detection, 
to determine the capsular sequence type of the colonising strain before any possible interactions 
with the virus could have occurred. CST was not successful in three samples from the week before 
RSV detection, probably due to low pneumococcal loads or lower quality swabs. Extending the 
window by an additional week may also provide the identification of the pre-RSV strains in these 
episodes, further strengthening the results of the study. 
 
In the subset of episodes characterised by CST, the same set of capsular sequence types were found 
in both colonised and acquired samples. The majority of serotypes associated with the identified 
capsular sequence types are not currently covered by PCV7 or PCV13, consistent with the complete 
PCV immunisation reported for the majority of participants in the study. One of the most common 
capsular sequence types identified, 23F-01, could be of the PCV7 vaccine serotype 23F, however 
CST cannot differentiate between serotypes 23F, 15B and 15C. It is perhaps more likely that these 
participants were therefore colonised by 15B or C, rather than 23F. Globally, since the introduction 
of PCV13 in 2010 or 2011 (depending on country), 15B and C have been among the most common 
serotypes reported to be carried by young children (75, 276). Other common serotypes from these 
studies include 23B, 21 and serogroup 35, similar to the serotypes associated with the capsular 
sequence types observed in this study.  
 
Comparable to the results reported in Chapter 2, S. pneumoniae was co-detected in approximately 
half of RSV episodes, and co-detection was equally frequent with RSV-A or RSV-B detection, 
suggesting that pneumococcal colonisation is not preferentially associated with either RSV subtype. 
While the study size was not sufficient to statistically confirm associations between RSV and 
individual S. pneumoniae capsular sequence types, RSV-B was exclusively detected with capsular 
sequence types 23B-01 and 23F-01. However, these were also the two most common pneumococcal 
strains detected and it is probable that the three RSV-B episodes characterised occurred with these 
strains by chance. Both this study and the one in Chapter 2 were carried out over multiple RSV 
seasonal epidemics, and the dominant RSV subtype circulating shifted from a predominance of 
RSV-A in 2012 towards an equal distribution of both by 2014 (refer to Appendix 8.3 Table A4.3 for 
comparison of thesis cohorts). One mechanism of RSV and S. pneumoniae interactions involves 
binding between S. pneumoniae and RSV surface glycoproteins (128, 136-138, 140). The RSV G 
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glycoprotein is the most variable between genotypes (186-188, 190), thus some RSV genotypes 
may interact better with S. pneumoniae than others, and changes in the dominant genotypes between 
seasons may disrupt such interactions. In an attempt to exclude seasonal variation, in Chapter 4 
genotype-specific associations between RSV and S. pneumoniae were investigated during a single 
RSV season. 
 
Within the patients infected with RSV in this community cohort, approximately 46% of those with 
S. pneumoniae co-detections experienced symptoms of LRT infections, compared to 34% of those 
without an S. pneumoniae co-detection. Infants and young children with RSV and S. pneumoniae 
co-detections also tended to visit a GP and be prescribed antibiotics more often, whereas those 
negative for S. pneumoniae experienced asymptomatic RSV infections more frequently. S. 
pneumoniae load in participants with co-detections also tended to increase during RSV infection 
during symptomatic ARI, compared to asymptomatic RSV detections. However, none of these 
trends were statistically significant, and no clear associations were observed between S. pneumoniae 
presence and measures of more severe disease. The results from the PISP cohort investigated in 
Chapter 2 identified an association between RSV and S. pneumoniae co-detection and increased 
disease severity based on validated clinical severity criteria. Other studies have also identified 
associations between RSV and S. pneumoniae co-detection and enhanced disease severity (5, 9-11, 
13-15); however, like the PISP cohort, these studies have recruited hospital in- and out-patients, 
with severity data measured by professionals and often related to severe illness, e.g. use of 
supplemental oxygen and length of stay in hospital. The community-based ORChID cohort had 
symptoms measured by parents trained to recognise pre-defined respiratory symptoms or diagnoses 
(100), thus some variation between families would be expected, potentially masking the effect of S. 
pneumoniae colonisation on ARI symptoms. 
 
A potentially important confounding factor of this study was the correlation observed between 
detection of S. pneumoniae, M. catarrhalis and H. influenzae. Co-colonisation has been previously 
reported between these three species in the healthy paediatric URT (21, 277, 278), although 
competition has also been observed between H. influenzae and S. pneumoniae in experimental 
models of co-colonisation (279-282). Synergism and competition have been demonstrated in animal 
models and potential molecular mechanisms governing these interactions have also been 
experimentally validated. For example, outer membrane vesicles produced by M. catarrhalis have 
been shown to inhibit the complement system, protecting both M. catarrhalis and co-colonising H. 
influenzae from complement-mediated killing (283). S. pneumoniae colonisation has been shown to 
 75 
 
increase H. influenzae density in the nasopharynx of neonatal rats (280). However, the same study 
found that H. influenzae colonisation reduced S. pneumoniae density (280), and another study in a 
murine model has demonstrated complement-dependent phagocytosis of S. pneumoniae induced by 
co-colonisation with H. influenzae (279). Possible interactions between S. pneumoniae and the other 
two species may be particularly important to consider when investigating the role of bacteria in 
paediatric RSV infections, since an association between H. influenzae and RSV has also been 
previously observed in paediatric ARI (11, 14, 15, 25, 54-56, 263), as discussed in Chapter 2.4. The 
presence of Moraxella has also been shown to contribute to the severity of RSV infections in infants 
(5). In this study, H. influenzae was only detected in 16% of RSV positive samples, and M. 
catarrhalis in 42% of RSV positive samples. However, it is possible that both bacteria could have 
influenced S. pneumoniae colonisation dynamics, and simultaneous detection of all three species 
should always be conducted in studies investigating viral and bacterial interactions during paediatric 
ARI.  
 
A limitation of this study was the use of real-time PCR CT value as a proxy for bacterial load. 
Without a standard curve performed each PCR run, variation between PCR runs could not be 
controlled, thus CT value could only be used loosely as an indication for bacterial load. Nasal swab 
quality can also impact detection of viruses and bacteria (56, 284). Detection of the human genomic 
DNA marker ERV3 was used as an internal control for each sample, and low quality samples where 
ERV3 was not detected were excluded by the ORChID team. In the future, the ERV3 CT value of 
samples passing quality control could be used to normalise pathogen CT values, to further control 
for sample quality (this data was not available from collaborators at the time this thesis was 
completed). It should also be noted that higher quality swabs may be more easily obtained during 
symptomatic ARI, when more respiratory secretions are produced (285). Thus, bacterial detection 
and higher loads of bacteria might have been more easily detected during ARI symptoms. 
Additional controlling for sample quality could better resolve these potential study limitations. 
 
The approach used to characterise the strains of S. pneumoniae in this study, CST using Sanger 
sequencing, only allowed for the identification of the dominant pneumococcal strain. Simultaneous 
carriage of multiple S. pneumoniae strains has been reported in young children (286). Deep 
sequencing of CST amplicons could allow the identification of multiple strains in a sample. Since 
evidence of the dominant strain changing to another capsular sequence type during RSV infection 
was not observed in this study, it was decided that determining the fluctuations in minor strain 
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abundances in each sample would not greatly add to the findings of the study, given the resources 
required for next generation sequencing.  
 
The results from this study suggest that S. pneumoniae is detected in approximately 33% of RSV 
infections from strains already colonising the URT, while in another 14% S. pneumoniae is acquired 
with the virus. The same subset of strains was detected in both colonised and acquired episodes, and 
no differences were observed between RSV-A and RSV-B infection. Pneumococcal strain-specific 
associations with specific RSV genotypes were investigated in a cohort of children with ARI 
symptoms, as discussed in Chapter 4. 
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4. RSV and S. pneumoniae diversity 
4.1 Introduction 
The work presented in the previous chapters identified a strong association between RSV and S. 
pneumoniae during ARI in young children and a pathogenic role for S. pneumoniae during RSV 
infection (Chapter 2), possibly from growth of S. pneumoniae in the URT flora triggered by the 
virus infection or co-transmission of S. pneumoniae and RSV (Chapter 3). We have previously 
hypothesised that the association with RSV is likely to be advantageous to S. pneumoniae, 
potentially leading to co-transmission and selection of pneumococcal strains that utilise 
glycoproteins expressed by RSV to facilitate adherence to the URT (6). Since molecular variation 
exists between both RSV and S. pneumoniae strains (188, 236), in this chapter the co-circulation of 
viral and bacterial strains was investigated in young children. 
 
RSV G is the most variable region of the virus, commonly used to genotype strains circulating in 
the population (186-188, 190). G has also been shown to be involved in direct binding interactions 
with S. pneumoniae (128, 136, 137). S. pneumoniae colonisation of the URT has been shown to 
vary between different serotypes and strains (76, 242). Previous epidemiological studies of ARI 
have described the genetic diversity of RSV based on G (190, 193-204). Studies of serotype 
distribution and genetic diversity of S. pneumoniae during asymptomatic carriage and disease have 
also been performed (75, 76, 79-81, 227, 245, 247, 250, 287), and some studies of paediatric LRT 
infections have reported pneumococcal serotypes in addition to respiratory virus and bacteria 
detections (99, 104, 228, 288-290). However, no simultaneous investigations of both RSV and S. 
pneumoniae genetic diversity in the same population have been conducted to date.  
 
It was hypothesised that specific genotypes in RSV G would be associated with specific strains of S. 
pneumoniae circulating in young children with respiratory infections. This hypothesis was 
retrospectively investigated in a cohort of children under the age of five years with respiratory 
symptoms, in the 2012 RSV season in Brisbane, Australia. Variation in HVR2 of G was determined 
in RSV strains, while core MLST sequence type and molecular serotype was characterised in 
pneumococcal clinical isolates. 
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4.2 Methods 
4.2.1 Study population, sample collection and pathogen detection 
This retrospective study was an extension of a previously published prospective study of viral and 
bacterial co-detection in young children with respiratory symptoms (1). The study population, 
sample collection and pathogen detection were described in detail in Chappell et al. (1). Briefly, 201 
NPAs were accessed from those sent to Pathology Queensland Central at the Royal Brisbane and 
Women’s Hospital from children under the age of five years for routine screening of respiratory 
virus presence. Samples were collected from clinical settings in southeast Queensland, Australia, 
over an eight week period during the 2012 seasonal RSV epidemic (late March to mid May). 
Samples were de-identified, with date of birth available. The study was approved by the Children’s 
Health Services Queensland Human Research Ethics Committee (HREC reference number 
HREC/12/QRCH/196).  
 
All NPAs were screened for RSV, PIV1-3, IAV, influenza B virus, human adenovirus and MPV by 
reverse transcription PCR by Queensland Health Pathology Services following routine procedures. 
The presence of hRV was also determined by reverse transcription PCR as previously described 
(291). All NPAs were screened for respiratory bacteria by culturing 10 µl of each sample onto 
blood agar and chocolate agar plates (5% horse blood unlysed or lysed through heating to 56
o
C for 
1 hr, respectively) with overnight incubation at 37
o
C in 5% CO2. Plates with > 100 colonies of 
conserved morphological features (>10,000 colony forming units (CFU)/ml) were considered to 
have high density bacterial growth. Representative colonies were identified by sequencing of 
variable regions 1 and 2 of the 16S rRNA gene as described in Chappell et al. (1). 
 
4.2.2 RSV characterisation and phylogenetic analysis 
Sequencing of HVR2 of RSV strains was previously performed by Dr Keith Chappell and the 
sequences were provided for use in this study. Briefly, RSV sequencing analysis was performed as 
described in Goto-Sugai et al. (292). Reverse transcription of viral RNA was performed using the 
Tetro cDNA Synthesis Kit (Bioline, Australia) and PCR was performed using Phusion DNA 
polymerase (New England Biolabs (NEB), USA) and the oligonucleotide primers RSVG490  
(5’-ATGATTWYCAYTTTGAAGTGTTC-3’) and RSVF164  
(5’-GTTATGACACTGGTATACCAACC-3’). PCR products were purified using the PureLink 
PCR Purification Kit (Thermo Fisher Scientific, Australia) and submitted for Sanger sequencing 
through AGRF. 
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For genotyping, RSV G reference sequences were downloaded from GenBank (accession numbers 
provided in Appendix 8.3 Table A4.1) and aligned with the study strains using the MUSCLE 
algorithm (271) in MEGA7 (272) with default parameters. Study strains were assigned to subtype A 
or B based on homology with reference sequences. Separate alignments were then generated for the 
two subtypes with the reference sequences. The amino acid sequence was deduced and the four 
alignments were trimmed to the region spanning HRV2 (amino acid positions 177-298 on the 
prototype A2 protein sequence). Positions in the four alignments with ambiguous sequences that 
might negatively impact phylogenetic resolution were removed in ARB (273) by filtering out 
positions with < 50% similarity across the position, resulting in sequences of 336 nucleotides (A) or 
402 nucleotides (B) and 112 (A) or 133 (B) amino acids in length. Phylogenetic trees of these data 
were estimated using the maximum likelihood method implemented in RAxML assuming a 
GAMMA model of rate heterogeneity, a GTR substitution model of nucleotide evolution and a 
WAG substitution model of amino acid evolution (274). Bootstrapping was carried out to determine 
the robustness of individual nodes on the phylogenies, using 100 bootstrap replicates under the 
same substitution models described above. Phylogenies were viewed and annotated in MEGA7 
(272). The study and reference sequences were screened for the presence of recombination using 
the seven default methods available within the Recombination Detection Program 4 (RDP4) with 
default settings (293). 
 
4.2.3 S. pneumoniae isolation 
Dr Keith Chappell provided the S. pneumoniae clinical strains previously isolated from the 
pathology cohort. Briefly, representative colonies matching the morphology of S. pneumoniae on 
blood agar were cultured in Todd Hewitt + 5% yeast extract (THY) broth (Oxoid, Australia) + 5% 
foetal bovine serum (FBS, Bovogen Biologicals, Australia) overnight at 37
o
C in 5% CO2 and stored 
in 30% glycerol at -80
o
C. The RSV G sequencing of one RSV and S. pneumoniae positive sample 
was unsuccessful, thus this S. pneumoniae isolate was excluded from analysis. 
 
After isolates were identified as S. pneumoniae by 16S rRNA sequencing, the isolates were cultured 
from the glycerol stocks by touching a pipette tip to the frozen stock, inoculating 12 ml cultures of 
THY broth + 5% FBS and incubating overnight at 37
o
C in 5% CO2. Genomic DNA extractions 
were then carried out using the PureLink Genomic DNA Minikit (Thermo Fisher Scientific, 
Australia), as per manufacturer’s instructions. Purified DNA was stored at -20oC.    
 
 80 
 
Sequencing of variable region 1 and 2 of the 16S rRNA gene does not always provide species level 
resolution. Furthermore, closely related Streptococcus species have been found to confound 
sequence-based molecular serotyping techniques (294). Isolates identified as S. pneumoniae by 16S 
rRNA sequencing were therefore tested for presence of lytA by real-time PCR as previously 
described in Carvalho Mda et al. (66) and in Chapter 2.2.2, using 4 µl of purified DNA diluted 1:5 
in 10 µl reactions with TaqMan Fast Universal PCR Master Mix (Life Technologies, Australia). 
The lytA assay has been shown to have high specificity in distinguishing S. pneumoniae from other 
closely related Streptococcus species in respiratory samples (66). Isolates with confirmed S. 
pneumoniae identification by the lytA assay were further characterised (two isolates were excluded 
due to a negative result (CT > 40) in the lytA assay). 
 
4.2.4 S. pneumoniae MLST 
MLST was carried out previously by Dr Keith Chappell and the sequences provided for this study. 
Briefly, PCRs of seven housekeeping genes (genes and oligonucleotide primer pairs in Table 4.1) 
were performed using Phusion polymerase (NEB, USA). PCR products were purified using the 
PureLink PCR Purification Kit (Thermo Fisher Scientific, Australia) and submitted for Sanger 
sequencing through AGRF. The sequences were entered into the S. pneumoniae MLST database 
available at http://pubmlst.org/spneumoniae/ (sited at the University of Oxford (295), funded by the 
Wellcome Trust) and the seven-component allelic profile determined with a sequence type (ST) 
assigned where possible. One isolate had an allelic profile that was not in the database, and will be 
referred to as ‘STnew’. 
  
Table 4.1. The seven housekeeping genes and primers used for S. pneumoniae MLST. 
Gene Gene name Forward primer Reverse primer 
aroE shikimate dehydrogenase 5'-GCCTTTGAGGCGACAGC 5'-TGCAGTTCARAAACATWTTCTAA 
gdh glucose-6-phosphate 
dehydrogenase 
5'-ATGGACAAACCAGCNAGYTT 5'-GCTTGAGGTCCCATRCTNCC 
gki glucose kinase 5'-GGCATTGGAATGGGATCACC 5'-TCTCCCGCAGCTGACAC 
recP transketolase 5'-GCCAACTCAGGTCATCCAGG 5'-TGCAACCGTAGCATTGTAAC 
spi signal peptidase I 5'-TTATTCCTCCTGATTCTGTC 5'-GTGATTGGCCAGAAGCGGAA 
xpt xanthine 
phosphoribosyltransferase 
5'-TTATTAGAAGAGCGCATCCT 5'-AGATCTGCCTCCTTAAATAC 
ddl D-alanine-D-alanine ligase 5'-TGCYCAAGTTCCTTATGTGG 5'-CACTGGGTRAAACCWGGCAT 
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To compare the relatedness of the study isolates to the entire known pneumococcal population, 
eBURST (296, 297) was used to cluster the STs in the S. pneumoniae PubMLST database into 
clonal complexes. The allelic profile ‘STnew’ was included in the analysis. The eBURST algorithm 
uses a model of bacterial evolution in which an ancestral genotype expands in the population, 
diversifying into a cluster of closely related strains, referred to as a clonal complex (248, 296). The 
stringent setting was used, where all STs in a clonal complex had to be single locus variants of at 
least one other ST in the group (i.e. 6 out of 7 shared components of the allelic profile). While not 
directly relevant in the context of this study, the founder ST, from which the other STs in the clonal 
cluster evolved, was also predicted for each clonal complex, defined as the ST that had the greatest 
number of single locus variants (296). High levels of homologous recombination is common in 
bacterial populations, including between S. pneumoniae strains (248, 250), thus representing the 
evolutionary relationships among distantly related strains in phylogenetic trees is often inaccurate 
(296, 297). eBURST overcomes this problem by focusing on each ST’s relationship to its predicted 
founding genotype. The algorithm therefore does not infer evolutionary relationships between 
separate clonal complexes (296).  
 
4.2.5 S. pneumoniae molecular serotyping 
CST was carried out as previously described by Elberse et al. (247) and in Chapter 3.2.3. The 
procedure in Chapter 3.2.3 was modified for PCRs of 20 µl in volume and used 5 µl of 1:10 diluted 
purified DNA from each S. pneumoniae clinical isolate. Approximately 5 ng/µl of purified CST 
PCR product was submitted to Sanger sequencing at AGRF with forward and reverse sequencing 
primers (247). Good quality forward and reverse sequences were merged and compared to the CST 
database available at http://www.rivm.nl/mpf/spn/cst/ using BLAST (270). Capsular sequence types 
were assigned based on >99% similarity to capsular sequence types in the database. 
 
Often a single capsular sequence type may have multiple possible serotypes associated with it. 
Thus, a second method of molecular serotyping was performed using multiplex PCR (246), to 
confirm the results of the CST. The method described by Pai et al. (246) implements a sequential 
procedure of seven multiplex PCR reactions with primers targeting serotype-specific regions of the 
capsular cps locus for four serotypes (or serogroups) per reaction and a positive control primer pair 
targeting cpsA, with each set of five primers producing different sized bands for identification by 
agarose gel electrophoresis. Because CST had already narrowed down the possible serotypes for 
each isolate, the procedure was modified to only perform reactions specific to those subsets of 
serotypes, with the inclusion of the positive cpsA control. Reactions were performed with 1X 
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ThermoPol Reaction Buffer (NEB, USA), 0.2 mM dNTP Solution Mix (NEB, USA), 2.5 units Taq 
DNA polymerase (NEB, USA), primer concentrations recommended in Pai et al. (246), and 2.5 µl 
of purified isolate DNA. Cycling conditions were 95
o
C for 4 minutes followed by 30 cycles of 95
o
C 
for 45 seconds, 54
o
C for 45 seconds and 65
o
C for 2.5 minutes, with a final extension of 65
o
C for 5 
minutes. Products were viewed by 1% agarose gel electrophoresis and serotypes assigned based on 
band sizes. One isolate was excluded from analysis because the capsular sequence type was 
ambiguous and the molecular serotype could not be determined by the multiplex PCR method. 
 
4.2.6 Statistical analysis of pathogen co-detection 
Statistical analysis was conducted in R (257). Based on the phylogenies, RSV strains were clustered 
into subtypes and genotypes. S. pneumoniae isolates were clustered into molecular serotyping 
groups and MLST clonal complex groups. Pneumococcal molecular serotypes were also separated 
into those assumed to be included in PCV13 and non-vaccine molecular serotypes (as molecular 
serotype is only a prediction of gold standard serotyping with the Quellung reaction, results from 
this analysis must be interpreted cautiously). Univariable analysis was carried out with the R 
package epicalc (258). Median patient ages with IQR were compared with the Wilcoxon rank sum 
test between different RSV or S. pneumoniae groups. Co-pathogen detection rates (proportion of 
samples positive for that co-pathogen) were compared with Fisher’s exact test. Given the large 
number of molecular serotyping groups and clonal complexes with a small number of members, 
pathogen co-detections for S. pneumoniae isolates were reported individually, rather than providing 
summary statistics. 
 
The work conducted in Chapter 2 found that age and presence of multiple viruses may affect S. 
pneumoniae co-detection during paediatric RSV infection. Thus, the analysis of co-pathogen 
detection was repeated using penalised logistic regression with adjustment for patient age and 
presence of multiple viruses. This regression was conducted using the R package logistf (259) with 
Firth’s correction for small sample bias. Only the two dominant RSV genotypes were compared, 
due to the small sample numbers in the other genotype groups. Likewise, pathogen co-detection was 
only compared between pneumococcal vaccine and non-vaccine molecular serotypes. Effect sizes 
with 95% confidence intervals and p values were reported for each. 
 
To better depict co-detection of specific RSV genotypes and S. pneumoniae molecular serotypes, a 
network diagram was produced in Cytoscape 3.3.0 (261). No statistical measures of confidence 
could be added to the network, due to the large number of groups with small numbers of members. 
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4.3 Results 
4.3.1 Pathogen detection 
NPAs from 201 children under the age of five years with respiratory symptoms were collected 
during the RSV seasonal epidemic from mid March to late May 2012. Detailed results from the 
study have been published elsewhere (1) and do not form part of this thesis. Here the focus was on 
the 58 RSV positive samples that were successfully genotyped (87% of the 67 RSV positive 
samples from the cohort) and the 23 S. pneumoniae positive samples that were successfully isolated 
from culture and characterised (82% of the 28 S. pneumoniae positive samples from the cohort). 
The total number of samples included in this study was 68; fully characterised RSV and S. 
pneumoniae data were obtained from 13 samples (76% of the 17 samples from the cohort in which 
RSV and S. pneumoniae were co-detected). Sample collection date and pathogen detection results 
for the 68 samples are presented in Appendix 8.3 Table A4.2. 
 
4.3.2 RSV G diversity 
Of the 58 RSV strains, 44 were identified as subtype A (75.9%) and 14 were subtype B (24.1%). 
Maximum likelihood phylogenies were built of each subtype for both the nucleotide and the 
deduced amino acid sequences, with inclusion of reference sequences downloaded from GenBank. 
Similar branching patterns were observed in the nucleotide (Figure 4.1) and the amino acid 
phylogenies (data not shown). No evidence for recombination between strains was found by RDP4 
analysis of either RSV-A or RSV-B strains (data not shown). 
 
The RSV-A study strains clearly separated into two main genotypes (Figure 4.1A). Three sequences 
(6.8% of RSV-A strains) clustered with genotype GA5, sharing on average 95% nucleotide and 
93% amino acid identity with each other and the GA5 references sequences, and only 88% 
nucleotide and 78% amino acid identity with the other study sequences. The remaining 41 strains 
were classified as genotype GA2, and 39 of those (88.6% of RSV-A study sequences) clustered 
with genotype NA1, which emerged as divergent from GA2 in the mid 2000s (194, 201). The NA1 
study sequences shared 96-100% nucleotide and 93-100% amino acid identity with each other and 
NA1 reference sequences. Within NA1, two study strains had the 72 nucleotide duplication 
consistent with genotype ON1, first identified in Canada in 2010 (207). A number of additional 
subgroups were identified within NA1 however, bootstrap support for these groups was generally 
low (< 70%). One particularly large subgroup, labelled as NA1-sub on Figure 4.1A, contained 12 
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sequences, 11 of which were identical in the region of HVR2 that was sequenced and the remaining 
one which shared 99% nucleotide and 100% amino acid identity with the others.  
 
All RSV-B study sequences contained the 60 nucleotide duplication in HVR2 consistent with 
genotype BA, which emerged in Argentina in 1999 (211) and disseminated globally in the 
following ten years (298). The study sequences shared 88-100% nucleotide and 84-100% amino 
acid identity with each other and BA reference sequences. Low bootstrap support for internal nodes 
limited the definition of subgroups (Figure 4.1B). 
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Figure 4.1 (previous page). Maximum likelihood phylogenies of RSV-A (A) and RSV-B (B) study 
strains (red circles) and reference strains (black circles). Bootstrap support values are shown for 
nodes with > 50% support. Reference strains were downloaded from GenBank and labelled with the 
genotype, strain name and accession ID. Genotypes and sub-genotypes of study sequences are 
annotated with square brackets. Scale bar represents nucleotide substitutions per site. 
 
 
4.3.3 RSV diversity and pathogen co-detection 
Co-pathogen detection was first investigated between RSV subtypes. No variable reached statistical 
significance at p < 0.05 in the univariable analysis (Table 4.2); however, co-detection with hRV 
was more common with RSV-B strains (p = 0.112). While high loads of bacteria (> 10,000 CFU/ml 
of NPA) were detected in equal amounts between subtypes, H. influenzae and S. aureus were 
detected exclusively with RSV-A. S. pneumoniae co-detection was also more frequent with RSV-A. 
There were no strong associations between co-detection of specific pathogens and RSV subtype 
after adjustment for confounding factors (Figure 4.2), however, similar trends to those found in the 
univariable analysis were observed.   
 
 
Table 4.2. Univariable analysis of patient age and pathogen co-detection between RSV subtypes. 
Variable RSV-A 
(n=44) 
RSV-B 
(n=14) 
p value 
Median patient age (IQR) 0.5 (0.2,1) 0.8 (0.2,1.1) 0.683 
>1 virus detected (%) 9 (20.5) 5 (35.7) 0.291 
hRV detected (%) 6 (13.6) 5 (35.7)   0.112 
Adenovirus detected (%) 2 (4.5) 0 (0) 1 
PIV detected (%) 2 (4.5) 0 (0) 1 
High bacterial load detected (%) 31 (70.5) 12 (85.7) 0.317 
S. pneumoniae detected (%) 11 (25) 2 (14.3) 0.489 
H. influenzae detected (%) 5 (11.4) 0 (0) 0.322 
M. catarrhalis detected (%) 14 (31.8) 6 (42.9) 0.525 
S. aureus detected (%) 5 (11.4) 0 (0) 0.322 
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Figure 4.2. Associations between pathogen detection and RSV subtype with adjustment for 
confounding factors. Detection of hRV and detection of >1 virus were adjusted for patient age, 
while the bacterial detection variables were adjusted for patient age and detection of >1 virus. The 
effect size and 95% confidence intervals (CI) are shown, calculated by penalised logistic regression 
with Firth’s correction for small sample bias. Sp: S. pneumoniae, Hi: H. influenzae, Mc: M. 
catarrhalis, Sa: S. aureus. 
 
 
Co-detection was also investigated by RSV genotype, comparing NA1, GA2, GA5 and BA. 
Pathogen co-detection was not significantly different across RSV genotypes in the univariable 
analysis (Table 4.3). Because of the small sample numbers belonging to genotypes GA2 and GA3, 
multivariable analysis was only carried out comparing NA1 with BA. Similar results were found to 
the full subtype analysis; i.e. multiple virus detection, specifically hRV, was more frequent with BA 
detection, while there was a trend towards increased S. pneumoniae, H. influenzae and S. aureus co-
detected with NA1 strains (Appendix 8.3 Figure A4.1). 
 
Within the NA1 genotype, both ON1 strains were S. pneumoniae positive, while all 12 ‘NA1-sub’ 
strains were negative for S. pneumoniae and H. influenzae (Table 4.3). When NA1 was broken into 
these sub-genotypes and pathogen co-detection compared across all the RSV samples, S. 
pneumoniae detection was significantly different between the groups. However, as ON1 only 
contained 2 samples and the grouping of ‘NA1-sub’ had fairly low bootstrap support (Figure 4.1A), 
further statistical analysis was not conducted. 
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Table 4.3. Univariable analysis of patient age and pathogen co-detection between RSV genotypes and between RSV NA1 sub-genotypes.  
Variable GA2 
(n=2) 
GA5 
(n=3) 
BA 
(n=14) 
NA1 
(n=39) 
p value
1
 NA1 sub-genotypes p value
2
 
ON1 
(n=2) 
NA1-sub 
(n=12) 
NA1 other 
(n=25) 
Median patient age (IQR)
 3
 0.8 
(0.6,0.9) 
0.7 
(0.4,0.7) 
0.8 
(0.2,1.1) 
0.4  
(0.2,1) 
NA 0.9  
(0.9,1) 
0.5 
(0.2,1.2) 
0.3 
(0.2,0.9) 
NA 
>1 virus detected (%) 1 (50) 0 (0) 5 (35.7) 8 (20.5) 0.344 0 (0) 4 (33.3) 4 (16) 0.419 
hRV detected (%) 1 (50) 0 (0) 5 (35.7) 5 (12.8) 0.132 0 (0) 3 (25) 2 (8) 0.178 
Adenovirus detected (%) 0 (0) 0 (0) 0 (0) 2 (5.1) 1 0 (0) 1 (8.3) 1 (4) 0.788 
PIV detected (%) 0 (0) 0 (0) 0 (0) 2 (5.1) 1 0 (0) 0 (0) 2 (8) 0.788 
High bacterial load detected (%) 1 (50) 3 (100) 12 (85.7) 27 (69.2) 0.366 2 (100) 6 (50) 19 (76) 0.244 
S. pneumoniae detected (%) 1 (50) 0 (0) 2 (14.3) 10 (25.6) 0.455 2 (100) 0 (0) 8 (32) 0.014 
H. influenzae detected (%) 0 (0) 0 (0) 0 (0) 5 (12.8) 0.567 0 (0) 0 (0) 5 (20) 0.242 
M. catarrhalis detected (%) 1 (50) 1 (33.3) 6 (42.9) 12 (30.8) 0.769 1 (50) 4 (33.3) 7 (28) 0.885 
S. aureus detected (%) 0 (0) 1 (33.3) 0 (0) 4 (10.3) 0.243 0 (0) 2 (16.7) 2 (8) 0.326 
1
p value from Wilcoxon rank sum test and Fisher’s exact test comparing median age and pathogen detection proportions, respectively, between GA2, GA5, BA and 
NA1. 
2
p value from tests as above comparing age and pathogen detection between GA2, GA5, BA, ON1, NA1-sub and NA1 other. 
3
Sample size in GA2 (n=2) too 
small for comparison between median patient ages with Wilcoxon rank sum test. 
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4.3.4 S. pneumoniae core genetic and molecular serotype diversity 
The 23 S. pneumoniae isolates were characterised into 16 unique STs by MLST. The most common 
were ST 199 (3, 13.0%), 2042 (3, 13.0%), 62 (3, 13.0%) and 320 (2, 8.7%). One isolate had an 
MLST profile sequence that had not previously been defined in the PubMLST S. pneumoniae 
database, and the ST was labelled ‘STnew’. 
 
eBURST clustering of the entire population of STs available from the PubMLST S. pneumoniae 
database with the addition of the new ST found that 14 of the sequence types clustered into 11 
predicted clonal complexes (consisting of 19 of the 23 isolates), while ST2042 and the new ST were 
classified as singletons (Figure 4.3B-C). Only two clonal complexes contained more than one study 
ST: clonal complex 6 (ST 1448, 355 and 439) and clonal complex 15 (ST 2068 and 446). 
 
Eleven molecular serotypes were identified in the 23 S. pneumoniae isolates. The most common 
molecular serotypes were 15B/C (5, 21.7%), 23B (3, 13.0%), 11A (3, 13.0%) and 16F (3, 13.0%). 
Four isolates (17%) were presumed to be vaccine-covered serotypes (though it should be noted that 
molecular serotype was used as a proxy for the expressed capsular serotype): one 19F isolate, one 
19A isolate and two 6A/B isolates. Serotypes 19F and 6B are included in PCV7 while 19A and 6A 
are included in PCV13. 
 
When the MLST results and molecular serotyping data were compared (Figure 4.3A-C), core 
genetic diversity varied between molecular serotypes. 11A and 16F were homogenous, with each 
isolate within the molecular serotype sharing the same ST. Some core genetic homogeneity was 
observed in 23B, where all three isolates had STs that were genetically related in the same predicted 
clonal complex. Similarly, in 15B/C three of the five isolates shared the same ST. In contrast, 6A/B 
and 35F were genetically diverse. The 19A and 19F isolates (i.e. different serotypes of the same 
serogroup) also had the same ST. 
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Figure 4.3. Molecular characterisation of S. pneumoniae isolates and pathogen co-detection. The molecular serotype, MLST clonal complexes and STs 
of the isolates are shown (A-C), where the width of each is proportional to the number of isolates of that type. Isolates that share a molecular serotype 
but have different STs (or vice versa) are placed next to each other; otherwise placement of the groups is arbitrary. Singleton STs (i.e. no clonal 
complex could be assigned) are also shown (clonal complex ‘NA’). Viral co-detection (D) is indicated by circles (purple: RSV, orange: hRV, black: 
other virus, including adenovirus and IAV) and bacterial co-detection (E) by squares (red: H. influenzae, green: M. catarrhalis, grey: other bacteria, 
including Moraxella species). Four samples were negative for respiratory viruses. Patient ID is also shown (F). 
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4.3.5 S. pneumoniae diversity and pathogen co-detection 
Due to the small number of samples in each ST, clonal complex and molecular serotype, this study 
lacked the statistical power to determine associations between pathogen co-detection and S. 
pneumoniae diversity. Pathogen co-detection is indicated in Figure 4.3D-E. Some general patterns 
could be observed; for example, molecular serogroups 6 and 19 were both exclusively co-detected 
with hRV, while molecular serotypes 11A, 15B/C and 16F tended to be co-detected with RSV.  
 
Pathogen co-detections and patient ages were also compared between vaccine and non-vaccine 
molecular serotypes. In the univariable analysis, PCV molecular serotypes were associated with 
older children and hRV detection, while non-PCV serotypes were associated with younger age and 
RSV detection (Table 4.4). All four PCV isolates were co-detected with hRV from patients older 
than one year in age. However, for the 19 non-PCV isolates, similar percentages of hRV were 
detected in isolates from patients older and younger than one year in age (33% and 23%, 
respectively). Likewise, RSV was detected in 66% and 69% of these isolates from older and 
younger patients, respectively. Reflecting these findings, the associations with hRV or RSV 
detection and PCV or non-PCV serotype detection persisted after adjustment for age and detection 
of multiple viruses (Figure 4.4). 
 
 
Table 4.4. Univariable analysis of patient age and pathogen co-detection between PCV and non-
PCV pneumococcal molecular serotypes. 
Variable Non-PCV 
(n=19) 
PCV 
(n=4) 
p value 
Median patient age (IQR) 0.7 (0.4,1.2) 2.1 (1.4,2.9) 0.023 
Virus detected (%) 15 (78.9) 4 (100) 1 
>1 virus detected (%) 4 (21.1) 1 (25) 1 
RSV detected (%) 13 (68.4) 0 (0) 0.024 
hRV detected (%) 5 (26.3) 4 (100) 0.014 
Adenovirus detected (%) 1 (5.3) 1 (25) 0.324 
IAV detected (%) 0 (0) 1 (25) 0.174 
H. influenzae detected (%) 2 (10.5) 1 (25) 0.453 
M. catarrhalis detected (%) 9 (47.4) 0 (0) 0.127 
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Figure 4.4. Associations between pathogen detection and S. pneumoniae isolates with molecular 
serotypes presumed to be protected against by the latest pneumococcal conjugate vaccines (PCV), 
with adjustment for confounding factors. Detection of >1 virus was adjusted for patient age, while 
the bacterial detection variables were adjusted for patient age and detection of >1 virus. The effect 
size and 95% confidence intervals (CI) are shown, calculated by penalised logistic regression with 
Firth’s correction for small sample bias. Hi: H. influenzae, Mc: M. catarrhalis. 
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4.3.6 RSV and S. pneumoniae co-detection diversity 
Co-detection of specific RSV genotypes/sub-genotypes and S. pneumoniae molecular serotypes 
were viewed in a network (Figure 4.5). Both ON1 strains were co-detected with isolates of 
molecular serotype 15B/C, while all three 11A S. pneumoniae isolates were co-detected with NA1 
strains. 15B/C was the most well-connected pneumococcal molecular serotype, detected with ON1, 
NA1 and BA strains, followed by 16F, while BA and NA1 were the most well-connected RSV 
genotypes. Univariable analysis found no significant difference between groups when comparing 
the distribution of S. pneumoniae molecular serotypes between RSV groups (p = 0.122, Fisher’s 
exact test), or comparing the distribution of RSV genotypes/sub-genotypes between S. pneumoniae 
groups (p = 0.319, Fisher’s exact test). However, the study lacked the statistical power to perform a 
rigorous comparison between groups. 
 
 
Figure 4.5. Network of co-detection between RSV genotypes/sub-genotypes and S. pneumoniae 
molecular serotypes. RSV groups are in blue, S. pneumoniae molecular serotypes are in green. The 
group of samples S. pneumoniae positive but RSV negative (light green), and the group of samples 
RSV positive but S. pneumoniae negative (light blue), are also shown. The RSV genotype NA1 has 
been broken in the sub-genotypes ON1, the 12 almost identical NA1 sequences (NA1-sub) and the 
remaining NA1 strains (NA1 other). Node size is proportional to the number of samples in that 
node (e.g. 33F = 1 sample, Sp negative = 45 samples). Edge line width is proportional to the 
number of samples forming that edge. Sp: S. pneumoniae. 
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4.4 Discussion 
This retrospective study included samples from 201 children under the age of five years with 
respiratory symptoms; however, the sample size lacked the power to identify associations between 
specific RSV and S. pneumoniae strains, the original goal of the study. The results did identify 
some possible trends indicating co-pathogen interactions, i.e. more frequent co-detection of 
potentially pathogenic bacteria (S. pneumoniae, H. influenzae and S. aureus) and RSV-A compared 
to RSV-B, an association between hRV and RSV-B, and an association between RSV and non-PCV 
pneumococcal strains. However, it needs to be noted that the same trends were not always present 
in the other cohorts investigated in this thesis; the severe ARI cohort investigated in Chapter 2 (the 
PISP cohort) and the community-based cohort investigated in Chapter 3 (the ORChID cohort). In 
both of these cohorts, S. pneumoniae was detected in equal proportions between RSV-A and RSV-
B samples (Table 4.5). H. influenzae was more commonly co-detected with RSV-A compared to 
RSV-B in the ORChID cohort, similar to the results in this pathology cohort; however, in the PISP 
cohort H. influenzae detection was similar between RSV subtypes. Detection of hRV was also more 
common with RSV-A in both the PISP and ORChID cohorts, compared to the association with 
RSV-B identified in this study. 
 
As discussed in Chapter 1.4, viral and bacterial interactions in the diverse environment of the 
paediatric URT are complex, and many factors can influence the results of any one study. The three 
cohorts discussed in this thesis were selected to investigate different hypotheses, and study design 
thus varied between them. Participant recruitment targeted different levels of ARI severity across 
the cohorts, from only severe ARI requiring a hospital visit in the PISP cohort to all RSV detections 
regardless of symptoms in the ORChID cohort. Pathogen detection would be expected to vary 
extensively across such a wide spectrum of ARI severity, potentially affecting the identification of 
co-pathogen interactions. The distribution of ages also varied between the three studies, from 
participants aged < 2 years in the PISP and ORChID cohorts to those aged < 5 years in the 
pathology cohort. In Chapter 2 and in other studies, age has been identified as a confounding factor 
of viral and bacterial detection (56), complicating comparison of pathogen co-detection between 
studies of differently aged cohorts. 
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Table 4.5. Comparison of viral and bacterial co-detection results from the three cohorts investigated in this thesis.  
Cohort Study design Timing of 
study 
Sample 
size
1
 
Bacterial 
detection 
method 
Viral and bacterial co-detection trends 
Pathology 
(Chapter 4) 
Young children 
< 5 years with 
ARI symptoms 
March-May 
2012 
201 
samples
2
  
(44 RSV-A, 
14 RSV-B) 
Culture of NPAs Trend for increased S. pneumoniae co-detection with RSV-A (25%) 
compared with RSV-B (14.3%).  
Trend for increased H. influenzae co-detection with RSV-A (11.4%) 
compared with RSV-B (0%). No trend for increased M. catarrhalis 
co-detection with RSV-A (31.8%) or RSV-B (42.9%). 
Association between hRV co-detection with RSV-B (35.7%) 
compared with RSV-A (13.6%). 
PISP 
(Chapter 2) 
Infants and 
young children 
< 2 years with 
severe ARI at 
hospital ED 
2011-2014 58 samples
2
  
(21 RSV-A, 
8 RSV-B) 
Real-time PCR 
of NPAs 
No trend for increased S. pneumoniae co-detection with RSV-A 
(52.4%) compared with RSV-B (50.0%).  
No trend for increased H. influenzae co-detection with RSV-A 
(47.6%) or RSV-B (37.5%). Trend for increased M. catarrhalis co-
detection with RSV-A (81.0%) compared with RSV-B (37.5%). 
Trend for increased hRV co-detection with RSV-A (28.6%) 
compared with RSV-B (12.5%).  
ORChID 
(Chapter 3) 
RSV positive 
samples 
(including 
asymptomatic) 
from birth 
cohort of 
participants < 2 
years followed 
weekly  
2011-2014 79 RSV 
positive 
episodes  
(55 RSV-A, 
24 RSV-B) 
Real-time PCR 
of nasal swabs 
No trend for increased S. pneumoniae with RSV-A (52.7%) 
compared with RSV-B (50.0%).  
Trend for increased H. influenzae co-detection with RSV-A (20.0%) 
compared with RSV-B (8.3%). No trend for increased M. 
catarrhalis co-detection with RSV-A (40.0%) or RSV-B (37.5%). 
Trend for increased hRV co-detection with RSV-A (16.4%) 
compared with RSV-B (8.3%) 
1
Number of samples included in the study analysis (number RSV-A, number RSV-B). 
2
Including RSV negative samples.
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The three different studies also used different methods for pathogen screening. Bacterial detection 
in the PISP and the ORChID cohorts was conducted using real-time PCR, whereas culture was used 
in the pathology cohort. Real-time PCR is more sensitive than culture, reflected by the increased 
bacterial detection in the first two cohorts; however, it cannot distinguish between viable bacteria 
and bacteria that might have been recently killed by antibiotics or the host immune response. 
Sample type also varied between the studies, with the PISP and pathology cohorts using NPAs 
taken by professionals, whereas the ORChID cohort used nasal swabs taken by parents. NPAs have 
been identified as having higher sensitivity for respiratory virus identification during ARI (299), 
while it is currently unclear whether nasal swabs are as effective as nasopharyngeal samples for 
detection of S. pneumoniae carriage in young children (285). Differences between pathogen 
detection methods and sample sites could affect pathogen co-detections. 
 
Finally, the three studies were not undertaken simultaneously. The PISP study and the ORChID 
study collected samples from 2011 to 2014, whereas the pathology study focused on an eight week 
period during the RSV season of 2012. The RSV strains circulating in the population are constantly 
changing, as the virus evolves to overcome herd immunity and new strains emerge (210). Variation 
in the dominant pneumococcal strains carried in the population can also change over time, 
particularly as a result of PCV introduction (22). RSV and S. pneumoniae strain variation over 
different time frames may have affected identification of strain-specific associations in each of the 
three studies.  
 
Given the many differences between the three studies presented in this thesis, a large prospective 
study would be needed to accurately investigate differences in the co-detection of S. pneumoniae 
between RSV genotypes and subtypes. Using the 2012 data presented in this chapter, the sample 
size required for such a prospective study was estimated for a single RSV season, through the 
power and sample size calculator provided at http://powerandsamplesize.com/Calculators/Compare-
2-Proportions/2-Sample-Equality (300, 301). Of the 58 RSV samples that were typed, 25% of the 
44 RSV-A samples and 14% of the 14 RSV-B samples were S. pneumoniae positive by culture. 
Assuming these samples were adequately representative of the Brisbane population of children < 5 
years, to compare the proportions of RSV-A and RSV-B samples that were S. pneumoniae positive 
with 80% power and a type I error rate of 5%, a sample size of approximately 120 RSV-B and 360 
RSV-A samples would need to be collected (300, 301), i.e. a total of almost 500 RSV positive 
samples. Two hundred and one respiratory samples were obtained from pathology from infants and 
young children with respiratory symptoms, and RSV was detected in 67 (33%) of samples (1). 
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Therefore, around 1500 samples from children with respiratory symptoms aged < 5 years would 
need to be screened. A study of this size would require multi-centre collaboration and extensive 
resources to process and screen such a large number of samples.  
 
One of the assumptions in the above calculation is that in a future study, the ratio of RSV-A and 
RSV-B samples would remain around 76% to 24% (or vice versa). Given the constant evolution of 
RSV strains in the population, it is likely that over the last four years the ratio of RSV-A to RSV-B 
has frequently shifted; indeed, collection date data from the PISP and ORChID cohorts 
demonstrated an increase in RSV-B cases in 2013 and 2014 (Appendix 8.3 Table A4.3). A 
prospective study covering several years of RSV seasonal epidemics would be ideal to capture 
changes in the dominant RSV subtype in the population. Such a study could also capture 
fluctuations in individual genotypes circulating each season, and might be able to provide better 
insight into the differences in S. pneumoniae detection between genotypes than this study was able 
to achieve. However, such a study would likely need to be even larger than the 1500 samples 
estimated in the previous paragraph, to have sufficient power to detect year-to-year differences in 
associations between RSV and S. pneumoniae, and is probably infeasible.  
 
The above sample size calculation also assumed that this study sample population accurately 
represented the population of children aged < 5 years in Brisbane. A comparison of the RSV and S. 
pneumoniae strains detected in this study with global circulation patterns suggests that this was an 
acceptable assumption. In 2012 the majority of the RSV strains circulating in this Brisbane cohort 
were of the genotype NA1. However, evidence of multiple strains circulating in a single season was 
clear, with almost a quarter of RSV strains identified as genotype BA and around 5% identified as 
genotype GA5. It is common for multiple RSV genotypes to co-circulate and these results are 
consistent with the global circulation patterns of RSV strains between 2010 and 2012, where BA 
was the dominant B genotype and NA1 was the dominant A genotype, with some circulation of 
GA5 (189, 194, 195, 197, 198, 207). Two study strains (5% of RSV-A strains) were also identified 
as the RSV-A genotype ON1, which was first identified in the 2010/2011 Canadian winter in 10% 
of RSV-A study strains, and is notable for the 72 nucleotide duplication present in HVR2 (207). 
The prevalence of ON1 has been increasing globally; in the northern hemisphere studies have 
identified ON1-related strains in 10-20% of RSV-A study sequences in the 2011/2012 winter and 
30-88% in the 2012/2013 winter (192, 194, 195, 197, 198, 202, 203, 302). To my knowledge, this 
study is the first time ON1 has been reported to be circulating in Australian children, and reflects 
the well-known ability of RSV strains to rapidly disseminate around the world (298). 
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A diverse range of S. pneumoniae strains were identified in this study, and the majority of isolates 
(83%) were of molecular serotypes not covered by PCV13. These included 15B/C, 23B, 11A, 16F 
and 35 (B or F). The median age of the four children colonised by the vaccine serotypes (6A/B and 
19A/F) was significantly older than those with non-vaccine strains. Vaccination status of the 
children in this study was unknown; however, PCV13 replaced PCV7 in the Australian National 
Immunisation Program in July 2011, approximately nine months before this study took place. It is 
possible that older children (> 1 year old when samples were collected) may not have been 
vaccinated with PCV13 and thus not protected against the PCV13-specific serotypes 6A and 19A. 
An Australian report of IPD surveillance found that while the incidence of IPD cases attributable to 
vaccine serotypes in children aged < 5 years decreased between 2011 and 2012, vaccine serotypes 
still accounted for 52% of IPD cases in that population in 2012 (303). Since this study was 
concerned with nasopharyngeal carriage of S. pneumoniae (albeit in association with ARI 
symptoms), perhaps more relevant for comparison are the paediatric carriage rates of S. pneumoniae 
reported by studies of pneumococcal colonisation in the PCV13 era. In the United States, 91% of 
the serotypes colonising the nasopharynx of young children were identified as non-vaccine 
serotypes after the introduction of PCV13, including serotypes 35 (particularly 35B), 23B, 15A/B/C 
and 21 (76). The study also found a significant increase in the 16 serogroup in the PCV13 era (after 
2010) compared to the PCV7 era (2006-2010) (76). Similarly, post PCV13 introduction in Korea, 
88% of pneumococcal isolates carried by young children were non-vaccine serotypes, including 
23A/B, 15B/C, 10A and 35B (75). The results of this study are therefore consistent with the 
serotype prevalence found by other studies. 
 
The S. pneumoniae isolates were also characterised by MLST. STs 199, 62, 2042 and 320 were the 
most common. The core genetic background of isolates varied between molecular serotypes, with 
some serotypes reflecting homogenous core genetic backgrounds (e.g. 11A and ST62, 16F and 
ST2042) and others heterogeneous (e.g. 6A/B, 35F). Variability in the level of core genetic 
homogeneity between different serotypes has previously been reported (247, 250). The United 
States pneumococcal carriage study found that STs 199, 62 and 558 were most common among 
young children after PCV13 introduction (76). ST199 was associated with serotypes 15A/B/C while 
ST62 was associated with 11A among other serotypes (76), similar to the findings of this study.  
 
We have previously hypothesised that the interaction with RSV may be beneficial to S. 
pneumoniae, potentially resulting in positive selection pressures on pneumococcal strains that 
interact better with the virus, and thereby leading to strain-specific co-transmission and co-detection 
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(6). Therefore, the main focus of this study was to investigate pathogen co-detection patterns 
between RSV and S. pneumoniae strains. However, the study was conducted nine months after the 
introduction of PCV13 in Australia. The majority of infants and young children assessed would 
have likely received this new vaccine, which targets seven of the most prevalent serotypes post 
PCV7. It is possible that PCV13 might have disrupted RSV interactions with the common 
pneumococcal strains, while strains newly emerging through serotype replacement might not have 
had sufficient opportunity to establish robust interactions with RSV. Thus, studies of RSV and S. 
pneumoniae interactions in the population undertaken during this time might have been confounded 
by PCV13 immunisation.  
 
The results of this study suggested that RSV may be more frequently detected with non-PCV13 S. 
pneumoniae strains, a result which is perhaps best explained by age and vaccination status. It would 
be interesting to perform a prospective study investigating strain-specific associations between RSV 
and S. pneumoniae now, four years after the introduction of PCV13, when selection pressure may 
have favoured an increase in molecular interactions with RSV in serotype replacement strains. Such 
selection pressure may result in stronger associations between S. pneumoniae strains and specific 
RSV strains several years post PCV13 introduction. If this is the case, the estimated sample size of 
1500 participants to detect an association between S. pneumoniae presence and RSV subtype may 
be able to be reduced without affecting study power, thus making such a study more manageable.  
 
A retrospective study comparing detection of paediatric respiratory viruses and serotype-specific S. 
pneumoniae co-detection in the pre- and post-PCV13 eras may also be of value, by providing 
insight into the wider effects of PCV13 on the URT environment and the co-evolution of URT 
pathogens. However, such a study would probably be limited to hospital or surveillance data for 
invasive pneumococcal pneumonia, as serotyping is not routinely performed for URT infections. To 
my knowledge, the only paediatric studies of IPD and respiratory viruses to date were performed 
pre-PCV13 (104, 290). Techasaensiri et al. (104) found no association between pneumococcal 
serotypes and specific respiratory viruses, while Launes et al. (290) observed an increase in 
detection of respiratory viruses with serotypes known to be less invasive. A pre-PCV13 study of 
influenza virus and IPD in adults also identified an association between less invasive serotypes and 
influenza activity (304). The effect of PCV13 on interactions between S. pneumoniae and 
respiratory viruses is therefore currently unclear, and the results of this study suggest that further 
investigation into RSV interactions with non-PCV13 serotypes would be worthwhile. 
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Future studies should also correct for other limitations of this study. The study design, accessing 
samples from pathology, meant that important demographic and clinical data was unable to be 
collected, including participant vaccination status, prior antibiotic usage and contact with older 
children. Such factors have previously been found to confound studies of viral and bacterial 
carriage and disease in young children (56, 176, 268) (see also Chapter 2). The methods of 
characterising RSV and S. pneumoniae only allowed the detection of the most dominant strain. 
Young children can be simultaneously colonised by multiple S. pneumoniae serotypes (286), and 
co-infections with both RSV-A and RSV-B have been reported during paediatric ARI (266). 
Culture amplified microarray analysis has been shown to out-perform other molecular serotyping 
methods when the ability to accurately detect multiple pneumococcal serotypes was assessed (235), 
while specific real-time PCRs for RSV-A and RSV-B would at least establish co-infection by both 
RSV subtypes. In this retrospective study, only representative isolates of S. pneumoniae were stored 
during the original bacterial screen, thus multiple serotype carriage could not be evaluated. RSV G 
sequencing chromatograms were examined for evidence of multiple sequences in a sample, but such 
a method would not detect low levels of co-infecting genotypes. 
 
While this study lacked the power to identify associations between specific RSV and S. pneumoniae 
strains, the data collected here can be used to better inform future study designs. The study also 
provided a large panel of characterised clinical S. pneumoniae isolates with pathogen co-detection 
data for subsequent use in exploring the mechanisms of interaction between S. pneumoniae and 
RSV. Chapter 5 reports the binding interactions of these isolates with RSV in epithelial cell culture.  
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5. In vitro analysis of S. pneumoniae adherence to airway epithelia during RSV infection 
5.1 Introduction 
S. pneumoniae was co-detected in half of the paediatric RSV infections investigated in Chapter 2, 
and the results from Chapter 3 suggested that the virus may promote growth of the bacteria from the 
URT flora or be simultaneously co-transmitted in respiratory secretions. It was therefore 
hypothesised that the molecular mechanisms governing RSV and S. pneumoniae interactions may 
be pneumococcal strain-specific and stronger in strains frequently co-detected with RSV. This 
hypothesis was investigated in vitro using the panel of characterised S. pneumoniae strains isolated 
from the pathology cohort of young children with ARI symptoms utilised in Chapter 4.  
 
As discussed in Chapter 1.6.1, the most well described interaction mechanism between RSV and S. 
pneumoniae is viral enhancement of bacterial adherence to airway epithelial cells, resulting in 
improved pneumococcal colonisation of the respiratory tract (6). While RSV has been shown to 
upregulate epithelial cell surface molecules that act as bacterial receptors (138), S. pneumoniae can 
also bind to the RSV G glycoprotein, both directly to the virion and to the protein embedded in the 
host cell membrane during viral infection (128, 136, 137). Variability in the adherence of six 
pneumococcal clinical isolates to airway epithelial cells following RSV infection has been reported 
in vitro between S. pneumoniae serotypes (137, 140). However, multiple pneumococcal factors can 
affect S. pneumoniae adherence to host epithelial cells (236), and studies have reported that genetic 
diversity of pneumococcal isolates does not always correspond with serotype (247, 250). 
Comparison of RSV enhancement of adherence between multiple S. pneumoniae strains from the 
same serotype has not been previously performed, thus in this chapter the effect of RSV on 
pneumococcal adherence was investigated in a subset of thirteen S. pneumoniae isolates from the 
panel described in Chapter 4. This subset included multiple isolates of the same molecular serotype 
and ST, to investigate variation in RSV and S. pneumoniae binding interactions between closely 
related strains.  
 
Previously our laboratory had established that S. pneumoniae cells bound to RSV infected airway 
epithelial cells (unpublished data by Dr Keith Chappell, Appendix 8.4 Figure A5.1). Building upon 
this initial work, an in vitro binding assay was developed to further investigate S. pneumoniae 
adherence to airway epithelia during RSV infection, using immunofluorescence microscopy and 
automated particle counting to quantify S. pneumoniae particle adherence to immortalised airway 
epithelial cells infected with the reference RSV strain A2. Both RSV and S. pneumoniae antigens 
were targeted, allowing simultaneous evaluation of RSV infection as well as S. pneumoniae 
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adherence. The assay was developed in a 96 well plate format, in order to investigate several S. 
pneumoniae isolates in a single experiment. The binding assay developed and used in this 
investigation suffered from significant variation between repeated experiments, probably due to 
inter-experiment differences in bacterial growth phase and integrity of cellular monolayers. 
Nevertheless, the assay allowed the direct comparison of different S. pneumoniae clinical isolates 
and quantification of RSV-mediated pneumococcal adherence within a single experiment.  
 
The clinical S. pneumoniae isolates were derived from the paediatric study of bacterial co-detection 
during viral ARI reported in Chappell et al. (1) and further investigated in Chapter 4, providing the 
opportunity to determine whether pneumococcal strains isolated during co-infections with other 
respiratory pathogens displayed differential binding patterns. It was hypothesised that 
pneumococcal strains isolated from children with a concurrent RSV infection would exhibit 
increased RSV-mediated binding in vitro, compared to isolates from children where RSV was not 
detected. The subtype and genotype of each co-detected RSV strain was also determined in Chapter 
4, thus it was hypothesised that pneumococcal strains would bind better to airway epithelia infected 
with the same RSV subtype as the virus strain co-detected in the patient. To investigate this 
hypothesis, the binding assay was modified to compare S. pneumoniae adherence following 
infection with clinical strains of RSV-A and RSV-B isolated from the same pathology cohort 
described in Chapter 4. 
 
Previously, direct binding of RSV virions to multiple S. pneumoniae clinical isolates has been 
shown to enhance bacterial adherence to uninfected airway epithelia, independent of pneumococcal 
strain (137). The binding assay was also modified to replicate this experiment with the S. 
pneumoniae clinical isolates characterised in Chapter 4, by pre-incubating S. pneumoniae and RSV-
A2 before assessing the binding of the complexes to uninfected immortalised airway epithelial cells. 
It was hypothesised that RSV-bacteria complex binding patterns would reflect pneumococcal 
adherence patterns to RSV infected epithelial cells, i.e. strains that bound well to RSV infected cells 
would also bind well to uninfected epithelial cells after forming complexes with RSV. 
 
 103 
 
5.2 Methods 
5.2.1 Epithelial cell culture 
A549 cells (human lung epithelial carcinoma cells) were grown in Dulbecco’s Modified Eagle 
Medium/Nutrient Mixture F-12 (DMEM/F-12) media (Gibco, Australia) supplemented with 5% 
FBS (Bovogen Biologicals, Australia). Cells were passaged regularly as required (1:5 to 1:10 
dilutions) using 0.5% Trypsin-ethylenediaminetetraacetic acid (EDTA) (Gibco, Australia).  
 
5.2.2 Bacterial strains 
Clinical strains of S. pneumoniae were isolated from children < 5 years of age with ARI symptoms 
and their molecular serotype and ST determined, as described in Chapter 4.2. The well-
characterised reference strain D39 was kindly provided by Prof. Alastair McEwan (UQ, School of 
Chemistry and Molecular Biosciences). 
 
For binding studies, bacteria were originally grown in 12 ml cultures of THY media (Oxoid, 
Australia) + 5% FBS, however, during assay optimisation it was found that FBS non-specifically 
inhibited binding of bacteria to epithelial cells. Thus, bacteria were grown from glycerol stocks in 
12 ml cultures of THY media without FBS with overnight incubation at 37
o
C in 5% CO2. Bacterial 
cells were collected by centrifugation at 2000 x g for 10 minutes and the cell pellet resuspended in 5 
ml PBS. Isolates were quantified on the BioPhotometer spectrophotometer (Eppendorf, Australia) at 
600 nm and CFU/ml calculated (optical density of 1 ≈ 1.4 x 108 CFU/ml).  
 
5.2.3 Virus strains 
The prototype strain RSV-A2 was used in the majority of binding experiments. Two clinical strains 
of RSV were previously isolated by Dr Keith Chappell from the same cohort as the S. pneumoniae 
clinical isolates, from patient BNE-2 and BNE-20. Briefly, NPAs were added to A549 cells in 24 
well plates in the presence of penicillin, streptomycin and gentamycin (Gibco, Australia). After 7 
days, supernatant was harvested and further passaged on A549 cells to allow the virus to amplify. 
Cytopathic effect was used as an indicator of virus replication. Supernatant containing RSV was 
snap-frozen in liquid nitrogen and stored at -80°C. RSV strains were genotyped as per the methods 
described in Chapter 4.2.2 and found to be of genotype NA1 (BNE-20) and BA (BNE-2).  
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Virus stocks for binding experiments were obtained from infection of A549 cells at 80% confluency 
in T175 flasks with virus in DMEM/F-12 + 2% FBS. RSV-A2 was added at 0.01-0.001 plaque 
forming units (PFU) per cell, while approximately 0.3 ml per flask of first passage clinical RSV 
strains was used. Flasks were incubated at 37
o
C in 5% CO2. Supernatant was harvested 5-7 days 
post infection, based on appearance of cytopathic effects and syncytia formation. Cell debris was 
removed by centrifugation at 3000 x g for 10 minutes at 4
o
C. Virus was then collected by 
centrifugation at 8000 x g for 2 hours at 4
o
C. Supernatant was removed and virus pellet was 
incubated on ice for 3 minutes in Opti-MEM Reduced Serum Media (Gibco, Australia). Aliquots of 
purified virus were snap-frozen in liquid nitrogen and stored at -80
o
C. 
 
Virus stock titres were established by viral plaque assays. Serial 10-fold dilutions of viral stocks in 
DMEM/F-12 + 2% FBS were made and 100 µl per well were used to infect confluent A549 cells in 
96 well plates in duplicate. An overlay, such as agarose or methylcellulose, was not used because 
within the time frame utilised RSV remains cell-associated, spreading by syncytial formation. Our 
laboratory has found that an overlay is not necessary, as a comparable number of plaques can be 
visualised with and without an overlay (unpublished data). Cells were incubated for 3 nights at 37
o
C 
in 5% CO2. Cells were then fixed in ice cold 80% acetone in PBS and incubated for 20 minutes at -
20
o
C. Fixative was then removed and plates dried at room temperature. Dry plates were blocked in 
200 µl per well of PBS + 0.1% Tween 20 (PBS-T) with 5% skim milk powder (Devondale, 
Australia) for 30 minutes at room temperature. Primary anti-RSV antibody (human motavizumab, 
described in Chapter 5.2.6) was added at 0.002 mg/ml (50 µl per well) in 5% skim milk powder + 
PBS-T and plates were incubated for 1 hour at 37
o
C. Primary antibody was removed and plates 
washed three times in water. Secondary antibody (anti-human IRDye 800, LI-COR Biosciences, 
USA) was added at 1:5000 dilution (50 µl per well) in 5% skim milk powder + PBS-T and plates 
incubated for 1 hour at 37
o
C. Secondary antibody was removed and plates washed three times in 
water. Plates were dried at room temperature. Virus plaques were visualised on the Odyssey Imager 
(LI-COR Biosciences, USA). Plaques were counted by eye from scanned images (for wells with 10-
100 plaques) and viral titres in PFU/ml were calculated for the original viral stock. 
 
5.2.4 Binding assay 
Several conditions were evaluated during optimisation of the in vitro binding assay, summarised in 
Appendix 8.4 Table A5.1 and detailed in Appendix 8.4 Figures A5.2 to A5.5. The following 
procedure was established to be the most optimal at the time, although evaluation of the variation 
between repeated experiments from the final binding assay suggested that further optimisation 
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would be required to improve reproducibility. A549 cells were grown to confluency in 96 well 
plates. Cells were infected with 100 µl per well of RSV in DMEM/F-12 + 2% FBS media (RSV-A2 
at 1 x 10
5
 PFU/ml, clinical strain RSV-NA1 at 1.4 x 10
4
 PFU/ml or clinical strain RSV-BA at 2 x 
10
2
 PFU/ml), or mock infected with media, and incubated for 2 nights (RSV-A2) or 3 nights 
(clinical strains) at 37
o
C in 5% CO2. The day of the binding assay, bacteria cultures (grown up the 
night before) were quantified as described in Chapter 5.2.2 and diluted to 1 x 10
7
 CFU/ml in PBS. 
Media was then removed from each plate and 100 µl per well of diluted bacteria or 100 µl per well 
of PBS (as a negative control) was added in triplicate. Since the purpose of the binding assay was to 
investigate first-contact interactions between S. pneumoniae and host cells during RSV infection, 
plates were incubated for only 30 minutes at 37
o
C in 5% CO2. Bacteria and PBS were then removed 
and wells were washed three times in 100 µl per well of PBS. Cells were then fixed in 100 µl per 
well of 4% paraformaldehyde (PFA) in PBS, followed by a final wash in 100 µl per well of PBS. 
Plates were then immediately used in immunofluorescence, or stored overnight at 4
o
C in 100 µl per 
well PBS. D39 and the PBS negative control were included on every plate. Each binding assay was 
repeated 2-5 times independently for each pneumococcal isolate.  
 
5.2.5 S. pneumoniae and RSV-A2 pre-binding assay 
The adherence of S. pneumoniae and RSV-A2 complexes was investigated in a subset of seven 
pneumococcal isolates, D39 and the PBS negative control in triplicate. Unlike in the previous 
binding assays, bacteria were diluted in serum-free DMEM/F-12 media instead of PBS, to prevent 
pneumococcal cell lysis from osmotic pressure. A549 cells were grown to confluency in 96 well 
plates. The following day, 500 µl of each bacterial strain (or PBS) at 1 x 10
7
 CFU/ml in serum-free 
DMEM/F-12 media was added to 50 µl of RSV-A2 (or media) at 1 x 10
6
 PFU/ml in serum-free 
DMEM/F-12 media, mixed by gentle pipetting, and incubated for 30 minutes at 37
o
C in 5% CO2. 
Media was then removed from A549 cells and 100 µl per well of each bacteria-virus mixture was 
added and the plate incubated for 30 minutes at 37
o
C in 5% CO2. The binding assay was then 
performed as above, i.e. plate was washed three times in PBS and fixed in 4% PFA.  
 
5.2.6 Immunofluorescence microscopy 
For immunofluorescence, S. pneumoniae primary rabbit polyclonal antibody PA1-7259 (Thermo 
Fisher Scientific, Australia) was used at 1:500 dilution. While several polyclonal and monoclonal 
antibodies are available for RSV surface proteins, our laboratory has developed a range of in-house 
reagents for RSV and other viruses. One such reagent has been the development of chimeric 
 106 
 
antibodies comprising the motavizumab anti-RSV fusion protein variable regions (305) and mouse 
or human constant regions, following a cloning procedure adapted from Jones et al. (306). Chimeric 
motavizumab antibodies were generated and validated by Dr Keith Chappell, Dr Daniel Watterson 
and Imogen Bermingham. In this study chimeric motavizumab antibodies were used to mark RSV 
infection in the binding assays at 0.002 mg/ml. Secondary antibodies included donkey anti-rabbit 
488 or donkey anti-rabbit 555 for the S. pneumoniae primary, and donkey anti-mouse 555 or goat 
anti-human IgG FITC for the RSV primary (Thermo Fisher Scientific, Australia). Nucleic acid in 
A549 cells was stained with Hoechst 33342 (Invitrogen, Australia).   
 
Fixed cells were blocked in 5% blocking solution (KPL, USA) in PBS-T for 30 minutes at room 
temperature. Primaries were diluted to the concentrations given above in 5% blocking solution in 
PBS-T and 50 µl per well added. Cells were incubated at 37
o
C for 1 hour, and then washed three 
times in 100 µl per well PBS-T. Secondaries and Hoechst 33342 were diluted to 1:2000 in 5% 
blocking solution in PBS-T and 50 µl per well added. Cells were incubated at 37
o
C for 1 hour, and 
then washed three times in 100 µ per well PBS-T. Microscopy was then immediately performed, or 
plates were stored in the dark at 4
o
C overnight.  
 
5.2.7 Image analysis 
Plates were viewed on the IN Cell Analyzer 1000 (GE Healthcare Life Sciences, Australia) with a 
20X objective lens (Nikon, USA). Five (RSV-A2 binding assays and pre-binding assays) or eight 
(clinical RSV binding assays) microscopic fields-of-view per well were captured in fluorescence 
channels 360-460 nm, 480-535 nm and 565-620 nm and bright field, resulting in a maximum of 15 
or 24 images per channel for each isolate and infection condition.  
 
Images were viewed and analysed in the Fiji distribution of ImageJ (307, 308). Images were 
manually curated to exclude out of focus fields; those where substantial A549 cell monolayer loss 
had occurred, to control for variation in bacterial binding to the plate in the absence of cells; and 
those where cell debris obscured binding results. The control wells (only RSV, only S. pneumoniae 
or only PBS) were checked for cross-channel interference and cross-well viral or bacterial 
contamination. After manual quality control, basic image statistics of the fluorescence channels 
were measured (e.g. mean fluorescence). Automatic thresholding via the Triangle method (309) was 
used to reduce the effects of background fluorescence and cross-channel interference, converting 
the images to binary. Holes between close-lying regions of fluorescence were filled and a watershed 
algorithm was performed to separate touching particles. Basic image statistics were re-measured for 
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the binary images (e.g. percent area above threshold). Particle counting was performed for the S. 
pneumoniae channel for all assays and the RSV channel in the pre-binding assay, using the ImageJ 
standard Particle Analyzer and counting S. pneumoniae particles between 5 and 2000 pixels in size. 
For binding assays with clinical RSV strains and pre-binding assays, co-localisation of RSV 
positive S. pneumoniae particles was determined with geodesic reconstruction by dilation (pixel 
connectivity of 4) using the MorphoLibJ library (310) and the RSV positive S. pneumoniae particles 
counted as above. Various basic image statistics and the S. pneumoniae and RSV particles counts 
were reported as appropriate. To ensure consistent analysis between experiments, the entire analysis 
was written into a script substantially adapted from one provided by Dr Keith Schulze (Monash 
Micro Imaging, Monash University, Australia) during a workshop at the 2014 BioInfoSummer 
summer school (Monash University, Australia). 
 
For immunofluorescence images presented in this thesis, the minimum and maximum pixel values 
were set to 100 and 190 for the host cell nuclei staining in the 360-460 nm channel, 100 and 140 for 
the RSV staining in the 480-535 nm channel, and 110 and 135 for the S. pneumoniae staining in the 
565-620 nm channel. The three channels were also merged to create composite images. 
 
5.2.8 Statistical analysis 
For technical replicates within an experiment, mean number of fluorescent S. pneumoniae particles 
per field was calculated for each isolate during mock and RSV infection and compared with t-tests 
in Prism 7 (GraphPad Software, Australia). Comparison of median mock adherence between mock 
and RSV infection for each isolate was performed using Wilcoxon matched-pairs signed rank tests 
in Prism. Fold change in adherence during RSV-A2 infection compared to mock infection was 
calculated for each isolate and log-transformed to base 10, to fit a normal distribution. Increase in 
adherence of pneumococcal particles during RSV-A2 infection compared to mock infection was 
also calculated, by subtracting the mean mock adherence of each isolate in each experiment from 
the mean RSV-A2 adherence. As both fold change and increase in adherence followed a normal 
distribution, one-way ANOVA was performed to compare measures of adherence across isolates in 
Prism. Correlation between fold change during RSV-A2 infection and mock adherence was 
determined with a nonparametric Spearman correlation test in Prism. 
 
Median mock adherence, mean fold change and mean increase in adherence during RSV-A2 
infection was investigated between pathogen co-detections in the patient from which each strain 
was isolated. Univariable analysis was performed in R (257) with the package epicalc (258), using 
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Wilcoxon signed rank sum tests (for median mock adherence) and t-tests (for fold change and 
increase in adherence). The three measures of adherence were also compared between isolate 
molecular serotype and co-detected RSV genotype, using Kruskal-Wallis tests (mock adherence) 
and one-way ANOVA (fold change and increase in adherence) in Prism. Correlations with patient 
age were determined with Spearman (mock adherence) and Pearson (fold change and increase in 
adherence) correlation tests in Prism. 
 
For the binding assays using clinical RSV strains, the RSV positive S. pneumoniae particle count 
for each field was used to approximate the number of S. pneumoniae particles that theoretically 
would be present if 100% RSV infection was achieved across the field, by multiplying the number 
of RSV positive S. pneumoniae particles by the percent of field not infected by RSV.  Due to the 
low levels of RSV infection by clinical virus strains, this calculation was only carried out for fields 
where > 1% contained RSV fluorescence above the value determined for image thresholding (the 
cut-off of 1% was determined from comparison of background fluorescence in the RSV channel of 
mock fields). For each isolate, mean mock adherence and normalised RSV-A2 adherence were 
compared using multiple t-tests with Holm-Sidak’s correction for multiple comparisons in Prism.  
 
For the pre-binding experiments, mean number of fluorescent RSV particles per field was 
calculated in addition to S. pneumoniae adherence. For each isolate, mean adherence with virus-free 
media and RSV-A2 was compared using multiple t-tests with Holm-Sidak’s correction for multiple 
comparisons in Prism, to determine whether each isolate’s binding pattern was similar to those 
observed in the binding assays to mock and RSV infected cells. Mean virion adherence was 
compared between isolates with one way ANOVA in Prism, to evaluate any strain-specific effects 
of S. pneumoniae isolates on the ability of RSV-A2 to bind to host cells after incubation. 
 
5.3 Results 
5.3.1 In vitro binding assay 
Results from the optimisation of the in vitro binding assay are represented in Appendix 8.4 Table 
A5.1 and Figures A5.2 to A5.5. Thirteen pneumococcal isolates derived from the paediatric cohort 
discussed in Chappell et al. (1) were included in the optimised in vitro binding assays comparing 
mock and RSV-A2 infection. The molecular serotype and ST of twelve of these isolates were 
characterised in Chapter 4. The remaining isolate examined had been excluded from the analysis in 
Chapter 4 due to failed RSV genotyping. The reference strain D39 was included as a positive S. 
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pneumoniae control, while PBS was used as a negative S. pneumoniae control. The characteristics 
of the pneumococcal clinical isolates, first described in Chapter 4, are summarised with D39 in 
Appendix 8.4 Table A5.2. 
 
The in vitro binding assay was developed as a semi-high-throughput method, in a 96 well plate 
format with automated analysis of immunofluorescence microscopy images. Complete infection of 
A549 cell monolayers was achieved after 48 hours of infection with RSV-A2, at which point 
attachment of S. pneumoniae to infected and control mock infected cells was assessed. S. 
pneumoniae particles were detected by immunofluorescence and counted across multiple fields 
within each well (example fluorescent images from one experiment are shown in Figure 5.1). Five 
microscopic fields-of-view were captured for each well, and the binding of each isolate was 
compared between mock and RSV-A2 infected cells in triplicate, resulting in a maximum number 
of 15 fields per isolate for mock and RSV-A2 infection (some fields were excluded due to factors 
affecting particle counting, e.g. out of focus fields or cell monolayer loss). Technical error within an 
experiment was generally low, although for S. pneumoniae strains that bound well to airway 
epithelia, such as D39, larger standard deviations were observed (Figure 5.2 and Appendix 8.4 
Figure A5.6).  
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A D39 
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 A549 cell nuclei Anti-RSV Anti-S. pneumoniae Merge 
RSV-A2 
    
C BNE-119 
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RSV-A2 
    
24 
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 A549 cell nuclei Anti-RSV Anti-S. pneumoniae Merge 
D PBS 
mock 
    
RSV-A2 
    
 
Figure 5.1. Example immunofluorescence images from S. pneumoniae isolates binding to mock or RSV-A2 infected A549 airway epithelial cells. D39 
(A), BNE-139 (B), BNE-119 (C) and PBS negative control (D) are shown with A549 cell nuclei staining using Hoechst 33342 (blue), anti-RSV (red) 
and anti-S. pneumoniae (green). D39, BNE-139 and BNE-119 tended to bind well, moderately and poorly to uninfected epithelia, respectively, 
reflecting the variation observed across the isolates tested. Composite images of the merged channels are also shown. Number of S. pneumoniae 
particle counts are shown in the upper right-hand corner of each anti-S. pneumoniae image.
0 
0 
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Figure 5.2. Example particle counts for S. pneumoniae adherence to mock (grey circles) and RSV-
A2 infected (blue squares) A549 airway epithelial cells from a single binding assay experiment. The 
remaining four experiments are presented in Appendix 8.4 Figure A5.6. Pneumococcal fluorescent 
particle counts per field are shown, with error bars representing the mean and standard deviation. 
Not every isolate was repeated in each experiment. Mean particle counts were compared between 
mock and RSV-A2 infection for each isolate: ***: p < 0.001, **: p < 0.01, *: p < 0.05, ns: p > 0.05 
(t-tests). 
 
5.3.2 Pneumococcal binding to airway epithelial cells 
For each isolate, the mean pneumococcal fluorescent particle count (referred to here on in as 
pneumococcal adherence) was calculated during mock infection of airway epithelial cells or 
infection with the reference strain RSV-A2. Between two and five individual binding assay 
experiments were performed for each isolate. Substantial variation in adherence to mock infected 
airway epithelial cells was observed between clinical isolates (Figure 5.3). There was also 
substantial variation between repeated binding assay experiments. For example, in four of the five 
experiments, D39 adhered well to airway epithelia, while in one experiment the bacteria exhibited 
low adherence (Figure 5.2 and Appendix 8.4 Figure A5.6). It is likely that this outlier occurred 
through an error in the experimental procedure. The same experiment (experiment 4 in Appendix 
8.4 Figure A5.6) yielded adherence data consistent with previous experiments for the other isolates 
tested, e.g. BNE-77, suggesting that any potential error occurred only in the D39 isolate. It is 
possible that cross-contamination occurred between bacterial cultures, or a culture was mislabelled, 
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although care was taken throughout to minimise such errors. However, other isolates also exhibited 
variation in adherence to mock infected airway epithelia, though generally to a lesser extent, 
possibly due to variation in bacterial growth in culture before each binding experiment was 
performed. As the possibility of natural variation in bacterial adherence could not be eliminated, the 
D39 outlier was not excluded from the analysis.  
 
Overall, however, D39 consistently adhered well to airway epithelia. Some isolates of the same 
molecular serotype had similar adherence, for example, both 6A/B isolates generally did not adhere 
well to uninfected airway epithelia. However, one of the three 23B isolates bound in greater 
numbers than the other two isolates, as did one of the four 15B/C isolates (BNE-8) compared to the 
other three. The variation within 15B/C was not related to MLST sequence type, as both BNE-8 and 
BNE-119 were of ST199. 
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Figure 5.3. Adherence of pneumococcal clinical isolates and strain D39 to A549 airway epithelial 
cells. Points represent the mean number of fluorescent pneumococcal particles across technical 
replicates within an experiment on a logarithmic axis, with error bars representing the median and 
IQR of multiple repeated experiments (between 2 and 5 replicates per isolate). Isolates are labelled 
by patient ID and molecular serotype is indicated above the graph.  
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5.3.3 RSV-A2 enhancement of pneumococcal adherence 
The adherence of pneumococcal isolates was compared between mock and RSV-A2 infected A549 
cells in two to five individual experiments, depending on the isolate. The results of each individual 
experiment are summarised in Table 5.1 and graphed in Figure 5.2 and Appendix 8.4 Figure A5.6. 
In the majority of experiments adherence of D39, BNE-8, BNE-139 and BNE-77 to airway epithelia 
was not significantly different between mock and RSV-A2 infection, while in the majority of 
experiments BNE-119, BNE-117, BNE-6, BNE-100, BNE-83, BNE-144, BNE-103, BNE-21 and 
BNE-88 adherence was significantly increased during RSV-A2 infection. BNE-157 tended to 
exhibit increased adherence during RSV-A2 infection, however, the difference was only significant 
in two of four repeated experiments. 
 
Comparison of median pneumococcal adherence across repeated experiments did not demonstrate 
statistical differences between mock and RSV-A2 infection for any isolate, due to the wide levels of 
variation observed between experiments (p > 0.05 for all). Generally, however, isolates like D39 
that tended to adhere well to mock infected epithelia also adhered equally well during RSV-A2 
infection, while isolates like BNE-119 that generally adhered poorly to mock infected cells tended 
to bind in greater numbers during RSV-A2 infection (Figure 5.4A). 
 
To reduce the effects of inter-experiment variation, log-transformed fold change in adherence 
between mock and RSV-A2 infection was calculated for each experiment (Figure 5.4B). This 
normalisation of the data to compare only relative binding between mock and RSV-A2 infected cell 
culture substantially reduced variability between experiments, presumably by removing inter-
experiment variation relating to bacterial growth and epithelial monolayer integrity (discussed 
further in Chapter 5.4). However, some variability still remained between experiments, including 
the D39 outlier discussed in Chapter 5.3.2. Despite the occasional outlier, log-transformed fold 
changes were significantly different between isolates (p < 0.0001, one-way ANOVA), ranging from 
a mean of 0.099 (D39, equivalent to an untransformed fold change of 1.256) to 1.155 (BNE-119, 
untransformed fold change of 14.280).  
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Table 5.1. Summary of pneumococcal clinical isolate adherence to mock and RSV-A2 infected A549 cells across technical replicates in each repeated 
experiment (n=2-5 depending on isolate), including fold change in adherence mediated by RSV in bold. Significant differences at p < 0.05 are 
highlighted in grey. 
 
 D39 BNE-
119 
BNE- 
8 
BNE-
117 
BNE- 
6 
BNE-
139 
BNE-
100 
BNE- 
83 
BNE-
144 
BNE-
157 
BNE-
103 
BNE- 
77 
BNE- 
21 
BNE- 
88 
E
x
p
er
im
en
t 
1
 
Mean mock 
(SD) 
407 
(153.9) 
NA 228.4 
(69.1) 
18.4 
(11) 
14 (6.2) 21 (7.5) 18.8 
(8.2) 
50 (17) 21.2 
(16) 
NA 173.1 
(79.9) 
NA 39.7 
(23.8) 
NA 
Mean RSV 
(SD) 
403 
(173.9) 
 
 304.5 
(38.6) 
216.7 
(49.5) 
83 
(50.1) 
41.5 
(8.9) 
103 
(36.3) 
134.8 
(53.6) 
121.6 
(19.4) 
 323.8 
(96.3) 
 111 
(21.6) 
 
p 0.963  0.147 <0.001 0.027 0.027 0.027 0.027 <0.001  <0.001  0.002  
Fold change 1.0  1.3 11.8 5.9 2.0 5.5 2.7 5.7  1.9  2.8  
E
x
p
er
im
en
t 
2
 
Mean mock 
(SD) 
308.2 
(230.2) 
NA 34 (24) 1.1 (1.4) 0.7 (1.3) 1.6 (1.5) 0.9 (1.8) 2.6 (2.6) 1.4 (1.7) 3.2 (7.2) 20.1 
(19.8) 
NA 1.1 (1.6) 5.6 (5.2) 
Mean RSV 
(SD) 
183.1 
(181.7) 
 19.7 
(18.6) 
15.1 
(12.6) 
8.3 (7.3) 4.6 (6.1) 1.5 (2.4) 12.4 
(9.3) 
2.7 (2.6) 12.5 
(13.5) 
26.3 
(24.7) 
 1.5 (1.8) 46.7 
(29.8) 
p 0.583  0.583 0.004 0.005 0.458 0.860 0.012 0.525 0.273 0.860  0.860 0.001 
Fold change 0.6  0.6 13.7 11.9 2.9 1.7 4.8 1.9 3.9 1.3  1.4 8.3 
E
x
p
er
im
en
t 
3
 
Mean mock 
(SD) 
657.3 
(91.5) 
NA 70.4 
(29.6) 
1.5 (2.8) 7.7 (7) 60.2 
(21.3) 
2.1 (2.1) 1.9 (1.8) 4.2 (5) 18.5 
(16.5) 
NA 68.9 
(52.9) 
24 (6.9) NA 
Mean RSV 
(SD) 
515 
(73.9) 
 118.6 
(16.1) 
40.7 
(34.1) 
43.9 
(31.7) 
49.9 
(14.9) 
13.5 
(9.1) 
22.2 
(6.8) 
31.8 
(13.3) 
23.4 
(12.6) 
 106.8 
(70.3) 
21.8 
(21.2) 
 
p 0.020
1 
 0.005 0.001 0.002 0.560 0.001 <0.001 <0.001 0.757  0.560 0.769  
Fold change 0.8  1.7 27.1 5.7 0.8 6.4 11.7 7.6 1.3  1.6 0.9  
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 D39 BNE-
119 
BNE- 
8 
BNE-
117 
BNE- 
6 
BNE-
139 
BNE-
100 
BNE- 
83 
BNE-
144 
BNE-
157 
BNE-
103 
BNE- 
77 
BNE- 
21 
BNE- 
88 
E
x
p
er
im
en
t 
4
 
Mean mock 
(SD) 
3.1 (6) 2.4 (3.3) 28.2 
(20.8) 
6 (7) 1.1 (1.7) 15.2 
(14.4) 
NA 4.9 (7.6) 0.4 (1.1) 2.8 (3) NA 108.2 
(39.5) 
1.2 (1.5) 49 
(11.4) 
Mean RSV 
(SD) 
27.9 
(13.2) 
34.5 
(12.5) 
43.2 
(17.1) 
59.4 
(20.1) 
37.3 
(6.5) 
43.9 
(23.7) 
 25.4 
(11.7) 
17.3 
(5.1) 
25.8 
(12.8) 
 106 
(21.5) 
8.3 (5.5) 154.7 
(40.4) 
p <0.001 <0.001 0.090 <0.001 <0.001 0.003  <0.001 <0.001 <0.001  0.860 0.001 <0.001 
Fold change 9.0 14.4 1.5 9.9 33.9 2.9  5.2 43.3 9.2  1.0 6.9 3.2 
E
x
p
er
im
en
t 
5
 
Mean mock 
(SD) 
227.1 
(93.3) 
1.4 (1.6) NA NA 0.3 (0.8) 12.7 
(9.8) 
0.6 (1.6) NA 4.6 (4.8) 1.8 (2.7) 22.1 
(10.9) 
26 
(14.4) 
3.3 (2.9) 4.1 (5.4) 
Mean RSV 
(SD) 
230.8 
(77.7) 
12.9 (8)   2.3 (2.5) 22.1 
(13.5) 
28 
(15.1) 
 29.8 
(9.6) 
9.2 (9) 47.8 
(17.4) 
63.4 
(26.9) 
23.9 
(14.4) 
53.3 
(20.4) 
p 0.926 <0.001   0.030 0.105 <0.001  <0.001 0.032 0.004 0.001 <0.001 <0.001 
Fold change 1.0 9.2   7.7 1.7 46.7  6.5 5.1 2.2 2.4 7.2 13.0 
No. of experiments 
showing 
significantly 
increased adherence 
during RSV 
infection (% of total 
per isolate) 
1 of 5 
(20%) 
2 of 2 
(100%) 
1of 4 
 (25%) 
4 of 4 
(100%) 
5 of 5 
(100%) 
2 of 5 
(40%) 
3 of 4 
(75%) 
4 of 4 
(100%) 
4 of 5  
(80%) 
2 of 4 
(50%) 
2 of 3 
(67%) 
1 of 3 
(33%) 
3 of 5 
(60%) 
3 of 3 
(100%) 
1
Significant decrease in adherence during RSV infection compared to mock infection. SD: standard deviation.
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Figure 5.4 (previous page). Effect of RSV-A2 infection on adherence of S. pneumoniae clinical 
isolates and D39 to airway epithelial cells. Mean number of pneumococcal particles adhering to 
A549 cells was compared during mock (grey circles) and RSV-A2 (blue squares) infection for each 
experiment, repeated 2-5 times for each isolate (A). Log-transformed fold change in mean 
adherence during RSV-A2 compared to mock infection was compared between D39 and clinical 
isolates for each experiment (B). Increase in pneumococcal particle count during RSV-A2 
compared to mock infection was also compared between D39 and clinical isolates (C). Particle 
adherence in A is shown on a logarithmic axis. Error bars in B and C represent mean and standard 
deviation, and the dotted line in at y = 0 indicates no change in adherence between RSV-A2 and 
mock infection. 
 
 
Fold change in adherence was found to be inversely proportional to mock adherence to epithelial 
cells (Figure 5.5) (correlation r = -0.815, p < 0.0001). This correlation suggests that isolates that 
tended to bind well to airway epithelia were at the limit of detection in the assay during mock 
infection, resulting in no measurable effect of RSV-A2 infection on adherence. The correlation may 
have also been an artefact of the fold change calculation, since a smaller absolute increase in 
adhering particles was needed in a lower binding isolate to produce the same fold change as in a 
higher binding isolate. 
 
To partially overcome this potential limitation of the binding assay, mean increase in particle counts 
during RSV-A2 compared to mock infection was also investigated (Figure 5.4C). Notably in this 
analysis, the majority of S. pneumoniae isolates (excluding the D39 laboratory strain) showed 
increased binding following RSV infection. Overall, the differences in adherence between isolates 
did not reach statistical significance (p = 0.0628, one-way ANOVA). D39 had the widest variation 
between experiments, ranging from a decrease of almost 200 particles during RSV infection to an 
increase of almost 25 particles. BNE-139 and BNE-157 had, on average, the smallest increases in 
particle count during RSV infection (< 20 particles), while BNE-103, BNE-117 and BNE-88 had 
the largest increases (>50 particles), followed by BNE-144 (average increase of 44 particles). The 
majority of replicates for BNE-144 and BNE-88 fell on the upper side of the trend line comparing 
fold change in adherence to mock adherence in Figure 5.5, while the reverse was true of isolates 
BNE-139 and BNE-157.  
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BNE-88 and BNE-144 consistently displayed enhanced binding to airway epithelia during RSV-A2 
compared to mock infection in all three analyses, suggesting that RSV-A2 infection did have an 
effect on the adherence of these isolates. Some of the other poorly and moderately binding isolates 
also tended to exhibit enhancement of adherence by RSV-A2; however, these trends were less 
consistent across the different analyses and between repeated experiments. BNE-139 and BNE-157 
had consistently similar adherence to mock and RSV-A2 infected airway epithelia, suggesting 
limited interactions with RSV.  
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Figure 5.5. Relationship between S. pneumoniae adherence to mock infected airway epithelial cells 
and fold change in adherence between RSV-A2 and mock infection. Log-transformed fold change 
in adherence between RSV-A2 and mock infection is plotted against mean fluorescent 
pneumococcal particles during mock infection on a logarithmic axis. The dotted line at y = 0 
represents no difference between mock and RSV-A2 adherence. Correlation was computed and the 
trend line is shown with the Spearman coefficient r and the test p value. Isolates that clustered 
above or below the trend line, suggesting consistent increases or decreases in binding to RSV-A2 
infected cells, respectively, are coloured (BNE-139 in red, BNE-144 in green, BNE-157 in orange 
and BNE-88 in blue), while isolates distributed both sides of the trend line are in black. 
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5.3.4 Associations between isolate characteristics and binding patterns 
The median mock adherence, mean fold change and mean increase in particle count during RSV 
infection was calculated for each isolate and the associations with patient age, pathogen detection 
and isolate characteristics investigated (Figure 5.6 and Table 5.2). It was hypothesised that 
pneumococcal strains isolated from young children with RSV infections would exhibit greater 
enhancement of adherence during RSV-A2 infection in vitro. Isolates co-detected with RSV tended 
to display increased adherence following RSV infection, assessed both by fold changes in 
adherence (Figure 5.6D) and direct increases in pneumococcal particle counts (Figure 5.6F), 
although neither measure was significant at p < 0.05.  
 
Isolates co-detected with M. catarrhalis had significantly increased adherence to mock infected 
airway epithelial cells compared to those negative for M. catarrhalis (Table 5.2). They also had 
decreased fold change in adherence due to RSV-A2 infection. However, given the small sample 
size, the study was underpowered to provide significance for such an association. No other factors 
were significantly associated with mock adherence, fold change due to RSV-A2 infection, or 
increase in pneumococcal adherence due to RSV-A2 infection, including patient age (Appendix 8.4 
Figure A5.7), isolate molecular serotype or the genotype of the co-detected RSV strain (Figure 5.6). 
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Figure 5.6. Median adherence of S. pneumoniae clinical isolates to mock infected airway epithelial 
cells (A-B), fold change in adherence between mock and RSV-A2 infection (C-D) and 
pneumococcal particle count increase during RSV-A2 infection compared to mock infection (E-F), 
compared between molecular serotype (A,C,E) and co-detection with RSV genotype (B,D,F). Mock 
adherence is shown on a logarithmic scale. Solid lines represent the median (mock adherence) or 
mean (fold change, particle count increase) of isolates between molecular serotypes or co-detected 
RSV genotypes. The Kruskal-Wallis test was performed for A-B to compare medians between 
groups with > 1 isolate, while one-way ANOVA was performed for C-F to compare means between 
groups with >1 isolate. Dotted lines in C-F at y = 0 represent no change between RSV-A2 and mock 
infection. 
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Table 5.2. Univariable analysis of differences in pneumococcal clinical isolate adherence to mock infected cells, log-transformed fold change in 
adherence between RSV-A2 and mock infection, and increase in pneumococcal particle counts during RSV-A2 infection, compared between patient 
co-pathogen detection.   
Pathogen co-
detection 
Number Median mock adherence (IQR) Mean fold change (SD) Mean increase due to RSV (SD) 
FALSE TRUE FALSE TRUE p
1 
FALSE TRUE p
2 
FALSE TRUE p
2 
Virus positive 1 12 69.3 (NA) 4.1 (2.9,14.4) NA 0.192 (NA) 0.718 (0.382) NA 25.9 (NA) 37.5 (21.4) NA 
RSV detected 4 9 10.2 (4,29.4) 3.9 (2.1,13.8) 0.396 0.518 (0.391) 0.749 (0.396) 0.350 22.6 (15.9) 42.8 (20.2) 0.107 
hRV detected 8 5 9.8 (3.2,29.5) 3.9 (3.1,4.3) 0.421 0.642 (0.438) 0.736 (0.35) 0.694 44.6 (20.7) 23.8 (14.4) 0.076 
AdV detected 12 1 4.1 (2.9,15.7) 16.1 (NA) NA 0.713 (0.389) 0.255 (NA) NA 38.7 (19.9) 9.6 (NA) NA 
PIV detected 13 0    NA    NA    NA 
IAV detected 13 0    NA    NA    NA 
>1 virus detected 10 3 5 (3.3,19.6) 3.9 (2.9,10) 0.673 0.676 (0.408) 0.684 (0.425) 0.976 41.2 (21.1) 21.3 (11.3) 0.153 
Hi detected 12 1 5.0 (3.5,17.4) 2.1 (NA) NA 0.643 (0.389) 1.101 (NA) NA 36.1 (21.6) 43.0 (NA) NA 
Mc detected 9 4 3.6 (2.1,4.3) 37.5 (17.6,57.5) 0.017 0.829 (0.322) 0.338 (0.348) 0.031 32.6 (20.5) 45.7 (20.9) 0.314 
Sa detected 13 0     NA     NA     NA 
1
Median mock adherence compared with Wilcoxon signed rank sum test. 
2
Mean fold change compared with t-test. SD: standard deviation, AdV: 
Adenovirus, Hi: H. influenzae, Mc: M. catarrhalis, Sa: S. aureus. 
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5.3.5 Pneumococcal adherence during infection with RSV clinical isolates 
To investigate RSV and S. pneumoniae interactions using clinically relevant RSV strains, the 
binding assay was repeated for a subset of six pneumococcal isolates and D39 with two clinical 
strains of RSV isolated from patients in this study’s cohort, an NA1 (RSV-A) strain and a BA 
(RSV-B) strain. The viral clinical isolates did not replicate as well in cell culture as the cell culture-
adapted strain RSV-A2 and 100% infection could not be achieved. Some microscopy fields of view 
had very low levels of RSV infection, while others had localised regions of infection, including 
formation of syncytia. As with previous binding assays, variation between experiments was high. In 
addition to the S. pneumoniae particle counting performed for the previous binding assays, the 
numbers of RSV positive S. pneumoniae particles were also determined for fields that were between 
1% and 25% positive for RSV. Particle counts were normalised for percent of RSV infection to 
estimate S. pneumoniae adherence during 100% RSV infection (see Chapter 5.2.8) and are shown 
with mock adherence for each isolate in Figure 5.7. 
 
Example images of D39 binding during mock infection or infection with the RSV clinical strains 
are presented in Figure 5.8. Comparison of this figure with Figure 5.1A during RSV-A2 infection 
clearly shows the reduced replication between RSV-A2 infection and infection with the clinical 
viral strains. Note that the poor replication in cell culture also resulted in clinical viral stocks at 
lower titres than RSV-A2, therefore cells were infected with almost 10-fold and 500-fold lower 
concentrations of RSV-NA1 and RSV-BA, respectively, compared to the binding assays with RSV-
A2. Normalised pneumococcal adherence to RSV-NA1 or RSV-BA infected cells tended to be 
higher than to mock infected cells (Figure 5.7). For the majority of isolates tested, this difference 
was significant in at least two of the three repeated RSV-NA1 experiments (Table 5.3 and Appendix 
8.4 Figure A5.8), however, similar to RSV-A2 infection, pneumococcal adherence between mock 
and RSV infection was not significantly different across repeated experiments for any isolate 
(Figure 5.7).  
 
Some trends in the data were observed that could be further investigated in an optimised binding 
assay. Visual inspection of images revealed that isolates that tended to bind well during mock 
infection, i.e. D39, BNE-8 and BNE-77, clearly did not co-localise with RSV infection, with an 
even distribution of S. pneumoniae particles across areas of RSV infection and uninfected cells 
(example images in Appendix 8.4 Figure A5.9). Normalised RSV-NA1 and RSV-BA adherence 
was generally similar to mock adherence for these isolates, despite some slight increases in RSV-
NA1 (Figure 5.7). Some evidence of possible co-localisation was observed visually in BNE-119, an 
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isolate that tended to bind poorly during mock infection, and slight increases were observed in 
normalised RSV-NA1 and RSV-BA adherence compared to mock adherence. Increased normalised 
RSV adherence was observed for BNE-103 during RSV infection, particularly with RSV-NA1, and 
possible co-localisation was also observed. Possible co-localisation with RSV-NA1 was observed in 
BNE-144 and normalised RSV adherence was also higher for RSV-NA1 and RSV-BA compared to 
mock infection. Some evidence for co-localisation was also observed for BNE-139, and normalised 
RSV adherence increased, particularly for RSV-NA1. 
 
 
 
D
3
9
B
N
E
-1
1
9
B
N
E
-8
B
N
E
-1
3
9
B
N
E
-1
4
4
B
N
E
-1
0
3
B
N
E
-7
7
0
2 5 0
5 0 0
7 5 0
1 0 0 0
P a tie n t ID
A
d
h
e
re
n
c
e
m o c k
R S V -N A 1
R S V -B A
2 1 5 B /C 2 3 B 6 A /B 1 6 F
 
Figure 5.7. Adherence of S. pneumoniae isolates to mock (grey circles), RSV-NA1 (purple 
triangles) and RSV-BA (green inverted triangles) infection of A549 cells. The binding assay was 
repeated 2-3 times per isolate. Each point denotes mean fluorescent particle count per field across 
multiple fields and technical replicates for an individual experiment. Particle counts for RSV-NA1 
and RSV-BA adherence were normalised for RSV infection (see Chapter 5.2.8 for details). The 
mean of these calculations over technical replicates of an experiment is shown. Error bars represent 
mean and standard deviation. The difference between adherence to mock infected A549 cells and 
normalised adherence to RSV-NA1 or RSV-BA infected A549 cells was not significant at p < 0.05 
for any isolate (multiple t-tests with Holm-Sidak’s correction for multiple hypotheses).  
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 A549 cell nuclei Anti-RSV Anti-S. pneumoniae Merge 
mock 
 
    
RSV-NA1 
    
RSV-BA 
    
Figure 5.8. Example immunofluorescence images from S. pneumoniae D39 binding to mock, RSV-NA1 or RSV-BA infected A549 airway epithelial 
cells, with A549 cell nuclei staining with Hoechst 33342 (blue), anti-RSV (red) and anti-S. pneumoniae (green). Composite images of the merged 
channels are also shown. Number of S. pneumoniae particle counts are shown in the upper right-hand corner of each anti-S. pneumoniae image. 
253 
116 
116 
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Table 5.3. Summary of pneumococcal clinical isolate adherence to A549 cells during mock, RSV-
NA1 and RSV-BA infection across technical replicates in each repeated experiment (n=2-3 
depending on isolate). Significant differences at p < 0.05 are highlighted in grey. Pneumococcal 
adherence during infection with clinical virus strains was normalised for extent of virus infection. 
 
 D39 BNE- 
119 
BNE- 
8 
BNE- 
139 
BNE- 
144 
BNE- 
103 
BNE- 
77 
E
x
p
er
im
en
t 
1
 
Mean mock (SD) 162.9 
(62.4) 
3.3 (3) 20 (13.3) 38.3 
(22.2) 
9.5 (4.2) 41.4 
(15.9) 
123.4 
(29.6) 
Mean RSV-NA1 
(SD) 
753 
(490.3) 
42.4 
(61.2) 
133 
(99.9) 
143.4 
(107.4) 
132.2 
(76.3) 
486 
(282.1) 
312.8 
(169.6) 
p <0.001 0.003 <0.001 <0.001 <0.001 <0.001 <0.001 
Mean RSV-BA
 
(SD) 179.6 (0) NA 22.8 
(12.7) 
64.5 
(82.9) 
68.2 
(21.5) 
139.6 
(24.4) 
257.9 
(49.5) 
p NA NA 0.729 0.306 <0.001 <0.001 <0.001 
E
x
p
er
im
en
t 
2
 
Mean mock (SD) 42.8 
(15.3) 
2.1 (1.8) 4.8 (5) 19 (11.3) 0.6 (0.6) 17.2 (6.8) 6.2 (7.2) 
Mean RSV-NA1 
(SD) 
548.4 
(283.6) 
67.1 
(89.6) 
59.7 
(105) 
207.4 
(239.7) 
54.4 
(110.2) 
515.9 
(451.5) 
55.6 
(73.8) 
p <0.001 0.016 0.037 0.006 0.060 <0.001 0.016 
Mean RSV-BA
 
(SD) 244.5 
(66.1) 
98.3 
(139) 
24.1 
(48.2) 
NA 0 (0) NA 15.6 
(38.3) 
p <0.001 0.004 0.159 NA 0.416 NA 0.416 
E
x
p
er
im
en
t 
3
 
Mean mock (SD) 0.1 (0.5) 1.1 (1.5) 0.8 (1.3) 2.3 (3.5) 0.5 (1.1) 5.2 (5.8) 7.5 (10.9) 
Mean RSV-NA1 
(SD) 
17.8 
(37.2) 
5 (11.6) 5.2 (14.4) 22.7 
(39.3) 
7.2 (12.2) 83.9 
(108.3) 
5.6 (8.3) 
p 0.306 0.349 0.404 0.086 0.086 0.036 0.572 
Mean RSV-BA
 
(SD) 6.2 (8.7) 7 (12.2)  0 (0) 0 (0) 74 (31.4) 40.4 (0.3) 0 (0) 
p 0.019 0.069 0.601 0.601 <0.001 <0.001 NA 
No. of experiments showing 
significantly increased 
adherence during RSV 
infection (%) 
       
RSV-NA1 2 of 3 
(67%) 
2 of 3 
(67%) 
2 of3 
(67%) 
2 of 3 
(67%) 
1 of 3 
(33%) 
3 of 3 
(100%) 
2 of 3 
(67%) 
RSV-BA 2 of 2 
(100%) 
1 of 2 
(50%) 
0 of 3 
(0%) 
0 of 2 
(0%) 
2 of 3 
(67%) 
2 of 2 
(100%) 
1 of 2 
(50%) 
SD: standard deviation 
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5.3.6 Pre-binding of S. pneumoniae with RSV-A2 
To investigate the hypothesis that S. pneumoniae can bind directly to RSV virions, and that these 
complexes increase pneumococcal adherence to airway epithelial cells, pneumococcal isolates and 
D39 were pre-incubated with RSV-A2 before addition to A549 cells (raw data from each pre-
binding experiment shown in Appendix 8.4 Figure A5.10). Similar to infection with RSV-A2, 
numbers of pneumococcal particles adhering to epithelial cells after incubation with RSV-A2 
increased compared to mock incubation for isolates that tended to adhere poorly to uninfected 
epithelia (Figure 5.9A), although this difference was generally only significant in one of three 
repeated experiments (Table 5.4) and was not significant across repeated experiments (p > 0.8 for 
most isolates). Likewise, isolates that generally adhered well to uninfected epithelia tended to have 
low log-transformed fold changes in adherence, while the effect of RSV-A2 incubation on 
adherence of poorly adhering isolates was greater (Figure 5.9B). Numbers of fluorescent RSV 
virions adhering to airway epithelia was similar between isolates and the bacteria-free media 
negative control (Appendix 8.4 Figure A5.11A). Visually, both fluorescent S. pneumoniae particles 
and fluorescent RSV virions could be seen in microscope images (example images in Appendix 8.4 
Figure A5.11B); however, no evidence of co-localisation between the virions and bacterial cells 
was observed for any isolate, in contrast to the results from the S. pneumoniae particle counts. 
Bacterial binding to the virion may have interfered with the RSV antibody binding site.  
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Figure 5.9. Adherence of S. pneumoniae isolates to A549 airway epithelial cells after pre-incubation 
with mock (grey circles) or RSV-A2 (blue squares) (A) and fold change in adherence after RSV-A2 
compared to mock pre-incubation (B). Points in A represent the mean particles counts per field 
across multiple fields and technical replicates for each experiment (2-3 experiments per isolate). 
Points in B represent the log-transformed fold difference of mean adherence of isolates during 
RSV-A2 compared to mock pre-incubation for each experiment, with error bars representing mean 
and standard deviation, and a dotted line at y = 0 indicating no change in adherence between RSV-
A2 and mock pre-incubation. 
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Table 5.4. Summary of pneumococcal clinical isolate adherence to A549 cells after pre-incubation 
with virus-free media and RSV-A2 across technical replicates in each repeated experiment (n=2-3 
depending on isolate). Significant differences at p < 0.05 are highlighted in grey. 
 
 D39 BNE-
119 
BNE- 
8 
BNE-
139 
BNE-
144 
BNE-
103 
BNE- 
77 
BNE- 
88 
E
x
p
er
im
en
t 
1
 Mean mock (SD) 7.6 (9.6) 0.1 (0.3) 1.8 (2.3) 18.2 
(13.4) 
0.6 (1) 2.9 (2.7) NA 0.7 (1) 
Mean RSV (SD) 12.4 
(10.6) 
0.6 (0.8) 2.2 (2.6) 24.6 
(19.2) 
2 (1.8) 7.8 (5.1)  1.5 (1.5) 
p 0.567 0.265 0.647 0.567 0.084 0.084  0.439 
E
x
p
er
im
en
t 
2
 Mean mock (SD) 30.8 
(16) 
0.9 (1.4) NA 57 
(25.9) 
2.6 (2.2) 10 (10) 44.7 
(16.2) 
6.9 (6.7) 
Mean RSV (SD) 38.9 
(24.2) 
4.9 (4.1)  77.1 
(31.3) 
9.7 (4.3) 49 (9.5) 149.2 
(43.3) 
22.7 
(9.4) 
p 0.307 0.008  0.202 <0.001 <0.001 <0.001 <0.001 
E
x
p
er
im
en
t 
3
 Mean mock (SD) 12.1 
(8.1) 
2.9 (4.1) 3.9 (5.5) 53.2 
(18) 
5.2 (6.6) 15.7 
(7.7) 
27.8 
(22.1) 
NA 
Mean RSV (SD) 14.8 
(6.9) 
9.6 (6.4) 1 (1.5) 67.3 
(26.9) 
12.7 
(8.9) 
32.1 
(17.7) 
38.3 
(31.6) 
 
p 0.554 0.056 0.323 0.323 0.160 0.043 0.554  
No. of experiments 
showing significantly 
increased adherence 
during RSV infection 
(%) 
0 of 3 
(0%) 
1 of 3 
(33%) 
0 of 2 
(0%) 
0 of 3 
(0%) 
1 of 3 
(33%) 
2 of 3 
(67%) 
1 of 3 
(33%) 
1 of 2 
(50%) 
SD: standard deviation. 
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5.4 Discussion 
The design of experiments aiming to quantify and elucidate factors involved in pneumococcal 
adherence in the URT is challenging, and investigation of the effect of RSV infection on bacterial 
adherence even more so, as viral, bacterial and host variables all play a role in determining the 
outcome. Experimental models of the URT include animal models and in vitro cell culture models 
using immortalised cell lines or primary, differentiated airway cells from donors. Immortalised 
epithelial cell culture is the most feasible; however, it provides a poor representation of the 
mammalian URT, as the majority of cell lines are propagating tumour cells that do not reflect the 
tight barrier of the epithelia, lined with ciliated and mucus-secreting cells. Attachment of bacteria to 
immortalised epithelial cells is therefore likely to be substantially different to the true situation in 
the URT. The confluence of the epithelial cell monolayer can also affect the binding of bacteria, as 
fully confluent cells form tight junctions, potentially hiding additional bacterial receptors that are 
exposed in propagating cells. Primary, differentiated airway epithelial cells grown at air-liquid 
interface are better models of the human URT, with ciliated cells and mucus secretion, however, 
they require donors, time and expertise to maintain, and are not feasible for high-throughput 
experiments. While animal models provide a live model of the URT, viral infection and bacterial 
colonisation with human pathogens rarely proceeds as it does in the natural host. Animal models 
also require the resources, expertise and ethical considerations to house and work with them. 
 
Consistent bacterial growth and virus infection is also a challenge of RSV and S. pneumoniae 
binding experiments. Bacterial growth in the laboratory setting in defined culture medium does not 
optimally model bacterial growth in the URT. Variation in bacterial growth phase and gene 
expression during culturing before use in an experiment can result in altered binding interactions 
with viral and host cell receptors. For example, S. pneumoniae adherence to airway epithelia has 
been shown to be affected by capsule thickness, as a thinner capsule can better expose 
pneumococcal adhesins (311, 312). Individual S. pneumoniae strains have been shown to undergo 
phase variation in capsule expression, resulting in different levels of capsule that may affect results 
of binding assays (311-313). Furthermore, both growth phase and gene expression can be affected 
by experimental factors like batch-variation in culture media and amount of culture inoculation 
material from glycerol stocks (314). In vitro models of viral infection may also not be ideal. The 
absence of a fully functional immune system affects both bacterial colonisation and viral infection. 
Laboratory viral strains are often passaged numerous times to generate strains capable of replicating 
to high titres in cell culture. The extent and timing of viral infection is also likely to affect bacterial 
binding due to variations in the level of expression of viral glycoproteins and virus-induced host 
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genes, as well as the induction of apoptosis. Furthermore, without 100% viral infection bacterial 
adherence may vary between sites of infection and uninfected cells. 
 
Quantification of S. pneumoniae adherence can also be difficult. Quantitative cultures to detect live 
bacteria or real-time PCR to detect adhering bacterial DNA both require disruption of the cell 
monolayer, potentially affecting bacterial adherence. Both are time-consuming and real-time PCR 
may be inhibited by extensive concentrations of host cell DNA from the cell monolayer. 
Immunofluorescence techniques can be faster, as cells can be fixed and stained the day of the 
experiment, although such techniques require good primary and secondary antibodies. Flow 
cytometry can be used to count and sort fluorescently labelled host cells infected by virus and with 
bacteria attached, however, cell suspensions are required and thus the cell monolayer must be 
disrupted. The technique is also more laborious when testing several different conditions as usually 
each sample must be analysed by the flow cytometer separately. Immunofluorescence microscopy 
maintains epithelial monolayer integrity, thereby allowing host cell, virus and bacteria interactions 
to be observed directly. Multiple conditions can also be tested on a single plate, provided accurate 
image capture and analysis systems are available. While heat-killed, FITC-labelled S. pneumoniae 
isolates have been used effectively by previous studies (137, 140, 315), FITC labelling has been 
shown to affect respiratory bacteria viability and alter the action of virulence factors (316). The use 
of non-viable bacteria may not provide a realistic model of viral and bacterial binding interactions 
in the URT, thus approaches using live bacteria are needed. 
 
In this chapter, a binding assay was developed to investigate the binding interactions of RSV with 
live S. pneumoniae strains isolated from children with ARI symptoms in immortalised airway 
epithelial cells. Despite attempts to control experimental conditions as much as possible, inter-
experiment variation was high. The two greatest factors affecting reproducibility were likely 
variation in bacterial growth in culture and variation in epithelial cell monolayer integrity. These 
factors would require further optimisation to improve inter-experiment reproducibility. Optimally, 
bacterial growth kinetics should have been controlled to ensure S. pneumoniae strains were always 
actively replicating in logarithmic phase when the binding study was initiated. However, as multiple 
strains (usually 8-10) were used in each binding assay, ensuring that they were all at the same 
growth phase was impractical. Instead only bacteria concentrations were standardised prior to 
binding. Furthermore, better quality control testing, e.g. pH monitoring, could have reduced batch-
variation in growth media, while minimising the number of freeze-thaw cycles for glycerol stocks 
used to inoculate bacterial cultures could have further reduced bacterial growth variation. The A549 
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epithelial cell cultures were set up the day before infection and then infected with RSV (or mock 
infected) for approximately 48 hours. Inter-experiment variations in mock and/or infected cell 
monolayer integrity could also have affected bacterial adherence. Despite the problems of 
reproducibility, the assay developed here allowed easy confirmation of both RSV and S. 
pneumoniae presence through immunofluorescence microscopy and the ability to directly observe 
the virus and bacteria interactions on the epithelial cell monolayer, as well as a means of 
investigating several experimental conditions concurrently in a 96 well plate format. 
 
The binding assay demonstrated that some isolates consistently bound well to mock infected airway 
epithelia, while others did not. This variation did not directly correspond with molecular serotype or 
ST. These results are consistent with previous studies that have demonstrated variation in adherence 
of S. pneumoniae clinical isolates to airway epithelial cells, often independent of serotype (311, 
314, 317). Adherence to epithelial cells is the first step of IPD, as after adherence S. pneumoniae 
can trigger internalisation by the epithelial cell, resulting in transcellular migration through the 
respiratory epithelium and vascular endothelium into the blood stream (147). If the adherence 
phenotype of isolates that tended to bind well to airway epithelia was confirmed to be clinically 
relevant in the human URT, e.g. through a modified binding assay using primary, differentiated 
epithelial cell culture at air-liquid interface, factors involved in the extensive epithelial cell 
adherence by these isolates may provide candidates for improved vaccine or prophylactic 
therapeutics design. Several pneumococcal virulence factors have been found to be involved in 
strain-specific adherence to airway epithelial cells. For example, adherence can be affected by 
capsule thickness (as previously discussed above), which has been shown to vary between isolates 
(311, 312, 318), thus it is possible that highly binding isolates may express lower levels of capsule 
than lower binding isolates. Isolates with different adherence phenotypes may also utilise different 
adhesins, such as different types of pili, two types of which have been shown to be involved in 
epithelial cell adherence and have only been identified in a subset of pneumococcal isolates (319, 
320). While not the main focus of this thesis, understanding natural S. pneumoniae variation in 
adherence to uninfected airway epithelia is an important part of understanding the changes caused 
by viral infection. 
 
In the majority of the repeated binding experiments, nine of the thirteen S. pneumoniae clinical 
isolates tested displayed increased adherence during RSV-A2 infection (Table 5.1). Analysis of fold 
change in adherence during RSV-A2 infection compared to mock infection reduced the effects of 
inter-experiment variation. Six of the isolates consistently adhered between 5- and 30-fold more to 
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cell culture following RSV infection (Table 5.1 and Figure 5.4B). Overall, fold change in adherence 
was significantly different across the different isolates, and inversely correlated to the inherent 
ability of the isolate to bind to uninfected airway epithelia. It is important to establish whether the 
more highly binding isolates did not exhibit increased adherence to RSV because they did not 
interact as well with the virus as less adherent isolates, either directly or indirectly through viral 
upregulation of host cell receptors, or whether the result was caused by a limitation of the binding 
assay to measure RSV-mediated binding of highly adherent isolates. The strong negative 
association between mock adherence and fold change due to RSV-A2 infection suggests that the 
adherence of some isolates was already at the upper limit of detection of the binding assay, 
therefore a substantial increase due to RSV infection was unable to be detected. The concentration 
of bacteria added was kept consistent in the experiments, to allow comparison between isolates. 
Performing a dilution series of S. pneumoniae concentrations for the more highly adherent isolates 
during mock and RSV infection would determine the limits of the binding assay, and better 
determine the effect of RSV infection on adherence of these isolates. Alternatively, focusing on 
direct binding interactions between S. pneumoniae isolates and RSV, thereby removing the host 
epithelium from the experiment, would establish the role of RSV surface glycoproteins in 
pneumococcal strain-specific binding to RSV (discussed in more detail below). The role of host 
epithelial cell factors and viral infection of the epithelia could then be investigated in isolates 
showing similar binding to RSV virions but differential binding to RSV infected epithelia. 
 
For the purposes of this study, the potential limitation of the fold change calculation was addressed 
by calculating the increase in number of pneumococcal particle counts due to RSV-A2 infection 
compared to mock infection. A potential impediment to utilising these raw counts as a measure of 
RSV-mediated adherence was that particle counts between fields showed large variation, 
particularly with more highly binding isolates. As with fold change, increase in adherence varied 
between isolates, although the differences did not quite reach statistical significance. Together, the 
results of the three analyses indicated that RSV-A2 infection consistently promoted the adherence 
of isolates BNE-88 (molecular serotype 33F) and BNE-144 (6A/B) to airway epithelia. In contrast, 
BNE-139 (23B) and BNE-157 (6A/B) consistently adhered equally well to RSV-A2 and mock 
infected cells. Clearly, the effect of RSV was independent of molecular serotype in the case of 
6A/B. The results of the analyses also suggested that other isolates sharing the same molecular 
serotype and ST, such as BNE-8 and BNE-119 (both 15B/C and ST199) did not exhibit similar 
patterns of binding to RSV infected airway epithelia. 
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Other studies of RSV and S. pneumoniae interactions have observed increases in pneumococcal 
adherence to epithelial cells after RSV infection (138, 140, 146, 315). Serotypes of S. pneumoniae 
associated with respiratory disease were found to bind less well to uninfected immortalised airway 
epithelial cells than serotypes associated with meningitis, however, RSV infection enhanced 
adherence of all strains (315). A comparison of multiple clinical isolates found between 3- and 10-
fold increases in adherence of heat-killed S. pneumoniae to RSV infected A549 cells in a cytometric 
fluorescence assay (140), similar to the fold changes observed in this study’s less adherent isolates, 
despite the differences in methods. Human adenovirus strains known to cause ARI have also been 
shown to increase adherence of some strains of S. pneumoniae (139). Hakansson et al. (139) found 
that, highly adherent strains of S. pneumoniae had enhanced adherence after adenovirus infection, 
while virus infection had no effect on poorly adherent strains. Pneumococcal adherence was 
quantified by counting of numbers of S. pneumoniae particles bound to A549 cells in suspension. 
Such an approach is limited by the removal of the epithelial cells from an URT-like monolayer, as 
additional pneumococcal receptors usually hidden by tight junctions would be exposed, such as 
fibronectin (321). The results of the above study and ours cannot therefore be directly compared, 
however, the results of this chapter suggest the reverse situation during RSV infection, where RSV 
enhances adherence of less adherent isolates but has little effect on more adherent isolates. In future 
studies this hypothesis could be investigated in a further optimised binding assay.  
 
The panel of S. pneumoniae isolates used in this study were unique, as they provided a comparison 
between strains isolated directly from young children with and without an RSV infection. There 
was a tendency for S. pneumoniae strains that were isolated from patients with an RSV infection to 
exhibit increased adherence in vitro during RSV compared to mock infection, however, this 
difference was not significant. While both BNE-139 and BNE-157, isolates with similar adherence 
between mock and RSV infected airway epithelia, were collected from patients negative for RSV, 
BNE-144 was also from a patient without RSV, yet exhibited enhanced adherence during virus 
infection. Interestingly, an association was observed between isolates co-detected with M. 
catarrhalis and significantly higher adherence to mock infected airway epithelial cells. Synergism 
between S. pneumoniae and M. catarrhalis has been previously reported (21, 322); however, the 
small study investigated in this thesis was underpowered to accurately identify associations between 
S. pneumoniae adherence and pathogen co-detection. Expanding the panel of S. pneumoniae 
isolates and testing them in an optimised binding assay may better evaluate a potential relationship 
between RSV or M. catarrhalis co-detection and pneumococcal adherence. 
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As re-iterated throughout this thesis, there is evidence that S. pneumoniae can bind to RSV G (128, 
136-138, 140), the most variable region of the virus between subtypes (186-188, 190). It was 
therefore hypothesised that S. pneumoniae strains isolated from patients in which RSV-B was co-
detected might bind better to airway epithelia infected with RSV-B, whereas those co-detected with 
RSV-A might adhere better during RSV-A infection. This hypothesis was tested using clinical 
RSV-A and RSV-B strains, however, low levels of viral replication, particularly for RSV-B, 
complicated image analysis of pneumococcal adherence and resulted in an inconclusive comparison 
of the two subtypes. Ideally, higher titres of RSV were needed, however, clinical strains often 
replicate less efficiently in tissue culture than culture-adapted strains like RSV-A2 (323, 324). They 
also must be kept at low passage numbers, to prevent adaption to tissue culture conditions that may 
result in a loss of clinical phenotype. A better option may be to first compare pneumococcal 
adherence during RSV-A2 infection with infection by a cell culture-adapted RSV-B strain, e.g. 
strain 9320 (ATCC VR-955) (unfortunately not available in our laboratory at the time these 
experiments were conducted). A small subset of isolates with differential adherence during RSV-A 
and RSV-B infection could then be tested against clinical virus strains to validate those associations 
in clinically relevant viruses. An older study has demonstrated similar enhancement of 
pneumococcal adherence between RSV-A and RSV-B infection of airway epithelia across multiple 
S. pneumoniae strains (315). Another study has reported interactions between D39 and either RSV-
A2 or purified G protein from an RSV-B strain (128). The studies suggest that S. pneumoniae 
isolates can interact with both subtypes; however, confirmation of pneumococcal adherence in a 
direct comparison of RSV-A and RSV-B, using clinically relevant virus strains, would have been 
ideal. 
 
The low levels of clinical virus replication resulted in the use of co-localisation of green S. 
pneumoniae particles to red RSV infected epithelial cells to evaluate pneumococcal adherence. 
Immunofluorescence microscopy is not the best technique to determine co-localisation, as two 
targets in the same vertical plane but separated physically will incorrectly appeared co-localised, 
and fluorescent channels can ‘bleed’ into each other, creating the appearance of co-localisation. It 
has been shown previously that S. pneumoniae binds closely to RSV infected airway epithelial cells 
(Appendix 8.4 Figure A5.1). The plates were also washed thoroughly before fixing, to remove any 
bacteria in the supernatant or loosely attached to the epithelial monolayer. It is therefore unlikely 
that pneumococcal particles would be in the same vertical plane as an infected cell without being 
attached to the cell surface. S. pneumoniae labelled with the primary polyclonal antibody forms 
readily discernible fluorescent particles, while RSV infected cells labelled with the primary anti-F 
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antibody form distinct fans of fluorescence inside the cell (Figure 5.1 and Figure 5.8). The PBS 
only, RSV only and S. pneumoniae only wells were used to control for cross-channel interference 
between the green and red fluorescence channels. In future experiments, if improved clinical virus 
replication across entire airway epithelial cell monolayers cannot be achieved, flow cytometry may 
offer an alternative and complimentary technique to analyse co-localisation of S. pneumoniae with 
host cells infected by clinical RSV strains. 
 
Despite the complications resulting from low replication of clinical RSV strains, some S. 
pneumoniae isolates, particularly isolates that generally exhibited low adherence to uninfected 
airway epithelia, tended to have increased adherence to RSV-NA1 infected airway epithelia after 
normalisation for the extent of the virus infection. Visual inspection of immunofluorescence images 
also suggested that some less adherent isolates tended to cluster around sites of RSV infection. 
These results were generally consistent with those observed with RSV-A2 infection, i.e. little RSV-
mediated adherence by more adherent isolates like D39 or BNE-77 (molecular serotype 16F), and 
some RSV-mediated adherence by less adherent isolates like BNE-144 (6A/B) or BNE-119 
(151B/C). Some evidence of enhanced binding and co-localisation during RSV-NA1 infection was 
observed with BNE-139 (23B), whereas in the binding assay with RSV-A2, little evidence for 
enhanced binding was observed. These results suggest that there may be differences in 
pneumococcal interactions between culture-adapted and clinical strains of the same subtype; 
however, this hypothesis needs to be investigated in an optimised binding assay where infection 
with RSV-NA1 and RSV-A2 are compared simultaneously. 
 
Pre-incubation of RSV-A2 and S. pneumoniae isolates tended to result in similar patterns of 
pneumococcal adherence to those observed in the RSV-A2 infection binding assay. For example, 
D39 and BNE-139 tended to adhere similarly to airway epithelia after pre-incubation with RSV-A2 
or virus-free media, whereas BNE-103, BNE-144 and BNE-88 tended to have increased adherence 
after pre-incubation with RSV-A2, although the difference was not statistically significant in most 
repeated experiments. Other studies have shown that RSV virions can bind directly to S. 
pneumoniae (128, 136, 137), and S. pneumoniae in these complexes adhere better to A549 cells 
than control S. pneumoniae (137). Unlike the study by Hament et al. (137), the results from the pre-
binding assay in this study suggest that this effect varies between S. pneumoniae isolates. However, 
no evidence of co-localisation was observed in immunofluorescence microscopy images for any 
isolate. Since the plates were fixed after pathogen addition, the antibodies used to detect RSV and S. 
pneumoniae could not have interfered with pathogen attachment to host cells. Both RSV and S. 
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pneumoniae fluorescent particles were detected separately, indicating that both antibodies were 
functioning correctly and both pathogens were in close contact with host cells. Since RSV enters the 
host cell via membrane fusion, bacteria bound to viral surface glycoproteins should have remained 
attached to these glycoproteins and thus the host cell after virus entry. It is possible that the binding 
of RSV virions to S. pneumoniae cells, and subsequent attachment to epithelial cells, could possibly 
have obscured the target epitope or sterically inhibited attachment of the anti-RSV antibody used in 
immunofluorescence, thereby resulting in no visual evidence of co-localisation. In this study the 
formation of RSV and S. pneumoniae complexes before addition to airway epithelial cells was not 
determined. In future studies, fluorescence-activating cell sorting (FACS) flow cytometry could be 
used to collect virus-bacteria complexes before use in the binding assay. The complexes could also 
be visualised by electron microscopy.  
 
Future directions for the investigation of RSV promotion of bacterial colonisation could focus 
further on differences between pneumococcal strains during interactions with the virus. In each of 
the three binding assays discussed above (i.e., infection with RSV-A2, infection with clinical 
isolates of RSV and pre-incubation of S. pneumoniae with RSV-A2), the effect of RSV on the 
adherence of specific S. pneumoniae strains to airway epithelia was not associated with molecular 
serotype or ST. S. pneumoniae strains are well-known for their ability to acquire different genes 
from other strains and species through horizontal gene transfer and recombination (247, 250), and 
capsular switching, where one clone changes its serotype through these processes, has been reported 
frequently (325, 326). Thus, isolates with the same serotype can have diverse genetic backgrounds 
(247, 250), and may interact differently with RSV. Different S. pneumoniae strains may utilise to 
different extents host cell receptors upregulated by RSV during infection, such as ICAM-1 and 
PAFR (138). S. pneumoniae has also been shown to bind to RSV G embedded in host cell 
membranes, although this has only been directly demonstrated with an individual serotype 19 
nasopharyngeal isolate (136). Given that in this study the pre-binding of S. pneumoniae with RSV-
A2 generally resulted in increased pneumococcal adherence to airway epithelia in a majority, but 
not all, S. pneumoniae isolates, different strains may differ in their ability to use RSV G or other 
viral glycoproteins as additional receptors at the URT epithelium.  
 
Multiple approaches could be used to investigate the role of RSV G in strain-specific pneumococcal 
adherence. A molecular cloning methodology like that used by Avadhanula et al. (136) could be 
applied to a modified binding assay, using epithelial cells expressing membrane-bound G in place 
of live RSV infection. A similar approach was initially tried concurrent to the live virus binding 
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assays in this project, however, due to inefficient transfection of the G construct and poor 
purification of the whole protein, this work was not completed in time for inclusion in this thesis. 
Furthermore, as previously discussed it is difficult to establish the effect of RSV infection or RSV 
glycoproteins embedded in the host cell membrane on the adherence of isolates that adhere well to 
uninfected airway epithelial cells. It may therefore be more productive to focus on direct binding 
interactions between S. pneumoniae and RSV. Since RSV and S. pneumoniae have been shown to 
directly bind together (128, 137), FACS flow cytometry or immunoprecipitation could be used to 
investigate differences in RSV virion binding to various S. pneumoniae strains. RSV virions or 
purified glycoproteins could be used in these assays, allowing comparison between multiple RSV 
strains without the complication surrounding differential replication in cell culture.  
 
Once strain-specific binding is established, future work could include identification of the 
pneumococcal factors involved in binding interactions with G. PBP1a has previously been 
identified as a potential pneumococcal binding partner of RSV in the laboratory strain D39, through 
mass spectrometry following immunoprecipitation of denatured pneumococcal proteins binding to 
the RSV G glycoprotein (128). However, the role of PBP1a in binding to RSV G has yet to be 
further validated, nor has this association been confirmed in other clinically relevant S. pneumoniae 
strains. Furthermore, given the large number of known epithelial cell adhesins identified in S. 
pneumoniae (236), it is possible that a number of pneumococcal surface proteins could be involved 
in the binding interaction with RSV G. To repeat and improve upon the experiment conducted by 
Smith et al. (128), cross-linking could be performed on RSV bound to a panel of S. pneumoniae 
strains and the pneumococcal proteins bound to RSV G immunoprecipitated using anti-G antibody, 
followed by identification by mass spectrometry. Alternatively or concurrently, comparative 
genomics of a pair of isolates exhibiting different binding phenotypes but sharing the same 
molecular serotype and ST, such as BNE-8 (a more adherent isolate) and BNE-119 (a less adherent 
isolate), could be undertaken to determine potentially different adhesins utilised by S. pneumoniae 
strains sharing the same core genetic background. Confirmation of potential G binding partners 
identified by either method would then need to be carried out, for example, by measuring the 
affinity of each factor with G through surface plasmon resonance, and investigating changes in 
surface protein levels of the pneumococcal candidates by sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) during mock and RSV infection. 
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The work undertaken in this chapter and Chapter 4 has provided a diverse panel of clinically 
relevant S. pneumoniae strains which exhibit differential adherence to airway epithelia. Despite the 
problems of reproducibility between experiments, the results suggest that the effect of RSV on 
pneumococcal adherence to the epithelial cells also differed between S. pneumoniae strains and 
isolates. These isolates could be used for further investigation of RSV and S. pneumoniae 
interactions during ARI. Use of the isolates in the direct RSV and S. pneumoniae binding 
experiments discussed above could establish possible S. pneumoniae binding partners of RSV G, 
which might represent potential candidates for vaccine or drug design. As established in Chapter 2, 
high S. pneumoniae nasopharyngeal load is associated with more severe RSV infection, and it is 
likely that this interaction is in part mediated through S. pneumoniae binding to G, directly to the 
virion and in the host cell membrane. Disruption of the RSV and S. pneumoniae binding interaction 
through specifically designed therapeutics may be able to reduce the pathogenic effects of the 
interaction during ARI. However, multiple factors are likely involved in RSV and S. pneumoniae 
interactions in the URT, and the host epithelium is an important aspect excluded from the suggested 
direct binding experiments. Further investigation of RSV and S. pneumoniae interactions in the 
context of the host epithelium would be best performed using primary, differentiated epithelial cells 
cultured at air-liquid interface. While moving to such a system increases the complexity of 
experiments, the change would result in more relevant information as the approach is currently the 
most optimal in vitro model of the human URT. In this system, clinically relevant S. pneumoniae 
strains like those investigated here could again be compared, providing a better understanding of the 
mechanisms of RSV promotion of S. pneumoniae strain-specific colonisation in the URT. 
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6. Conclusions and future directions 
6.1 Role of S. pneumoniae during RSV infection 
This thesis aimed to further our understanding of the role of potentially pathogenic bacteria, in 
particular S. pneumoniae, during RSV infections in young children. Previous studies have identified 
an association between RSV and bacterial co-detection and enhanced disease severity (9-11, 13-15); 
however, the clinical significance of these co-detections is still debated due to conflicting evidence 
from other studies (54, 57, 60, 98, 99). The results presented in Chapter 2 provide strong support for 
the pathogenic role of S. pneumoniae during RSV infection in infants and young children. S. 
pneumoniae was detected in 52% of RSV positive infants and young children presenting at a 
Brisbane hospital emergency department with ARI symptoms. These infants and young children 
had significantly higher disease severity scores compared to those without the RSV and S. 
pneumoniae co-detection. Consequently, the subsequent chapters focused on interactions between 
RSV and S. pneumoniae that might help explain this association with disease severity.  
 
The dynamics of the interaction between RSV and S. pneumoniae had not previously been 
investigated in young children. In Chapter 3, a Brisbane longitudinal community-based birth cohort 
was utilised to investigate S. pneumoniae colonisation in the weeks surrounding an RSV infection, 
covering the spectrum of disease severity from asymptomatic infection to those requiring a hospital 
visit. S. pneumoniae was co-detected in 51% of infants and young children with RSV infections. 
Approximately 33% of RSV positive infants and young children were colonised by S. pneumoniae 
for at least four weeks before the RSV detection, while in approximately 14%, S. pneumoniae was 
first detected at the same time as RSV. For those participants already colonised with S. pneumoniae, 
pneumococcal load tended to increase during virus infection, and CST of a subset of these samples 
determined that the same pneumococcal strain was detected in the week prior, during and 
subsequent to the RSV infection. These results suggested that in infants and young children 
colonised by S. pneumoniae, RSV infection might have promoted an increase in growth of 
pneumococcal strains that were already part of the URT microbiota. In contrast, the infants and 
young children who seemingly acquired S. pneumoniae and RSV in the same week might have 
simultaneously acquired both pathogens through co-transmission events. We have previously 
hypothesised that co-transmission of RSV and S. pneumoniae may be possible in respiratory 
secretions, due to the ability of the virus and bacteria to bind together in co-pathogen complexes (6). 
 
The co-circulation of RSV and S. pneumoniae strains was therefore investigated retrospectively in 
Chapter 4, exploiting nasopharyngeal samples sent to Pathology Queensland Central from young 
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children with symptoms of ARI. The study was underpowered to detect specific associations 
between RSV and S. pneumoniae strains; however, the results can be used to inform future study 
designs. Furthermore, the study provided an extensive panel of characterised, clinically relevant S. 
pneumoniae isolates for use in mechanistic experiments. 
 
These clinical isolates were used for in vitro investigation of RSV and S. pneumoniae binding 
interactions in Chapter 5. RSV promotion of pneumococcal adherence to the URT is the most well 
characterised interaction mechanism between the virus and the bacteria (128, 136-138, 140). In 
Chapter 5, variation in the ability of S. pneumoniae isolates to adhere to uninfected airway epithelial 
cells was observed, independent of molecular serotype or core genetic background (i.e. sequence 
type), consistent with previous reports (311, 314, 317). The results also suggested that RSV-
mediated adherence of S. pneumoniae isolates to airway epithelia may be pneumococcal strain-
dependent, and that the formation of RSV and S. pneumoniae complexes may enhance 
pneumococcal adherence in the URT. However, further optimisation and experimentation is needed 
to confirm these results, particularly for isolates that adhere well to uninfected airway epithelia.  
 
The analysis of the paediatric clinical and community cohorts and in vitro studies undertaken in this 
thesis provides evidence for two scenarios that may together govern RSV/S. pneumoniae co-
infections in infants and young children. In infants and young children already colonised by S. 
pneumoniae, RSV infection may promote outgrowth of pre-existing pneumococcal strains in the 
URT. In other cases, RSV and S. pneumoniae may also be co-transmitted and simultaneously 
acquired. In both situations, S. pneumoniae attachment to the URT may be enhanced by the 
presence of RSV. Infants and young children co-infected with RSV and S. pneumoniae may 
experience more severe ARI, and evidence also suggests that interactions between the virus and the 
bacteria may be dependent on the pneumococcal strain.  
 
The majority of children experience an RSV infection at least once by the age of two years (177). 
The results of this thesis suggest that half of all RSV infections are likely to be associated with 
elevated levels of S. pneumoniae in the URT, and infants and young children co-infected with RSV 
and S. pneumoniae may be more likely to experience severe ARI. Together these findings support 
the need for future work into this important area of human health. Confirmation of the role of RSV 
and S. pneumoniae in paediatric ARI and further analysis of the dynamics and individual strains 
associated with such co-infections will require larger, independent studies. Improved understanding 
in this area could lead to novel prevention and treatment strategies for paediatric ARI.  
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6.2 Contribution of thesis to the field 
The work conducted for this thesis contributed to the field in the following ways: 
1. Further statistically significant evidence supporting a clinically relevant role for S. pneumoniae 
in enhancing disease severity during paediatric RSV infection; the first to be conducted in an 
Australian subtropical climate (Chapter 2). 
2. Characterisation of the different pneumococcal colonisation patterns that might lead to RSV/S. 
pneumoniae co-infection, the first to be conducted in otherwise healthy young children 
including samples collected over the course of infection (Chapter 3). 
3. Genetic characterisation of a clinically relevant set of S. pneumoniae isolates that can be used as 
a tool for future molecular studies (Chapter 4). 
4. Further evidence suggesting strain-specific binding interactions of S. pneumoniae during RSV 
infection in vitro, and a critical evaluation of the methods used in this study and previously in 
the literature to quantify these S. pneumoniae and RSV in vitro binding interactions (Chapter 5). 
 
6.3 Future directions 
The work of this thesis has highlighted the complexity of studying microbial interactions in an 
environment as diverse and dynamic as the paediatric URT. While evidence of interactions between 
RSV and S. pneumoniae, potentially with an effect on disease severity, were identified in the three 
cohorts and in vitro experiments, analysis was confounded by the presence of other respiratory 
viruses and bacteria including hRV, M. catarrhalis and H. influenzae, participant demographic 
factors such as age and immunisation status, and variations in viral and bacterial strain circulation 
over time. Samples from all three cohorts were also confined to the URT due to the difficulties in 
sampling the LRT; however, URT samples may not accurately reflect the aetiology of LRT 
infections (as discussed in Chapter 1.3.1). Further investigation of the contribution of confounding 
factors to paediatric ARI susceptibility, clinical course and outcome would be important when 
considering prevention and treatment strategies, and long-term sequelae of RSV/S. pneumoniae co-
infections. Future studies investigating the polymicrobial nature of paediatric ARI should try to 
account for these potential confounding factors as much as possible. Such studies require collection 
of healthy samples, to provide a baseline to study paediatric ARI within individuals, collection of 
relevant demographic and clinical data, characterisation of the URT microbiota and viral carriage 
during health and illness, and confirmation of LRT involvement during infection. Species- and 
strain-specific characterisation of pathogens like RSV and S. pneumoniae may also be highly 
relevant for understanding microbial interactions, but add a further layer of complexity. 
Longitudinal cohorts are ideal for these investigations, however, the large studies required to fully 
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elucidate the role of polymicrobial infections in disease are resource-intensive and not viable 
without extensive funding and collaboration.  
 
Similar large, longitudinal studies are needed to investigate the long-term sequelae of polymicrobial 
ARI in infants and young children. In the paediatric cohorts investigated in Chapter 2 and Chapter 
3, S. pneumoniae co-detection was observed during approximately half of RSV infections. Both 
RSV and S. pneumoniae infections have been independently associated with  acute wheezy episodes 
in young children (109-111), and wheezy LRT infections in early infancy have been associated with 
increased risk of later development of persistent wheeze, a hallmark of asthma (107, 108). 
Furthermore, colonisation by potentially pathogenic bacteria, such as S. pneumoniae, during ARI 
has also been found to increase risk of febrile LRT infection, resulting in increased risk of asthma in 
later childhood (5). It is therefore possible that paediatric RSV/S. pneumoniae co-infections may 
play a role in the induction or progression of asthma. However, studies investigating this hypothesis 
would need to account for variation in participant immune response and development, and genetic 
susceptibility to asthma (106, 327, 328), in addition to the potential confounding factors discussed 
above. Such studies would also need to follow-up participants during later childhood, e.g. at age 10 
years, to determine the subsequent development of persistent wheeze and asthma, as well as 
analysis of ARI episodes during early life.   
 
To add to the complexity surrounding studies of paediatric ARI and potential long-term sequelae, 
there is growing evidence to suggest that the interaction between RSV and S. pneumoniae may be 
bidirectional and of benefit to both pathogens (91, 159, 160). The majority of this thesis, and much 
of the literature in the field, has focused on RSV promotion of S. pneumoniae colonisation, where 
the bacteria opportunistically exploits RSV infection to expand within the URT and potentially 
favour its transmission (or co-transmission) to new hosts (5, 14, 15, 128, 136, 137, 262). However, 
the frequency of RSV/S. pneumoniae co-infections within children, their localisation to the same 
ecological niche, and their transmission through direct contact with nasal secretions, could 
potentially favour the co-evolution of a synergistic relationship, in which RSV also benefits from 
promoting S. pneumoniae colonisation and outgrowth (6). One study has demonstrated strain-
specific pneumococcal enhancement of RSV infection in primary, differentiated human bronchial 
epithelial cells and in a cotton rat model of RSV infection after established S. pneumoniae nasal 
colonisation (160). Another study has shown enhanced RSV infection in vitro with simultaneous 
addition of synthetic bacterial lipopeptides, suggesting that bacteria may facilitate viral attachment 
to host cells (159). In infants, early colonisation by Streptococcus has also been associated with 
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earlier first LRT infections (5). In the ORChID cohort investigated in Chapter 3, around 33% of 
infants and young children with an RSV infection were colonised by S. pneumoniae in the 
preceding weeks. While pneumococcal carriage rates in young children are high during health, 
estimated to be 30-60% in children under five years in high-income countries (75-77, 224), it is 
possible that S. pneumoniae could predispose young children to RSV infection. As discussed in 
Chapter 3.4, the relative risk of RSV infection due to prior pneumococcal colonisation could be 
determined using additional data from the ORChID cohort, comparing the prevalence of S. 
pneumoniae colonisation during health with prevalence during RSV infection. 
 
The results of Chapter 3 also suggested that co-transmission of RSV and S. pneumoniae might 
occur in almost 15% of infants and young children with RSV infections. The possibility of co-
transmission could be further clinically investigated in settings of rapid transmission like childcare 
centres. Regular sampling by nasal swabs of children in close contact would be an optimal way to 
directly examine co-transmission. Further mechanistic analysis in vitro and fluorescent visualisation 
of pathogens within nasal secretions could be used to determine whether the two pathogens form 
complexes that are co-transmitted or whether both are simultaneously but separately transmitted in 
respiratory secretions between children, with RSV enhancement of S. pneumoniae adherence to the 
URT upon entry to a new host. Studies identifying the molecular factors involved in these binding 
interactions, both directly and indirectly at the URT epithelium, may provide future targets for 
therapeutic intervention. Compounds capable of inhibiting these interactions may be able to reduce 
the severity of disease associated with RSV/S. pneumoniae co-infections during paediatric ARI. 
Although, as multiple factors may be involved in RSV and S. pneumoniae interactions, and in the 
resulting more severe disease, the development of targeted therapeutics may prove challenging. 
 
Current treatment and clinical management of paediatric ARI is another area requiring further 
investigation in light of the findings of this thesis and other recent studies (9-11, 13-15). Increased 
disease severity was found to be associated with S. pneumoniae presence during RSV infection; 
however, the best treatment strategies for RSV/S. pneumoniae co-infection are currently unclear. 
Administration of antibiotics during bronchiolitis, most commonly caused by RSV, has not been 
shown to improve clinical outcomes in young children, despite reductions in URT loads of bacteria 
(72, 73). However, these studies did not specifically target infections where high nasopharyngeal 
loads of S. pneumoniae were detected with RSV. It has previously been suggested that the 
unnecessary use of antibiotics should be minimised, as the development of resistance is a global 
problem, and there is evidence that antibiotic disruption of young children’s gut and respiratory 
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microbiome might contribute to long-term health issues like asthma (5, 329). Thus, antibiotic 
treatment of uncomplicated ARI in young children is not generally recommended (70). Clinical 
studies specifically following antibiotic treatment and resulting clinical outcomes of infants and 
young children with probable RSV/S. pneumoniae co-infection could be used to determine whether 
antibiotics are a beneficial treatment option. The development of rapid diagnostics to assess S. 
pneumoniae nasopharyngeal load in confirmed RSV infection is also needed, to determine threshold 
levels of pneumococcal density above which antibiotic treatment may become beneficial. 
 
Vaccination strategies to prevent RSV infection are a high priority, with multiple approaches 
currently in pre-clinical and clinical trials (330). Beyond the obvious benefits of preventing the 
most clinically important respiratory virus of infants and young children, the development of an 
RSV vaccine could potentially reduce rates of severe disease due to S. pneumoniae co-infection. 
Furthermore, such a vaccine might also reduce rates of S. pneumoniae transmission and 
colonisation in young children by preventing co-transmission of virus and bacteria. Should 
colonisation by S. pneumoniae be found to increase host susceptibility to RSV infections, 
vaccination strategies targeting pneumococcal strains that frequently colonise the paediatric URT 
may be needed, in addition to the focus on IPD serotypes by the current PCVs.  
 
Future studies and developments, such as those discussed in this chapter that build on the work of 
this thesis, will further our understanding of the complex, polymicrobial nature of the paediatric 
URT, and could potentially lead to improved health outcomes for infants and young children 
experiencing ARI. 
 
 147 
 
7. References 
1. Chappell KJ, Brealey JC, Mackay IM, et al. Respiratory syncytial virus infection is associated 
with increased bacterial load in the upper respiratory tract in young children. J Medical Microbiol 
Diagnosis. 2013;S1:005. 
2. Nair H, Simoes EA, Rudan I, et al. Global and regional burden of hospital admissions for severe 
acute lower respiratory infections in young children in 2010: a systematic analysis. Lancet. 
2013;381:1380-1390. 
3. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to 
respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 
2010;375:1545-1555. 
4. Simoes EAF, Cherian T, Chow J, et al. Acute respiratory infections in children. In: Jamison DT, 
Breman JG, Measham AR, et al., eds. Disease Control Priorities in Developing Countries. 2 ed. 
Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 
2006. 
5. Teo SM, Mok D, Pham K, et al. The infant nasopharyngeal microbiome impacts severity of 
lower respiratory infection and risk of asthma development. Cell Host Microbe. 2015;17:704-715. 
6. Brealey JC, Sly PD, Young PR, et al. Viral bacterial co-infection of the respiratory tract during 
early childhood. FEMS Microbiol Lett. 2015;362. 
7. McCullers JA. The co-pathogenesis of influenza viruses with bacteria in the lung. Nat Rev 
Microbiol. 2014;12:252-262. 
8. Zhou H, Thompson WW, Viboud CG, et al. Hospitalizations associated with influenza and 
respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis. 2012;54:1427-1436. 
9. Resch B, Gusenleitner W, Mueller WD. Risk of concurrent bacterial infection in preterm infants 
hospitalized due to respiratory syncytial virus infection. Acta Paediatr. 2007;96:495-498. 
10. Kneyber MC, Blusse van Oud-Alblas H, van Vliet M, et al. Concurrent bacterial infection and 
prolonged mechanical ventilation in infants with respiratory syncytial virus lower respiratory tract 
disease. Intensive Care Med. 2005;31:680-685. 
11. Thorburn K, Harigopal S, Reddy V, et al. High incidence of pulmonary bacterial co-infection in 
children with severe respiratory syncytial virus (RSV) bronchiolitis. Thorax. 2006;61:611-615. 
12. Cebey-Lopez M, Pardo-Seco J, Gomez-Carballa A, et al. Bacteremia in children hospitalized 
with respiratory syncytial virus infection. PLoS One. 2016;11:e0146599. 
13. Leung TF, Lam DS, Miu TY, et al. Epidemiology and risk factors for severe respiratory 
syncytial virus infections requiring pediatric intensive care admission in Hong Kong children. 
Infection. 2014;42:343-350. 
 148 
 
14. de Steenhuijsen Piters WA, Heinonen S, Hasrat R, et al. Nasopharyngeal microbiota, host 
transcriptome and disease severity in children with respiratory syncytial virus infection. Am J 
Respir Crit Care Med. 2016. 
15. Suarez-Arrabal MC, Mella C, Lopez SM, et al. Nasopharyngeal bacterial burden and antibiotics: 
influence on inflammatory markers and disease severity in infants with respiratory syncytial virus 
bronchiolitis. J Infect. 2015;71:458-469. 
16. Dominguez-Bello MG, Costello EK, Contreras M, et al. Delivery mode shapes the acquisition 
and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad 
Sci U S A. 2010;107:11971-11975. 
17. Bosch AA, Levin E, van Houten MA, et al. Development of upper respiratory tract microbiota 
in infancy is affected by mode of delivery. EBioMedicine. 2016;9:336-345. 
18. Biesbroek G, Tsivtsivadze E, Sanders EA, et al. Early respiratory microbiota composition 
determines bacterial succession patterns and respiratory health in children. Am J Respir Crit Care 
Med. 2014;190:1283-1292. 
19. Vissing NH, Chawes BL, Bisgaard H. Increased risk of pneumonia and bronchiolitis after 
bacterial colonization of the airways as neonates. Am J Respir Crit Care Med. 2013;188:1246-1252. 
20. Bogaert D, Keijser B, Huse S, et al. Variability and diversity of nasopharyngeal microbiota in 
children: a metagenomic analysis. PLoS ONE. 2011;6:e17035. 
21. van den Bergh MR, Biesbroek G, Rossen JW, et al. Associations between pathogens in the 
upper respiratory tract of young children: interplay between viruses and bacteria. PLoS One. 
2012;7:e47711. 
22. Mehr S, Wood N. Streptococcus pneumoniae - a review of carriage, infection, serotype 
replacement and vaccination. Paediatr Respir Rev. 2012;13:258-264. 
23. Duell BL, Su YC, Riesbeck K. Host-pathogen interactions of nontypeable Haemophilus 
influenzae: from commensal to pathogen. FEBS Lett. 2016. 
24. Murphy TF, Parameswaran GI. Moraxella catarrhalis, a human respiratory tract pathogen. Clin 
Infect Dis. 2009;49:124-131. 
25. Rosas-Salazar C, Shilts MH, Tovchigrechko A, et al. Nasopharyngeal microbiome in respiratory 
syncytial virus resembles profile associated with increased childhood asthma risk. Am J Respir Crit 
Care Med. 2016;193:1180-1183. 
26. Jacoby P, Watson K, Bowman J, et al. Modelling the co-occurrence of Streptococcus 
pneumoniae with other bacterial and viral pathogens in the upper respiratory tract. Vaccine. 
2007;25:2458-2464. 
 149 
 
27. Jansen RR, Wieringa J, Koekkoek SM, et al. Frequent detection of respiratory viruses without 
symptoms: toward defining clinically relevant cutoff values. J Clin Microbiol. 2011;49:2631-2636. 
28. Jartti T, Jartti L, Peltola V, et al. Identification of respiratory viruses in asymptomatic subjects: 
asymptomatic respiratory viral infections. Pediatr Infect Dis J. 2008;27:1103-1107. 
29. Singleton RJ, Bulkow LR, Miernyk K, et al. Viral respiratory infections in hospitalized and 
community control children in Alaska. J Med Virol. 2010;82:1282-1290. 
30. Sarna M, Alsaleh A, Lambert SB, et al. Respiratory viruses in neonates: a prospective, 
community-based birth cohort study. Pediatr Infect Dis J. 2016. 
31. Kusel MM, de Klerk NH, Holt PG, et al. Role of respiratory viruses in acute upper and lower 
respiratory tract illness in the first year of life: a birth cohort study. Pediatr Infect Dis J. 
2006;25:680-686. 
32. Annamalay AA, Khoo SK, Jacoby P, et al. Prevalence of and risk factors for human rhinovirus 
infection in healthy aboriginal and non-aboriginal Western Australian children. Pediatr Infect Dis J. 
2012;31:673-679. 
33. Bochkov YA, Gern JE. Clinical and molecular features of human rhinovirus C. Microbes Infect. 
2012;14:485-494. 
34. Messacar K, Abzug MJ, Dominguez SR. 2014 outbreak of enterovirus D68 in North America. J 
Med Virol. 2016;88:739-745. 
35. Babakir-Mina M, Ciccozzi M, Perno CF, et al. The human polyomaviruses KI and WU: 
virological background and clinical implications. APMIS. 2013;121:746-754. 
36. Martin ET, Fairchok MP, Kuypers J, et al. Frequent and prolonged shedding of bocavirus in 
young children attending daycare. J Infect Dis. 2010;201:1625-1632. 
37. Asner SA, Rose W, Petrich A, et al. Is virus coinfection a predictor of severity in children with 
viral respiratory infections? Clin Microbiol Infect. 2015;21:264 e261-266. 
38. Martin ET, Fairchok MP, Stednick ZJ, et al. Epidemiology of multiple respiratory viruses in 
childcare attendees. J Infect Dis. 2013;207:982-989. 
39. Nokso-Koivisto J, Marom T, Chonmaitree T. Importance of viruses in acute otitis media. Curr 
Opin Pediatr. 2015;27:110-115. 
40. Marom T, Alvarez-Fernandez PE, Jennings K, et al. Acute bacterial sinusitis complicating viral 
upper respiratory tract infection in young children. Pediatr Infect Dis J. 2014;33:803-808. 
41. Ede LC, Loeffelholz MJ, Alvarez-Fernandez P, et al. Effect of the 2009 influenza A/H1N1 
pandemic on viral respiratory infections in the first year of life. Pediatr Infect Dis J. 2012;31:1107-
1112. 
 150 
 
42. Baer G, Engelcke G, Abele-Horn M, et al. Role of Chlamydia pneumoniae and Mycoplasma 
pneumoniae as causative agents of community-acquired pneumonia in hospitalised children and 
adolescents. Eur J Clin Microbiol Infect Dis. 2003;22:742-745. 
43. Meyer Sauteur PM, Unger WW, Nadal D, et al. Infection with and carriage of Mycoplasma 
pneumoniae in children. Front Microbiol. 2016;7:329. 
44. Zlamy M. Rediscovering Pertussis. Front Pediatr. 2016;4:52. 
45. Martin-Loeches I, Sanchez-Corral A, Diaz E, et al. Community-acquired respiratory coinfection 
in critically ill patients with pandemic 2009 influenza A(H1N1) virus. Chest. 2011;139:555-562. 
46. O'Brien KL, Walters MI, Sellman J, et al. Severe pneumococcal pneumonia in previously 
healthy children: the role of preceding influenza infection. Clin Infect Dis. 2000;30:784-789. 
47. Palacios G, Hornig M, Cisterna D, et al. Streptococcus pneumoniae coinfection is correlated 
with the severity of H1N1 pandemic influenza. PLoS ONE. 2009;4:e8540. 
48. Chen CJ, Lin PY, Tsai MH, et al. Etiology of community-acquired pneumonia in hospitalized 
children in northern Taiwan. Pediatr Infect Dis J. 2012. 
49. De Schutter I, De Wachter E, Crokaert F, et al. Microbiology of bronchoalveolar lavage fluid in 
children with acute nonresponding or recurrent community-acquired pneumonia: identification of 
nontypeable Haemophilus influenzae as a major pathogen. Clin Infect Dis. 2011;52:1437-1444. 
50. Honkinen M, Lahti E, Osterback R, et al. Viruses and bacteria in sputum samples of children 
with community-acquired pneumonia. Clin Microbiol Infect. 2011;18:300-307. 
51. Juven T, Mertsola J, Waris M, et al. Etiology of community-acquired pneumonia in 254 
hospitalized children. Pediatr Infect Dis J. 2000;19:293-298. 
52. Kurz H, Gopfrich H, Huber K, et al. Spectrum of pathogens of in-patient children and youths 
with community acquired pneumonia: a 3 year survey of a community hospital in Vienna, Austria. 
Wien Klin Wochenschr. 2013;125:674-679. 
53. Michelow IC, Olsen K, Lozano J, et al. Epidemiology and clinical characteristics of 
community-acquired pneumonia in hospitalized children. Pediatrics. 2004;113:701-707. 
54. Duttweiler L, Nadal D, Frey B. Pulmonary and systemic bacterial co-infections in severe RSV 
bronchiolitis. Arch Dis Child. 2004;89:1155-1157. 
55. Hishiki H, Ishiwada N, Fukasawa C, et al. Incidence of bacterial coinfection with respiratory 
syncytial virus bronchopulmonary infection in pediatric inpatients. J Infect Chemother. 2011;17:87-
90. 
56. O'Grady KF, Grimwood K, Sloots TP, et al. Prevalence, codetection and seasonal distribution of 
upper airway viruses and bacteria in children with acute respiratory illnesses with cough as a 
symptom. Clin Microbiol Infect. 2016;22:527-534. 
 151 
 
57. Lehtinen P, Jartti T, Virkki R, et al. Bacterial coinfections in children with viral wheezing. Eur J 
Clin Microbiol Infect Dis. 2006;25:463-469. 
58. Okada T, Morozumi M, Sakata H, et al. A practical approach estimating etiologic agents using 
real-time PCR in pediatric inpatients with community-acquired pneumonia. J Infect Chemother. 
2012. 
59. Thornton HV, Blair PS, Lovering AM, et al. Clinical presentation and microbiological diagnosis 
in paediatric respiratory tract infection: a systematic review. Br J Gen Pract. 2015;65:e69-81. 
60. Wei L, Liu W, Zhang XA, et al. Detection of viral and bacterial pathogens in hospitalized 
children with acute respiratory illnesses, Chongqing, 2009-2013. Medicine (Baltimore). 
2015;94:e742. 
61. Tollefson SJ, Cox RG, Williams JV. Studies of culture conditions and environmental stability of 
human metapneumovirus. Virus Res. 2010;151:54-59. 
62. Pyrc K, Sims AC, Dijkman R, et al. Culturing the unculturable: human coronavirus HKU1 
infects, replicates, and produces progeny virions in human ciliated airway epithelial cell cultures. J 
Virol. 2010;84:11255-11263. 
63. Somerville LK, Ratnamohan VM, Dwyer DE, et al. Molecular diagnosis of respiratory viruses. 
Pathology (Phila). 2015;47:243-249. 
64. Chartrand C, Tremblay N, Renaud C, et al. Diagnostic accuracy of rapid antigen detection tests 
for respiratory syncytial virus infection: systematic review and meta-analysis. J Clin Microbiol. 
2015;53:3738-3749. 
65. Dominguez J, Blanco S, Rodrigo C, et al. Usefulness of urinary antigen detection by an 
immunochromatographic test for diagnosis of pneumococcal pneumonia in children. J Clin 
Microbiol. 2003;41:2161-2163. 
66. Carvalho Mda G, Tondella ML, McCaustland K, et al. Evaluation and improvement of real-time 
PCR assays targeting lytA, ply, and psaA genes for detection of pneumococcal DNA. J Clin 
Microbiol. 2007;45:2460-2466. 
67. Dunne EM, Manning J, Russell FM, et al. Effect of pneumococcal vaccination on 
nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus influenzae, Moraxella 
catarrhalis, and Staphylococcus aureus in Fijian children. J Clin Microbiol. 2012;50:1034-1038. 
68. Greiner O, Day PJ, Bosshard PP, et al. Quantitative detection of Streptococcus pneumoniae in 
nasopharyngeal secretions by real-time PCR. J Clin Microbiol. 2001;39:3129-3134. 
69. Wang X, Mair R, Hatcher C, et al. Detection of bacterial pathogens in Mongolia meningitis 
surveillance with a new real-time PCR assay to detect Haemophilus influenzae. Int J Med 
Microbiol. 2011;301:303-309. 
 152 
 
70. Thorburn K, Riordan A. Pulmonary bacterial coinfection in infants and children with viral 
respiratory infection. Expert Review of Anti-Infective Therapy. 2012;10:909-916. 
71. Venekamp RP, Sanders SL, Glasziou PP, et al. Antibiotics for acute otitis media in children. 
Cochrane Database Syst Rev. 2015:CD000219. 
72. McCallum GB, Morris PS, Chang AB. Antibiotics for persistent cough or wheeze following 
acute bronchiolitis in children. Cochrane Database Syst Rev. 2012;12:CD009834. 
73. Spurling GK, Doust J, Del Mar CB, et al. Antibiotics for bronchiolitis in children. Cochrane 
Database Syst Rev. 2011:CD005189. 
74. McCallum GB, Morris PS, Grimwood K, et al. Three-weekly doses of azithromycin for 
indigenous infants hospitalized with bronchiolitis: a multicentre, randomized, placebo-controlled 
trial. Front Pediatr. 2015;3:32. 
75. Choe YJ, Lee HJ, Lee H, et al. Emergence of antibiotic-resistant non-vaccine serotype 
pneumococci in nasopharyngeal carriage in children after the use of extended-valency 
pneumococcal conjugate vaccines in Korea. Vaccine. 2016. 
76. Kaur R, Casey JR, Pichichero ME. Emerging Streptococcus pneumoniae strains colonizing the 
nasopharynx in children after 13-valent pneumococcal conjugate vaccination in comparison to the 
7-valent era, 2006-2015. Pediatr Infect Dis J. 2016;35:901-906. 
77. Yahiaoui RY, den Heijer C, van Bijnen EM, et al. Prevalence and antibiotic resistance of 
commensal Streptococcus pneumoniae in nine European countries. Future Microbiol. 2016;11:737-
744. 
78. Van Eldere J, Slack MP, Ladhani S, et al. Non-typeable Haemophilus influenzae, an under-
recognised pathogen. Lancet Infect Dis. 2014;14:1281-1292. 
79. Lehmann D, Willis J, Moore HC, et al. The changing epidemiology of invasive pneumococcal 
disease in aboriginal and non-aboriginal western Australians from 1997 through 2007 and 
emergence of nonvaccine serotypes. Clin Infect Dis. 2010;50:1477-1486. 
80. Weil Olivier C. Ten years of experience with the pneumococcal conjugate 7-valent vaccine in 
children. Med Mal Infect. 2013;43:309-321. 
81. Hsu KK, Shea KM, Stevenson AE, et al. Changing serotypes causing childhood invasive 
pneumococcal disease: Massachusetts, 2001-2007. Pediatr Infect Dis J. 2010;29:289-293. 
82. Krammer F. Novel universal influenza virus vaccine approaches. Curr Opin Virol. 2016;17:95-
103. 
83. Graham BS. Vaccines against respiratory syncytial virus: The time has finally come. Vaccine. 
2016;34:3535-3541. 
 153 
 
84. Karron RA, Luongo C, Thumar B, et al. A gene deletion that up-regulates viral gene expression 
yields an attenuated RSV vaccine with improved antibody responses in children. Sci Transl Med. 
2015;7:312ra175. 
85. Schmidt AC, Schaap-Nutt A, Bartlett EJ, et al. Progress in the development of human 
parainfluenza virus vaccines. Expert Rev Respir Med. 2011;5:515-526. 
86. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus 
monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk 
infants. Pediatrics. 1998;102:531-537. 
87. Brady MT, Byington CL, Davies HD, et al. Updated guidance for palivizumab prophylaxis 
among infants and young children at increased risk of hospitalization for respiratory syncytial virus 
infection. Pediatrics. 2014;134:e620-e638. 
88. Elhassan NO, Sorbero ME, Hall CB, et al. Cost-effectiveness analysis of palivizumab in 
premature infants without chronic lung disease. Arch Pediatr Adolesc Med. 2006;160:1070-1076. 
89. Tessmer A, Welte T, Schmidt-Ott R, et al. Influenza vaccination is associated with reduced 
severity of community-acquired pneumonia. Eur Respir J. 2011;38:147-153. 
90. Heikkinen T, Block SL, Toback SL, et al. Effectiveness of intranasal live attenuated influenza 
vaccine against all-cause acute otitis media in children. Pediatr Infect Dis J. 2013;32:669-674. 
91. Madhi SA, Klugman KP, Group TVT. A role for Streptococcus pneumoniae in virus-associated 
pneumonia. Nat Med. 2004;10:811-813. 
92. Weinberger DM, Klugman KP, Steiner CA, et al. Association between Respiratory Syncytial 
Virus activity and pneumococcal disease in infants: a time series analysis of US hospitalization 
data. PLoS Med. 2015;12:e1001776. 
93. Abrahams A, Hallows N, French H. A further investigation into influenzo-pneumococcal and 
influenzo-streptococcal septicaemia: epidemic influenzal "pneumonia" of highly fatal type and its 
relation to "purulent bronchitis". Lancet. 1919;193:1-11. 
94. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause 
of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis. 
2008;198:962-970. 
95. Oseasohn R, Adelson L, Kaji M. Clinicopathologic study of thirty-three fatal cases of Asian 
influenza. N Engl J Med. 1959;260:509-518. 
96. Centers for Disease Control and Prevention. Bacterial coinfections in lung tissue specimens 
from fatal cases of 2009 pandemic influenza A (H1N1) - United States, May-August 2009. MMWR 
Morb Mortal Wkly Rep. 2009;58:1071-1074. 
 154 
 
97. Ricart S, Marcos MA, Sarda M, et al. Clinical risk factors are more relevant than respiratory 
viruses in predicting bronchiolitis severity. Pediatr Pulmonol. 2013;48:456-463. 
98. Vissers M, Ahout IM, van den Kieboom CH, et al. High pneumococcal density correlates with 
more mucosal inflammation and reduced respiratory syncytial virus disease severity in infants. 
BMC Infect Dis. 2016;16:129. 
99. Vu HT, Yoshida LM, Suzuki M, et al. Association between nasopharyngeal load of 
Streptococcus pneumoniae, viral coinfection, and radiologically confirmed pneumonia in 
Vietnamese children. Pediatr Infect Dis J. 2011;30:11-18. 
100. Lambert SB, Ware RS, Cook AL, et al. Observational Research in Childhood Infectious 
Diseases (ORChID): a dynamic birth cohort study. BMJ Open. 2012;2. 
101. Ghani AS, Morrow BM, Hardie DR, et al. An investigation into the prevalence and outcome of 
patients admitted to a pediatric intensive care unit with viral respiratory tract infections in Cape 
Town, South Africa. Pediatric Critical Care Medicine. 2012;13:e275-281. 
102. Stockman LJ, Reed C, Kallen AJ, et al. Respiratory syncytial virus and Staphylococcus aureus 
coinfection in children hospitalized with pneumonia. Pediatr Infect Dis J. 2010;29:1048-1050. 
103. Lauinger IL, Bible JM, Halligan EP, et al. Patient characteristics and severity of human 
rhinovirus infections in children. J Clin Virol. 2013;58:216-220. 
104. Techasaensiri B, Techasaensiri C, Mejias A, et al. Viral coinfections in children with invasive 
pneumococcal disease. Pediatr Infect Dis J. 2010;29:519-523. 
105. Nuolivirta K, Koponen P, He QS, et al. Bordetella pertussis infection is common in 
nonvaccinated infants admitted for bronchiolitis. Pediatr Infect Dis J. 2010;29:1013-1015. 
106. Vuillermin PJ, Ponsonby AL, Saffery R, et al. Microbial exposure, interferon gamma gene 
demethylation in naive T-cells, and the risk of allergic disease. Allergy. 2009;64:348-353. 
107. Jackson DJ, Gangnon RE, Evans MD, et al. Wheezing rhinovirus illnesses in early life predict 
asthma development in high-risk children. Am J Respir Crit Care Med. 2008;178:667-672. 
108. Kusel MM, de Klerk NH, Kebadze T, et al. Early-life respiratory viral infections, atopic 
sensitization, and risk of subsequent development of persistent asthma. J Allergy Clin Immunol. 
2007;119:1105-1110. 
109. Lemanske RF, Jr., Jackson DJ, Gangnon RE, et al. Rhinovirus illnesses during infancy predict 
subsequent childhood wheezing. J Allergy Clin Immunol. 2005;116:571-577. 
110. Sigurs N, Bjarnason R, Sigurbergsson F, et al. Respiratory syncytial virus bronchiolitis in 
infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med. 
2000;161:1501-1507. 
 155 
 
111. Bisgaard H, Hermansen MN, Bonnelykke K, et al. Association of bacteria and viruses with 
wheezy episodes in young children: prospective birth cohort study. BMJ. 2010;341:c4978. 
112. Kloepfer KM, Lee WM, Pappas TE, et al. Detection of pathogenic bacteria during rhinovirus 
infection is associated with increased respiratory symptoms and asthma exacerbations. J Allergy 
Clin Immunol. 2014;133:1301-1307, 1307 e1301-1303. 
113. Koppe U, Suttorp N, Opitz B. Recognition of Streptococcus pneumoniae by the innate immune 
system. Cell Microbiol. 2012;14:460-466. 
114. Kolli D, Velayutham TS, Casola A. Host-viral interactions: role of pattern recognition 
receptors (PRRs) in human pneumovirus infections. Pathogens. 2013;2. 
115. Albiger B, Dahlberg S, Sandgren A, et al. Toll-like receptor 9 acts at an early stage in host 
defence against pneumococcal infection. Cell Microbiol. 2007;9:633-644. 
116. Davis KM, Nakamura S, Weiser JN. Nod2 sensing of lysozyme-digested peptidoglycan 
promotes macrophage recruitment and clearance of S. pneumoniae colonization in mice. J Clin 
Invest. 2011;121:3666-3676. 
117. Koppe U, Hogner K, Doehn JM, et al. Streptococcus pneumoniae stimulates a STING- and 
IFN regulatory factor 3-dependent type I IFN production in macrophages, which regulates 
RANTES production in macrophages, cocultured alveolar epithelial cells, and mouse lungs. J 
Immunol. 2012;188:811-817. 
118. Kurt-Jones EA, Popova L, Kwinn L, et al. Pattern recognition receptors TLR4 and CD14 
mediate response to respiratory syncytial virus. Nat Immunol. 2000;1:398-401. 
119. Murawski MR, Bowen GN, Cerny AM, et al. Respiratory syncytial virus activates innate 
immunity through Toll-like receptor 2. J Virol. 2009;83:1492-1500. 
120. Rudd BD, Burstein E, Duckett CS, et al. Differential role for TLR3 in respiratory syncytial 
virus-induced chemokine expression. J Virol. 2005;79:3350-3357. 
121. Fang R, Tsuchiya K, Kawamura I, et al. Critical roles of ASC inflammasomes in caspase-1 
activation and host innate resistance to Streptococcus pneumoniae infection. J Immunol. 
2011;187:4890-4899. 
122. Segovia J, Sabbah A, Mgbemena V, et al. TLR2/MyD88/NF-kappaB pathway, reactive oxygen 
species, potassium efflux activates NLRP3/ASC inflammasome during respiratory syncytial virus 
infection. PLoS One. 2012;7:e29695. 
123. Bellinghausen C, Gulraiz F, Heinzmann AC, et al. Exposure to common respiratory bacteria 
alters the airway epithelial response to subsequent viral infection. Respir Res. 2016;17:68. 
124. Lee LN, Dias P, Han D, et al. A mouse model of lethal synergism between influenza virus and 
Haemophilus influenzae. Am J Pathol. 2010;176:800-811. 
 156 
 
125. Jamieson AM, Pasman L, Yu S, et al. Role of tissue protection in lethal respiratory viral-
bacterial coinfection. Science. 2013;340:1230-1234. 
126. McAuley JL, Hornung F, Boyd KL, et al. Expression of the 1918 influenza A virus PB1-F2 
enhances the pathogenesis of viral and secondary bacterial pneumonia. Cell Host and Microbe. 
2007;2:240-249. 
127. Smith MW, Schmidt JE, Rehg JE, et al. Induction of pro- and anti-inflammatory molecules in 
a mouse model of pneumococcal pneumonia after influenza. Comparative Medicine. 2007;57:82-
89. 
128. Smith CM, Sandrini S, Datta S, et al. RSV increases the virulence of Streptococcus 
pneumoniae by binding to PBP1a: a new paradigm in respiratory infection. Am J Respir Crit Care 
Med. 2014;190:196-207. 
129. Vissers M, Remijn T, Oosting M, et al. Respiratory syncytial virus infection augments NOD2 
signaling in an IFN-beta-dependent manner in human primary cells. Eur J Immunol. 2012;42:2727-
2735. 
130. Kash JC, Walters KA, Davis AS, et al. Lethal synergism of 2009 pandemic H1N1 influenza 
virus and Streptococcus pneumoniae coinfection is associated with loss of murine lung repair 
responses. MBio. 2011;2. 
131. Jamieson AM, Yu S, Annicelli CH, et al. Influenza virus-induced glucocorticoids compromise 
innate host defense against a secondary bacterial infection. Cell Host and Microbe. 2010;7:103-114. 
132. Loh E, Kugelberg E, Tracy A, et al. Temperature triggers immune evasion by Neisseria 
meningitidis. Nature. 2013;502:237-240. 
133. Marks LR, Davidson BA, Knight PR, et al. Interkingdom signaling induces Streptococcus 
pneumoniae biofilm dispersion and transition from asymptomatic colonization to disease. Mbio. 
2013;4. 
134. Pettigrew MM, Marks LR, Kong Y, et al. Dynamic changes in the Streptococcus pneumoniae 
transcriptome during transition from biofilm formation to invasive disease upon influenza A virus 
infection. Infect Immun. 2014;82:4607-4619. 
135. Leung RK, Zhou JW, Guan W, et al. Modulation of potential respiratory pathogens by pH1N1 
viral infection. Clin Microbiol Infect. 2012. 
136. Avadhanula V, Wang Y, Portner A, et al. Nontypeable Haemophilus influenzae and 
Streptococcus pneumoniae bind respiratory syncytial virus glycoprotein. J Med Microbiol. 
2007;56:1133-1137. 
 157 
 
137. Hament JM, Aerts PC, Fleer A, et al. Direct binding of respiratory syncytial virus to 
pneumococci: a phenomenon that enhances both pneumococcal adherence to human epithelial cells 
and pneumococcal invasiveness in a murine model. Pediatr Res. 2005;58:1198-1203. 
138. Avadhanula V, Rodriguez CA, DeVincenzo JP, et al. Respiratory viruses augment the 
adhesion of bacterial pathogens to respiratory epithelium in a viral species- and cell type-dependent 
manner. J Virol. 2006;80:1629-1636. 
139. Hakansson A, Kidd A, Wadell G, et al. Adenovirus infection enhances in vitro adherence of 
Streptococcus pneumoniae. Infect Immun. 1994;62:2707-2714. 
140. Hament JM, Aerts PC, Fleer A, et al. Enhanced adherence of Streptococcus pneumoniae to 
human epithelial cells infected with respiratory syncytial virus. Pediatr Res. 2004;55:972-978. 
141. Ishizuka S, Yamaya M, Suzuki T, et al. Effects of rhinovirus infection on the adherence of 
Streptococcus pneumoniae to cultured human airway epithelial cells. J Infect Dis. 2003;188:1928-
1939. 
142. Raza MW, El Ahmer OR, Ogilvie MM, et al. Infection with respiratory syncytial virus 
enhances expression of native receptors for non-pilate Neisseria meningitidis on HEp-2 cells. FEMS 
Immunol Med Microbiol. 1999;23:115-124. 
143. van der Sluijs KF, van Elden LJ, Nijhuis M, et al. Involvement of the platelet-activating factor 
receptor in host defense against Streptococcus pneumoniae during postinfluenza pneumonia. Am J 
Physiol Lung Cell Mol Physiol. 2006;290:L194-199. 
144. Wang JH, Kwon HJ, Jang YJ. Rhinovirus enhances various bacterial adhesions to nasal 
epithelial cells simultaneously. Laryngoscope. 2009;119:1406-1411. 
145. Li N, Ren A, Wang X, et al. Influenza viral neuraminidase primes bacterial coinfection 
through TGF-beta-mediated expression of host cell receptors. Proc Natl Acad Sci U S A. 
2015;112:238-243. 
146. Kimaro Mlacha SZ, Peret TC, Kumar N, et al. Transcriptional adaptation of pneumococci and 
human pharyngeal cells in the presence of a virus infection. BMC Genomics. 2013;14:378. 
147. Cundell DR, Gerard NP, Gerard C, et al. Streptococcus pneumoniae anchor to activated human 
cells by the receptor for platelet-activating factor. Nature. 1995;377:435-438. 
148. Huber VC, Peltola V, Iverson AR, et al. Contribution of vaccine-induced immunity toward 
either the HA or the NA component of influenza viruses limits secondary bacterial complications. J 
Virol. 2010;84:4105-4108. 
149. McCullers JA, Bartmess KC. Role of neuraminidase in lethal synergism between influenza 
virus and Streptococcus pneumoniae. J Infect Dis. 2003;187:1000-1009. 
 158 
 
150. Plotkowski MC, Puchelle E, Beck G, et al. Adherence of type I Streptococcus pneumoniae to 
tracheal epithelium of mice infected with influenza A/PR8 virus. Am Rev Respir Dis. 
1986;134:1040-1044. 
151. Pittet LA, Hall-Stoodley L, Rutkowski MR, et al. Influenza virus infection decreases tracheal 
mucociliary velocity and clearance of Streptococcus pneumoniae. Am J Respir Cell Mol Biol. 
2010;42:450-460. 
152. Suzuki K, Bakaletz LO. Synergistic effect of adenovirus type 1 and nontypeable Haemophilus 
influenzae in a chinchilla model of experimental otitis media. Infect Immun. 1994;62:1710-1718. 
153. McGillivary G, Mason KM, Jurcisek JA, et al. Respiratory syncytial virus-induced 
dysregulation of expression of a mucosal beta-defensin augments colonization of the upper airway 
by non-typeable Haemophilus influenzae. Cell Microbiol. 2009;11:1399-1408. 
154. Ghoneim HE, Thomas PG, McCullers JA. Depletion of alveolar macrophages during influenza 
infection facilitates bacterial superinfections. J Immunol. 2013;191:1250-1259. 
155. Nakamura S, Davis KM, Weiser JN. Synergistic stimulation of type I interferons during 
influenza virus coinfection promotes Streptococcus pneumoniae colonization in mice. J Clin Invest. 
2011;121:3657-3665. 
156. Sun K, Metzger DW. Inhibition of pulmonary antibacterial defense by interferon-gamma 
during recovery from influenza infection. Nat Med. 2008;14:558-564. 
157. Shahangian A, Chow EK, Tian X, et al. Type I IFNs mediate development of postinfluenza 
bacterial pneumonia in mice. J Clin Invest. 2009;119:1910-1920. 
158. Verkaik NJ, Nguyen DT, de Vogel CP, et al. Streptococcus pneumoniae exposure is associated 
with human metapneumovirus seroconversion and increased susceptibility to in vitro HMPV 
infection. Clin Microbiol Infect. 2011;17:1840-1844. 
159. Nguyen DT, de Witte L, Ludlow M, et al. The synthetic bacterial lipopeptide Pam3CSK4 
modulates respiratory syncytial virus infection independent of TLR activation. PLoS Pathog. 
2010;6:e1001049. 
160. Nguyen DT, Louwen R, Elberse K, et al. Streptococcus pneumoniae enhances human 
respiratory syncytial virus infection in vitro and in vivo. PLoS One. 2015;10:e0127098. 
161. Sajjan US, Jia Y, Newcomb DC, et al. H. influenzae potentiates airway epithelial cell 
responses to rhinovirus by increasing ICAM-1 and TLR3 expression. FASEB J. 2006;20:2121-
2123. 
162. Gulraiz F, Bellinghausen C, Bruggeman CA, et al. Haemophilus influenzae increases the 
susceptibility and inflammatory response of airway epithelial cells to viral infections. FASEB J. 
2015;29:849-858. 
 159 
 
163. Smith AM, Adler FR, Ribeiro RM, et al. Kinetics of coinfection with influenza A virus and 
Streptococcus pneumoniae. PLoS Pathog. 2013;9:e1003238. 
164. Tashiro M, Ciborowski P, Reinacher M, et al. Synergistic role of staphylococcal proteases in 
the induction of influenza virus pathogenicity. Virology. 1987;157:421-430. 
165. Nishikawa T, Shimizu K, Tanaka T, et al. Bacterial neuraminidase rescues influenza virus 
replication from inhibition by a neuraminidase inhibitor. PLoS One. 2012;7:e45371. 
166. Barretto N, Hallak LK, Peeples ME. Neuraminidase treatment of respiratory syncytial virus-
infected cells or virions, but not target cells, enhances cell-cell fusion and infection. Virology. 
2003;313:33-43. 
167. Trappetti C, Kadioglu A, Carter M, et al. Sialic acid: a preventable signal for pneumococcal 
biofilm formation, colonization, and invasion of the host. J Infect Dis. 2009;199:1497-1505. 
168. Gut H, Xu G, Taylor GL, et al. Structural basis for Streptococcus pneumoniae NanA inhibition 
by influenza antivirals zanamivir and oseltamivir carboxylate. J Mol Biol. 2011;409:496-503. 
169. Parker D, Soong G, Planet P, et al. The NanA neuraminidase of Streptococcus pneumoniae is 
involved in biofilm formation. Infect Immun. 2009;77:3722-3730. 
170. Diavatopoulos DA, Short KR, Price JT, et al. Influenza A virus facilitates Streptococcus 
pneumoniae transmission and disease. FASEB J. 2010;24:1789-1798. 
171. McCullers JA, McAuley JL, Browall S, et al. Influenza enhances susceptibility to natural 
acquisition of and disease due to Streptococcus pneumoniae in ferrets. J Infect Dis. 2010;202:1287-
1295. 
172. Kunzelmann K, Sun J, Meanger J, et al. Inhibition of airway Na+ transport by respiratory 
syncytial virus. J Virol. 2007;81:3714-3720. 
173. Tamaoki J, Sakai N, Isono K, et al. Lipopolysaccharide from Klebsiella pneumoniae inhibits 
Na+ absorption in canine tracheal epithelium. Infect Immun. 1991;59:716-717. 
174. Chu HY, Kuypers J, Renaud C, et al. Molecular epidemiology of respiratory syncytial virus 
transmission in childcare. J Clin Virol. 2013;57:343-350. 
175. Rodrigues F, Foster D, Nicoli E, et al. Relationships between rhinitis symptoms, respiratory 
viral infections and nasopharyngeal colonization with Streptococcus pneumoniae, Haemophilus 
influenzae and Staphylococcus aureus in children attending daycare. Pediatr Infect Dis J. 
2013;32:227-232. 
176. Jacoby P, Carville KS, Hall G, et al. Crowding and other strong predictors of upper respiratory 
tract carriage of otitis media-related bacteria in Australian Aboriginal and non-Aboriginal children. 
Pediatr Infect Dis J. 2011;30:480-485. 
 160 
 
177. Glezen WP, Taber LH, Frank AL, et al. Risk of primary infection and reinfection with 
respiratory syncytial virus. Am J Dis Child. 1986;140:543-546. 
178. Hall CB, Douglas RG, Jr. Modes of transmission of respiratory syncytial virus. J Pediatr. 
1981;99:100-103. 
179. Paynter S. Humidity and respiratory virus transmission in tropical and temperate settings. 
Epidemiol Infect. 2015;143:1110-1118. 
180. Afonso CL, Amarasinghe GK, Banyai K, et al. Taxonomy of the order Mononegavirales: 
update 2016. Arch Virol. 2016;161:2351-2360. 
181. Collins PL, Graham BS. Viral and host factors in human respiratory syncytial virus 
pathogenesis. J Virol. 2008;82:2040-2055. 
182. Spann KM, Tran KC, Chi B, et al. Suppression of the induction of alpha, beta, and lambda 
interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial 
cells and macrophages. J Virol. 2004;78:4363-4369. 
183. Spann KM, Tran KC, Collins PL. Effects of nonstructural proteins NS1 and NS2 of human 
respiratory syncytial virus on interferon regulatory factor 3, NF-kappaB, and proinflammatory 
cytokines. J Virol. 2005;79:5353-5362. 
184. Walsh EE, Hall CB, Briselli M, et al. Immunization with glycoprotein subunits of respiratory 
syncytial virus to protect cotton rats against viral infection. J Infect Dis. 1987;155:1198-1204. 
185. Anderson LJ, Hierholzer JC, Tsou C, et al. Antigenic characterization of respiratory syncytial 
virus strains with monoclonal antibodies. J Infect Dis. 1985;151:626-633. 
186. Mufson MA, Orvell C, Rafnar B, et al. Two distinct subtypes of human respiratory syncytial 
virus. J Gen Virol. 1985;66 ( Pt 10):2111-2124. 
187. Johnson PR, Spriggs MK, Olmsted RA, et al. The G glycoprotein of human respiratory 
syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically 
related proteins. Proc Natl Acad Sci U S A. 1987;84:5625-5629. 
188. Bose ME, He J, Shrivastava S, et al. Sequencing and analysis of globally obtained human 
respiratory syncytial virus A and B genomes. PLoS One. 2015;10:e0120098. 
189. Do LA, Wilm A, Van Doorn HR, et al. Direct whole-genome deep-sequencing of human 
respiratory syncytial virus A and B from Vietnamese children identifies distinct patterns of inter- 
and intra-host evolution. J Gen Virol. 2015;96:3470-3483. 
190. Peret TC, Hall CB, Schnabel KC, et al. Circulation patterns of genetically distinct group A and 
B strains of human respiratory syncytial virus in a community. J Gen Virol. 1998;79 ( Pt 9):2221-
2229. 
 161 
 
191. Rebuffo-Scheer C, Bose M, He J, et al. Whole genome sequencing and evolutionary analysis 
of human respiratory syncytial virus A and B from Milwaukee, WI 1998-2010. PLoS One. 
2011;6:e25468. 
192. Schobel SA, Stucker KM, Moore ML, et al. Respiratory Syncytial Virus whole-genome 
sequencing identifies convergent evolution of sequence duplication in the C-terminus of the G gene. 
Sci Rep. 2016;6:26311. 
193. Arnott A, Vong S, Mardy S, et al. A study of the genetic variability of human respiratory 
syncytial virus (HRSV) in Cambodia reveals the existence of a new HRSV group B genotype. J 
Clin Microbiol. 2011;49:3504-3513. 
194. Khor CS, Sam IC, Hooi PS, et al. Displacement of predominant respiratory syncytial virus 
genotypes in Malaysia between 1989 and 2011. Infect Genet Evol. 2013;14:357-360. 
195. Panayiotou C, Richter J, Koliou M, et al. Epidemiology of respiratory syncytial virus in 
children in Cyprus during three consecutive winter seasons (2010-2013): age distribution, 
seasonality and association between prevalent genotypes and disease severity. Epidemiol Infect. 
2014;142:2406-2411. 
196. Parveen S, Sullender WM, Fowler K, et al. Genetic variability in the G protein gene of group 
A and B respiratory syncytial viruses from India. J Clin Microbiol. 2006;44:3055-3064. 
197. Pierangeli A, Trotta D, Scagnolari C, et al. Rapid spread of the novel respiratory syncytial 
virus A ON1 genotype, central Italy, 2011 to 2013. Euro Surveill. 2014;19. 
198. Prifert C, Streng A, Krempl CD, et al. Novel respiratory syncytial virus a genotype, Germany, 
2011-2012. Emerg Infect Dis. 2013;19:1029-1030. 
199. Reiche J, Schweiger B. Genetic variability of group A human respiratory syncytial virus 
strains circulating in Germany from 1998 to 2007. J Clin Microbiol. 2009;47:1800-1810. 
200. Sato M, Saito R, Sakai T, et al. Molecular epidemiology of respiratory syncytial virus 
infections among children with acute respiratory symptoms in a community over three seasons. J 
Clin Microbiol. 2005;43:36-40. 
201. Shobugawa Y, Saito R, Sano Y, et al. Emerging genotypes of human respiratory syncytial 
virus subgroup A among patients in Japan. J Clin Microbiol. 2009;47:2475-2482. 
202. Tabatabai J, Prifert C, Pfeil J, et al. Novel respiratory syncytial virus (RSV) genotype ON1 
predominates in Germany during winter season 2012-13. PLoS One. 2014;9:e109191. 
203. Tsukagoshi H, Yokoi H, Kobayashi M, et al. Genetic analysis of attachment glycoprotein (G) 
gene in new genotype ON1 of human respiratory syncytial virus detected in Japan. Microbiol 
Immunol. 2013;57:655-659. 
 162 
 
204. Zhang ZY, Du LN, Chen X, et al. Genetic variability of respiratory syncytial viruses (RSV) 
prevalent in Southwestern China from 2006 to 2009: emergence of subgroup B and A RSV as 
dominant strains. J Clin Microbiol. 2010;48:1201-1207. 
205. Choi EH, Lee HJ. Genetic diversity and molecular epidemiology of the G protein of subgroups 
A and B of respiratory syncytial viruses isolated over 9 consecutive epidemics in Korea. J Infect 
Dis. 2000;181:1547-1556. 
206. Dapat IC, Shobugawa Y, Sano Y, et al. New genotypes within respiratory syncytial virus 
group B genotype BA in Niigata, Japan. J Clin Microbiol. 2010;48:3423-3427. 
207. Eshaghi A, Duvvuri VR, Lai R, et al. Genetic variability of human respiratory syncytial virus 
A strains circulating in Ontario: a novel genotype with a 72 nucleotide G gene duplication. PLoS 
One. 2012;7:e32807. 
208. Faghihloo E, Salimi V, Rezaei F, et al. Genetic diversity in the G protein gene of human 
respiratory syncytial virus among Iranian children with acute respiratory symptoms. Iran J Pediatr. 
2011;21:58-64. 
209. van Niekerk S, Venter M. Replacement of previously circulating respiratory syncytial virus 
subtype B strains with the BA genotype in South Africa. J Virol. 2011;85:8789-8797. 
210. Botosso VF, Zanotto PM, Ueda M, et al. Positive selection results in frequent reversible amino 
acid replacements in the G protein gene of human respiratory syncytial virus. PLoS Pathog. 
2009;5:e1000254. 
211. Trento A, Galiano M, Videla C, et al. Major changes in the G protein of human respiratory 
syncytial virus isolates introduced by a duplication of 60 nucleotides. J Gen Virol. 2003;84:3115-
3120. 
212. Trento A, Viegas M, Galiano M, et al. Natural history of human respiratory syncytial virus 
inferred from phylogenetic analysis of the attachment (G) glycoprotein with a 60-nucleotide 
duplication. J Virol. 2006;80:975-984. 
213. Baek YH, Choi EH, Song MS, et al. Prevalence and genetic characterization of respiratory 
syncytial virus (RSV) in hospitalized children in Korea. Arch Virol. 2012;157:1039-1050. 
214. Tozer S, Whiley DM, Lum G, et al. Identification of Australian human respiratory syncytial 
virus strains containing a 60-nucleotide duplication within the G glycoprotein gene. Pathology 
(Phila). 2008;40:632-635. 
215. Choudhary ML, Wadhwa BS, Jadhav SM, et al. Complete genome sequences of two human 
respiratory syncytial virus genotype A strains from India, RSV-A/NIV1114046/11 and RSV-
A/NIV1114073/11. Genome Announc. 2013;1. 
 163 
 
216. Lee WJ, Kim YJ, Kim DW, et al. Complete genome sequence of human respiratory syncytial 
virus genotype A with a 72-nucleotide duplication in the attachment protein G gene. J Virol. 
2012;86:13810-13811. 
217. Walsh EE, McConnochie KM, Long CE, et al. Severity of respiratory syncytial virus infection 
is related to virus strain. J Infect Dis. 1997;175:814-820. 
218. McIntosh ED, De Silva LM, Oates RK. Clinical severity of respiratory syncytial virus group A 
and B infection in Sydney, Australia. Pediatr Infect Dis J. 1993;12:815-819. 
219. Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in 
Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with 
respiratory syncytial viral lower respiratory tract infection. J Pediatr. 1995;126:212-219. 
220. Zhang RF, Jin Y, Xie ZP, et al. Human respiratory syncytial virus in children with acute 
respiratory tract infections in China. J Clin Microbiol. 2010;48:4193-4199. 
221. Tran DN, Pham TM, Ha MT, et al. Molecular epidemiology and disease severity of human 
respiratory syncytial virus in Vietnam. PLoS One. 2013;8:e45436. 
222. Gilca R, De Serres G, Tremblay M, et al. Distribution and clinical impact of human respiratory 
syncytial virus genotypes in hospitalized children over 2 winter seasons. J Infect Dis. 2006;193:54-
58. 
223. Yoshihara K, Le MN, Okamoto M, et al. Association of RSV-A ON1 genotype with increased 
pediatric acute lower respiratory tract infection in Vietnam. Sci Rep. 2016;6:27856. 
224. Regev-Yochay G, Raz M, Dagan R, et al. Nasopharyngeal carriage of Streptococcus 
pneumoniae by adults and children in community and family settings. Clin Infect Dis. 2004;38:632-
639. 
225. Adegbola RA, DeAntonio R, Hill PC, et al. Carriage of Streptococcus pneumoniae and other 
respiratory bacterial pathogens in low and lower-middle income countries: a systematic review and 
meta-analysis. PLoS One. 2014;9:e103293. 
226. Pennington K, Glynn-Robinson A, Toms C, et al. Invasive pneumococcal disease surveillance, 
1 January to 31 March 2016. Commun Dis Intell Q Rep. 2016;40:E308-312. 
227. Chiu C, Dey A, Wang H, et al. Vaccine preventable diseases in Australia, 2005 to 2007. 
Commun Dis Intell Q Rep. 2010;34 Supp:S1-167. 
228. Ampofo K, Bender J, Sheng XM, et al. Seasonal invasive pneumococcal disease in children: 
role of preceding respiratory viral infection. Pediatrics. 2008;122:229-237. 
229. Kim PE, Musher DM, Glezen WP, et al. Association of invasive pneumococcal disease with 
season, atmospheric conditions, air pollution, and the isolation of respiratory viruses. Clin Infect 
Dis. 1996;22:100-106. 
 164 
 
230. Murdoch DR, Jennings LC. Association of respiratory virus activity and environmental factors 
with the incidence of invasive pneumococcal disease. J Infect. 2009;58:37-46. 
231. Stensballe LG, Hjuler T, Andersen A, et al. Hospitalization for respiratory syncytial virus 
infection and invasive pneumococcal disease in Danish children aged <2 years: a population-based 
cohort study. Clin Infect Dis. 2008;46:1165-1171. 
232. Talbot TR, Poehling KA, Hartert TV, et al. Seasonality of invasive pneumococcal disease: 
Temporal relation to documented influenza and respiratory syncytial viral circulation. Am J Med. 
2005;118:285-291. 
233. Watson M, Gilmour R, Menzies R, et al. The association of respiratory viruses, temperature, 
and other climatic parameters with the incidence of invasive pneumococcal disease in Sydney, 
Australia. Clin Infect Dis. 2006;42:211-215. 
234. Weinberger DM, Grant LR, Steiner CA, et al. Seasonal drivers of pneumococcal disease 
incidence: impact of bacterial carriage and viral activity. Clin Infect Dis. 2014;58:188-194. 
235. Satzke C, Dunne EM, Porter BD, et al. The PneuCarriage Project: a multi-centre comparative 
study to identify the best serotyping methods for examining pneumococcal carriage in vaccine 
evaluation studies. PLoS Med. 2015;12:e1001903; discussion e1001903. 
236. Kadioglu A, Weiser JN, Paton JC, et al. The role of Streptococcus pneumoniae virulence 
factors in host respiratory colonization and disease. Nat Rev Microbiol. 2008;6:288-301. 
237. Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal 
conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 
2006;368:1495-1502. 
238. Hausdorff WP, Hoet B, Schuerman L. Do pneumococcal conjugate vaccines provide any 
cross-protection against serotype 19A? BMC Pediatr. 2010;10:4. 
239. Le Polain De Waroux O, Flasche S, Prieto-Merino D, et al. The efficacy and duration of 
protection of pneumococcal conjugate vaccines against nasopharyngeal carriage: a meta-regression 
model. Pediatr Infect Dis J. 2015;34:858-864. 
240. Robbins JB, Austrian R, Lee CJ, et al. Considerations for formulating the second-generation 
pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within 
groups. J Infect Dis. 1983;148:1136-1159. 
241. Song JY, Nahm MH, Moseley MA. Clinical implications of pneumococcal serotypes: invasive 
disease potential, clinical presentations, and antibiotic resistance. J Korean Med Sci. 2013;28:4-15. 
242. Scott JA, Hall AJ, Dagan R, et al. Serogroup-specific epidemiology of Streptococcus 
pneumoniae: associations with age, sex, and geography in 7,000 episodes of invasive disease. Clin 
Infect Dis. 1996;22:973-981. 
 165 
 
243. Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic evaluation of serotypes causing 
invasive pneumococcal disease among children under five: the pneumococcal global serotype 
project. PLoS Med. 2010;7. 
244. Australian Technical Advisory Group on Immunisation (ATAGI). The Australian 
immunisation handbook, 10th ed (2016 update). 10 ed. Canberra: Australian Government 
Department of Health; 2016. 
245. Nair H, Watts AT, Williams LJ, et al. Pneumonia hospitalisations in Scotland following the 
introduction of pneumococcal conjugate vaccination in young children. BMC Infect Dis. 
2016;16:390. 
246. Pai R, Gertz RE, Beall B. Sequential multiplex PCR approach for determining capsular 
serotypes of Streptococcus pneumoniae isolates. J Clin Microbiol. 2006;44:124-131. 
247. Elberse KE, van de Pol I, Witteveen S, et al. Population structure of invasive Streptococcus 
pneumoniae in The Netherlands in the pre-vaccination era assessed by MLVA and capsular 
sequence typing. PLoS One. 2011;6:e20390. 
248. Feil EJ, Spratt BG. Recombination and the population structures of bacterial pathogens. Annu 
Rev Microbiol. 2001;55:561-590. 
249. Muzzi A, Donati C. Population genetics and evolution of the pan-genome of Streptococcus 
pneumoniae. Int J Med Microbiol. 2011;301:619-622. 
250. Donati C, Hiller NL, Tettelin H, et al. Structure and dynamics of the pan-genome of 
Streptococcus pneumoniae and closely related species. Genome Biol. 2010;11:R107. 
251. Hiller NL, Janto B, Hogg JS, et al. Comparative genomic analyses of seventeen Streptococcus 
pneumoniae strains: insights into the pneumococcal supragenome. J Bacteriol. 2007;189:8186-
8195. 
252. Kulohoma BW, Cornick JE, Chaguza C, et al. Comparative genomic analysis of meningitis- 
and bacteremia-causing pneumococci identifies a common core genome. Infect Immun. 
2015;83:4165-4173. 
253. Maiden MC, Bygraves JA, Feil E, et al. Multilocus sequence typing: a portable approach to the 
identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S 
A. 1998;95:3140-3145. 
254. Enright MC, Spratt BG. A multilocus sequence typing scheme for Streptococcus pneumoniae: 
identification of clones associated with serious invasive disease. Microbiology. 1998;144 ( Pt 
11):3049-3060. 
255. Dagerhamn J, Blomberg C, Browall S, et al. Determination of accessory gene patterns predicts 
the same relatedness among strains of Streptococcus pneumoniae as sequencing of housekeeping 
 166 
 
genes does and represents a novel approach in molecular epidemiology. J Clin Microbiol. 
2008;46:863-868. 
256. O'Grady KA, Torzillo PJ, Rockett RJ, et al. Successful application of a simple specimen 
transport method for the conduct of respiratory virus surveillance in remote Indigenous 
communities in Australia. Trop Med Int Health. 2011;16:766-772. 
257. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R 
Foundation for Statistical Computing; 2013. 
258. Chongsuvivatwong V. Analysis of epidemiological data using R and Epicalc. Epidemiology 
Unit, Prince of Songkla University, Thailand; 2008. 
259. Heinze G, Ploner M, Dunkler D, et al. logistf: Firth's bias reduced logistic regression. 2013. 
260. Kim S. ppcor: an R package for a fast calculation to semi-partial correlation coefficients. 
Commun Stat Appl Methods. 2015;22:665-674. 
261. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated 
models of biomolecular interaction networks. Genome Res. 2003;13:2498-2504. 
262. Stark JM, Stark MA, Colasurdo GN, et al. Decreased bacterial clearance from the lungs of 
mice following primary respiratory syncytial virus infection. J Med Virol. 2006;78:829-838. 
263. Korppi M, Leinonen M, Koskela M, et al. Bacterial coinfection in children hospitalized with 
respiratory syncytial virus infections. Pediatr Infect Dis J. 1989;8:687-692. 
264. Karppinen S, Toivonen L, Schuez-Havupalo L, et al. Interference between respiratory 
syncytial virus and rhinovirus in respiratory tract infections in children. Clin Microbiol Infect. 
2016;22:208 e201-206. 
265. Mansbach JM, Piedra PA, Teach SJ, et al. Prospective multicenter study of viral etiology and 
hospital length of stay in children with severe bronchiolitis. Arch Pediatr Adolesc Med. 
2012;166:700-706. 
266. Kouni S, Karakitsos P, Chranioti A, et al. Evaluation of viral co-infections in hospitalized and 
non-hospitalized children with respiratory infections using microarrays. Clin Microbiol Infect. 
2013;19:772-777. 
267. Greer RM, McErlean P, Arden KE, et al. Do rhinoviruses reduce the probability of viral co-
detection during acute respiratory tract infections? J Clin Virol. 2009;45:10-15. 
268. Simoes EA. Environmental and demographic risk factors for respiratory syncytial virus lower 
respiratory tract disease. J Pediatr. 2003;143:S118-126. 
269. Bentley SD, Aanensen DM, Mavroidi A, et al. Genetic analysis of the capsular biosynthetic 
locus from all 90 pneumococcal serotypes. PLoS Genet. 2006;2:e31. 
 167 
 
270. Altschul SF, Madden TL, Schaffer AA, et al. Gapped BLAST and PSI-BLAST: a new 
generation of protein database search programs. Nucleic Acids Res. 1997;25:3389-3402. 
271. Edgar RC. MUSCLE: a multiple sequence alignment method with reduced time and space 
complexity. BMC Bioinformatics. 2004;5:113. 
272. Kumar S, Stecher G, Tamura K. MEGA7: Molecular Evolutionary Genetics Analysis Version 
7.0 for Bigger Datasets. Mol Biol Evol. 2016;33:1870-1874. 
273. Ludwig W, Strunk O, Westram R, et al. ARB: a software environment for sequence data. 
Nucleic Acids Res. 2004;32:1363-1371. 
274. Stamatakis A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large 
phylogenies. Bioinformatics. 2014;30:1312-1313. 
275. Bosch AA, Biesbroek G, Trzcinski K, et al. Viral and bacterial interactions in the upper 
respiratory tract. PLoS Path. 2013;9:e1003057. 
276. Khatri P, Sirota M, Butte AJ. Ten years of pathway analysis: current approaches and 
outstanding challenges. PLoS Comput Biol. 2012;8:e1002375. 
277. Dunne EM, Smith-Vaughan HC, Robins-Browne RM, et al. Nasopharyngeal microbial 
interactions in the era of pneumococcal conjugate vaccination. Vaccine. 2013;31:2333-2342. 
278. Verhaegh SJC, Snippe ML, Levy F, et al. Colonization of healthy children by Moraxella 
catarrhalis is characterized by genotype heterogeneity, virulence gene diversity and co-colonization 
with Haemophilus influenzae. Microbiology-Sgm. 2011;157:169-178. 
279. Lysenko ES, Ratner AJ, Nelson AL, et al. The role of innate immune responses in the outcome 
of interspecies competition for colonization of mucosal surfaces. PLoS Pathog. 2005;1:e1. 
280. Margolis E, Yates A, Levin BR. The ecology of nasal colonization of Streptococcus 
pneumoniae, Haemophilus influenzae and Staphylococcus aureus: the role of competition and 
interactions with host's immune response. BMC Microbiol. 2010;10:59. 
281. Pericone CD, Overweg K, Hermans PWM, et al. Inhibitory and bactericidal effects of 
hydrogen peroxide production by Streptococcus pneumoniae on other inhabitants of the upper 
respiratory tract. Infect Immun. 2000;68:3990-3997. 
282. Shakhnovich EA, King SJ, Weiser JN. Neuraminidase expressed by Streptococcus 
pneumoniae desialylates the lipopolysaccharide of Neisseria meningitidis and Haemophilus 
influenzae: a paradigm for interbacterial competition among pathogens of the human respiratory 
tract. Infect Immun. 2002;70:7161-7164. 
283. Tan TT, Morgelin M, Forsgren A, et al. Haemophilus influenzae survival during complement-
mediated attacks is promoted by Moraxella catarrhalis outer membrane vesicles. J Infect Dis. 
2007;195:1661-1670. 
 168 
 
284. Alsaleh AN, Whiley DM, Bialasiewicz S, et al. Nasal swab samples and real-time polymerase 
chain reaction assays in community-based, longitudinal studies of respiratory viruses: the 
importance of sample integrity and quality control. BMC Infect Dis. 2014;14:15. 
285. Satzke C, Turner P, Virolainen-Julkunen A, et al. Standard method for detecting upper 
respiratory carriage of Streptococcus pneumoniae: updated recommendations from the World 
Health Organization Pneumococcal Carriage Working Group. Vaccine. 2013;32:165-179. 
286. Valente C, Hinds J, Gould KA, et al. Impact of the 13-valent pneumococcal conjugate vaccine 
on Streptococcus pneumoniae multiple serotype carriage. Vaccine. 2016;34:4072-4078. 
287. Donkor ES, Stabler RA, Hinds J, et al. Comparative phylogenomics of Streptococcus 
pneumoniae isolated from invasive disease and nasopharyngeal carriage from West Africans. BMC 
Genomics. 2012;13:569. 
288. Esposito S, Zampiero A, Terranova L, et al. Pneumococcal bacterial load colonization as a 
marker of mixed infection in children with alveolar community-acquired pneumonia and respiratory 
syncytial virus or rhinovirus infection. Pediatr Infect Dis J. 2013;32:1199-1204. 
289. Wolter N, Tempia S, Cohen C, et al. High nasopharyngeal pneumococcal density, increased by 
viral coinfection, is associated with invasive pneumococcal pneumonia. J Infect Dis. 
2014;210:1649-1657. 
290. Launes C, de-Sevilla MF, Selva L, et al. Viral coinfection in children less than five years old 
with invasive pneumococcal disease. Pediatr Infect Dis J. 2012;31:650-653. 
291. Mackay IM, Lambert SB, Faux CE, et al. Community-wide, contemporaneous circulation of a 
broad spectrum of human rhinoviruses in healthy Australian preschool-aged children during a 12-
month period. J Infect Dis. 2013;207:1433-1441. 
292. Goto-Sugai K, Tsukagoshi H, Mizuta K, et al. Genotyping and phylogenetic analysis of the 
major genes in respiratory syncytial virus isolated from infants with bronchiolitis. Jpn J Infect Dis. 
2010;63:393-400. 
293. Martin DP, Murrell B, Golden M, et al. RDP4: Detection and analysis of recombination 
patterns in virus genomes. Virus Evolution. 2015;1. 
294. Carvalho Mda G, Pimenta FC, Moura I, et al. Non-pneumococcal mitis-group streptococci 
confound detection of pneumococcal capsular serotype-specific loci in upper respiratory tract. 
PeerJ. 2013;1:e97. 
295. Jolley KA, Maiden MC. BIGSdb: Scalable analysis of bacterial genome variation at the 
population level. BMC Bioinformatics. 2010;11:595. 
 169 
 
296. Feil EJ, Li BC, Aanensen DM, et al. eBURST: inferring patterns of evolutionary descent 
among clusters of related bacterial genotypes from multilocus sequence typing data. J Bacteriol. 
2004;186:1518-1530. 
297. Spratt BG, Hanage WP, Li B, et al. Displaying the relatedness among isolates of bacterial 
species - the eBURST approach. FEMS Microbiol Lett. 2004;241:129-134. 
298. Trento A, Casas I, Calderon A, et al. Ten years of global evolution of the human respiratory 
syncytial virus BA genotype with a 60-nucleotide duplication in the G protein gene. J Virol. 
2010;84:7500-7512. 
299. Sung RY, Chan PK, Choi KC, et al. Comparative study of nasopharyngeal aspirate and nasal 
swab specimens for diagnosis of acute viral respiratory infection. J Clin Microbiol. 2008;46:3073-
3076. 
300. Chow S, Shao J, H. W. Sample Size Calculations in Clinical Research. 2 ed: Chapman & 
Hall/CRC Press; 2008. 
301. HyLown Consulting LLC. Calculate Sample Size Needed to Compare 2 Proportions: 2-
Sample, 2-Sided Equality 2016. Available at: 
http://powerandsamplesize.com/Calculators/Compare-2-Proportions/2-Sample-Equality. Accessed 
15/10/2016. 
302. Auksornkitti V, Kamprasert N, Thongkomplew S, et al. Molecular characterization of human 
respiratory syncytial virus, 2010-2011: identification of genotype ON1 and a new subgroup B 
genotype in Thailand. Arch Virol. 2014;159:499-507. 
303. Toms C, de Kluyver R, Enhanced Invasive Pneumococcal Disease Surveillance Working 
Group for the Communicable Diseases Network Australia. Invasive pneumococcal disease in 
Australia, 2011 and 2012. Commun Dis Intell Q Rep. 2016;40:E267-284. 
304. Weinberger DM, Harboe ZB, Viboud C, et al. Serotype-specific effect of influenza on adult 
invasive pneumococcal pneumonia. J Infect Dis. 2013;208:1274-1280. 
305. Wu H, Pfarr DS, Johnson S, et al. Development of motavizumab, an ultra-potent antibody for 
the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol 
Biol. 2007;368:652-665. 
306. Jones ML, Seldon T, Smede M, et al. A method for rapid, ligation-independent reformatting of 
recombinant monoclonal antibodies. J Immunol Methods. 2010;354:85-90. 
307. Schindelin J, Arganda-Carreras I, Frise E, et al. Fiji: an open-source platform for biological-
image analysis. Nat Methods. 2012;9:676-682. 
308. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. 
Nat Methods. 2012;9:671-675. 
 170 
 
309. Zack GW, Rogers WE, Latt SA. Automatic measurement of sister chromatid exchange 
frequency. J Histochem Cytochem. 1977;25:741-753. 
310. Legland D, Arganda-Carreras I, Andrey P. MorphoLibJ: integrated library and plugins for 
mathematical morphology with ImageJ. Bioinformatics. 2016. 
311. Hammerschmidt S, Wolff S, Hocke A, et al. Illustration of pneumococcal polysaccharide 
capsule during adherence and invasion of epithelial cells. Infect Immun. 2005;73:4653-4667. 
312. Weiser JN, Austrian R, Sreenivasan PK, et al. Phase variation in pneumococcal opacity: 
relationship between colonial morphology and nasopharyngeal colonization. Infect Immun. 
1994;62:2582-2589. 
313. Kim JO, Weiser JN. Association of intrastrain phase variation in quantity of capsular 
polysaccharide and teichoic acid with the virulence of Streptococcus pneumoniae. J Infect Dis. 
1998;177:368-377. 
314. Andersson B, Eriksson B, Falsen E, et al. Adhesion of Streptococcus pneumoniae to human 
pharyngeal epithelial cells in vitro: differences in adhesive capacity among strains isolated from 
subjects with otitis media, septicemia, or meningitis or from healthy carriers. Infect Immun. 
1981;32:311-317. 
315. Elahmer OR, Raza MW, Ogilvie MM, et al. The effect of respiratory virus infection on 
expression of cell surface antigens associated with binding of potentially pathogenic bacteria. Adv 
Exp Med Biol. 1996;408:169-177. 
316. Weingart CL, Broitman-Maduro G, Dean G, et al. Fluorescent labels influence phagocytosis of 
Bordetella pertussis by human neutrophils. Infect Immun. 1999;67:4264-4267. 
317. Andersson B, Gray BM, Dillon HC, Jr., et al. Role of adherence of Streptococcus pneumoniae 
in acute otitis media. Pediatr Infect Dis J. 1988;7:476-480. 
318. Hathaway LJ, Brugger SD, Morand B, et al. Capsule type of Streptococcus pneumoniae 
determines growth phenotype. PLoS Pathog. 2012;8:e1002574. 
319. Bagnoli F, Moschioni M, Donati C, et al. A second pilus type in Streptococcus pneumoniae is 
prevalent in emerging serotypes and mediates adhesion to host cells. J Bacteriol. 2008;190:5480-
5492. 
320. Barocchi MA, Ries J, Zogaj X, et al. A pneumococcal pilus influences virulence and host 
inflammatory responses. Proc Natl Acad Sci U S A. 2006;103:2857-2862. 
321. van der Flier M, Chhun N, Wizemann TM, et al. Adherence of Streptococcus pneumoniae to 
immobilized fibronectin. Infect Immun. 1995;63:4317-4322. 
 171 
 
322. Krishnamurthy A, McGrath J, Cripps AW, et al. The incidence of Streptococcus pneumoniae 
otitis media is affected by the polymicrobial environment particularly Moraxella catarrhalis in a 
mouse nasal colonisation model. Microbes Infect. 2009;11:545-553. 
323. Villenave R, O'Donoghue D, Thavagnanam S, et al. Differential cytopathogenesis of 
respiratory syncytial virus prototypic and clinical isolates in primary pediatric bronchial epithelial 
cells. Virol J. 2011;8:43. 
324. Kumaria R, Iyer LR, Hibberd ML, et al. Whole genome characterization of non-tissue culture 
adapted HRSV strains in severely infected children. Virol J. 2011;8:372. 
325. Hanage WP, Bishop CJ, Huang SS, et al. Carried pneumococci in Massachusetts children: the 
contribution of clonal expansion and serotype switching. Pediatr Infect Dis J. 2011;30:302-308. 
326. Wyres KL, Lambertsen LM, Croucher NJ, et al. Pneumococcal capsular switching: a historical 
perspective. J Infect Dis. 2013;207:439-449. 
327. Holt PG, Upham JW, Sly PD. Contemporaneous maturation of immunologic and respiratory 
functions during early childhood: implications for development of asthma prevention strategies. J 
Allergy Clin Immunol. 2005;116:16-24; quiz 25. 
328. Semic-Jusufagic A, Belgrave D, Pickles A, et al. Assessing the association of early life 
antibiotic prescription with asthma exacerbations, impaired antiviral immunity, and genetic variants 
in 17q21: a population-based birth cohort study. Lancet Respir Med. 2014;2:621-630. 
329. Vangay P, Ward T, Gerber JS, et al. Antibiotics, pediatric dysbiosis, and disease. Cell Host 
Microbe. 2015;17:553-564. 
330. Jorquera PA, Anderson L, Tripp RA. Understanding respiratory syncytial virus (RSV) vaccine 
development and aspects of disease pathogenesis. Expert Rev Vaccines. 2016;15:173-187. 
331. Chanock R, Roizman B, Myers R. Recovery from infants with respiratory illness of a virus 
related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization. Am J Hyg. 
1957;66:281-290. 
332. Lewis FA, Rae ML, Lehmann NI, et al. A syncytial virus associated with epidemic disease of 
the lower respiratory tract in infants and young children. Med J Aust. 1961;2:932-933. 
333. Moura FE, Blanc A, Frabasile S, et al. Genetic diversity of respiratory syncytial virus isolated 
during an epidemic period from children of northeastern Brazil. J Med Virol. 2004;74:156-160. 
334. Yun MR, Kim AR, Lee HS, et al. Complete genome sequences of human respiratory syncytial 
virus genotype a and B isolates from South Korea. Genome Announc. 2015;3. 
335. Blanc A, Delfraro A, Frabasile S, et al. Genotypes of respiratory syncytial virus group B 
identified in Uruguay. Arch Virol. 2005;150:603-609. 
 172 
 
336. Hierholzer JC, Hirsch MS. Croup and pneumonia in human infants associated with a new 
strain of respiratory syncytial virus. J Infect Dis. 1979;140:826-828. 
337. Galiano MC, Palomo C, Videla CM, et al. Genetic and antigenic variability of human 
respiratory syncytial virus (groups a and b) isolated over seven consecutive seasons in Argentina 
(1995 to 2001). J Clin Microbiol. 2005;43:2266-2273. 
338. Scott PD, Ochola R, Ngama M, et al. Molecular epidemiology of respiratory syncytial virus in 
Kilifi district, Kenya. J Med Virol. 2004;74:344-354. 
339. Karron RA, Buonagurio DA, Georgiu AF, et al. Respiratory syncytial virus (RSV) SH and G 
proteins are not essential for viral replication in vitro: clinical evaluation and molecular 
characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc Natl Acad Sci U S A. 
1997;94:13961-13966. 
340. Sullender WM, Mufson MA, Anderson LJ, et al. Genetic diversity of the attachment protein of 
subgroup B respiratory syncytial viruses. J Virol. 1991;65:5425-5434. 
341. Cui G, Zhu R, Qian Y, et al. Genetic variation in attachment glycoprotein genes of human 
respiratory syncytial virus subgroups a and B in children in recent five consecutive years. PLoS 
One. 2013;8:e75020. 
342. Choudhary ML, Anand SP, Wadhwa BS, et al. Genetic variability of human respiratory 
syncytial virus in Pune, Western India. Infect Genet Evol. 2013;20:369-377. 
343. Lemon K, Nguyen DT, Ludlow M, et al. Recombinant subgroup B human respiratory syncytial 
virus expressing enhanced green fluorescent protein efficiently replicates in primary human cells 
and is virulent in cotton rats. J Virol. 2015;89:2849-2856. 
344. Tan L, Coenjaerts FE, Houspie L, et al. The comparative genomics of human respiratory 
syncytial virus subgroups A and B: genetic variability and molecular evolutionary dynamics. J 
Virol. 2013;87:8213-8226. 
345. Zlateva KT, Lemey P, Moes E, et al. Genetic variability and molecular evolution of the human 
respiratory syncytial virus subgroup B attachment G protein. J Virol. 2005;79:9157-9167. 
 
 
 
 173 
 
8. Appendices 
8.1 Chapter 2 
Table A2.1. Univariable analysis of associations between pathogen detection, clinical parameters and participant demographics. 
The following tables display the analysis results using as outcome variables viral pathogen detection (1), bacterial pathogen bacteria (2) and 
participant demographics (3). Categorical explanatory variables are reported as number (%) while continuous explanatory variables are reported 
as median (IQR). Associations significant at p < 0.05 are highlighted in bold. 
 
1. Analysis by viral pathogen detection: 
Variable RSV detected RSV not 
detected 
p value hRV detected hRV not 
detected 
p value Single virus 
detected 
Multiple viruses 
detected 
p value 
Total 29 29  28 30  32 26  
Demographics   
Age in months 4.8 (2.4,7.2) 4.8 (2.4,8.4) 0.697 4.8 (2.4,6.0) 4.8 (2.4,9.6) 0.732 3.6 (2.4,6.0) 6.0 (4.8,13.2) 0.021 
Male 16 (55.2) 15 (51.7) 1 13 (46.4) 18 (60) 0.44 18 (56.2) 13 (50) 0.834 
ED visit during 
autumn/winter 
17 (58.6) 17 (58.6) 1 14 (50) 20 (66.7) 0.307 19 (59.4) 15 (57.7) 1 
Diagnosed asthma 2 (6.9) 0 (0) 0.491 0 (0) 2 (6.7) 0.492 2 (6.2) 0 (0) 0.497 
History of 
wheezing illness 
9 (36) 7 (24.1) 0.514 6 (23.1) 10 (35.7) 0.473 9 (30) 7 (29.2) 1 
Clinical parameters   
Supplemental 
oxygen 
7 (25) 4 (14.8) 0.544 5 (18.5) 6 (21.4) 1 7 (22.6) 4 (16.7) 0.738 
Hospitalised 15 (55.6) 16 (59.3) 1 16 (59.3) 15 (55.6) 1 19 (63.3) 12 (50) 0.479 
Assisted 
ventilation 
2 (7.1) 2 (7.4) 1 2 (7.4) 2 (7.1) 1 2 (6.5) 2 (8.3) 1 
Clinical disease 
severity score 
 
 
 
1.5 (1,2.5) 1 (0.2,1.5) 0.031 1 (1,2.4) 1.2 (0.4,2) 0.713 1 (0,1.5) 1.5 (1,2.5) 0.035 
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Variable RSV detected RSV not 
detected 
p value hRV detected hRV not 
detected 
p value Single virus 
detected 
Multiple viruses 
detected 
p value 
Severity score criteria   
Oxygen saturation 0 (0,0) 0 (0,0) 0.376 0 (0,0) 0 (0,0) 0.427 0 (0,0) 0 (0,0) 0.65 
Inspiratory breath 
sounds 
0 (0,0) 0 (0,0.2) 0.524 0 (0,0.5) 0 (0,0) 0.006 0 (0,0) 0 (0,0.5) 0.084 
Expiratory 
wheezing 
0.5 (0.2,1) 0.2 (0,0.6) 0.064 0.5 (0,1) 0.5 (0,0.6) 0.467 0 (0,0.5) 0.5 (0.5,1) 0.004 
Accessory 
muscles 
0.5 (0.5,1) 0.5 (0,0.5) 0.017 0.5 (0.4,1) 0.5 (0,1) 0.71 0.5 (0,1) 0.5 (0.5,1) 0.865 
Cerebral function 0 (0,0) 0 (0,0.5) 0.217 0 (0,0.5) 0 (0,0) 0.166 0 (0,0) 0 (0,0.5) 0.606 
Bacterial detection   
Sp 15 (51.7) 11 (37.9) 0.428 16 (57.1) 10 (33.3) 0.119 8 (25) 18 (69.2) 0.002 
Hi 13 (44.8) 15 (51.7) 0.793 14 (50) 14 (46.7) 1 12 (37.5) 16 (61.5) 0.119 
Mc 20 (69) 22 (75.9) 0.769 23 (82.1) 19 (63.3) 0.191 20 (62.5) 22 (84.6) 0.114 
Sp ply load
1
 1.2 x 10
3
 (0, 1.1 
x 10
4
) 
0 (0, 1.3 x 10
4
) 0.142 1.2 x 10
3
 (0, 5.2 
x 10
3
) 
7.3 x 10
0
 (0, 1.2 
x 10
3
) 
0.336 0 (0, 1.6 x 10
2
) 1.8 x 10
3
 (0, 2.6 
x 10
4
) 
0.009 
Hi load
1
 0 (0, 4.0 x 10
3
) 1.1 x 10
1
 (0, 4.0 
x 10
3
) 
0.627 5.3 x 10
0
 (0, 4.8 
x 10
3
) 
0 (0, 3.5 x 10
3
) 0.887 0 (0, 1.4 x 10
3
) 6.5 x 10
1
 (0, 6.3 
x 10
3
) 
0.141 
Mc load
1
 5.5 x 10
2
 (0, 7.4 
x 10
3
) 
5.7 x 10
2
 (1.8 x 
10
1
, 2.5 x 10
4
) 
0.753 8.5 x 10
2
 (7.4 x 
10
1
, 3.2 x 10
4
) 
3.4 x 10
2
 (0, 7.0 
x 10
3
) 
0.197 2.2 x 10
2
 (0, 9.6 
x 10
2
) 
4.4 x 10
3
 (3.5 x 
10
2
, 3.6 x 10
4
) 
0.018 
Total microbial 
load
2
 
1.5 x 10
5
 (4.3 x 
10
4
, 6.0 x 10
5
) 
1.9 x 10
5
 (2.6 x 
10
4
, 1.4 x 10
6
) 
0.857 2.5 x 10
5
 (4.4 x 
10
4
, 1.8 x 10
6
) 
9.3 x 10
4
 (3.7 x 
10
4
, 5.1 x 10
5
) 
0.195 7.5 x 10
4
 (2.9 x 
10
4
, 4.2 x 10
5
) 
4.5 x 10
5
 (7.4 x 
10
4
, 2.1 x 10
6
) 
0.01 
Viral detection   
RSV NA NA NA 7 (25) 22 (73.3) <0.001 17 (53.1) 12 (46.2) 0.792 
hRV 7 (24.1) 21 (72.4) <0.001 NA NA NA 8 (25) 20 (76.9) <0.001 
EV 1 (3.4) 7 (24.1) 0.052 6 (21.4) 2 (6.7) 0.138 0 (0) 8 (30.8) < 0.001 
PIV 1 (3.4) 6 (20.7) 0.102 3 (10.7) 4 (13.3) 1 3 (9.4) 4 (15.4) 0.689 
MPV 1 (3.4) 4 (13.8) 0.352 2 (7.1) 3 (10) 1 1 (3.1) 4 (15.4) 0.163 
IAV 1 (3.4) 1 (3.4) 1 0 (0) 2 (6.7) 0.492 1 (3.1) 1 (3.8) 1 
AdV 4 (13.8) 2 (6.9) 0.67 3 (10.7) 3 (10) 1 0 (0) 6 (23.1) 0.006 
BoV 0 (0) 4 (13.8) 0.112 4 (14.3) 0 (0) 0.048 0 (0) 4 (15.4) 0.035 
PyV 2 (6.9) 3 (10.3) 1 3 (10.7) 2 (6.7) 0.665 1 (3.1) 4 (15.4) 0.163 
CoV 0 (0) 2 (6.9) 0.491 1 (3.6) 1 (3.3) 1 1 (3.1) 1 (3.8) 1 
Viruses/sample 1 (1,2) 1 (1,2) 0.579 2 (1,2) 1 (1,1) <0.001 1 (1,1) 2 (2,3) <0.001 
Multiple viruses 
detected 
12 (41.4) 14 (48.3) 0.792 20 (71.4) 6 (20) <0.001 NA NA NA 
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2. Analysis by bacterial pathogen detection: 
Variable Sp detected Sp not detected p value Hi detected Hi not detected p value Mc detected Mc not detected p value 
Total 26 32  28 30  42 16  
Demographics   
Age in months 6.0 (4.8,13.2) 2.4 (1.2,4.8) <0.001 6.0 (4.8, 13.2) 2.4 (2.4,4.8) <0.001 4.8 (2.4,9.6) 3.6 (2.4,4.8) 0.144 
Male 16 (61.5) 15 (46.9) 0.396 14 (50) 17 (56.7) 0.806 20 (47.6) 11 (68.8) 0.251 
ED visit during 
autumn/winter 
15 (57.7) 19 (59.4) 1 14 (50) 20 (66.7) 0.307 22 (52.4) 12 (75) 0.206 
Diagnosed asthma 1 (3.8) 1 (3.1) 1 2 (7.1) 0 (0) 0.229 1 (2.4) 1 (6.2) 0.479 
History of 
wheezing illness 
9 (37.5) 7 (23.3) 0.405 10 (37) 6 (22.2) 0.371 12 (30.8) 4 (26.7) 1 
Clinical parameters   
Supplemental 
oxygen 
7 (29.2) 4 (12.9) 0.18 7 (26.9) 4 (13.8) 0.38 10 (25) 1 (6.7) 0.255 
Hospitalised 12 (50) 19 (63.3) 0.479 13 (50) 18 (64.3) 0.432 23 (59) 8 (53.3) 0.946 
Assisted 
ventilation 
3 (12.5) 1 (3.2) 0.307 4 (15.4) 0 (0) 0.044 4 (10) 0 (0) 0.565 
Clinical disease 
severity score 
1.5 (1,2.8) 1 (0,1.8) 0.01 1.5 (0.5,3) 1 (0.5,2) 0.325 1.5 (1,2.5) 1 (0.5,1.5) 0.122 
Severity score criteria   
Oxygen saturation 0 (0,0) 0 (0,0) 0.763 0 (0,0) 0 (0,0) 0.293 0 (0,0) 0 (0,0) 0.473 
Inspiratory breath 
sounds 
0 (0,0.5) 0 (0,0) 0.011 0 (0,0.5) 0 (0,0) 0.115 0 (0,0.5) 0 (0,0) 0.094 
Expiratory 
wheezing 
1 (0.5,1) 0 (0,0.5) <0.001 0.5 (0,1) 0.5 (0,0.5) 0.419 0.5 (0,1) 0 (0,0.5) 0.057 
Accessory 
muscles 
0.5 (0.5,1) 0.5 (0,0.5) 0.098 0.5 (0,1) 0.5 (0.5,1) 0.966 0.5 (0.5,1) 0.5 (0,1) 0.94 
Cerebral function 0 (0,0.5) 0 (0,0) 0.606 0 (0,0.5) 0 (0,0) 0.125 0 (0,0.5) 0 (0,0) 0.046 
Bacterial detection   
Sp NA NA NA 18 (64.3) 8 (26.7) 0.009 22 (52.4) 4 (25) 0.114 
Hi 18 (69.2) 10 (31.2) 0.009 NA NA NA 25 (59.5) 3 (18.8) 0.013 
Mc 22 (84.6) 20 (62.5) 0.114 25 (89.3) 17 (56.7) 0.013 NA NA NA 
Sp ply load
1
 5.2 x 10
3
 (1.6 x 
10
3
, 6.8 x 10
4
) 
0 (0, 0) <0.001 9.7 x 10
2
 (5.5 x 
10
0
, 1.1 x 10
4
) 
0 (0, 1.3 x 10
3
) 0.014 1.8 x 10
2
 (0, 5.6 
x 10
3
) 
0 (0, 1.2 x 10
3
) 0.151 
Hi load
1
 2.0 x 10
3
 (0, 1.2 
x 10
5
) 
0 (0, 2.6 x 10
1
) 0.001 4.0 x 10
3
 (1.6 x 
10
2
, 1.4 x 10
5
) 
0 (0, 0) <0.001 6.4 x 10
1
 (0, 1.9 
x 10
4
) 
0 (0, 0) 0.01 
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Variable Sp detected Sp not detected p value Hi detected Hi not detected p value Mc detected Mc not detected p value 
Mc load
1
 3.2 x 10
3
 (4.9 x 
10
2
, 3.7 x 10
4
) 
2.2 x 10
2
 (0, 2.3 
x 10
3
) 
0.013 4.4 x 10
3
 (2.5 x 
10
2
, 3.9 x 10
4
) 
2.0 x 10
2
 (0, 7.1 
x 10
2
) 
0.003 3.2 x 10
3
 (4.6 x 
10
2
, 3.9 x 10
4
) 
0 (0, 0) <0.001 
Total microbial 
biomass
2
 
4.8 x 10
5
 (1.2 x 
10
5
, 1.6 x 10
6
) 
6.7 x 10
4
 (2.1 x 
10
4
, 3.1 x 10
5
) 
0.004 4.5 x 10
5
 (6.0 x 
10
4
, 1.0 x 10
6
) 
7.5 x 10
4
 (2.8 x 
10
4
, 2.5 x 10
5
) 
0.051 3.6 x 10
5
 (4.5 x 
10
4
, 1.3 x 10
6
) 
4.7 x 10
4
 (1.1 x 
10
4
, 9.9 x 10
4
) 
0.002 
Viral detection   
RSV 15 (57.7) 14 (43.8) 0.428 13 (46.4) 16 (53.3) 0.793 20 (47.6) 9 (56.2) 0.769 
hRV 16 (61.5) 12 (37.5) 0.119 14 (50) 14 (46.7) 1 23 (54.8) 5 (31.2) 0.191 
EV 4 (15.4) 4 (12.5) 1 5 (17.9) 3 (10) 0.464 6 (14.3) 2 (12.5) 1 
PIV 2 (7.7) 5 (15.6) 0.442 4 (14.3) 3 (10) 0.701 5 (11.9) 2 (12.5) 1 
MPV 3 (11.5) 2 (6.2) 0.648 1 (3.6) 4 (13.3) 0.354 3 (7.1) 2 (12.5) 0.609 
IAV 1 (3.8) 1 (3.1) 1 2 (7.1) 0 (0) 0.229 2 (4.8) 0 (0) 1 
AdV 6 (23.1) 0 (0) 0.006 6 (21.4) 0 (0) 0.009 6 (14.3) 0 (0) 0.173 
BoV 4 (15.4) 0 (0) 0.035 3 (10.7) 1 (3.3) 0.344 3 (7.1) 1 (6.2) 1 
PyV 3 (11.5) 2 (6.2) 0.648 5 (17.9) 0 (0) 0.021 5 (11.9) 0 (0) 0.309 
CoV 1 (3.8) 1 (3.1) 1 2 (7.1) 0 (0) 0.229 2 (4.8) 0 (0) 1 
Viruses/sample 2 (1,3) 1 (1,1.2) <0.001 2 (1,3) 1 (1,2) 0.021 2 (1,2) 1 (1,1.2) 0.058 
Multiple viruses 
detected 
18 (69.2) 8 (25) 0.002 16 (57.1) 10 (33.3) 0.119 22 (52.4) 4 (25) 0.114 
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3. Analysis by participant demographics: 
Variable 
 
Male Female p value ED visit in 
autumn/winter 
ED visit in 
spring/summer 
p value History of 
wheezing illness 
No history of 
wheezing illness 
p value 
Total 31 27  34 24  16 38  
Demographics   
Age in months 4.8 (2.4,7.2) 4.8 (2.4,7.2) 0.994 4.8 (2.4,9.6) 4.8 (2.4,7.2) 0.734 7.2 (3.6,14.4) 4.8 (2.4,6.0) 0.011 
Male NA NA NA 18 (52.9) 13 (54.2) 1 7 (43.8) 22 (57.9) 0.514 
ED visit during 
autumn/winter 
18 (58.1) 16 (59.3) 1 NA NA NA 7 (43.8) 25 (65.8) 0.229 
Diagnosed asthma 0 (0) 2 (7.4) 0.212 1 (2.9) 1 (4.2) 1 2 (12.5) 0 (0) 0.084 
History of 
wheezing illness 
7 (24.1) 9 (36) 0.514 7 (21.9) 9 (40.9) 0.229 NA NA NA 
Clinical parameters   
Supplemental 
oxygen 
7 (24.1) 4 (15.4) 0.636 5 (16.1) 6 (25) 0.505 2 (13.3) 8 (22.2) 0.703 
Hospitalised 15 (53.6) 16 (51.6) 0.752 18 (60) 13 (54.2) 0.878 9 (60) 20 (57.1) 1 
Assisted 
ventilation 
3 (10.3) 1 (3.8) 0.613 2 (6.5) 2 (8.3) 1 2 (13.3) 2 (5.6) 0.571 
Clinical disease 
severity score 
1.5 (0.5,2) 1 (0,2) 0.521 1 (0.2,2) 1.5 (0.8,2.2) 0.607 1.5 (0.5,2.5) 1 (0.5,2) 0.007 
1
Median genomes per µl. 
2
Median 16S ribosomal RNA gene copies per µl. ED: emergency department, Sp: S. pneumoniae, Hi: H. influenzae, 
Mc: M. catarrhalis, RSV: respiratory syncytial virus, hRV: human rhinovirus, EV: enterovirus, PIV: parainfluenza virus, MPV: 
metapneumovirus, IAV: influenza A virus, AdV: adenovirus, BoV: bocavirus, PyV: polyomavirus, CoV: coronavirus. 
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Table A2.2. Associations between pathogen detections and severity parameters with adjustment for confounding factors – clinical parameters 
with no significant associations with pathogen detection. 
Explanatory variables
1 
Oxygen saturation score Cerebral function score Admitted to hospital Received supplemental oxygen 
ES SE p value ES SE p value ES SE P value ES SE p value 
Age 0.174 0.173 0.323 0.045 0.104 0.669 -0.126 0.858 0.868 1.197 1.056 0.252 
Male 0.089 0.134 0.513 -0.023 0.080 0.776 -0.293 0.670 0.631 0.152 0.877 0.860 
History of wheezing illness -0.061 0.157 0.699 0.053 0.094 0.575 0.383 0.787 0.585 -1.838 1.243 0.109 
ED visit during autumn/winter -0.097 0.141 0.496 0.088 0.084 0.300 0.456 0.709 0.478 -0.360 0.916 0.686 
RSV detected 0.170 0.162 0.299 0.016 0.097 0.873 0.448 0.825 0.550 1.117 1.058 0.252 
hRV detected -0.003 0.189 0.986 0.084 0.113 0.458 0.635 0.981 0.471 0.558 1.209 0.620 
Multiple viruses detected 0.004 0.161 0.979 -0.006 0.096 0.950 -0.509 0.812 0.488 -0.643 1.007 0.489 
Sp detected -0.147 0.166 0.381 -0.133 0.099 0.188 -0.564 0.822 0.444 0.866 0.971 0.332 
Hi detected 0.073 0.151 0.633 0.075 0.090 0.410 -0.344 0.748 0.610 0.754 1.044 0.473 
Mc detected 0.139 0.158 0.385 0.111 0.094 0.248 0.249 0.793 0.729 -0.048 1.145 0.967 
RSV and Sp interaction             
RSV + Sp - 0.227 0.217 0.302 0.017 0.130 0.897 0.068 1.077 0.945 2.194 1.598 0.138 
RSV - Sp + -0.094 0.215 0.665 -0.131 0.128 0.313 -0.896 1.057 0.336 1.829 1.460 0.174 
RSV + Sp + 0.021 0.179 0.907 -0.117 0.107 0.280 -0.102 0.882 0.897 2.392 1.402 0.060 
hRV and Sp interaction             
hRV + Sp - -0.112 0.217 0.608 0.109 0.131 0.412 1.509 1.150 0.135 -0.187 1.661 0.913 
hRV - Sp + -0.282 0.212 0.193 -0.103 0.128 0.430 0.478 1.072 0.616 0.401 1.189 0.712 
hRV + Sp + -0.128 0.209 0.544 -0.053 0.127 0.677 -0.083 1.066 0.931 1.367 1.296 0.246 
                                       Hi and Mc interaction             
Hi + Mc - -0.052 0.337 0.878 -0.103 0.199 0.607 -0.700 1.621 0.597 1.392 2.155 0.494 
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Explanatory variables
1 
Oxygen saturation score Cerebral function score Admitted to hospital Received supplemental oxygen 
ES SE p value ES SE p value ES SE P value ES SE p value 
Hi - Mc + 0.103 0.182 0.576 0.059 0.107 0.585 0.133 0.909 0.872 -0.090 1.268 0.943 
Hi + Mc + 0.210 0.183 0.258 0.184 0.108 0.097 -0.095 0.899 0.906 0.678 1.119 0.509 
RSV and hRV interaction             
RSV + hRV - 0.115 0.204 0.575 0.047 0.122 0.699 1.344 1.091 0.164 1.689 1.655 0.234 
RSV - hRV + -0.051 0.217 0.817 0.112 0.130 0.395 1.456 1.203 0.167 1.063 1.679 0.471 
RSV + hRV + 0.208 0.330 0.532 0.076 0.197 0.700 0.690 1.733 0.662 1.492 2.161 0.439 
hRV and >1 virus interaction             
hRV + 1 virus 0.133 0.233 0.572 0.094 0.141 0.508 1.839 1.341 0.115 1.077 1.647 0.501 
hRV - >1 virus 0.160 0.225 0.480 0.005 0.136 0.969 0.663 1.176 0.524 -0.235 1.290 0.842 
hRV + >1 virus -0.005 0.179 0.976 0.078 0.109 0.478 0.082 0.889 0.918 -0.066 1.155 0.952 
RSV and Hi interaction             
RSV + Hi - -0.003 0.216 0.988 0.035 0.131 0.789 -0.443 1.101 0.658 -0.260 1.554 0.869 
RSV - Hi + -0.062 0.187 0.743 0.091 0.114 0.431 -1.035 0.956 0.220 -0.326 1.356 0.816 
RSV + Hi + 0.239 0.226 0.298 0.091 0.138 0.513 0.091 1.190 0.933 1.251 1.541 0.415 
1
For each severity parameter, a simple model was built with patient demographics and pathogen detection variables. Multiple interaction models 
were then built to reflect co-detections between specific pathogens with adjustment for patient demographics and other pathogen detections. Full 
results are shown for each simple model. In the interaction models, only results for the interaction term are shown, as there was little difference 
in the other parameters between the models. The effect size (ES), the standard error (SE) of the coefficient and the p value (testing whether the 
coefficient is significantly different from zero) are displayed. Sp: S. pneumoniae, Hi: H. influenzae, Mc: M catarrhalis, +: detected, -: not 
detected. 
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Figure A2.1. S. pneumoniae load (ply gene estimate of genomes per µl) in infants and young 
children positive (A) and negative (B) for RSV infection. Participants are stratified by clinical 
disease severity scores into scores > 0 and < 1 (denoted ‘<1’ in graph), scores > 1 and < 2 (‘<2’), 
scores > 2 and < 3 (‘<3’), scores > 3 and < 4 (‘<4’), scores > 4 (‘4+’). Box and whisker plots with 
median and IQR are shown. 
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Table A2.3. Univariable analysis of associations between RSV subtype (A or B) and pathogen co-
detection, clinical parameters and participant demographics, for the subset of 29 RSV positive 
samples. Categorical variables are reported as number (%) while continuous variables are reported 
as median (IQR). Associations significant at p < 0.05 are highlighted in bold. 
Variable RSV-A detected 
(n=21) 
RSV-B detected 
(n=8) 
p value 
Age in months 4.8 (2.4,7.2) 4.8 (2.4,9.6) 0.608 
Male 11 (52.4) 5 (62.5) 0.697 
ED visit during autumn/winter 14 (66.7) 6 (75) 1 
Diagnosed asthma 1 (4.8) 1 (12.5) 0.483 
History of wheezing illness 5 (29.4) 4 (50) 0.394 
Supplemental oxygen 7 (35) 0 (0) 0.075 
Hospitalised 12 (63.2) 3 (37.5) 0.398 
Assisted ventilation 2 (10) 0 (0) 1 
Clinical disease severity score 1.5 (1,3) 2 (0.75,2.25) 0.759 
Oxygen saturation 0 (0,0) 0 (0,0) 0.195 
Inspiratory breath sounds 0 (0,0) 0 (0,0) 0.774 
Expiratory wheezing 0.5 (0.4,1) 1 (0.2,1) 0.603 
Accessory muscles 0.5 (0.5,1) 0.5 (0.4,1) 0.387 
Cerebral function 0 (0,0) 0 (0,0) 0.673 
Sp 11 (52.4) 4 (50) 1 
Hi 10 (47.6) 3 (37.5) 0.697 
Mc 17 (81) 3 (37.5) 0.067 
Sp ply load
1
 1.3 x 10
3
 (0, 2.8 x 
10
4
) 
6.4 x 10
2
 (0, 3.5 x 10
3
) 0.640 
Hi load
1
 0 (0, 2.3 x 10
4
) 0 (0, 1.4 x 10
3
) 0.521 
Mc load
1
 7.0 x 10
2
 (2.9 x 10
2
, 
3.0 x 10
4
) 
0 (0, 7.2 x 10
2
) 0.063 
Total microbial load
2
 3.5 x 10
5
 (4.5 x 10
4
, 
7.1 x 10
5
) 
5.5 x 10
4
 (3.1 x 10
4
, 1.6 x 
10
5
) 
0.039 
RSV NA NA NA 
hRV 6 (28.6) 1 (12.5) 0.635 
EV 1 (4.8) 0 (0) 1 
PIV 1 (4.8) 0 (0) 1 
MPV 0 (0) 1 (12.5) 0.276 
IAV 0 (0) 1 (12.5) 0.276 
AdV 3 (14.3) 1 (12.5) 1 
BoV 0 (0) 0 (0) NA 
PyV 2 (9.5) 0 (0) 1 
CoV 0 (0) 0 (0) NA 
No. of viruses per sample 1 (1,2) 1 (1,2) 0.803 
Multiple viruses detected 9 (42.9) 3 (37.5) 1 
1
Median genomes per µl. 
2
Median 16S ribosomal RNA gene copies per µl. ED: emergency 
department, Sp: S. pneumoniae, Hi: H. influenzae, Mc: M. catarrhalis, RSV: respiratory syncytial 
virus, hRV: human rhinovirus, EV: enterovirus, PIV: parainfluenza virus, MPV: metapneumovirus, 
IAV: influenza A virus, AdV: adenovirus, BoV: bocavirus, PyV: polyomavirus, CoV: coronavirus. 
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8.2 Chapter 3 
Table A3.1. Univariable analysis of associations between the four pneumococcal colonisation 
patterns and clinical factors. 
Variable Acquired and 
cleared  
(n=7) 
Acquired and 
persisted 
(n=5) 
Colonised 
and cleared  
(n=7) 
Colonised 
and persisted 
(n=21) 
p 
value 
Mean age in days (SD) 440.5 (98.2) 374.5 (181.8) 526.7 (126.4) 386.7 (157) 0.487 
Episode during 
autumn/winter (%) 
5 (71.4) 4 (80.0) 3 (42.9) 16 (76.2) 0.442 
RSV-A detected (%) 
RSV-B detected (%) 
A+B detected (%) 
4 (57.1) 
3 (42.9) 
0 (0) 
5 (100) 
0 (0) 
0 (0) 
5 (71.4) 
2 (28.6) 
0 (0) 
16 (76.2) 
5 (23.8) 
0 (0) 
0.507 
Asymptomatic
1 
URT infection 
LRI infection 
1 (14.3) 
1 (14.3) 
5 (71.4) 
1 (25.0) 
1 (25.0) 
2 (50.0) 
1 (14.3) 
3 (42.9) 
3 (42.9) 
4 (20.0) 
8 (40.0) 
8 (40.0) 
0.877 
Visited GP
1
 3 (42.9) 2 (66.7) 5 (83.3) 9 (47.4) 0.442 
Visited hospital
1
 0 (0) 0 (0) 0 (0) 2 (10.5) 1 
Prescribed antibiotics 
during ARI
1
 
1 (16.7) 0 (0) 4 (57.1) 6 (31.6) 0.269 
Any respiratory virus 
co-detected (%) 
1 (14.3) 4 (80.0) 5 (71.4) 7 (33.3) 0.048 
hRV co-detected (%) 1 (14.3) 3 (60.0) 3 (42.9) 2 (9.5) 0.035 
H. influenzae co-
detected (%) 
0 (0) 1 (20.0) 1 (14.3) 6 (28.6) 0.491 
M. catarrhalis co-
detected (%) 
4 (57.1) 3 (60.0) 3 (42.9) 14 (66.7) 0.743 
1
Missing data: Complete clinical data were missing in six episodes (2 missing ARI symptoms, 5 
missing GP and hospital visits and 4 missing antibiotic prescription). 
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20-01 OR53 S159 E03
 OR13 S096 E28
 OR12 S096 E28
 OR07 S096 E28
19F-03
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 OR26 S104 E39
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23F-01
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 OR43 S109 E10
23B-01
06C-01 OR21 S127 E02
06C-01 OR27 S134 E09
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 OR05 S072 E26
 OR06 S072 E26
21-01
  
Figure A3.1. Maximum likelihood phylogenetic tree of study CST sequences (including both 
colonised and acquired episodes). Bootstrap support values are shown for nodes with > 50% 
support. Sequences are labelled with sample ID (OR), subject ID (S) and episode ID (E), and 
sequences from the same RSV episode are in the same colour. The matching capsular sequence 
types identified from the CST databases are annotated with square brackets. Tree has been 
arbitrarily rooted on the longest branch (sequence OR53_S159_E03). Scale bar represents 
nucleotide substitutions per site. 
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Table A3.2. Associations of mean S. pneumoniae load the week before, during and after an RSV detection with participant demographic, clinical and 
pathogen co-detection factors. S. pneumoniae load was approximated by CT value, thus a CT value closer to 40 indicates a lower S. pneumoniae load. 
Variable Before
 
During After 
Mean (SD) p
1
 Mean (SD) p
1
 Mean (SD) p
1
 
Female (n=7) 
Male (n=4) 
30.9 (3)  
31.7 (5.1) 
0.756 27.1 (2.3)  
27.8 (4.3) 
0.732 28.7 (5.4)  
29.1 (2) 
0.875 
Only child (n=5) 
Siblings (n=6) 
30.2 (2.7)  
32 (4.4) 
0.428 26.2 (2.9)  
28.3 (3) 
0.281 26.7 (2.9)  
30.7 (4.6) 
0.131 
Full PCV13 (n=8)
2 
Partial/supplementary PCV13 (n=2) 
31 (2.8) 
31 (8.6) 
NA 27.2 (2.2) 
29.1 (6.5) 
NA 29.7 (4.6) 
27.7 (1.5) 
NA 
Attended childcare (n=9) 
Did not attend childcare (n=2) 
31.3 (4) 
30.9 (2.3) 
NA 27.1 (3.3) 
28.2 (0.2) 
NA 28.6 (4.7) 
29.8 (2.1) 
NA 
Episode during autumn/winter (n=9) 
Episode during spring/summer (n=2) 
31.9 (3.7) 
28.2 (1.8) 
NA 27.6 (2.9) 
26.1 (4.2) 
NA 29.2 (4.6) 
27.4 (3.5) 
NA 
First RSV exposure (n=6)
2 
Previously exposed to RSV (n=4) 
29.4 (3.3) 
33.5 (3.5) 
0.100 26.3 (2.4) 
28.7 (3.9) 
0.246 29.9 (5.1) 
26.7 (2.7) 
0.302 
RSV-A detected (n=9) 
RSV-B detected (n=2) 
 
 
30.7 (3.8)  
33.5 (1.7) 
NA 27.6 (3.2)  
25.9 (1.7) 
NA 28.7 (4.8)  
29.6 (0.4) 
NA 
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Variable Before
 
During After 
Mean (SD) p
1
 Mean (SD) p
1
 Mean (SD) p
1
 
Asymptomatic (n=1) 
URT infection (n=4) 
LRT infection (n=6) 
33.6 (NA) 
31.1 (4.0) 
30.8 (4.0) 
NA 
0.911
3
 
24.7 (NA) 
28.6 (4.4) 
26.9 (1.9) 
NA 
0.492
3 
24.0 (NA) 
26.7 (2.1) 
31.1 (4.4) 
NA 
0.072
3 
Visited GP (n=5)
2 
Did not visit GP (n=5) 
32 (3) 
30.7 (4.7) 
0.619 27.4 (1.6) 
27.1 (4.4) 
0.904 32.0 (4.3) 
25.8 (1.9) 
0.030 
Visited hospital (n=1) 
Did not visit hospital (n=9)
2
 
32.5 (NA) 
31.3 (4.0) 
NA 28.0 (NA) 
27.1 (3.3) 
NA 31.3 (NA) 
28.6 (4.7) 
NA 
Prescribed antibiotics during ARI (n=3) 
No antibiotics prescription (n=7)
2
 
31 (3.6) 
31.6 (4.1) 
0.842 27.2 (2.3) 
27.2 (3.6) 
0.987 33.1 (5.6) 
27.1 (2.7) 
0.047 
Respiratory virus (not RSV) detected in swab  
(before n=4, during n=6, after n=6) 
Respiratory virus not detected in swab  
(before n=7, during n=5, after n=5) 
31 (2.4) 
 
31.3 (4.4) 
0.910 27.5 (2.3) 
 
27.1 (4) 
0.866 28 (1.9) 
 
29.9 (6.3) 
0.484 
hRV detected in swab  
(before n=3, during n=1, after n=4) 
hRV not detected in swab  
(before n=8, during n=10, after n=7) 
30.1 (1.9) 
 
31.6 (4.2) 
0.566 27.1 (NA) 
 
27.3 (3.2) 
NA 29.1 (0.7) 
 
28.7 (5.5) 
0.882 
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Variable Before
 
During After 
Mean (SD) p
1
 Mean (SD) p
1
 Mean (SD) p
1
 
H. influenzae detected in swab  
(before n=2, during n=3, after n=4) 
H. influenzae not detected in swab  
(before n=9, during n=8, after n=7) 
31.1 (3.5) 
 
31.2 (3.9) 
NA 25 (2) 
 
28.2 (2.9) 
0.115 25.8 (2.4) 
 
30.6 (4.2) 
0.039 
M. catarrhalis detected in swab  
(before n=8, during n=8, after n=9) 
M. catarrhalis not detected in swab  
(before n=3, during n=3, after n=2) 
29.7 (3) 
 
35.2 (1.7) 
0.016 26.3 (2.3) 
 
30.1 (3.4) 
0.054 29.2 (4.6) 
 
27.4 (3.5) 
NA 
1
Comparison of CT values using t-test was only possible for variables where n > 2. 
2
PCV13 immunisation status, first exposure to RSV, GP visit, 
hospital visit and antibiotics prescription were missing data for one episode each. 
 3
Comparison of asymptomatic, URT infection and LRT infection 
could not be conducted as only one participant experienced asymptomatic RSV detection. Instead, loads were compared between participants 
exhibiting symptoms of URT infection and those of LRT infection. SD: standard deviation. 
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Table A3.3. Univariable analysis of demographic, clinical and pathogen co-detection factors 
associated with pneumococcal capsular sequence type. 
Variable 06C-01 
(n=2) 
15C-01 
(n=2) 
21-02 
(n=2) 
23B-01 
(n=3) 
23F-01 
(n=3) 
p 
value 
Male (%) 0 (0) 0 (0) 1 (50) 2 (66.7) 1 (33.3) 0.685 
Mean age (SD) 248.5 
(6.4) 
322.5 
(0.7) 
309.5 
(0.7) 
547.7 
(98.6) 
544.3 
(103.4) 
NA 
Siblings (%) 1 (50)  1 (50) 1 (50) 2 (66.7) 1 (33.3) 1 
Full PCV13 (%)
1 
1 (100)  2 (100) 2 (100) 2 (66.7) 3 (100) 1 
Attended childcare (%) 2 (100)  2 (100) 1 (50) 3 (100) 3 (100) 0.500 
Episode during autumn/ 
winter (%) 
2 (100)  1 (50) 2 (100) 2 (66.7) 3 (100) 0.864 
First RSV exposure (%) 1 (50)  1 (50) 2 (100) 2 (66.7) 1 (33.3) 0.909 
RSV-A detected (%) 2 (100)  2 (100) 2 (100) 2 (66.7) 1 (33.3) 0.427 
Asymptomatic (%)
 
URT infection (%) 
LRT infection (%) 
1 (50)  
0 (0) 
1 (50) 
1 (50) 
0 (0) 
1 (50) 
0 (0) 
1 (50) 
1 (50) 
0 (0) 
3 (100) 
0 (0) 
0 (0) 
1 (33.3) 
2 (66.7) 
0.294 
Visited GP (%)
1 
1 (50)  1 (100) 1 (100) 0 (0)    2 (66.7) 0.286 
Visited hospital (%)
1 
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) NA 
Prescribed antibiotics (%)
1 
1 (50)  1 (100) 0 (0)    0 (0)    1 (33.3) 0.550 
Respiratory virus co-
detected with RSV (%) 
1 (50)  2 (100) 2 (100) 1 (33.3) 2 (66.7) 0.685 
hRV co-detected with RSV 
(%) 
0 (0)    1 (50) 1 (50) 0 (0)    1 (33.3) 0.755 
H. influenzae co-detected 
with RSV (%) 
1 (50)  1 (50) 0 (0)    1 (33.3) 1 (33.3) 1 
M. catarrhalis co-detected 
with RSV (%) 
2 (100)  2 (100) 1 (50) 1 (33.3) 1 (33.3) 0.576 
1
Missing data: one episode was missing GP, hospital and prescription of antibiotics data, while 
another was missing PCV immunisation status data. SD: standard deviation. 
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8.3 Chapter 4 
Table A4.1. RSV reference strains downloaded from GenBank. 
GenBank 
accession 
Subtype Genotype Strain Location Year Citation 
KJ672450 A GA2 
(TN1) 
LA2_46 USA 2013 (192) 
KM042384 A GA2 
(TN1) 
LA2_78 USA 2013 (192) 
KJ672436 A GA2 
(TN2) 
LA2_30 USA 2012 (192) 
AY911262 A GA1 Long (ATCC VR-
26) 
USA 1956 (331) 
M74568 A GA1 A2 (ATCC VR-
1540) 
Australia 1961 (332) 
JX069798 A GA2 A2001-02-20 USA 2001 Lorenzi et al. 
2012, JCVI
1 
AY472086 A GA2 sal/87/99 Brazil 1999 (333) 
AF065254 A GA4 CH09 USA 1993 (190) 
KF826850 A GA5 629-11-1 USA 2008 Lorenzi et al. 
2013, JCVI
1
 
KF826827 A GA5 ARG-159-2004 Argentina 2004 (188) 
KJ672483 A GA5 LA2_19 USA 2013 (192) 
KJ723483 A GA7 84I-215A-01 USA 1984 Das et al. 
2014, JCVI
1
 
KJ723464 A GA7 89I-150A-01 USA 1989 Das et al. 
2014, JCVI
1
 
JX069801 A GA7 A1998-03-02 USA 1998 Lorenzi et al. 
2012, JCVI
1 
KP663728 A NA1 IC688 South Korea 2012 (334) 
KJ939944 A NA1 VN-369-6/10 Vietnam 2010 (189) 
KJ672451 A GA2 
(ON1) 
 
LA2_103 USA 2012 (192) 
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GenBank 
accession 
Subtype Genotype Strain Location Year Citation 
JX627336 A GA2 
(ON1) 
GN435 South Korea 2011 (216) 
KC731482 A GA2 
(ON1) 
NIV1114046 India 2011 (215) 
JN257694 A GA2 
(ON1) 
ON138-0111A Canada 2011 (207) 
KC731483 A GA2 NIV1114073 India 2011 (215) 
AY488805 B URU1 mon/8/01 Uruguay 2001 (335) 
AY353550 B B 9320 (ATCC VR-
955) 
USA 1977 (336) 
M17213 B B 18537 USA 1962 (187) 
AY333361 B URU2 Mon/15/90 Uruguay 1990 (211) 
AY672691 B GB4 BA/3018/98 Argentina 1998 (337) 
KC342336 B THB CU2010/5 Thailand 2010 (302) 
AF065251 B GB2 CH93-9b USA 1990s (190) 
AY660684 B SAB1 Ken/2/03 Kenya 2003 (338) 
AF013254 B GB1 B1 USA 1985 (339) 
M73542 B GB1 WV15291 USA 1985 (340) 
DQ227398 B BA (BAI) BA/1326/99 Argentina 1999 (212) 
KC297492 B BA 
(BAVII) 
BJ/F9981 China 2009 (341) 
KF246585 B BA 
(BAXII) 
RSV/PUNE 
/NIV0934544 /09/B 
India 2009 (342) 
KC297426 B BA 
(BAX) 
BJ/20240 China 2009 (341) 
KF640637 B BA B05 UK 2005 (343) 
KF246629 B BA 
(BAIX) 
RSV/PUNE 
/NIV1065483 /10/B 
India 2010 (342) 
DQ227396 B BA 
(BAIV) 
BA/524/04 Argentina 2004 (212) 
GQ150691 B BA 
(BAIII) 
MAD/3743 /02-03 Spain 2002 (298) 
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GenBank 
accession 
Subtype Genotype Strain Location Year Citation 
DQ227370 B BA 
(BAIII) 
BA/495/02 Argentina 2002 (212) 
JX576762 B GB13 02-000467 Netherlands 2002 (344) 
AY751110 B BA 
(BAVI) 
BE/46/03 Belgium 2003 (345) 
1
Direct submission to GenBank database, unpublished data. JCVI: J. Craig Venter Institute, USA. 
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Table A4.2. Study sample collection date and pathogen detection. 
Key:  ● RSV    ● hRV     ● AdV     ● PIV     ● IAV 
 ■ Sp       ■ Hi         ■ Mc        ■ Sa       ■ Other 
Study 
week 
Date Patient 
ID 
Age at 
collection 
Virus 
detection 
Bacterial 
detection 
RSV 
genotype 
Sp ST (mol. 
serotype) 
1 22 Mar 2012       
 23       
 24       
 25       
 26 BNE-21 1.375 ● ■ BA 558 (35B) 
 27 BNE-19 
BNE-18 
BNE-20 
0.775 
0.708 
0.747 
● 
● 
● 
■ 
■ 
■ 
BA 
GA5 
NA1 
 
 28 BNE-16 
BNE-15 
0.981 
0.764 
●● 
● 
 
 
GA2 
NA1* 
 
2 29 Mar 2012 BNE-17 0.994 ●● ■ BA  
 30 BNE-11 
BNE-77 
BNE-10 
0.919 
0.394 
0.094 
● 
 
● 
■■ 
■■ 
■ 
NA1 
 
GA5 
62 (11A) 
2042 (16F) 
 31 BNE-13 0.033 ●  NA1  
 1       
 2 BNE-8 
BNE-6 
BNE-73 
BNE-9 
BNE-14 
BNE-7 
0.992 
0.836 
0.572 
0.439 
0.075 
0.197 
● 
● 
● 
●● 
● 
● 
■■ 
■ 
■■ 
■ 
 
 
ON1 
ON1 
 
NA1 
BA 
NA1* 
199 (15B/C) 
1027 (15B/C) 
new (35F) 
62 (11A) 
 3 BNE-5 1.775 ● ■■ NA1 2042 (16F) 
 4 BNE-1 
BNE-2 
BNE-3 
0.133 
0.942 
0.803 
● 
●● 
●● 
■ 
■ 
■ 
BA 
BA 
BA 
 
3 5 Apr 2012       
 6       
 7       
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Study 
week 
Date Patient 
ID 
Age at 
collection 
Virus 
detection 
Bacterial 
detection 
RSV 
genotype 
Sp ST (mol. 
serotype) 
 8       
 9       
 10       
 11       
4 12 Apr 2012       
 13       
 14       
 15       
 16       
 17       
 18       
5 19 Apr 2012       
 20 BNE-88 
BNE-202 
BNE-86 
BNE-87 
0.356 
0.072 
1.078 
2.244 
● 
 
● 
●● 
■■ 
■■ 
■ 
 
NA1 
 
NA1 
NA1* 
673 (33F) 
199 (15B/C) 
 
 21 BNE-81 0.081 ● ■ NA1  
 22       
 23 BNE-204 
BNE-90 
BNE-91 
BNE-93 
BNE-89 
BNE-92 
2.114 
1.553 
0.122 
0.342 
2.133 
1.119 
 
●● 
● 
● 
● 
●● 
■■ 
■ 
■ 
 
■ 
■ 
 
BA 
BA 
NA1 
NA1 
NA1* 
355 (23B) 
 24 BNE-94 0.708 ● ■ NA1  
 25       
6 26 Apr 2012 BNE-98 2.169 ●●●  NA1  
 27 BNE-99 
BNE-97 
BNE-101 
BNE-100 
0.331 
0.194 
0.036 
0.669 
● 
● 
● 
● 
■■ 
■ 
■ 
■■ 
NA1 
NA1 
NA1 
NA1 
 
 
 
1448 (23B) 
 28       
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Study 
week 
Date Patient 
ID 
Age at 
collection 
Virus 
detection 
Bacterial 
detection 
RSV 
genotype 
Sp ST (mol. 
serotype) 
 29       
 30 BNE-103 
BNE-102 
BNE-106 
BNE-104 
BNE-107 
BNE-109 
0.533 
0.206 
0.139 
1.008 
0.108 
0.214 
● 
● 
● 
●● 
● 
●● 
■■ 
■ 
 
 
■ 
 
GA2 
NA1 
NA1 
NA1 
NA1 
NA1* 
2042 (16F) 
 1 BNE-198 
BNE-110 
BNE-111 
BNE-112 
1.472 
0.297 
0.028 
0.275 
● 
● 
● 
● 
■■ 
■ 
■■ 
 
 
NA1* 
NA1* 
NA1* 
320 (19F) 
 2 BNE-128 
BNE-129 
BNE-126 
BNE-124 
0.269 
0.264 
0.239 
0.933 
● 
● 
● 
● 
■■ 
■■ 
 
■■ 
NA1 
BA 
NA1 
NA1* 
62 (11A) 
7 3 May 2012       
 4 BNE-121 0.192 ● ■■ NA1*  
 5 BNE-120 0.772 ● ■ GA5  
 6       
 7       
 8 BNE-117 
BNE-119 
BNE-178 
BNE-115 
BNE-118 
4.019 
1.164 
0.278 
0.258 
2.342 
● 
●● 
 
● 
● 
■ 
■ 
■■ 
■ 
NA1 
BA 
 
BA 
BA 
1888 (15B/C) 
199 (15B/C) 
446 (35F) 
 9       
8 10 May 2012 BNE-157 
BNE-131 
2.656 
0.042 
● 
● 
■ 
■ 
 
NA1 
1692 (6A/B) 
 11 BNE-132 2.078 ●  NA1*  
 12 BNE-140 1.350 ●● ■ NA1*  
 13       
 14 BNE-144 3.628 ● ■  1715 (6A/B) 
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Study 
week 
Date Patient 
ID 
Age at 
collection 
Virus 
detection 
Bacterial 
detection 
RSV 
genotype 
Sp ST (mol. 
serotype) 
BNE-134 
BNE-139 
BNE-136 
BNE-135 
1.253 
1.253 
0.247 
0.039 
●●● 
●● 
●● 
● 
■ 
■ 
■ 
■■ 
 
 
NA1 
BA 
320 (19A) 
439 (23B) 
2068 (10A) 
 15       
 16       
*Subgroup of 12 closely related NA1 study strains, ‘NA1-sub’. Sp: S. pneumoniae, mol. serotype: 
molecular serotype. 
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Figure A4.1. Associations between pathogen detection and the dominant two RSV genotypes, NA1 
and BA, with adjustment for confounding factors. Detection of hRV and detection of >1 virus were 
adjusted for patient age, while the bacterial detection variables were adjusted for patient age and 
detection of >1 virus. The effect size and 95% confidence intervals (CI) are shown, calculated by 
penalised logistic regression with Firth’s correction for small sample bias. Sp: S. pneumoniae, Hi: 
H. influenzae, Mc: M. catarrhalis, Sa: S. aureus. 
 
 
 
 
Table A4.3. Comparison of RSV-A and RSV-B detection each year in Brisbane, Australia, across 
the three cohorts investigated in this thesis.  
Year Chapter 2: PISP  
(severe ARI) 
Chapter 3: ORChID 
(community ARI) 
Chapter 4: Pathology 
(community ARI) 
No. RSV 
detected 
A B No. RSV 
detected 
A B No. RSV 
detected 
A B 
2011 6 100% 0% 9 56% 44% NA   
2012 10 90% 10% 30 83% 17% 58
1 
76% 24% 
2013 11 55% 45% 31 68% 32% NA   
2014 2 0% 100% 9 44% 56% NA   
1
58 samples were successfully typed, however, a total of 67 samples from the cohort were RSV 
positive. 
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8.4 Chapter 5 
 
 
 
Figure A5.1. S. pneumoniae cells bound to an RSV infected A549 airway epithelial cell visualised 
by scanning electron microscopy. RSV infection is known to stimulate the production of 
filamentous virions which extend from the cell surface (181). In this image a tight association can 
be observed between S. pneumoniae and what are believed to be RSV filaments (filaments were not 
observed in mock infected cells). S. pneumoniae was added to host cells 24 hours post RSV 
infection and allowed to bind for one hour before washing with PSB-T. Samples were fixed with 
2.5% glutaraldehyde and 1% osmium tetroxide, sequentially dehydrated and coated with platinum. 
Scale bar represents 1 µm. The experiment and images were entirely generated by Dr Keith 
Chappell and are reproduced here with permission. The in vitro binding assay developed and 
discussed in Chapter 5 was designed to further investigate the binding interactions observed here. 
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Table A5.1. Summary of optimisation binding assay experiments. All experiments, 
immunofluorescence and image analyses were performed as described in Chapter 5.2.4, 5.2.6 and 
5.2.7, respectively, apart from alterations to conditions described in the following table. The 
subsequent Figures A5.2 to A5.5 display optimisation data for a subset of conditions that were 
found to be particularly important in the optimisation process.  
Factor Conditions tested  
(final decision in bold) 
Justification for decision Data shown 
in Appendix 
Epithelial cell line BEAS-2B 
A549 
Similar S. pneumoniae binding 
levels in both cell lines; A549 
cells slightly easier to work with. 
Figure A5.2. 
RSV infection 
(concentration and 
hours post infection 
bacteria added) 
1.0 x 10
5
 PFU/ml at 
24 h p.i. 
48 h p.i. 
6.7 x 10
5
 PFU/ml at 
24 h p.i. 
1.0 x 106 PFU/ml at 
48 h p.i. 
Maximised infection while 
maintaining monolayer integrity; 
minimised RSV concentration at 
time of infection. 
Figure A5.3. 
Binding 
concentration of S. 
pneumoniae 
1 x 10
5
 CFU/ml 
1 x 10
7
 CFU/ml 
Higher numbers of S. pneumoniae 
bound to cells, allowing easier 
focusing of microscope. 
Figure A5.4. 
Growth conditions 
of S. pneumoniae 
THY media + 5% FCS 
THY media (no FCS) 
FCS was found to block S. 
pneumoniae adherence to 
epithelial cells during RSV 
infection. 
Figure A5.5. 
Washing in PBS of 
host cell monolayers 
prior to S. 
pneumoniae binding 
Included washing step 
Excluded washing step 
No difference in S. pneumoniae 
particle numbers with or without 
washing step, therefore excluded 
to improve speed of assay. 
Data not 
shown. 
Fix for plates before 
immunofluorescence 
staining 
80% acetone 
4% PFA 
No difference in S. pneumoniae 
particle numbers; PFA gentler fix 
than acetone; PFA worked well 
with final combination of 
antibodies. 
Data not 
shown. 
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Figure A5.2. Comparison of D39 and S. pneumoniae isolates binding to BEAS-2B (A) and A549 
(B) immortalised airway epithelial cell lines during mock (grey circles) and RSV-A2 (blue squares) 
infection. Pneumococcal fluorescent particle counts per field are shown, with error bars 
representing the mean and standard deviation. Isolates are labelled by patient ID. Isolate binding 
was similar to both BEAS-2B and A549 cells, though some isolates bound better to BEAS-2B cells 
(e.g. BNE-103) or A549 cells (e.g. BNE-8 and BNE-77). 
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Figure A5.3. Comparison of RSV-A2 infection of BEAS-2B immortalised airway epithelial cells at 
24 h and 48 h post infection with cells infected with 6.7 x 10
5
 PFU/ml and 1 x 10
5
 PFU/ml of virus, 
respectively. Points represent mean fluorescence in the RSV channel across each field, with error 
bars indicating the overall mean and standard deviation of each condition. Both mean background 
fluorescence during mock infection (grey circles) and mean fluorescence during RSV-A2 infection 
(blue squares) are shown. Note the two experiments were not conducted side by side and day-to-day 
variation may have affected results. Data from other infection conditions tested are not shown as 
cell loss due to excessive RSV infection obstructed collection of RSV fluorescence data. Infection 
at the lower virus concentration (1 x 10
5
 PFU/ml) and addition of bacteria at 48 h post infection was 
found to maximise RSV infection across the monolayer while minimising destruction of the cell 
monolayer.  
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Figure A5.4. Comparison of S. pneumoniae isolates at 1 x 10
5
 CFU/ml (A) or 1 x 10
7
 CFU/ml (B) 
of bacteria binding to A549 airway epithelial cells during mock (grey circles) and RSV-A2 (blue 
squares) infection. Pneumococcal fluorescent particle counts per field are shown, with error bars 
representing the mean and standard deviation. Isolates are labelled by patient ID. S. pneumoniae 
bound in higher numbers when the higher concentration of bacteria was used, improving the 
microscope auto-focusing algorithm, thus this concentration was used for the final binding assays. 
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Figure A5.5. Comparison of S. pneumoniae isolate BNE-11 binding to A549 airway epithelial cells 
during mock (grey circles) and RSV-A2 (blue squares) infection after growth in THY media with 
and without 5% FCS. Pneumococcal fluorescent particle counts per field are shown, with error bars 
representing the mean and standard deviation. While pneumococcal binding to mock infected cells 
was similar regardless of FCS presence, isolate binding during RSV-A2 infection was higher when 
bacteria were growth without FCS, suggesting that a component of FCS blocked the S. pneumoniae 
interaction with surface proteins during RSV infection. 
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Table A5.2. Summary of patient and bacteriological characteristics of isolates used in the binding 
assays. Isolates from patients BNE-11 (11A), BNE-128 (11A), BNE-5 (16F), BNE-136 (10A), 
BNE-178 (35F) and BNE-198 (19F) could not be used as they had limited growth without FBS. 
Isolates from patients BNE-9 (11A) and BNE-134 (19A) could not be recovered from the original 
stock. 
Patient ID Molecular serotype ST (clonal complex) RSV subtype (genotype) 
D39 2 595 (singleton) NA 
BNE-119 15B/C 199 (5) RSV-B (BA) 
BNE-8 15B/C 199 (5) RSV-A (ON1) 
BNE-117 15B/C 1888 (7) RSV-A (NA1) 
BNE-6 15B/C 1027 (36) RSV-A (ON1) 
BNE-139 23B 439 (6) Neg (hRV, AdV) 
BNE-100 23B 1448 (6) RSV-A (NA1) 
BNE-83
1 
23B 1373 (1) RSV-A (NA) 
BNE-88 33F 673 (31) RSV-A (NA1) 
BNE-144 6A/B 1715 (215) Neg (hRV) 
BNE-157 6A/B 1692 (25) Neg (hRV) 
BNE-103 16F 2042 (singleton) RSV-A (GA2) 
BNE-77 16F 2042 (singleton) Neg (virus negative) 
BNE-21 35B 558 (43) RSV-B (BA) 
1
BNE-83 was excluded from analysis in Chapter 4 as RSV genotyping was not successful (although 
sequencing was sufficient to class the viral strain as subtype A). Neg: Sample negative for RSV 
(other viruses detected in sample). 
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Figure A5.6. S. pneumoniae adherence during mock (grey circles) and RSV-A2 (blue squares) 
infection of A549 airway epithelial cells. Each repeated experiment is shown (1-4), and the fifth 
experiment is shown in the main text (Figure 5.2). Pneumococcal fluorescent particle counts per 
field are shown, with error bars representing the mean and standard deviation. Due to the variation 
between experiments, different scales are used on each y axis. Not every isolate was repeated in 
each experiment. Mean particle counts were compared between mock and RSV-A2 infection for 
each isolate within each experiment: ***: p < 0.001, **: p < 0.01, *: p < 0.05, ns: p > 0.05 (t-tests). 
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Figure A5.7. Median adherence of S. pneumoniae clinical isolates to mock infected airway 
epithelial cells (A), fold change in adherence between RSV-A2 and mock infection (B) and 
pneumococcal particle count increase during RSV-A2 infection compared to mock infection (C), 
plotted against patient age. Mock adherence is shown on a logarithmic scale. Spearman (A) or 
Pearson (B-C) test for correlation was performed, reported with trendline, goodness of fit (r) and 
significance (p) of test. Dotted line in C at y = 0 represent no change between RSV-A2 and mock 
infection. 
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Figure A5.8. S. pneumoniae adherence to A549 airway epithelial cells after mock infection (grey 
circles) or infection with clinical strains RSV-NA1 (purple triangles) or RSV-BA (green inverted 
triangles). Each repeated experiment is shown (1-3). For mock adherence, pneumococcal 
fluorescent particle counts per field are shown, whereas for RSV adherence, RSV positive 
pneumococcal particle counts were normalised by the extent of the RSV infection in each field. 
Error bars present the mean and standard deviation. Due to the variation between experiments, 
different scales are used on each y axis. Mean particle counts were compared between mock and 
RSV-NA1 (upper bars) or RSV-BA (lower bars) for each isolate within each experiment: ***: p < 
0.001, **: p < 0.01, *: p < 0.05, ns: p > 0.05 (t-tests). Fields with <1% RSV infection were excluded 
and in some experiments, some isolates had zero or one field with >1% RSV infection, thus in these 
cases statistical comparison of RSV and mock adherence could not be performed. 
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Figure A5.9. Example immunofluorescence microscopy composite images of S. pneumoniae adherence to cells infected with mock or clinical strains 
RSV-NA1 and RSV-BA. The blue, red and green channels have been merged into a single image, with A549 epithelial cell nuclei coloured blue, RSV 
infection red and S. pneumoniae particles green. All images were taken from a single experiment. Number of S. pneumoniae particle counts is shown in 
the upper right-hand corner of each image. 
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Figure A5.10. S. pneumoniae adherence to A549 airway epithelial cells after pre-incubation with 
mock (grey circles) or RSV-A2 (blue squares). Each repeated experiment is shown (1-3). 
Pneumococcal fluorescent particle counts per field are shown, with error bars representing the mean 
and standard deviation. Due to the variation between experiments, different scales are used on each 
y axis. Not every isolate was repeated in each experiment. Mean particle counts were compared 
between mock and RSV-A2 pre-incubation for each isolate within each experiment: ***: p < 0.001, 
**: p < 0.01, *: p < 0.05, ns: p > 0.05 (t-tests). 
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Figure A5.11. RSV-A2 virion adherence to A549 airway epithelial cells after pre-incubation with S. 
pneumoniae isolates (identified by patient ID), D39 or PBS (A). Points represent the mean particle 
counts per field across multiple fields and technical replicates for each experiment, with error bars 
representing mean and standard deviation across 2-3 experiments per isolate. Example 
immunofluorescence microscopy composite images of S. pneumoniae particle (green) and RSV 
virion (red) adherence to A549 cells (blue) after pre-incubation of RSV-A2 or media (mock) with 
D39 or PBS (B). The blue, red and green channels have been merged into a single image. All 
images were taken from a single experiment. 
